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Abstract  
Background: Fibrinogen is a large protein dimer that is composed of three 
polypeptide chains Aα, Bβ and γ and plays a vital role in haemostasis. Fibrinogen 
is suggested to be a risk factor for cardiovascular disease. The Aα-chain contains 
two RGD sequences, which provide the interaction sites of fibrinogen with 
integrins present on cells such as platelets and endothelial cells. New studies 
suggested that RBCs are not innocent bystanders in thrombus formation 
suggesting presence of polyhedral shaped RBCs inside the clot. An integrin-type 
receptor interaction between erythrocytes and fibrinogen was proposed but 
some controversy is still present regarding the possible receptor on the surface 
of the RBC involved in this interaction between fibrinogen and RBCs.   
Hypothesis: Interaction between fibrinogen and RBCs is mediated by the RGD 
sequence in the coiled-coil of the Aα-chain of fibrinogen through αIIbβ3-like 
integrin receptor. Mutating this RGD site may inhibit the interaction between 
fibrinogen and RBCs and subsequently thrombosis. 
Methods: Six recombinant fibrinogens variants (R95E, R95Q, G96V, D97K, 
D97N, and F98I) were generated by Site-Directed Mutagenesis. The integrity of 
the proteins were tested by SDS-PAGE and circular dichroism. Clots formed by 
variant fibrinogens were evaluated by clotability, turbidity and lysis, and laser 
scanning confocal microscopy. Interaction between fibrinogen and RBCs were 
studied by Plate-binding assay, solution-binding assay and flow cytometry. 
Involvement of the Aα-chain RGD sequence in binding between fibrinogen and 
platelets was tested by platelet spreading assay. 
Results: Clot structure studies showed thinner, shorter fibres but no effect on 
fibrinolysis.  Fibrinogen binding assays with both RBCs and platelets showed no 
effects of the mutations in the Aα-chain RGD sequence on cell binding. 
Conclusion: Aα-95-98 RGD has no obvious effect on the binding between red 
blood cells and fibrinogen, or platelets and fibrinogen. Nonetheless, mutations at 
this site change clot structure and polymerisation profile. 
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1.1 Cardiovascular Disease and Thrombosis 
Cardiovascular disease are one of the most common causes of morbidity and 
mortality worldwide. The tendency to develop cardiovascular disease is 
increased if the risk factors including obesity, diabetes, dyslipidaemia and 
hypertension are present from early childhood and adolescent life (Schwandt et 
al., 2009). The pathogenesis of cardiovascular disease is complex with intricate 
interactions between genetic, environmental and lifestyle factors. These factors 
affect the site and timing of onset, most seriously affected locations, type of 
initiation, in addition to the dynamics of progression of the disease and what type 
of cardiovascular outcome is produced (Messner and Bernhard, 2014). 
Complexity of cardiovascular disease is increased by the variation of the risk 
factors, type of cells, biological processes and physiochemical interactions that 
participate in the pathogenesis of the diseases (Messner and Bernhard, 2014). 
1.1.1 Atherosclerosis  
Atherosclerosis is a chronic systemic vascular disease, which is progressive and 
diffuse, involving the cerebro and cardiac-vasculature; heart and brain, as well 
as the peripheral circulation (Santos and Nasir, 2009). High mortality is 
associated with ischemic heart disease and cerebrovascular disease, which may 
be caused by acute thrombotic occlusions of the coronary or carotid arteries 
(Montecucco et al., 2009). Atherosclerosis and its complications, including the 
tendency to thrombosis, are caused by endothelial and vascular smooth muscles 
dysfunction (Creager et al., 2003). The disease is initiated by the accumulation 
of lipids, macrophages, foam cells, blood products, calcium deposits and 
carbohydrates within the sub-endothelial layer of the arteries’ walls causing their 
thickening and rigidity (Zaman et al., 2000).  
1.2 Thrombosis  
Thrombosis is referred to as the pathological formation of clot (Gale, 2011). For 
the three main cardiovascular diseases; stroke, venous thromboembolism (VTE) 
and ischemic heart disease (acute coronary syndrome), thrombosis is the 
greatest common end-point of the disease (Raskob et al., 2014). Pulmonary 
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embolism (PE) is the main complication of deep vein thrombosis (DVT), when 
combined, they both are known as VTE (Budnik and Brill, 2018).  
Differences between arterial and venous thrombosis are owed to the differences 
in blood flow between the two systems with higher shear rate for the arterial flow 
(Tangelder et al., 1988, Gale, 2011). Composition of arterial (platelets) and 
venous (fibrin and red blood cells) thrombi differ according to the different 
pathogenic mechanisms by which these two diseases occur. Although risk 
factors are different for arterial and venous thrombosis, some risk factors are 
common between both types such as obesity and high cholesterol (Gale, 2011). 
Hypercoagulability is a common pathogenic mechanism that is shared between 
arterial and venous thrombosis (Franchini and Mannucci, 2008). However, 
hypercoagulability is mainly associated as classical risk factor with venous 
thrombosis (Gale, 2011). A complex interplay between immune system, 
inflammation and lipids is more important for arterial than venous thrombosis 
(Previtali et al., 2011).  
Wall shear stress is the haemodynamic force that is generated by the flowing 
blood (Resnick et al., 1993). Shear stress is a measure of the force that is 
required by a viscous liquid to produce a flow rate. For the arterial and venous 
circulations, this force is applied on the surfaces of different blood cells such as 
platelets and red blood cells (RBCs) and can cause alterations in clustering, 
exposure or structure of externally oriented constituents that are present in the 
cell membrane (Moake et al., 1988). 
1.2.1 Arterial Thrombosis and Treatment 
The arterial thrombus is primarily generated by platelet aggregation on ruptured 
atherosclerotic plaques (Gale, 2011), with little fibrin or red blood cells, which 
gives the thrombus a white appearance. Ischemic stroke, peripheral artery 
disease and myocardial infarction are atherothrombotic diseases, which are 
caused by arterial thrombosis (Franchini and Mannucci, 2008). Thrombus of 
patients with these arterial diseases in addition to abdominal aortic aneurism 
were found to demonstrate unfavourable fibrin clot structures, which are stiffer, 
more resistant to lysis, with shorter and thicker fibres, and containing smaller 
pores (Bridge et al., 2014, Collet et al., 2006). These clots are less permeable 
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and faster in fibrin polymerisation. The changes of clot structure were also found 
in the healthy first-degree relatives of the patients who are having altered clot 
structure, suggesting a genetic component to the alteration (Bridge et al., 2014, 
Mills et al., 2002). Arterial thrombosis may cause ischemic injuries. Thrombosis 
arises through platelet-mediated thrombi, which occurs after rupture or erosion 
of the atherosclerotic plaque. Stroke and cardiac ischaemia are considered as 
the two most severe outcomes of atherothrombosis (Previtali et al., 2011). Risk 
factors for arterial thrombosis include hyperlipidaemia, diabetes, hypertension, 
obesity and smoking (Franchini and Mannucci, 2008). 
Aspirin (acetylsalicylic acid) is a well-known anti-platelet treatment of arterial 
thrombosis i.e. myocardial infarction and ischemic stroke (Patrono and Rocca, 
2008, He et al., 2009). The inhibition of platelets occurs through acetylation of a 
specific amino acid in the active site of cyclooxygenase (COX); serine-530, even 
at very low doses of aspirin (30-50) µM (Roth and Majerus, 1975, He et al., 2009, 
Lucido et al., 2016). This inhibition of COX by acetylation reduces platelet 
aggregation potential by inhibiting thromboxane 2 irreversibly (TXA2) (Ajjan et 
al., 2009). Another proposed mechanism by which aspirin is protective against 
arterial thrombosis is the inhibition of the production of thrombin, which might 
delay the growth of the clot in the narrowing artery (Szczeklik et al., 1992). Better 
fibrinolysis rate is thought to be another mechanism of the aspirin effect on 
thrombosis (Bjornsson et al., 1989). The latter two mechanisms may act on 
fibrinogen and prothrombin by the acetylation of their lysine residues (Williams 
et al., 1998). Aspirin was found to affect clot structure, formation and lysis, likely 
by acetylation of clotting factors such as fibrinogen, thrombin, tissue 
plasminogen activator (tPA) and factor XIII (FXIII) (Undas et al., 2007, Ajjan et 
al., 2009). Acetylation of fibrinogen by aspirin was studied by Ajjan et al in vitro 
using CHO cells expressing recombinant fibrinogen. The use of purified 
recombinant fibrinogen helped to eliminate the heterogeneity of the plasma-
purified fibrinogen resulting from genetic factors and post-transitional 
modifications, as well as ensuring the absence of other clotting factors that are 
present in the in vivo environment (Ajjan et al., 2009). The authors found that 
clots formed by aspirin-treated recombinant fibrinogen had higher final turbidity 
and permeation coefficients reflecting thicker fibres and larger pores 
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respectively, which were confirmed by electron microscopy. The clots were found 
to have reduced rigidity and were less compact, which may lead to the shorter 
fibrinolysis time that was observed (Ajjan et al., 2009). The results of clot 
structure modulations were confirmed by aspirin-treated plasma-purified 
fibrinogen. This study identified the Aα-chain of fibrinogen as the site of 
acetylation on fibrinogen using an antibody against acetylated lysine residues 
(Ajjan et al., 2009). 
Thienopyridine drugs ticlopidine and clopidogrel demonstrate antithrombotic 
effects by impairing platelet aggregation via inhibition of their response to 
adenosine diphosphate (ADP) (Mills et al., 1992). These drugs act specifically 
on ADP and on mediators that induce ADP secretion from the granules of the 
platelets such as thrombin. This specificity suggested that these drugs act on the 
ADP receptors on platelets instead of other receptors such as those for 
fibrinogen for example (Mills et al., 1992). Ticlopidine were approved as 
protective drugs against stroke in patients who are sensitive to aspirin. Similar to 
aspirin, Ticlopidine inhibits platelets response to ADP activation. (Mills et al., 
1992). Anti αIIbβ3 integrin drugs including abciximab, eptifibatide and tirofiban, 
which are administered intravenously, are used for short term treatment of 
arterial thrombosis in combination with other treatment options (Cohen, 2009, 
Gale, 2011).  
1.2.2 Venous Thrombosis and Treatment  
The venous thrombus is primarily associated with fibrin- and red blood cell-rich 
clots (Gale, 2011). Venous thrombosis in contrast to the arterial thrombosis 
occurs on an apparently normal vein wall, where the shear rate and blood flow 
are low, forming a red blood cell-rich thrombus that is also called a red thrombus 
(Lowe, 2008). DVT PE, and VTE are the primary diseases caused by venous 
thrombosis (Franchini and Mannucci, 2008). Clots of patients of venous 
thrombosis have similarities to arterial clots in that they were denser and less 
permeable, with slower fibrinolysis compared to normal controls (Bridge et al., 
2014, Undas et al., 2009b). However, interestingly, DVT clots showed slightly 
better properties of less dense, more permeable and faster fibrinolysis if the 
patients also had a PE. This may suggest that clot structure mechanism may 
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provide a mechanism for, or be a marker of the probability of formation of 
embolism in DVT patients (Bridge et al., 2014, Undas et al., 2009b).  
After stroke and acute myocardial infarction, VTE is the most common thrombotic 
vascular disease. Pathogenesis of venous thrombosis is suggested to occur 
much more through mechanisms of a combination of hypercoagulability and 
stasis than through endothelial damage (Previtali et al., 2011). Risk factors for 
venous thrombosis include pregnancy, oestrogen use, cancer, immobilisation, 
surgery and fractures (Franchini and Mannucci, 2008). 
Treatment of venous thrombosis is heparin associated with warfarin, the latter of 
which a is Vitamin K antagonist that is included in the treatment in the first 24 
hours of the onset of thrombosis (Bauer, 2003). Heparin can be used in any of 
its two main forms; unfractionated heparin (UFH) and low molecular weight 
heparin (LMWH) (Dahlback, 2005). The production of LMWH is possible by 
chemical or enzymatic cleavage of UFH. LMWH is better in its pharmacokinetic 
properties, making laboratory monitoring unnecessary, and a single daily dose 
is enough to achieve haemostatic control. LMWH has longer half-life, better 
bioavailability and it is easier to administrate than UFH (Bauer, 2003, Dahlback, 
2005). LMWHs produce less bleeding complications and immune-allergic 
thrombocytopenia than UFH so they are replacing many applications of UFH, 
although the latter is still in use (Bounameaux, 1998, Merli and Groce, 2010, 
Oduah et al., 2016). Reasons for this may include that UFH is less expensive 
than LMWH and studies are still ongoing regarding the efficacy and safety of the 
different types of heparin treatment (Bounameaux, 1998, Merli and Groce, 2010, 
Oduah et al., 2016). Heparin treatment can be stopped after a few days of 
concomitant treatment with warfarin, when the levels of functional vitamin K-
dependent coagulation proteins reach the therapeutic levels of prothrombin time 
or International Normalised Ratio. Vitamin K antagonist can last for 3-6 months 
until the prothrombin time is fully back to normal (Dahlback, 2005, Bauer, 2003). 
Treatment of DVT is based on anticoagulants and vasoactive drugs to avoid the 
enlargement of the clot; this is in addition to physical procedures that modulate 
the flow of blood such as physical exercise, surgical thrombectomy, systemic 
thrombolysis and catheter directed thrombolysis (Luther et al., 2016, Hillegass et 
al., 2016, Scarvelis and Wells, 2006, Fleck et al., 2017). 
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1.2.3 Cancer  
Thrombosis and coagulation abnormalities are strongly associated with 
malignant diseases; as evidenced by a high risk of thrombosis in patients with 
cancer (Falanga et al., 2015). The mechanism(s) by which cancer induces 
thrombosis involve expression of the tissue factor by tumour cells, in addition to 
the production of other prothrombotic molecules and complexes induced by the 
tumour such as microparticles, inflammatory cytokines tumour necrosis-α and 
interleukin 1-β, in addition to proangiogenic factors. Tumour cells also express 
adhesion molecules that bind to endothelial cells, platelets and leukocytes 
(Falanga et al., 2015). 
Major defective haemostatic abnormalities occur in cancer patients including 
haemorrhage, coagulation and migratory thrombophlebitis. A study with 
fibrinogen-deficient mice indicated a direct role of fibrinogen in cancer 
pathophysiology and metastasis production (Palumbo et al., 2000). In the 
vasculature of cancer affected organs, tumor cell-associated emboli adhesion 
and survival are improved by fibrinogen. However, this does not include the 
growth of the metastasis, only its facilitation (Palumbo et al., 2000). On the other 
hand, fibrin is involved in the cancer metastasis through a variety of mechanisms 
including the stabilisation of tumour cells or their associated emboli adhesion to 
the vessel’s wall, supporting tumour cells proliferation and migration in addition 
to the formation of stroma cells (Palumbo et al., 2000). Tumor embolism is a rare 
type of cancer spreading predominantly to the lung causing pulmonary 
embolism. This spreading is indicated by lymphatic, parenchymal and pleural 
metastasis. Embolism is difficult to be diagnosed because it is mostly sudden 
and causes death (Burchard and Carney, 1984, Laohachewin et al., 2014). 
1.2.4 Haemostasis 
Haemostasis involves a complex balance between coagulation and 
anticoagulation, which ensures normal blood flow while at the same time 
preventing excessive bleeding after injury (Guglietta and Rescigno, 2016). Blood 
is maintained in its fluid state by the anticoagulant luminal surface of the 
endothelium in the blood vessels, however, any damage of these vessels 
exposes the components of sub-endothelial matrix to the blood, activating the 
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haemostatic platelets and leading to fibrin formation, consequently initiating clot 
formation (Gale, 2011). Two main processes occur in physiologic conditions 
when an injury occurs to a blood vessel to stop bleeding (Guglietta and Rescigno, 
2016). The first process is called primary haemostasis, which involves the 
aggregation of activated platelets to initiate the formation of a clot. The second 
process is called secondary haemostasis, which involves the activation of the 
coagulation cascade to form fibrin polymers (see below) (Guglietta and 
Rescigno, 2016). While this process of clot formation is important for physiologic 
control of blood loss, hyperactivity of both processes may lead to cardiovascular 
disease such as stroke and myocardial infarction by pathologically blocking 
blood vessels, which can lead to death (Renne et al., 2005). 
1.2.5 Coagulation  
Thrombin is generated by a series of plasma serine proteases that lead to the 
conversion of fibrinogen to fibrin as shown in Figure 1-1. Thrombin is also able 
to activate platelets (Renne et al., 2005). Thrombin is activated by the active form 
of Factor X (FX); through (FXa)-mediated processing of prothrombin into 
thrombin. FX itself is activated by two different mechanisms; called the intrinsic 
and extrinsic pathways (Budnik and Brill, 2018). The extrinsic pathway is 
triggered by the exposure of a transmembrane protein that presents in the 
vessel’s sub-endothelial layer, but not the luminal surface of the endothelium and 
is called tissue factor (TF) (Budnik and Brill, 2018). TF is expressed on vascular 
cells surrounding the blood vessel, primarily fibroblasts, smooth muscle cells and 
other tissue cells. TF binds and activates FVIIa and the generated TF\FVIIa 
extrinsic tenase complex will activate FX into FXa, which in turn generates the 
conversion of prothrombin to thrombin as reviewed in (Butenas and Mann, 2002, 
Adams and Bird, 2009, Gailani and Broze, 1991). The generated thrombin itself 
undergoes amplification by activating FXI, FVIII (tenase complex) and FV 
(prothrombinase cpomlex) to form FXIa, FVIIIa and FVa respectively as reviewed 
in (Butenas and Mann, 2002, Adams and Bird, 2009, Gailani and Broze, 1991). 
The intrinsic pathway (blood-borne factors) is initiated by contact activation of 
FXII when the FXII zymogen interacts with negatively charged surfaces, which 
for example are provided by platelet phospholipids and released polyphosphates 
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in presence of calcium ions as reviewed in (Butenas and Mann, 2002, Adams 
and Bird, 2009). FXIIa in turn activates FXI to FXIa, which activates FIX. FIXa 
activates FX to convert prothrombin (FII) into thrombin (FIIa) in a higher amount 
than that produced by the extrinsic pathway by itself as reviewed in (Budnik and 
Brill, 2018, Renne et al., 2005, Butenas and Mann, 2002, Gailani and Broze, 
1991). In summary, FX is activated by both intrinsic and extrinsic pathways via a 
series of enzymatic transformation steps (cascade), ending in the conversion of 
prothrombin to thrombin through several positive feedback loops, which converts 
fibrinogen to fibrin that is subsequently stabilised by FXIIIa-dependent 
crosslinking as reviewed in (Budnik and Brill, 2018, Renne et al., 2005, Adams 
and Bird, 2009). 
The tenase and prothrombinase complexes both consist of the serine proteases, 
which are vitamin K-dependent coagulation factors, such as FII, FVII, FIX, and 
FX, in complex with cofactors VIIIa and Va respectively (Butenas and Mann, 
2002, Adams and Bird, 2009). Vitamin K-dependent factors are inhibited by the 
vitamin antagonists that play a role as anticoagulants such as warfarin (Butenas 
and Mann, 2002, Adams and Bird, 2009). 
Protein C is a blood coagulation protein inhibitor that also is a vitamin K-
dependent. When activated, it proteolytically cleaves and inactivates 
procoagulant cofactors Va (FVa) and VIIIa (FVIIIa). The protein is called 
activated protein C in this form (APC) (Rosendaal et al., 1995). A mutation, which 
affects the activity of APC was found in the cleavage site of the protein on the 
factor V (Factor V Leiden) which is required for the activity of the APC and thus 
results in its resistance (Bertina et al., 1994, Rosendaal et al., 1995). The risk of 
deep vein thrombosis is higher in homozygous factor V Leiden mutated 
individuals than heterozygous individuals (Rosendaal et al., 1995). 
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Figure 1-1 Schematic representation of the classical coagulation cascade. 
Generation of thrombin by the extrinsic and intrinsic pathways through the enzyme 
prothrombinase complex. Adapted from (Ajjan and Grant, 2006, Ajjan and Ariens, 2009). 
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1.2.6 Platelets  
Platelets are synthesized in the bone marrow from megakaryocytes as 
anucleated cells, and function to assess the integrity of the vascular system while 
they are circulating (Ruggeri, 2002). They are the smallest cells in the body with 
an average diameter of 2-5 µm, 0.5 µm thickness and a mean cell volume of 10 
femtoliter. Platelets are the second most abundant cell in the blood (after red 
blood cells) with a blood count of 150-450 109 platelets/L (Gremmel et al., 2016). 
Platelets circulate close to the endothelium at a rate of 85 million/ day and survive 
for 7-10 days (Walsh et al., 2015, Smyth, 2010). Platelets have the ability to 
distinguish between lesion areas that may progress to thrombosis and normal 
endothelial lining of the cells (Ruggeri, 2002). This function of platelets is called 
haemostasis in physiological conditions, but it can be a cause of thrombotic 
obstruction in diseased arteries. This may lead to tissue damage as a 
consequence of blockade of the blood flow (Ruggeri, 2002). The tendency of 
lesions to progress to thrombosis relies on factors that cause platelet activation 
such as exposure of collagen after rupture of unstable atherosclerotic plaques, 
coronary angioplasty causing altered vascular surfaces, inflammatory responses 
causing local endothelial cell dysfunction, and high shear stress in addition to 
genetic variations in the proteins that involved in the adhesion (Ruggeri, 2002). 
Besides their well-known role in haemostasis, platelets also involved in other 
physiological functions such as immunity, inflammation and angiogenesis (Senis 
et al., 2009). Platelet aggregation is known to be the first mechanism involved in 
haemostasis (Du et al., 2014). The process starts with adhesion of platelets that 
are exposed to rapid blood flow by the help of the adhesive protein von 
Willebrand Factor (vWF) that immobilises on collagen (Ruggeri, 2003). Next, the 
platelet aggregate forms by the recruitment of other platelets to bind to the 
already adhered platelets resulting in the formation of a seal covering the wound 
(Du et al., 2014). A cross-linked fibrin network then forms around the aggregate 
plug resulting in its stabilisation. The adhesion and aggregation processes 
induce changes in the shape of the platelets causing clot retraction to occur at 
the site of injury (Du et al., 2014). 
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To keep platelets in a resting state in the healthy vasculature, inhibitors such as 
nitric oxide (NO) and prostaglandin (PGI2) are released by the intact 
endothelium. An adequate balance of the way that platelets respond to these 
inhibitors is responsible to maintain the healthy state because any alteration in 
this balance would lead either to bleeding or pro-thrombotic phase (Atkinson et 
al., 2018).  
At the site of injury, platelets adhere and aggregate to form a plug in the presence 
of a multimeric plasma protein; vWF, which is required for this process especially 
in arterial haemostasis and thrombosis under high shear stress. This clustering 
is through two membrane-surface receptor glycoproteins; GPIb-IX-V and GPVI 
complexes expressed by the platelets initiating their aggregation (Andrews et al., 
2004, Chow et al., 1992, Moake et al., 1988). The interaction between platelet 
GPIb-IX-V and collagen is reversible and requires additional interaction between 
the platelets and extracellular matrix (ECM) through integrin receptors α2β1 and 
αIIbβ3 to stabilise the platelet plug on the ECM (Nieswandt and Watson, 2003). 
Another glycoprotein receptor is immunoglobulin (Ig) receptor GPVI, which binds 
to collagen ensuring activation of platelets under high shear by inducing the 
release of ADP, thromboxane A2 (TxA2) and thrombin generation (Nieswandt and 
Watson, 2003). vWF is synthesised in the megakaryocytes and stored in platelet 
α-granules and also synthesised by and stored in endothelial cells (Moake et al., 
1986). 
Platelet involvement in clot retraction, aggregation and adhesion requires the 
presence of the αIIbβ3 surface receptor, which is found in high copy numbers on 
the platelet membrane compared to other receptors (Senis et al., 2014). 
Stimulation of the αIIbβ3 by inside-out signals by the released ADP from damaged 
RBCs and blood vessels or from activated platelet dense granules induces 
conformational changes in the integrin increasing its affinity to bind to ligands 
such as fibrinogen (Senis et al., 2014, Hollopeter et al., 2001, Gremmel et al., 
2016). Binding of the integrin to fibrinogen forms intermediates that stimulate an 
outside-in signaling to induce platelet activation, aggregation, secretion, 
spreading and clot retraction (Senis et al., 2014, Hollopeter et al., 2001). 
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Platelet involvement in clot formation includes two separate steps, adhesion and 
aggregation as shown in Figure 1-2 (Ruggeri, 2000). Initial platelet cell contact 
(tethering) with the extravascular ECM and sub-endothelial constituents provides 
a substrate for the adhesion, which requires interaction of collagen or ECM to 
plasma vWF. The immobilised vWF then binds to glycoprotein receptors 
including α2β1, α5β1 and αIIbβ3 in synergetic action (Savage et al., 1998, Ruggeri, 
2000). In summary, in flowing blood, platelets need to attach to substrate 
surfaces to immobilise them; this mechanism is applied to both adhesion and 
aggregation. Collagen, sub-endothelial matrix and ECM components play this 
role in adhesion by forming a substrate for the initial tethering of platelets, which 
is mediated by vWF and GPIbα. Previously adhered platelets play a substrate 
role for other platelets to join and adhere in aggregation, which is mediated by 
fibrinogen and αIIbβ3 (Ruggeri, 2000, Ruggeri et al., 1999, Savage et al., 1998).  
 
Figure 1-2 Schematic representation of the involvement of platelet adhesion and 
aggregation in thrombus formation. Only identified adhesive interactions are 
considered in the figure with no exclusion of other ligand-receptor pairs of antagonists 
involved in platelets activation and thrombus formation. Starting from the left, platelets 
tethering to initiate a reactive surface and stable adhesion may occur at low shear rate 
independently of the initiation. When thrombus formation occurs at high shear rate, the 
balance between stable adhesion and activation usually shifts to the activation. Adapted 
from (Ruggeri, 2000) and modified from (Savage et al., 1998). 
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Platelets have structures that help to distinguish them from other cells comprising 
a dense tubular system that is the smooth endoplasmic reticulum, an open 
canalicular system in addition to their secretory granules (Westmoreland et al., 
2016). These granules are further classified into different types based on their 
appearance under electron microscope; dense granules containing ADP and 
serotonin, α-granules containing proteins and enzymes, and multi-vascular 
bodies and lysosomes (Westmoreland et al., 2016, Frojmovic and Milton, 1982). 
Integrity of these granules is very important for the role of platelets in 
haemostasis, because they release the bioactive molecules that are responsible 
for platelet function (Westmoreland et al., 2016). The α-granules play a role in 
platelets by storing proteins such as fibrinogen (synthesised outside the platelet) 
and vWF (synthesised inside the platelet) (Heijnen et al., 1998).  
Platelets are activated by a variety of immobilised and soluble agonists at the 
site of the injury leading to recruitment of more platelets as a response of positive 
feedback mechanisms that strengthen the activation signals. The response to 
this activation induces granule secretion, platelet aggregation and shape 
changes (Li et al., 2003). Prostaglandins (PGE) have several physiological roles 
such as modulation of hormonal, neuro-hormonal and other stimuli in addition to 
their role as a pro-inflammatory response generator (Ricciotti and FitzGerald, 
2011, Samuelsson et al., 1978). PGEs are synthesised in most mammalian 
tissues by unsaturated fatty acid; arachidonic acid via prostaglandin synthase, 
which is composed of two enzymes. The first is prostaglandin endoperoxide 
synthase, which converts arachidonic acid to prostaglandin endoperoxide 
(PGH). The second is  prostaglandin endoperoxide E isomerase which converts 
PGH to PGE  (Samuelsson et al., 1978). Thromboxane is a factor that induces 
platelet aggregation, which is derived from arachidonic acid and is an unstable 
intermediate agonist. Thromboxane plays a physiological role in haemostasis 
and a pathophysiological role in thromboembolic disease (Samuelsson et al., 
1978, Hamberg et al., 1975). ADP is stored at high concentration in platelet 
dense granules and plays a role as platelet activation agonist. ADP is secreted 
by granules when platelets are stimulated (Koessler et al., 2018). ADP plays its 
role through three purinergic receptors, namely P2Y1, P2Y12 and P2X1. The 
first and last receptor stimulations are required for initiation of the platelet 
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aggregation, however; P2Y12 is supporting the action of P2Y1 by ensuring rapid 
calcium influx required for platelet aggregation (Koessler et al., 2018). 
Prostaglandin and thromboxane are able to expose platelet fibrinogen receptors 
when they are stimulated with ADP, further supporting platelet aggregation 
(Bennett et al., 1981). 
1.2.6.1 Integrins  
Cell adhesion molecules were first recognized by their ability to allow cell 
adherence to the surrounding ECM or allow cell-to-cell adhesion (Murray et al., 
1999, Lam et al., 1987). Integrins were later found to allow interaction and 
communication of cells with the environment and with each other (Murray et al., 
1999). Therefore, adhesion receptors are able to regulate a variety of cell 
functions such as gene expression, proliferation, migration, differentiation and 
apoptosis. This may include recognition of the cell surface receptor to specific 
regions in specific adhesive proteins (Lam et al., 1987, Murray et al., 1999). 
These cell receptors are composed of different groups of surface adhesion 
receptors, which may represent at least five families including adhesion 
molecules belonging to the immunoglobulin superfamily, integrins, CD44 family, 
selectins, and the cadherins (Hynes, 1987, Murray et al., 1999). The 
physiological and pathological importance of integrins is acutely apparent when 
they are affected by mutations resulting in defects of their function. Integrins and 
their adhesive ligands are involved in immune response, development, 
haemostasis and leukocyte trafficking (Hynes, 2002). Integrins can be used as a 
therapeutic target for many diseases such as thrombosis, cancer and 
inflammation by interfering with their function using antibodies or peptides 
(Hynes, 1992). Integrins are capable of recognizing a number of ECM ligands 
including fibrinogen, fibronectin, collagen, vWF and vitronectin by the recognition 
of the RGD sequences on these ligands (Cheresh, 1987). 
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Structure of Integrins  
The integrin family of cell adhesion molecules consists of αβ heterodimers that 
are assembled into 24 different integrins formed by a non-covalent combination 
of different numbers and organisation of the two subunits (Hynes, 1992, Hynes, 
2002). There are 8 β subunits of approximately 90-110 kDa molecular weight 
and 18 α subunits of approximately 120-180 kDa molecular weight. Integrins 
mainly recognise short peptide sequences of acidic amino acids (Hynes, 1992, 
Hynes, 2002). The α subunits of the RGD sequence’s receptors are composed 
of αIIb, αV, α5 and α8 that form heterodimers with β1 and β3 subunits in different 
combinations and are able to recognise the RGD sequence in the ligands that 
are present in the ECM (Anderson et al., 2014). Each subunit consists of a large 
extra cellular domain in the N-terminal region, followed by a single-pass 
transmembrane section, and a short (most frequently) cytoplasmic domain at the 
C-terminal end of the protein (Zhu et al., 2008). Both subunits are formed by a 
ligand binding head connected to the transmembrane domain by “legs” that 
emerge from each subunit. The “legs” are divided into two levels; an upper and 
a lower level, which are connected by extremely bendy “knees” (Zhu et al., 2008). 
Integrins can be regulated either by variation in their expression, or by 
bidirectional signalling that includes inside-out signalling and outside-in 
signalling. The former includes conformational changes in the heterodimer that 
are induced by internal signals affecting the cytoplasmic tail of the integrin. This 
signal influences the affinity of the integrin for its ECM ligands [reviewed in 
(Anderson et al., 2014)]. In contrast, during outside-in signalling, the 
conformational changes are first induced by the binding of the integrin to the 
ECM ligand, after which they cluster to form large intracellular adhesion 
complexes [reviewed in (Anderson et al., 2014)] .  
Integrin αIIbβ3 is a classic specific integrin that is important to control bleeding at 
the site of vascular wounds, in addition to its pathological role in thrombosis that 
may cause cardiovascular diseases. Glanzmann thrombasthenia is a genetic 
bleeding disorder that is caused by mutations in either subunit of αIIbβ3 and can 
be treated by inhibiting the integrin’s binding ligands (Gkourogianni et al., 2018).   
 
 
17 
 
The specificity of the integrins vary, some receptors are specific for a single 
ligand whereas others are able to share more than one ligand (Pierschbacher 
and Ruoslahti, 1987). Using synthetic peptides, Pytela et al. suggested the 
presence of a receptor in platelets that can recognise the RGD sequence in 
fibrinogen, fibronectin and vitronectin and this receptor is αIIbβ3 (Pytela et al., 
1986). However, these authors reported that this receptor is different from the 
fibroblast receptor which is capable to recognise the RGD sequence on 
fibronectin and vitronectin only, but not fibrinogen (Pytela et al., 1986). They also 
suggested that fibrinogen, fibronectin and vWF share the same binding site on 
platelets but not with vitronectin (Pytela et al., 1986).  
1.3 Fibrinogen 
Fibrinogen is a large dimeric protein that plays a vital role in haemostasis 
(Alexander et al., 2011, Lovely et al., 2011). Fibrinogen is synthesised by 
hepatocytes (Ritchie and Fuller, 1983) and assembled in the endoplasmic 
reticulum and Golgi organelles (Kudryk et al., 1982, Weisel and Litvinov, 2017). 
Fibrinogen is a 340 kDa glycoprotein, with a multitude of heterogeneity due to 
proteolytic degradation, alternative splicing, and post-translational modifications 
(Herrick et al., 1999). It is composed of three chains that are encoded individually 
by distinct genes each present on chromosome 4; the genes are transcribed in 
opposite directions and oriented in tandem. Aα (6 exons) and γ (10 exons) genes 
are transcribed in one direction, whereas the Bβ (8 exons) gene is transcribed in 
the opposite direction (Herrick et al., 1999). Fibrinogen is composed of a dimer 
in which the three polypeptide chains Aα, Bβ and γ comprise one half of the 
molecule and are joined together by disulfide bonds (Alexander et al., 2011, 
Lovely et al., 2011). 
Fibrinogen polymerises to fibrin by the action of thrombin to form a meshwork 
like structure. During its growth, the clot is stabilised by crosslinking of fibrin fibres 
by the action of FXIIIa (Alexander et al., 2011, Lovely et al., 2011). Fibrinogen is 
suggested to be a risk factor for cardiovascular disease through a number of 
mechanisms, including its involvement in platelet aggregation by binding 
activated platelets via the αIIbβ3 receptor integrin. Other contributing factors 
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include the role of fibrinogen in plasma viscosity, its role in increasing fibrin 
formation as fibrinogen increases, and its inflammatory role as acute-phase 
protein (Stec et al., 2000). Plasma fibrin clot’s viscoelastic properties and 
morphological properties (fibre length, diameter and porosity) were measured in 
premature CAD compared to healthy controls and were found to be stiffer and 
more resistance to fibrinolysis, in addition to being shorter with a higher number 
of fibres compared to controls (Collet et al., 2006). 
The structural and functional properties of proteins can be determined by post-
transitional modifications including phosphorylation, glycosylation, lipidation and 
oxidation (Wani et al., 2015). Identification of post-transitional amino acid 
modifications has become more widely available through advanced protein 
characterisation and sequencing. Moreover, post-transitional modifications of 
proteins are found to have a vital role in blood coagulation and anticoagulant 
systems (Hansson and Stenflo, 2005). Fibrinogen is susceptible to oxidative 
modification that accounts for about 20 times of the level of oxidative modification 
of albumin; the most abundant plasma protein. This high level of oxidation can 
be caused by the presence of calcium binding sites, which provide targets for 
iron binding oxidation in addition to the carbohydrate part of the molecule 
(Shacter et al., 1994, Gorobets et al., 2018). These oxidative modifications are 
able to alter fibrinogen functional properties such as lateral aggregation, 
thrombin-induced clot formation, platelet aggregation and fibrinolysis (Shacter et 
al., 1994, Gorobets et al., 2018).   
1.3.1 Structure of Fibrinogen 
Human fibrinogen is present as several variants with molecular weight ranging 
between 270-420 kDa as a result of degradation and splicing, however the most 
abundant type is the 340 kDa glycoprotein (Boehm et al., 2010). Fibrinogen’s 
plasma concentrations range between 1-4 mg/ml in the healthy state, but 
increase up to 8 mg/ml in acute inflammation (Boehm et al., 2010).  As mentioned 
above, fibrinogen is formed by three polypeptide chains comprising three non-
identical chains arranged in two identical halves (Aα, Bβ, γ)2  forming a dimer with 
each of the polypeptide chains comprising 610, 461 and 411 amino acid residues 
respectively (Henschen et al., 1983). 
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1.3.1.1 Amino acid structure 
The three chains have different molecular weights, which are 67 kDa for Aα, 56 
kDa for Bβ and 47 kDa for the γ chain. The Bβ and γ chains are connected to 
carbohydrate side chains (glycosylated) through N-glycosidic bonds at position 
Bβ-Asn364 and γ-Asn52, making them glycoproteins (Zhang and Redman, 1992, 
Brennan, 2015, Henschen et al., 1983). These carbohydrate side-chains are 
attached to asparagine residue in a sequence that presents only once in these 
two chains; asparagine-X-threonine or asparagine-X–serine (Henschen et al., 
1983). However, this sequence is also found twice in the Aα-chain at position 
296 and 400; asparagine-proline-serine and asparagine-valine-serine-proline. In 
spite of this presence of serine according to the sequence asparagine-X-serine 
in the Aα-chain, both positions contain a proline residue that is neighbouring the 
sequence. This presence of proline may be the reason of the absence of the 
carbohydrate side-chain from the Aα-chain, because there is no presence of an 
O-glycosidic bond in human fibrinogen (Henschen et al., 1983). The 
carbohydrate side-chain is composed of a number of sugars that bind to the 
amino acid via N-glycosidic bonds, including galactose, mannose, sialic acid and 
N-acetylglucosamine (Henschen et al., 1983). The amino-termini (N-termini) of 
the fibrinogen chains are grouped together in a dimeric structure in the centre of 
the molecule forming the E-region (50 kDa) where two coiled-coil structures 
emerge and extend towards two distal D-regions (80 kDa) that contain the 
carboxylic ends (C-termini) of the chains (Mutch et al., 2010, Zhang and 
Redman, 1992, Doolittle et al., 1977). The molecule looks under the electron 
microscope as a tri-nodular structure; the E-region and two D-regions connected 
together by the coiled-coil structure (Huang et al., 1993a, Zhang and Redman, 
1992). This coiled-coil is a triple helix cord-like structure, made up of about 111 
amino acids, which are enclosed by two cysteines (Cys-X-X-X-Cys) at each end. 
The tri-nodular domains are hydrophobic and joined by hydrogen bonding 
(Huang et al., 1993a, Zhang and Redman, 1992). The coiled-coil is formed by 
supercoiling of each one of the three chains via six disulfide bonds to produce α-
helix-like structure (Fuss et al., 2001). The supercoil structure of each chain is a 
result of six disulfide bonds that also participate in the attachment of these chains 
to the central and lateral domains forming disulfide rings. The internal part of the 
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coiled-coil is hydrophobic whereas the external is polar according to the amino 
acid orientation (Fuss et al., 2001). Each Aα-chain extends, emerges and folds 
back from the corresponding D-region to form an αC-region consisting of Aα-
chain amino acid residues 221-610 divided into two parts; one of them is a 
flexible αC-connector (amino acid residues 221-391), and the other is a compact 
αC-domain (amino acid residues 392-610) (Tsurupa et al., 2011). The structure 
of the fibrinogen molecule is shown in Figure 1-3. 
1.3.1.2 Disulfide structure  
The two halves of the fibrinogen molecules are joined together by three disulfide 
bonds that are symmetrical between the adjacent same chains at the cysteine 
(Cys) residues, two of them are between the adjacent γ-chains at positions 8 and 
9 for each chain while the third is between the adjacent Aα at position 28 for each 
chain (Zhang and Redman, 1992). The N-terminal disulfide knot (N-SDK) is a 58 
kDa fibrinogen fragment dimer that is formed by cyanogen bromide cleavage of 
fibrinogen and composed of the three N-terminal fragments of the fibrinogen 
chains. It contains 11 disulfide bonds out of the 29 disulfide bridges that are found 
in human fibrinogen to hold the two halves of the molecule together (Blomback, 
1996, Herrick et al., 1999). Most of the other inter-chain disulfide bonds, which 
are not in the N-SDK are found in the C-terminal core fragment that is called 
fragment-D knot (Blomback, 1996).  
The relationships between the structure, function and evolution of fibrinogen can 
be determined by studying the genetic amino acid sequences of the three chains 
of fibrinogen. Since a single change in one amino acid can result in functional 
abnormalities, this elucidates the relationships between a structural error and its 
(dys)functional effect (Henschen et al., 1983). 
1.3.1.3 Calcium binding sites 
Fibrinogen has both high affinity binding sites for calcium as well as low affinity 
sites, the latter of which are non-specific and originate from weak interactions 
associated with the net charge of fibrinogen (Marguerie et al., 1977). 
Polymerisation and crosslinking of fibrin is a calcium-dependent process (Yee et 
al., 1997). 
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When fibrinogen is exposed to heat, this causes prolongation of thrombin clotting 
time. The elongation can be overcome by binding of fibrinogen to calcium, which 
protects fibrinogen from heat denaturation (Ly and Godal, 1972). Calcium ions 
were found to protect fibrinogen fragment D against further attack and 
degradation by plasmin (Haverkate and Timan, 1977). 
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Figure 1-3 Schematic representation of fibrinogen structure. E-region (yellow) which contains the N-termini, two D-regions which contain the 
carboxyl-termini of Bβ-chain (dark blue) and γ-chain (green) and two αC domains which contain the carboxyl-termini of the α-chain that contains 
RGD (572-574). In the middle is the coiled-coil rope-like structure, which contains the RGD (95-97) sequence, which is of this project’s interest. In 
blue: FXIII binding sites, green α-2antiplasmin binding sites, orange glycosylation sites. Adapted from (Undas and Ariens, 2011). 
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1.3.1.4 Gamma Chain Splice Variation 
In fibrinogen, two different species of γ-chain are found which separate according 
to their electrophoretic properties; the first one is the original γ-chain, which is 
also named γA. The second is a natural occurring alternative splicing form of γ-
chain that is called γ’-chain or γB. The difference in size and charge between the 
two chains is due to amino acid sequence differences that are present at the C-
terminal of each chain (Wolfenstein-Todel and Mosesson, 1980, Fornace et al., 
1984). Whereas γ’ termini are larger, it has a leucine end in comparison to the 
valine end of the γA-chain (Wolfenstein-Todel and Mosesson, 1980). Fibrinogen 
γ’ is produced by alternative splicing of the last intron of the γ-chain messenger 
(m) RNA. A unique amino acid sequence is produced for the γ’-chain that is 
highly negatively charged containing seven anionic residues, rich in glutamic and 
aspartic acids in addition to two sulfated tyrosines. (Fornace et al., 1984, 
Wolfenstein-Todel and Mosesson, 1981, Lord, 2007). These amino acid residues 
provide the γ’-chain with its electrophoretic heterogeneity from the γ-chain 
(Wolfenstein-Todel and Mosesson, 1981, Mosesson et al., 1972). It was found 
that γ’-chain accounts for around 11% of the total fibrinogen (Mosesson et al., 
1972, Chung and Davie, 1984). Formation of this chain leads to the substitution 
of the last four amino acids (408-411) in the original γ-chain, which are 
408AGDV411. This 4 amino acids sequence is replaced by a 20 amino acids 
sequence; 408VRPEHPAETEYDSLYPEDDL427 in the γ’-chain. (Chung and 
Davie, 1984, Sabo et al., 2006). According to Lord 2007, approximately 10% of 
fibrinogen are heterodimers; each composed of a single γ-chain in one D-region 
and a single γ’-chain in the other D-region (Lord, 2007, Cooper et al., 2003). 
However, the lower the presence of γ’-chain and its ratio to total fibrinogen, the 
higher the risk of arterial thrombotic diseases. Because γ’-chain has thrombin 
binding sites, Lord had suggested that when thrombin binding sites to fibrin clot 
reduced, the risk of thrombosis increased (Lord, 2007). However, the same has 
been reported for venous thromboembolic disease in which a lower ratio of γ’-
chain to total fibrinogen may increase the risk of DVT or thrombotic 
microangiopathy (Uitte de Willige et al., 2005, Mosesson et al., 2007). The 
controversy continued with Farrel 2014 who has demonstrated that γ’-chain is 
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related to arterial thrombosis, but not to venous thrombosis and discussed the 
controversial findings of this chain being thrombotic or antithrombotic (Farrell, 
2014). The fibrinogen γ’-chain lacks the binding site that is essential for platelet 
adhesion and aggregation, it is crosslinked faster with FXIII producing clots that 
highly resistance to fibrinolysis and have an altered architecture (Lovely et al., 
2007, Lovely et al., 2010). During clot structure functional analysis, turbidity and 
fibrinopeptides release showed a strong difference in the early polymerisation 
between the heterodimer γA/γ’ and the normal variant γA/γA that led to altered 
fibrin structure. Clots formed by γA/γ’ were found to have thinner fibres which are 
highly thrombotic, contained smaller pores and high branching (Cooper et al., 
2003). It was found that both thrombin and γ’ affect the protofibril packing. High 
concentrations of thrombin decrease protofibril packing but γA/γ’ give lower 
protofibril packing than γA/γA at low concentrations of thrombin. Decreased 
protofibril number packed per fibre was found to decrease clot stiffness and alter 
clot structure (Domingues et al., 2016). There are some suggestions that the 
mRNA of the γ-chain is synthesised in the liver, bone marrow, lung and brain 
whereas the alternative splicing form of fibrinogen’s γ-chain mRNA is 
synthesised in the liver only (Courtney et al., 1991, Haidaris and Courtney, 1990). 
1.3.1.5 Alpha chain 
The Aα-chain is the only non-glycosylated polypeptide chain of fibrinogen. It is 
the largest of the three chains and consists of 610 amino acids, with a molecular 
weight of 67 kDa (Doolittle et al., 1979, Zhang and Redman, 1992, Watt et al., 
1979). Two thirds of the carboxyl ends of each half of the Aα-chain are known as 
αC-regions that extend and fold back from the coiled-coil fragments towards the 
central E-region. FXIII crosslinking sites are found in this region together with 
some plasmin cleavage sites (Rudchenko et al., 1996). 
The fibrin(ogen) Aα-chain is heavily cross-linked by activated FXIII. Interactions 
between the αC region with the zymogen FXIII-A2B2 and the activated FXIII-A 
have been identified using truncations of recombinant αC region (233-425) of 
fibrinogen (Smith et al., 2011). A novel, high affinity interaction site for FXIII was 
identified within the αC region (371-425). FXIII-A was activated by thrombin and 
calcium, and a calcium dependent low affinity interaction of the activated FXIII-A 
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with αC region was also found (Smith et al., 2011). The binding site has been 
further studied and was further identified as a 14 amino acid peptide (Pep1) on 
the αC region (389-402) by chemical cross-linking derivatives of this site with 
recombinant activated FXIII-A2 (Smith et al., 2013). Three individual lysine 
residues (Lys446, Lys275, Lys113) in the β sandwich of activated FXIII-A2 were 
found that interact with Pep1 on the αC region, identifying residues 389-402 on 
the fibrinogen Aα-chain as a major site for FXIII substrate recognition (Smith et 
al., 2013). Finally, a central residue in the αC region that is involved in the 
interaction with FXIII-A2 was identified as Glu396 (Smith et al., 2011, Smith et al., 
2013). 
The Aα-chain contains two RGD sequences, which provide the interaction sites 
of fibrinogen with integrins present on cells such as platelets and endothelial 
cells. One of the RGDs is close to the αC region in the C-terminal at amino acid 
residues 572-574 while the other is located towards the N-terminal at amino acid 
residues 95-97 (Cheresh et al., 1989a).  
RGD Sequence 
Surface integrin receptors on different types of cells such as platelets (membrane 
glycoprotein αIIbβ3 receptor, also known as GPIIbIIIa receptor complex) (Shattil 
et al., 1994), endothelial cells (endothelial cell adhesion receptor complex) 
(Cheresh, 1987) and human melanoma cells  (α5β3 receptor) (Felding-
Habermann et al., 1992) can recognise fibrinogen through three different sites. 
Two of these sites are located on the Aα-chain, consist of the same three amino 
acids short sequence and can be differentiated from each other by a forth amino 
acid following them (Gailit et al., 1997). The first is RGDF (Arg-Gly-Asp-Phe), 
which is present in the coiled-coil region towards the N-terminal of the Aα-chain 
(Aα-95-98). The second is RGDS (Arg-Gly-Asp-Ser), which is present in the αC 
region towards the C-terminal of the Aα-chain (Aα-572-575) (Gailit et al., 1997, 
Doolittle et al., 1979). The third site is HHLGGAKQAGDV (His-His-Leu-Gly-Gly-
Ala-Lys-Gln-Ala-Gly-Asp-Val) (H12), which is also known as dodecapeptide and 
is present at the C-terminal of the γA-chain (400-411) (Kloczewiak et al., 1984, 
Gailit et al., 1997, Lam et al., 1987). 
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Before the discovery of the integrin-binding RGD sequence, Pierschbacher et al, 
1983 suggested the presence of specific binding sites on each of the two 
polypeptide chains of fibronectin responsible for its interaction with cells. The 
authors designed four synthetic peptides, each containing 29-30 amino acids as 
a part of the expected fragment that is involved in the cell interaction 
(Pierschbacher et al., 1983). A peptide that was composed of 30 amino acids 
and called peptide IV was found in the C-terminal of fibronectin that was 
responsible for the attachment of the original fragment to the cells 
(Pierschbacher et al., 1983). Next, Pierschbacher and Ruoslahti, 1984, produced 
a number of synthetic peptides with different sizes and compositions originating 
from peptide IV then tested their attachment to proteins coated to a plastic 
surface (Pierschbacher and Ruoslahti, 1984). It was found that all the synthetic 
peptide fragments of different lengths that bound to the fibroblast contained a 
tetra-peptide sequence of Arg-Gly-Asp-Cys (RGDC). The authors also showed 
that the effect of the peptides was decreased with the increase in size, which 
may cause a reduction in accessibility of the tetra-peptide to the coated proteins, 
or instability of its conformation (Pierschbacher and Ruoslahti, 1984).  
A number of proteins including fibrinogen, fibronectin, vWF, vitronectin, 
thrombospondin, osteopontin and collagens (under some conditions) contain 
RGD sequences that are involved in their surface adhesion and interaction with 
different cells via specific integrins (Ruoslahti, 1996). Nevertheless, not all 
proteins that contain RGD sequences are necessarily involved in cell 
attachment, this might be because the environment of the surrounding amino 
acids of the RGD is not compatible with the cell integrin binding or the sequence 
might not be exposed on the surface of the protein (Ruoslahti, 1996). 
Different binding sites on fibrinogen 
Studies about the binding of fibrinogen with different cell types have been 
conducted for some time. Three known binding sites were found in fibrinogen; γ-
400-411, Aα-RGDF and Aα-RGDS. A series of studies regarding the binding site 
of fibrinogen with ADP activated platelets via their integrin were performed. Using 
synthetic peptides, Kloczewiak et al 1984 were able to assign 12 amino acids 
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sequence (AGDV-containing dodecapeptide) which was found on γ-400-411 C-
terminal of fibrinogen (γC-12 ) as its site of interaction with the platelet integrin 
receptor (Kloczewiak et al., 1984). This study was followed by another study by 
Hawiger et al, 1989 who also used synthetic peptides to demonstrate the binding 
site on fibrinogen with platelet integrin αIIbβ3, which was known at the time as 
GPIIbIIa. The authors suggested both RGD sequences on the Aα-chain; RGDF 
(95-98) and RGDS (572-575) as the sites of interaction with platelets in addition 
to the γ-chain site (Hawiger et al., 1989). However, in an earlier study from the 
same group, it was postulated that the γ-chain binding site have stronger 
interaction with the platelet integrin than the Aα-chain’s sites without specifying 
which one of the two RGD sites (Hawiger et al., 1982). The cause of this weak 
interaction with platelets was later suggested to be that the position of the Aα-
95-97 RGD is in the coiled-coil region, which might not be accessible for 
interaction with the platelet integrin. On the other hand, the Aα-572-574 RGD is 
not conserved in all species; making its role in the binding between fibrinogen 
and platelets arguable (Farrell et al., 1992).  
The involvement of the RGDs in the fibrinogen binding was studied by Cheresh 
et al, 1989, in different cell types. They found that the αVβ3 integrin of the 
endothelial cells was able to bind the carboxylic end RGD in the Aα-572-574 of 
the fibrinogen, but not the N-terminal Aα-95-97 RGD or any other site on the 
fibrinogen (Cheresh et al., 1989b). However, in case of platelets, they confirm 
the role of γ-400-411 sequence on fibrinogen with the αIIbβ3 integrin of platelets 
in addition to its ability to recognise the Aα-572-574 RGD sequence (Cheresh et 
al., 1989b). This suggested that there is no competition between platelets and 
endothelial cells to bind fibrinogen since the former binds through the γ-chain 
mainly whereas the latter binds through the C-terminal Aα-chain. They indicated 
that the Aα-95-97 RGD does not have a role in cell adhesion although it was able 
to bind to cells when it was isolated from fibrinogen (Cheresh et al., 1989b). 
These results were partially agreed by Thiagarajan et al, 1996, who found that 
fibrinogen interaction with endothelial cells was via both the RGD sequences in 
the Aα-chain whereas there was no significant involvement of the γC-12 AGDV-
containing dodecapeptide in fibrinogen adhesion to endothelial cells 
(Thiagarajan et al., 1996).  
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1.3.2 Secretion of Fibrinogen 
Mature fibrinogen is secreted into the circulation after processing, glycosylation 
and assembly of each chain into the Aα2Bβ2γ2 hexamer. Fibrinogen assembly is 
an extensively debated issue concerning the intermediates and pathways 
involved in this multistep process (Huang et al., 1993b). One model of fibrinogen 
biosynthesis and assembly is that the Bβ-chain is the first to appear as a part of 
dimeric structure attached to a membrane-bound polymerase, followed by fast 
assembly with pre-existing Aα and γ pools (Roy et al., 1991, Yu et al., 1984, Yu 
et al., 1983). This makes the Bβ-chain synthesis the rate-limiting step of the 
biosynthesis. By the completion of its synthesis, the complexes Bβ-γ and Bβ-α 
are released into the lumen of the rough endoplasmic reticulum (Roy et al., 1991, 
Yu et al., 1984, Yu et al., 1983). The second assumption is by Hartwig and 
Danishefsky, 1991 (Figure 1-4), which showed that γ-chain combined with either 
Aα, Bβ or γ chains separately in the absence of the other two chains to yield αγ2, 
βγ2 or γ3 according to their molecular weight (Hartwig and Danishefsky, 1991). 
This is supported by the suggestion that in each half, the γ-chain is assembled 
first in a triple coiled-coil strands, and then the Aα and Bβ chains displace two of 
the γ-chains (Doolittle, 1984). The results of the Hartwig and Danishefsky study 
agreed with the Doolittle assumption and suggested a modified mechanism that 
they have summarised in an outline figure that can be expressed as described 
in Figure 1-4 (Hartwig and Danishefsky, 1991). In this mechanism, it was 
suggested that γ-chain is firstly self-assembled to form a trimer (γ3). The second 
step is formation of αγ2 trimer as a result of combination between the Aα and γ3 
releasing one γ-chain, however, this trimer do not join together (Hartwig and 
Danishefsky, 1991). The third step is similar to the second step, but the 
interaction is between the Bβ-chain with γ3 to form βγ2 with a release of one γ-
chain as well. The fourth and final step is the assembly of the molecule, which 
can be done by two ways after the interaction between αγ2 and βγ2 (Hartwig and 
Danishefsky, 1991). The first mechanism involves the production of αβγ and γ3, 
but the molecular mass of produced coiled-coil in this step is greater than what 
expected for αβγ. Subsequently, the second mechanism may be the right model 
of fibrinogen assembly (Hartwig and Danishefsky, 1991). In this model, αβγ2 and 
2γ-chains are produced by replacing one of the γ-chains either in the αγ2 by β of 
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βγ2, or in the βγ2 by α of αγ2. The last step is the formation of entire fibrinogen by 
the combination of two αβγ2 and release of 2γ-chains (Hartwig and Danishefsky, 
1991).  
 
Figure 1-4 Schematic representation of an outline summary of fibrinogen chains 
assembly. The outline represents different combination of the three chains and ends by 
the formation of the fibrinogen dimer (αβγ)2. Adapted from (Hartwig and Danishefsky, 
1991).  
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1.3.2.1 Fibrin Clot Formation  
Clot formation is a two steps process that involves conversion of fibrinogen to 
fibrin. The first step involves the proteolytic cleavage of two fibrinopeptides A and 
two fibrinopeptides B from the N-termini of Aα and Bβ chains respectively in the 
E region of fibrinogen by thrombin (Weisel and Litvinov, 2017, Li et al., 2016). 
Thrombin is a potent and specific serine protease originating from proteolytic 
cleavage of prothrombin by FXa. The result of fibrinogen cleavage is the 
formation of a fibrin monomer that is 45 nm long and 4.5 nm thick. (Weisel and 
Litvinov, 2017, Li et al., 2016). Then, a second, non-enzymatic step involves a 
spontaneous self-assembly of fibrin monomers in a half-staggered way to form 
oligomers that extend to form two-stranded protofibrils (Li et al., 2016, Weisel 
and Litvinov, 2017, Weisel et al., 1993). The protofibrils then aggregate laterally 
as well as longitudinally producing ~130 nm thick fibres that branch to form the 
clot; a three-dimensional mesh-like structure with a gel-like texture. This clot is 
further matured and stabilised by FXIIIa crosslinking (Li et al., 2016, Weisel and 
Litvinov, 2017, Weisel et al., 1993).  
1.3.2.2 Mechanisms Underpinning Protofibril Formation   
Removal of fibrinopeptides A and B from the central E region by thrombin 
converts fibrinogen to fibrin by freeing two A and B knobs respectively in the 
process of clot formation as shown in Figure 1-5 (Guthold and Cho, 2011).  
Firstly,  two fibrinopeptides A are removed to expose two A knobs (Gly-Pro-Arg) 
in the central region of Aα-chain that interact with complementary binding sites 
(a pockets) that are constitutively present in the distal γ-nodules in the D-region. 
This removal of the fibrinopeptides A is initiating the half-staggered assembly to 
form the two-stranded protofibrils; fibrin I (Ajjan et al., 2008, Guthold and Cho, 
2011). Secondly, two fibrinopeptides B are removed by thrombin at a slower rate 
and expose two B knobs (His-Gly-Arg) on the Bβ-chain that interact with 
constitutively exposed complementary regions (b pockets) on the Bβ-chain 
initiating lateral aggregation; leading to fibrin II. These b pockets are found in the 
D-regions of the β-nodules (Ajjan et al., 2008, Guthold and Cho, 2011). 
Interactions of the charged knobs with their corresponding holes (A:a and B:b) 
are the key stages for protofibril formation, whereby the former (A:a) is the key 
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step in half staggered assembly (fibrin I) while the latter (B:b) is the key to 
protofibril assembly and lateral aggregation (fibrin II) (Li et al., 2016, Guthold and 
Cho, 2011). The delay in fibrinopeptide B release is important to elucidate its role 
in lateral aggregation by protofibril assembly and fibre formation (Weisel et al., 
1993). At the same time of the release of fibrinopeptide B, the αC termini are 
released and become available for αC interactions that contribute to lateral 
aggregation of the protofibril (Mutch et al., 2010). 
Adsorption of fibrinogen on different surfaces has been reported to affect its 
properties and reduce its accessibility to thrombin by decreasing the available 
fibrinopeptides for thrombin cleavage compared to fibrinogen in solution (Riedel 
et al., 2011). Fibrin monomers are further crosslinked by the action of FXIII in the 
presence of calcium and thrombin, a γ-dimer subunit is rapidly formed by the 
crosslinking between a lysyl donor group and a glutaminyl acceptor group (ε-γ-
glutamyl-lysine crosslinks) in antiparallel fashion yielding the partially crosslinked 
fibrin (Fretto et al., 1978). A second, slower crosslinking occurs between Aα-
chains yielding α-polymer subunits representing a fully stabilised crosslinked 
fibrin. No crosslinking occurs in the Bβ-chains (Fretto et al., 1978). 
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Figure 1-5 Schematic representation of fibrin formation from fibrinogen in presence of thrombin. First step, cleavage of fibrinopeptide  A 
(FpA, blue) leads to protofibril formation. Second step cleavage of fibrinopeptide B (FpB, red) leads to release of αC domains and lateral 
aggregation. Adapted from (Undas and Ariens, 2011). 
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1.3.3 FXIII 
FXIII is a pro-transglutaminase composed of two A, and two B subunits (FXIII-A 
and FXIII-B), and is found in the circulation as a hetero-tetrameric zymogen 
called FXIII-A2B2 (Byrnes et al., 2015). FXIII is activated by the cleavage of 
activation peptide (AP-FXIII) from the N-terminus of FXIII-A by thrombin, and 
then in the presence of calcium, FXIII-B detaches from the molecule releasing 
its inhibitory effect from the activated A-subunit (Muszbek et al., 2011). FXIII 
crosslinks fibrin Aα-chain at Q221, Q237, Q328, Q366 in addition to various 
lysine residues, whilst it crosslinks the γ-chain in a faster rate between residues 
Q398 and/or Q399 and K406 (Duval et al., 2014). FXIII crosslinking is able to 
alter clot structure rather than to simply stabilise the existing preformed network 
structure of fibrin (Duval et al., 2014, Hethershaw et al., 2014). Fibrin clot 
formation and structure were found to be influenced by FXIII crosslinking, which 
was studied using recombinant fibrinogen with mutations in the γ-chain 
crosslinking sites (Duval et al., 2014). Crosslinking of the Aα- and γ-chains of 
fibrin plays a role in regulation of the ultrastructure of the fibrin clot (Duval et al., 
2014, Duval et al., 2016). Crosslinking of the γ-chain influenced fibre density, 
whereas crosslinking of the Aα-chain influenced fibrin polymerisation, 
polymerisation rate and fibrin fibre curvature by electron microscope (Duval et 
al., 2014). These changes may include increasing fibre density, decreasing fibre 
thickness and increasing the fibrin fibre resistance to fibrinolysis (Hethershaw et 
al., 2014, Duval et al., 2014). FXIII is able to crosslink fibrin to α2-plasmin inhibitor 
(α2-PI) to stabilise the fibrin clot and protect it against premature fibrinolysis 
(Sakata and Aoki, 1980, Duval et al., 2016). 
1.3.4 Fibrinolysis  
Plasmin, the active form of plasminogen is produced by proteolytic cleavage of 
plasminogen by the activity of either tissue plasminogen activator (tPA) or 
urinokinase plasminogen activator (uPA). Plasmin is found in the circulation in 
its inactive zymogen and when activated, it causes dissociation of thrombin or 
fibrin deposits in a process called fibrinolysis (Sakata and Aoki, 1980, Ajjan and 
Grant, 2006). The fibrinolytic system is composed of a series of enzymes that in 
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their active forms cleave fibrin into its degradation products. This process is the 
last control mechanism to restrict clot formation (Norris, 2003). The process can 
be inhibited by inhibiting either plasmin or plasminogen activators (Figure 1-6) 
(Sakata and Aoki, 1980, Ajjan and Grant, 2006).  
tPA is a serine protease that produced by endothelial cells (Norris, 2003)  
whereas uPA is produced in urinary epithelial cells, macrophages, and 
monocytes. The affinity of plasminogen is higher for tPA compared with uPA 
(Camiolo et al., 1971, Chapin and Hajjar, 2015). Due to the presence of high 
concentrations of activator inhibitors, both enzymes have short half-lives in the 
circulation of 4-8 minutes, when they are removed by the liver (Chapin and 
Hajjar, 2015). Plasmin activation is more effective in the presence of fibrin 
compared to fibrinogen, which make fibrinogen less susceptible to lysis 
compared to fibrin (Camiolo et al., 1971, Chapin and Hajjar, 2015). This means 
that fibrin both acts as a stimulator for the activation of plasmin and as a plasmin 
substrate at the same time (Hoylaerts et al., 1982). The binding of plasmin to C-
terminal lysine residues on fibrinogen catalyses the hydrolysis of fibrinogen by 
plasmin (Christensen, 1985). Continuous degradation of fibrin and generation of 
more C-terminal lysine residues on the degraded fibrin induces plasmin to control 
its own formation by a positive feedback loop, which is inhibited by the activity of 
activated Thrombin Activatable Fibrinolysis Inhibitor (TAFI) (Bouma and Mosnier, 
2003). Regulation of fibrinolysis includes a number of other inhibitors, such as 
inhibitors of the plasminogen activator (PAI) of which there are four types; PAI-
1, PAI-2, PAI-3 and protease nexin. Another inhibitor for fibrinolysis is α2-
antiplasmin, which binds to plasmin forming a stable irreversible complex (Norris, 
2003, Wiman and Collen, 1978, Ajjan and Grant, 2006). FXIII crosslinks fibrin 
molecules and fibrin with other proteins in the clot such as α2-antiplasmin, 
thereby increasing the resistance to fibrinolysis. Crosslinking of α2-antiplasmin 
occurs between Lys303 on the Aα-chain of fibrin and Gln2 or Gln14 on α2-
antiplasmin (Kimura and Aoki, 1986, Fraser et al., 2011, Bridge et al., 2014).    
Fibrinolysis rate is affected by changes in clot structure and architecture, with 
less dense clots, loosely packed fibres and larger pores sizes being lysed faster 
than denser clots with tightly packed fibres and smaller pores sizes (Bridge et 
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al., 2014). Although thin fibres are lysed faster than thick fibres, clots that are 
made up of more thin fibres lyse slower than clots made up of much thicker fibres 
(Collet et al., 2000, Bridge et al., 2014).  
A risk factor of the association between diabetes and cardiovascular diseases 
may be via decreasing fibrinolysis and subsequently reducing clot lysis. The 
effect of diabetes on clot lysis is a result of changes involving inhibition of the 
process of fibrinolysis, increase of anti-fibrinolytic proteins, and modification of 
fibrin mesh structure (Ajjan et al., 2013). The mechanism of this effect occurs 
through the glycation of plasminogen, which decreases its activation and 
functional activity and subsequently, reduces fibrinolysis (Ajjan et al., 2013). 
 
Figure 1-6 Schematic representation of fibrin polymerisation and fibrinolysis. 
Fibrinogen is converted to fibrin by the removal of fibrinopeptides in presence to 
thrombin to for a clot. FXIIIa stabilises the fibrin network by crosslinking. Plasminogen 
is converted to plasmin by activation on the surface of the fibrin causing clot proteolysis. 
Beige arrows represent the inhibitory control of the process. Adapted from (Weisel, 
2005). 
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1.3.5 Other Functions of Fibrinogen 
Fibrinogen is involved in a number of other functions including cell adhesion and 
inflammation; in addition to its role in several cardiovascular and metabolic 
diseases like atherosclerosis, hypertension and diabetes via the stimulation of 
erythrocytes hyperaggregation (de Almeida et al., 2009). Fibrinogen plays a role 
as acute-phase plasma protein in acute inflammation and infections. Changes in 
vascular permeability lead to rapid invasion of leukocytes followed by monocytes 
to the site of the injured vessels. A few hours later after the onset of infection, 
acute-phase plasma protein levels including fibrinogen are increased in the 
circulation as a sign of inflammation (Ritchie and Fuller, 1983). Fibrinogen 
structural properties support its role in proliferation and migration of some cell 
types in the body including platelets, endothelial, epithelial and fibroblast cells 
(Guadiz et al., 1997). Identification of extrahepatic tissues such as lungs, brain, 
bone marrow and non-hepatic epithelial cells that are able to synthesise 
fibrinogen has indicated that fibrinogen may be involved in functions other than 
haemostasis and thrombosis such as maintaining the structural integrity, as well 
as the cellular adhesive interactions in these tissues (Guadiz et al., 1997) 
Fibrinogen deficiency presents with different clinical outcomes, which vary 
between qualitative and quantitative deficiencies. Qualitative deficiency is called 
dysfibrinogenaemia, whilst there are two types of quantitative deficiencies, hypo-
fibrinogenaemia or a-fibrinogenaemia (Ariens, 2013). Yet the causes of the 
discrepancies in fibrinogen presentations, which vary in their symptoms between 
thrombosis and bleeding in addition to the possibility of being asymptomatic, are 
still uncertain. It has been suggested that some of the discrepancies in clinical 
outcomes may be the result of variations in clot structure, strength or stability. 
These variations provide the clot with instability that may lead either to 
thromboembolic or bleeding diseases (Ariens, 2013). A-fibrinogenaemia is a 
complete deficiency of circulating fibrinogen that is characterised by bleeding in 
tissues such as the umbilical cord at birth, soft tissues, genito-urinary tract, joints 
and central nervous system (Le Quellec et al., 2018). Additional symptoms may 
include spontaneous splenic rupture, poor wound healing, bone cysts, and 
tendency for venous and arterial thrombosis. Treatment of this disorder involves 
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fibrinogen replacement therapy (Le Quellec et al., 2018). Dysfibrinogenaemia 
and hypo-fibrinogenaemia are both associated with autosomal dominant 
inheritance. Hypo-fibrinogenaemia is largely an asymptomatic disorder that may 
be diagnosed incidentally due to abnormal coagulation tests, it is characterised 
by a functional and immuno-reactive proportional reduction of fibrinogen (Tiscia 
and Margaglione, 2018, de Moerloose et al., 2013). Dysfibrinogenaemia is 
characterised by a reduction of fibrinogen function with normal fibrinogen antigen 
concentration. Both disorders can cause miscarriages in pregnancy (Tiscia and 
Margaglione, 2018, de Moerloose et al., 2013). 
1.4 Red Blood Cells 
Human blood can be defined as a double-phase system that is composed of 
plasma, a low viscosity aqueous ionic solution, and a cellular fraction that 
occupies 0.45-0.5 of the volume of the blood (Picart et al., 1998). Of the cellular 
fraction, 0.99 is composed of RBCs, which are the most abundant cells of the 
blood, whereas white blood cells and platelets represent less than 0.01 of the 
cellular fraction (Picart et al., 1998). Thus, RBCs are a major determinant of 
blood rheological properties, which in turn affect the blood viscosity and fluidity 
(Baskurt and Meiselman, 2003, Lominadze et al., 2002). Blood viscosity is 
affected by haematocrit, plasma viscosity in addition to the two most important 
rheological properties of the RBCs; their deformability especially at high shear 
forces and their propensity to aggregate. RBCs are capable of aggregating in 
linear arrangements that are known as RBC rouleaux (Baskurt and Meiselman, 
2003, Lominadze et al., 2002). Depending on the degree of shear forces affecting 
the cells, large plasma glycoproteins such as fibrinogen stimulate RBC 
aggregation, which under low shear is the main determinant of blood viscosity 
(Baskurt and Meiselman, 2003). 
Human red blood cells originate in the bone marrow from haematopoietic stem 
cells that differentiate into erythroblasts and erythrocyte colony forming units 
(Pasini et al., 2006, Franco, 2012). Reticulocytes are secreted into the circulation 
after extrusion of nuclei from erythroblasts and degradation of endoplasmic 
reticulum; they then mature into anucleated RBCs capable of oxygen and carbon 
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dioxide transport between the blood and cells (Pasini et al., 2006, Franco, 2012). 
Mature RBCs survive in the blood for a mean lifespan of 115-120 days, after 
which they are removed by the reticuloendothelial system when they reach a 
specific age. The normal body is able to have a turnover pool of RBCs every 
three weeks to maintain an overall RBCs pool of 4-5 X1012 cells/L (Franco, 2012, 
Giarratana et al., 2005). The average diameter of the mature RBC is 8 µm, 
however, the RBC is capable to pass through small capillaries of 3-4 micron due 
to its deformability (Aarts et al., 1983, Meiselman, 1981). The RBC membrane is 
made up of three main parts; a lipid bilayer membrane, proteins that extend 
across or embedded inside the membrane and a third part that is composed of 
proteins that do not enter the membrane and form the membrane skeleton 
(Boivin, 1988, de Oliveira and Saldanha, 2010). These proteins can be further 
divided according to their function as cytoskeletal proteins such as actin and 
spectrin, integral structural proteins such as glycophorins and band 3, and finally, 
anchoring proteins such as ankyrin and protein 4.2 (de Oliveira and Saldanha, 
2010).  
An overview of the three dimensional structure of the membrane skeleton of the 
RBC shows that the membrane might be composed of a dense convoluted 
network of spectrin filaments that are joined at junctional complexes to actin 
filaments (Nans et al., 2011). The thickness of the network together with its 
surface density is less by approximately twofold at the edges (54 nm) compared 
to the centre (110 nm) supporting their resting biconcave shape. This specialised 
structure of the RBC and its membrane helps to accommodate the high stress 
and facilitate its deformability (Nans et al., 2011). These membrane 
characteristics give RBCs the flexibility of regular changes in their shape in an 
extensive and reversible manner. This allows RBCs to pass through the 
microcirculation vessels that have a smaller diameter than the size of the RBCs 
under the effect of the intravascular fluid forces (Cines et al., 2014). 
Cines et al, 2014 first reported on the presence of polyhedral shaped RBCs 
inside the clot, which they proposed are compressed erythrocytes. The name 
polyhedrocytes was given according to the shape nomenclature of the 
erythrocytes (Cines et al., 2014). Several explanations for this assumption were 
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suggested including that only RBCs are present in adequate amount in the blood 
to account for the large quantity of these polyhedral structures. Furthermore, 
partly compressed erythrocytes having an intermediary shape ranging between 
the biconcave and polyhedral shape were found (Cines et al., 2014). Moreover, 
normal biconcave erythrocytes were present outside and inside of the clot that 
formed by low platelet counts or low fibrin(ogen) concentrations with no presence 
of polyhedrocytes (Cines et al., 2014). These observations led to the conclusion 
that the polyhedral shape of erythrocytes are formed as a result of the platelet 
contraction on fibrin which caused the erythrocytes to compress. Both platelets 
and fibrin were found on the surface whereas the erythrocytes were packed in 
the centre of the clot (Cines et al., 2014). The polyhedral shape is formed by 
several flat surfaces that are connected by straight edges and can occupy a 
much smaller space than the normal biconcave shape of RBC (Ariens, 2014). 
This shape allows maximum cell-to-cell interaction in addition to lowest interstitial 
space occupation yielding stronger clots that are closely sealed by the packed 
polyhedrocytes. Polyhedrocytes are found in the center of the clot while normal 
biconcave shaped RBCs are located at the clot periphery as shown in Figure 1-7 
(Ariens, 2014).  
 
Figure 1-7 Schematic representation of the polyhedrocyte involvement in the clot.  
At the centre of the clot, contractile action of platelets on fibrin fibres lead to compression 
of the biconcave erythrocyte to polyhedrocytes producing a perfectly sealed clot. 
Adapted from (Ariens, 2014). 
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At low shear rate, erythrocytes sometimes aggregate, thereby increasing the 
viscosity of the blood whereas they disintegrate at high shear rate (Maeda et al., 
1984). This aggregation is enhanced by plasma glycoproteins such as fibrinogen 
and immunoglobulins bridging the neighboring cells, however, negative charges 
on the surface of the RBCs may resist this aggregation and cause the cells to 
separate (Maeda et al., 1984). A balance between electrostatic repulsive and 
attractive forces at the cell surface may be crucial for RBC aggregation to occur. 
Aggregation requires the macromolecular bridging force to be greater than both 
the mechanical shearing and the electrostatic repulsive forces in order for 
aggregation to develop (Chien and Jan, 1973). Increased haematocrit can lead 
to increased viscosity. An increase in haematocrit enhances the residence time 
of circulating coagulation factors and platelets on the activated endothelium 
supporting clot formation (Andrews and Low, 1999). 
Release of free extracellular haemoglobin into the blood because of RBC in vivo 
haemolysis comprises the pathogenic origin of haemolytic anaemias either of 
acquired or genetic cause. Haemolytic anaemia may lead to pro-thrombotic 
diseases of different severity (Litvinov and Weisel, 2017). Sickle cell disease is 
a well-characterised form of hereditary haemolytic anaemias that affects the 
RBC shape due to a recessive genetic mutation in haemoglobin. This mutation 
induces intracellular haemoglobin aggregation changing the RBC from 
biconcave to sickle shape (Tran et al., 2013). In this particular disease, the 
rheological and viscous properties of the blood are changed due to decreased 
deformability of the RBCs and increased membrane rigidity (Tran et al., 2013). 
Membrane stiffness of the RBCs is also increased in the diabetic patients 
possibly contributing to the increased risk of microvascular occlusion in this 
disease (Tran et al., 2013, Walton et al., 2015)  
1.4.1 Red Blood Cell Receptors  
Cell adhesion molecules (CAM) are a group of receptors that are present on the 
surface of the cells and are involved in their interaction with ECM or with other 
cells, but not to soluble molecules such as cytokines (Spring and Parsons, 2000). 
Mature RBCs are found to have some glycoproteins that either function as CAM 
or have similar functions. Several super-families of CAM are found in erythroid 
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cells of different ages include integrins, immunoglobulins, sialomucine in addition 
to selectin and cadherin families (Spring and Parsons, 2000). A number of 
membrane proteins on the RBC surface have been suggested to play a role as 
a target or receptor for soluble fibrinogen to interact with RBC. These receptors 
include (De Oliveira et al., 2012): 
1. Integrin cell adhesion molecule-4 (ICAM-4) 
2. Integrin associated protein (IAP) or CD47 
3. Basal cell adhesion molecule (BCAM/LU) 
4. CD147 
5. CD44 
6. CD58 
7. Glycosphingolipids (gangliosides) 
The adhesive role of RBCs is carried out by protein and glycolipid moieties, which 
are present on their surface. These molecules are composed of different 
structures comprising transmembrane proteins; glycosylphosphatidylinositol-
anchored proteins, carbohydrates or lipid structures (Telen, 2005). Some 
examples of these adhesion molecules are presented in Table 1-1 showing a 
summary of some receptors and their related functions. CD44 is an adhesion 
receptor found on the RBC membrane and identified as a 80 kDa adhesion 
protein which is known as Inhibitor (In) Lutheran (Lu)-related p80 that is down-
regulated by the inhibitor of Lutheran expression. The Indian antigen is found on 
the CD44, it is a blood group antigen that has two polymorphisms resulted from 
a single point mutation (Telen et al., 1983, Telen et al., 1996, Telen, 2005). IAP 
(CD47) is a 50 kDa protein that is composed of extracellular immunoglobulin 
binding domain and involves in several functions of αVβ3 and thrombospondin via 
the modulation of β1 integrin (Wang et al., 1999, Green et al., 1999, Telen, 2005). 
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Table 1-1 Examples of adhesion molecules expressed on circulating erythrocytes  
(Telen, 2005) 
Adhesion molecule and alternate 
name 
Ligand/adhesive function 
Indian [ln(lu)-related p80, CD44] Hyaluronan, possibly also fibronectin 
Rh-related integrin-associated protein 
(IAP, CD47) 
Thrombospodin 
Lymphocyte-associated antigen-3 
(LFA-3, CD58) 
CD2 
CD99, MIC2 gene product 
Lymphocyte CD99 is necessary for formation of 
T-cell rosettes 
JMH (semaphorin K1, SEMA7A, 
CD108 
Possible role in adhesion of activated 
lymphocytes 
Oka (neurothelin,, CD147) 
Type IV collagen, fibronectin, laminin and other 
tissues 
LW (ICAM-4, CD242) 
Leukocyte integrin (α4β1, α4β3, αVβ1), platelet 
integrin (αIIbβ3), vascular integrin (αVβ3) 
Lutheran (B-CAM/LU, CD239) Laminin, possibly also integrin 
Scianna (ERMAP) Putative adhesive function 
MER2 (CD151|) Forms laminin-binding complexes with integrin 
CD36 (reticulocytes only), platelet 
glycoprotein IV, Naka (platelets) 
Thrombospondin (platelets) 
VLA-4 (reticulocytes only), α4β1 
integrin (CD49d/CD29) 
Thrombospondin, VCAM-1, fibronectin 
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1.4.2 Red Blood Cells in Thrombosis 
As RBCs are the most abundant cells in the blood, they were classically thought 
to be passively involved in the process of thrombus formation, by being 
entrapped in the clot. However, new evidence from both laboratory or clinical 
studies support the idea that RBCs are not innocent bystanders in this process 
(Du et al., 2014). The effect of RBCs on clot formation and structure has not been 
extensively studied; this in spite of the fact that they have been suggested to 
have a contributing role in thrombosis and haemostasis (Gersh et al., 2009). This 
can be because their role in thrombus formation is uncontrolled and variable, and 
they interfere with many of the laboratory techniques that are used to investigate 
clot structure and function (Gersh et al., 2009). 
The size of a clot can depend to a large degree on its content of the RBCs, 
however, not much is known about the role of RBCs in clot contraction (Cines et 
al., 2014). It has been reported recently that RBC contents directly affect the size 
of a venous thrombus, and that FXIIIa has a vital role in active RBC retention in 
these thrombi (Aleman et al., 2014). These findings indicate that RBCs may 
entail a novel therapeutic target to decrease venous thrombosis and increase 
clot lysis rates. One possibility to achieve this may be via the inhibition of FXIIIa, 
thus reducing the size of the clot, its mechanical stability and its ability to resist 
fibrinolysis (Aleman et al., 2014). It has been suggested that FXIIIa activity 
together with fibrin network density independently play a role in RBC retention in 
the clot. Nevertheless, FXIII does not directly crosslink RBCs, but induces their 
retention in the clot by crosslinking fibrin, especially the Aα-chain (Byrnes et al., 
2015). While the fibrin network should be dense and stiff enough to enable RBCs 
to be retained, abnormal fibrin network density may not be the cause of RBCs 
extrusion from the clot by itself, but a defect in FXIII crosslinking would release 
the RBCs from the clot (Byrnes et al., 2015).  
One of the early studies about the involvement of RBCs in thrombosis was done 
by Horne et al, 2005. In this study, an assay to study thrombin generation in 
presence of intact and lysed RBCs was introduced, because it was found that all 
routine analyses for blood coagulation rely on cell-depleted plasma. There was 
a concern about providing physiological conditions to the new assay so thrombin 
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generation was initiated by tissue factor (Horne et al., 2006). Endogenous 
thrombin potential was increased threefold by the physiological increase in 
haematocrit compared to its increase by the increase in platelets. Subsequently, 
in non-flowing blood, the sensitivity of thrombin generation was more affected by 
RBC concentration than by platelet concentrations (Horne et al., 2006).   
A study by Lominadze et al, 2002 confirmed the presence of a non-specific 
binding of fibrinogen (Chien and Jan, 1973) with erythrocytes as well as a specific 
binding. A complete loss of the specific binding was found with the removal of 
calcium while a dose-dependent increase was shown in the presence of the 
cation. This suggested an integrin-type receptor interaction between 
erythrocytes and fibrinogen (Lominadze and Dean, 2002). This was confirmed 
by the use of an RGDS peptide antagonist that in a high concentration inhibits 
the fibrinogen-dependant erythrocyte aggregation as well as fibrinogen-
erythrocyte specific binding (Lominadze and Dean, 2002). The high affinity of 
both fibrinogen and platelet binding argues against the involvement of the 
platelets in the interaction between fibrinogen and RBCs (Lominadze and Dean, 
2002). 
More recently, a study by Carvalho et al, 2010 compared the binding of fibrinogen 
to both platelets and erythrocytes using atomic force microscopy (AFM). The 
experiment was conducted on samples from healthy donors and Glanzmann 
thrombastenia (an αIIbβ3 integrin deficient)  patients to evaluate the binding 
between fibrinogen and αIIbβ3 integrin both in RBCs and platelets (Carvalho et 
al., 2010). Because the activation of the integrin is calcium dependant, the 
influence of the presence of calcium ion was tested. To confirm if binding 
between fibrinogen and RBCs was through the αIIbβ3 integrin, the inhibitor of the 
integrin (eptifibatide) was used as well (Carvalho et al., 2010). It was found that 
in all cases both platelets and erythrocytes interaction to fibrinogen were 
inhibited (absence of calcium, absence of the αIIbβ3 integrin and presence of the 
inhibitor) but to a lesser extent in the erythrocytes, in addition to the presence of 
mutated β3 gene in these patients (Carvalho et al., 2010). It was shown that 
fibrinogen has more affinity to platelets than to RBCs although they both were 
comparable in their rupture force and binding frequency to fibrinogen (Carvalho 
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et al., 2010). The presence of an integrin on the surface of the RBC was 
concluded, this integrin was suggested to be an αIIbβ3-like integrin that is related 
to the platelets integrin (Carvalho et al., 2010). In a following study, the same 
group focused on the effect of aging of erythrocytes by studying different 
subpopulations of the cells. It was found that, the interaction between fibrinogen 
and erythrocytes decreased in frequency, but not in strength by the aging of 
erythrocytes (Carvalho et al., 2011). This was because the cells were having the 
same morphology and rupture forces, but they required less fibrinogen 
concentrations for the younger aged erythrocytes. The decrease in fibrinogen 
binding to RBCs was related to the dynamic reduction of sialic acid in aged 
erythrocytes, suggesting a possible causal relationship between sialic acid 
content and fibrinogen binding (Carvalho et al., 2011). Another study excluded 
the involvement of αIIbβ3 integrin in the interaction between soluble fibrinogen and 
RBCs and suggested that it is age-dependant rather than integrin-dependent. 
The involvement of CD47 receptor as a recognised mediator in this interaction 
was suggested by using antibodies against this receptor to inhibit the fibrinogen-
RBC interaction (De Oliveira et al., 2012). 
1.4.3  Fibrinogen-RBC binding 
The bridging of fibrinogen and its degradation products between neighbouring 
RBCs to support the erythrocytes aggregation was previously studied and 
demonstrated the presence of specific binding between the RBCs and fibrinogen 
(Zhang et al., 2008, Wagner et al., 2013, Maeda et al., 1987). It was suggested 
that fibrinogen and its derivatives may bind the RBCs on different sites avoiding 
a competition between these molecules on the binding of RBCs to induce rouleau 
formation (Zhang et al., 2008, Wagner et al., 2013, Maeda et al., 1987). Rouleau 
is a reversible aggregation of RBC in linear stacks of coin-like structures that is 
involved in bridging the cells and increasing viscosity (Zhang et al., 2008, 
Wagner et al., 2013, Maeda et al., 1987). Maeda et al found that the involvement 
of fibrinogen and its products in the rouleau formation was preserved in the whole 
molecule, which they called fragment X and fragment Y, the latter of which is 
composed of one D-domain with the E-domain (Maeda et al., 1987). However 
this ability of binding RBCs was lost in fragment D and fragment E, which 
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contains each region (D and E respectively) separately (Maeda et al., 1987). 
Another study has shown the presence of a specific binding between fibrinogen 
and erythrocytes that can be inhibited by using the integrin receptor antagonist 
RGDS peptides (Lominadze and Dean, 2002). The authors suggested that this 
interaction, which is involved in fibrinogen-induced erythrocyte aggregation could 
help in the production of therapeutic drugs against cardiovascular and metabolic 
diseases (Lominadze and Dean, 2002).  
1.4.4 Involvement of RBCs in clot structure 
Carr and Hardin, 1987 calculated the average pore diameter for the whole blood 
clot, by haemolysing the RBCs using water so that the haemoglobin and 
membrane fragments are easily flushed from the clot (Carr and Hardin, 1987). 
The authors then studied the residual fibrin gel to calculate the pore size. It was 
found that RBCs can affect the pore size of the clot, but not how the fibrin fibres 
structure were formed (Carr and Hardin, 1987). RBCs were found to increase 
the pore size to become large enough to allow the escape of some erythrocytes 
out of the clot. It was suggested that the increase in pore sizes is not a result of 
increasing the cell concentration, but by occupying a large space in the clot (Carr 
and Hardin, 1987). When RBCs leave the clot, their spaces become pores that 
cannot be filled by fibrin fibres (Carr and Hardin, 1987). Gersh et al, 2009 on the 
other hand found that addition of RBCs into fibrin clot was affected the clot 
structure significantly in a concentration-dependant manner as well as its 
mechanical properties. The authors suggested that this observation should be 
taken into account when assessing in vivo plasma clots (Gersh et al., 2009).   
A role for RBC in affecting clot structure and mechanical stability was studied by 
Guedes et al, 2018 using two variants of fibrinogen, normal γAγA and its 
alternative spliced variant γAγ’. It was found that incorporation of RBCs into the 
clot would change the behaviour of fibrinogen in the splice variant giving thinner 
fibres and stiffer clots with longer fibrinolysis time (Guedes et al., 2018b). The 
authors next investigated the effect of the homodimer γ’γ’ on the clot structure 
and interaction with the RBCs. Interestingly, γ’γ’ splice variant showed a stronger 
binding to the RBCs that was more frequent, compared with the γAγA variant, 
suggesting that it would promote RBC aggregation (Guedes et al., 2018a). Clots 
 
 
47 
 
made by this splice variant demonstrate more viscosity in presence of RBCs, 
they are more branched having larger pores and denser fibres compared to the 
γAγA as well as longer fibrinolysis. The effect of this variant on clot structure and 
fibrin polymerisation in presence of the RBCs make them more susceptible to 
embolism and induces erythrocyte hyper-aggregation (Guedes et al., 2018a).  
RBCs were found previously to provide the clot with more stability by supressing 
tPA-induced fibrinolysis (Wohner et al., 2011). In addition to that, RBC rich clots 
have the ability to respond to eptifibatide inhibition via its specific receptor for 
fibrinogen (Wohner et al., 2011). Carvalho et al. compared the clot structure of 
the D97E and WT using SEM and found that there was no significant change in 
clot structure in the absence of RBCs. In the presence of RBCs, D97E clots 
looked more disorganised having more clusters entrapping the RBCs (Carvalho 
et al., 2018). The clots were loosely packed increasing the risk of embolism. 
Addition of the RBCs to the clot was found to significantly alter the fibre thickness 
in the clot, which apparently resulted from the interaction between fibrinogen and 
RBCs (Carvalho et al., 2018).  
Based on the above-mentioned studies, it can be concluded that some 
controversy is still present regarding the interaction between fibrinogen and 
RBC, as well as regarding the possible receptor on the surface of the RBC 
involved in this interaction between fibrinogen and RBCs.  
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1.5 Aims and Hypothesis 
1.5.1 Hypothesis 
Conversion of fibrinogen to fibrin by thrombin is the principal step in clot formation 
followed by crosslinking of the fibrin network by FXIIIa to provide the clot with 
additional stability. Fibrinogen and consequently fibrin bind a variety of cells via 
ligand-receptor integrin complex such as αIIbβ3 for platelets, which gives the clot 
more strength. One of the key therapeutic targets in the treatment of 
cardiovascular diseases is blocking this interaction between platelets and 
fibrinogen. A new involvement of RBCs in clot formation has recently been 
suggested to involve integrin receptor binding to specific site on fibrinogen. This 
site could involve the RGD sequence in the coiled-coil of the Aα-chain of 
fibrinogen but the interaction between fibrinogen and RBCs is not well-
characterised and its role in clot formation has not been clearly established yet.  
The hypothesis of this project is that the interaction between fibrinogen and 
RBCs is mediated by the RGD sequence in the coiled-coil of the Aα-chain of 
fibrinogen through αIIbβ3-like integrin receptor, and that this interaction is 
responsible for stabilising the clot by RBC retention. 
1.5.2  Aims 
1.5.2.1 Overall Aims 
To investigate the role of the fibrinogen Aα-chain R95G96D97 sequence in 
regulating:  
1. fibrinogen-RBC interaction 
2. Fibrinogen-RBC binding site 
3. Clot structure and function 
 
1.5.2.2 Specific objectives: 
1. Production of six mutations (R95E, R95Q, G96V, D97K, D97N, 
F98I) in the RGD sequence of the Aα-chain of fibrinogen. New 
amino acids with neutral side chains (Q95 and N97) will be used to 
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replace the original amino acids that have charged side chains 
(positive charge of R95 and negative charge of D97). New amino 
acids with oppositely charged side chains, which are negative E95 
and positive K97, will also be used to replace the original charged 
side chains in R95 and D97. A similar mutation to G96V in 
fibronectin was found to decrease the interaction between 
fibroblasts and fibronectin. F98I is a naturally occurring mutant 
from a patient with dysfibrinogenaemia just next to the RGD. 
Original and mutated amino acid structures are shown in Table 1-2.  
2. The effect of the mutations on the interaction between fibrinogen 
and RBCs will be investigated by establishing several new 
methods; a plate binding assay, a solution-based interaction assay, 
a flow cytometric assay and clot retraction. 
3. Effects of the mutations on fibrinogen and fibrin clot structure and 
function will be investigated using circular dichroism spectra, clot 
turbidity and lysis assays, clotability assay, laser scanning confocal 
microscopy and scanning electron microscopy. 
4. The effect of the mutations on the interaction between platelets and 
fibrinogen will be investigated using platelet spreading assays. 
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Table 1-2 Original and mutated amino acid structure  .Structure are taken form 
Sigma-Aldrich (Meric) website (https://www.sigmaaldrich.com/life-
science/metabolomics/learning-center/amino-acid-reference-chart.html).  
 
Amino Acid 
Structure 
Arginine (R) 
 
Asparagine (N) 
 
Aspartic Acid (D) 
 
Glutamic Acid (E) 
 
Glutamine (Q) 
 
Glycine (G) 
 
Isoleucine (I) 
 
Lysine (K) 
 
Phenylalanine (F) 
 
Valine (V) 
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2.1 Site-Directed Mutagenesis 
2.1.1 Plasmid Design 
The cDNAs of the three fibrinogen chains were previously sub-cloned into 
plasmid p284, into the multiple cloning site that is located downstream from the 
adenovirus 2 major late promotor (MLP). The pMLP-α plasmid was constructed 
by S. Lord by insertion of a pVuII/SspI fibrinogen Aα cDNA fragments into SmaI-
cleaved p284. The vector also contains the SV40 polyadenylation promotor and 
enhancer site as shown in Figure 2-1 (Binnie et al., 1993).  
 
Figure 2-1 Representation of pMLP-Aα map.  The figure is showing the pMLP vector 
of A-chain gene of fibrinogen which has a length of 6265 bp. It is composed of 
Ampicillin resistance (AmpR) promotor, origin of replication, SV40 promotor, Fgb-A is 
inserted between SalI and NotI restriction sites. The map was kindly provided by Dr 
Cédric Duval. 
 
Chinese hamster Ovary (CHO) cells already transfected with Bβ- and γ-plasmids 
(βγ-CHO) of fibrinogen chains were used in this project. These cells, resistant to 
Geneticin G418, were co-transfected by the mutated pMLP-Aα plasmid together 
with the selection gene pMSV-his to allow the use of L-Histidinol as a selection 
marker for transfection.  
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2.1.2 Primer Design 
For the site-directed mutagenesis, primers were designed using QuickChange® 
Primer Design Program (Agilent Technologies, Stockport, UK) as follow in 
Table 2-1, and ordered from Invitrogen (Paisley, UK) 
Table 2-1 Primer sequences of the proposed mutations.  F is the forward primer, R 
is the reverse primer for each mutation, F2 and R2 represent a second set of primers 
designed for R95Q and D97N. Highlighted letters represent the mutated codon. R95Q 
primers introduce a mutation from AGA (R) to CAA (Q), R95E primers introduce a 
mutation from AGA (R) to GAA (E), D97N primers introduce a mutation from GAT (D) to 
AAT (N), D97K primers introduce a mutation from GAT (D) to AAA (K), F98I primers 
introduce a mutation from TTT (D) to ATT (I). 
Mutation Primer 
R95Q 
F1: CGTTGACCACTAATATAATGGAAATTTTGCAAGGCGATTTTTCCTCAGCC 
R1: GGCTGAGGAAAAATCGCCTTGCAAAATTTCCATTATATTAGTGGTCAACG 
F2: CGTTGACCACTAATATAATGGAAATTTTGCAAGGCGATTTTTC 
R2: GAAAAATCGCCTTGCAAAATTTCCATTATATTAGTGGTCAACG 
R95E 
F: CGTTGACCACTAATATAATGGAAATTTTGGAAGGCGATTTTTCCTCAGCC 
R: GGCTGAGGAAAAATCGCCTTCCAAAATTTCCATTATATTAGTGGTCAACG 
G96V 
F: TAATATAATGGAAATTTTGAGAGTCGATTTTTCCTCAGCCAATAACC 
R: GGTTATTGGCTGAGGAAAAATCGACTCTCAAAATTTCCATTATATTA 
D97N 
F1: TATAATGGAAATTTTGAGAGGCAATTTTTCCTCAGCCAATAACCG 
R1: CGGTTATTGGCTGAGGAAAAATTGCCTCTCAAAATTTCCATTATA 
F2: CGTTGACCACTAATATAATGGAAATTTTGAGAGGCGATTTTTCC 
R2: GGAAAAATCGCCTCTCAAAATTTCCATTATATTAGTGGTCAACG 
D97K 
F: AATATAATGGAAATTTTGAGAGGCAAATTTTCCTCAGCCAATAACCGTGAT 
R: ATCACGGTTATTGGCTGAGGAAAATTTGCCTCTCAAAATTTCCATTATATT 
F98I 
F: GGAAATTTTGAGAGGCGATATTTCCTCAGCCAATAACCG 
R: CGGTTATTGGCTGAGGAAATATCGCCTCTCAAAATTTCC 
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2.1.3 Mutagenesis reaction 
MATERIALS 
 100% Dimethyl Sulfoxide (DMSO) (New England BioLabs, Ipswich 
Massachusetts, USA). 
 Chinese hamster Ovary (CHO) cells were kindly provided by Dr Susan 
Lord, University of North Carolina, USA. 
 DpnI Restriction Enzyme (10 U/µl) (ThermoFisher Scientific, Paisley, UK). 
 Nuclease-free water ddH2O (Sigma-Aldrich, Dorset, UK). 
 PCR machine Veriti® 96-Well Thermal Cycler, Applied Biosystems™ 
(ThermoFisher Scientific). 
 PfuUltra High-Fidelity DNA polymerase (Agilent Technologies). 
 Phusion High-Fidelity DNA polymerase (New England BioLabs). 
 QuikChangeII Site-Directed Muatgenesis Kit (Agilent Technologies). 
 Thermo Molecular Biology PCR tubes and Domed Caps (ThermoFisher 
Scientific).  
 Water Bath (Grant, Shepreth, UK). 
 
For each mutant, the reaction mixtures using Phusion High-Fidelity DNA 
Polymerase were prepared as shown in Table 2-2. The generation of the 
mutations occurred after different attempts, each mutant was produced under 
different conditions. The table is showing the successful combination of the 
reaction mixtures that were used in producing the mutations. Before the use of 
this enzyme and in the first few optimisation experiments, PfuUltra High-Fidelity 
DNA polymerase was used, but each attempt was unsuccessful. 
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Table 2-2 PCR mix for Site-Directed Mutagenesis using Phusion High-Fidelity DNA 
Polymerase. 
Reaction 1 2 3 4 5 6 7 
Template DNA 20 ng 20 ng 10 ng 10 ng 20 ng 20 ng 20 ng 
5X Phusion HF Buffer 1X 
10 mM dNTPs 200 µM 
10 µM primers (F+R) 
mix 
0.5 
µM 
0.5 
µM 
0.5 
µM 
0.5 
µM 
0.5 
µM 
0.5 
µM 
0.5 
µM 
100%  DMSO 6% 12% 6% 12% 5% 3% 5% 
Phusion DNA 
Polymerase 
2U 3U 
Nuclease-free water 
(ddH2O) 
Up to 50 µl 
 
The reaction mixtures in the PCR tubes were transferred to the PCR machine in 
a 98°C pre-heated block. The PCR reaction steps are shown in Table 2-3. 
Table 2-3 PCR thermal cycling conditions. 
Step Temperature (°C) Time (sec) 
Initial Denaturation 98 30 
18 cycles 
Denaturation 98 
Annealing 60 
Extension 72 
30 
30 
210 
Final Extension 72 600 
Hold 4 ∞ 
 
Following the PCR, the tubes were transferred on ice and 1 µl of DpnI restriction 
enzyme (10 U/µl) was added directly to each tube and mixed by pipetting up and 
down, the tubes were then transferred to a 37°C water bath for 90 minutes (min). 
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2.1.4 Transformation 
MATERIALS 
 D-(−)-α-Aminobenzylpenicillin, Ampicillin (Sigma-Aldrich). 
 Falcon Tubes (Sigma-Aldrich). 
 Gallenkamp Economy Size 2 Incubator with Fan (Golndustry DoveBid, 
Leeds, UK). 
 Inoculation Loops (Sarstedt AG & Co.KG, Nümbrecht, Germany). 
 LB-medium: 1% w/v Tryptone (Lab M Limited, Heywood, Lancashire, UK), 
0.5% w/vg Yeast Extract, 1% w/v Sodium Chloride (NaCl), 500ml ddH2O, 
autoclaved. 
 Luria Broth (LB)-Agar: 3% w/v Tryptone, 0.5% w/v Yeast Extract (Lab M 
Ltd), 1% w/v NaCl 1.5% w/v Bacteriology Agar (Lab M Ltd), 300 ml ddH2O, 
autoclaved (Classic Prestige Medical, Coventry, UK) then cooled to 50°C, 
Ampicillin was added to 100 µg/ml final concentration, and the Agar was 
poured into petri Dishes. 
 NaCl (ThermoFisher Scientific). 
 NanoDrop (ND-1000 Spectrophotometer v3.10, ThermoFisher Scientific). 
 New Brunswick Scientific Model G-25 Incubator Shaker (Global Medical 
Instrumentation GMI, Ramsey, Minnesota, USA).  
 PureYieldᵀᴹ Plasmid MaxiPrep System Kit (Promega Corporation, 
Madison, WI, USA). 
 QIAprep® Spin MiniPrep Kit (QIAGEN®, Hilden, Germany). 
 ROTANTA 460R Centrifuge (Hettich Zentrifugen, Tuttlingen, Germany). 
 Super Optimal Broth with Catabolite Repression (SOC-medium) (Sigma-
Aldrich).  
 Water (Molecular Biology Reagent, Sigma-Aldrich). 
 X320 Petri Dish NUNC with Lid Vented (100X15) mm Sterile 
(ThermoFisher Scientific). 
 XL10-Gold Ultra-Competent Cells (Agilent Technologies). 
 XL1-Blue Super-Competent Cells (Agilent Technologies). 
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A total of 50 µl of XL10-Gold Ultra-Competent Cells (XL1-Blue Super-Competent 
Cells in the first optimisation experiments) were transferred into a pre-chilled 50 
ml falcon tube and 1 µl of the Dpn-I-treated DNA was added, they were then 
incubated on ice for 30 min. The bacteria were then heat shocked by transferring 
them to 42°C water bath for 45 sec and transferred on ice for 2 min, this step is 
required to insert the plasmid into the bacteria. 500 µl of SOC-medium were then 
added to the transformed bacteria and incubated at 37°C, in the G-25 Incubator 
Shaker at 225 rpm for 1 hr in order to start the bacterial growth. The bacteria 
were then inoculated using sterile inoculation loops in four different volumes (50 
µl, 100 µl, 150 µl, 200 µl) on LB-Agar with ampicillin dishes, and incubated 
overnight in a 37°C incubator for the bacteria to grow if they had been 
successfully transformed with the DNA constructs including ampicillin resistance. 
2.1.5 Plasmid DNA extraction 
Five different single colonies of bacteria were randomly selected from the plates, 
and each colony was streaked on a separate square on the master plate as 
shown in Figure 2-2 using a sterile loop. For each colony, the same loop was 
stirred in 5 ml of LB-Medium containing Ampicillin (100 µg/ml), in a 50 ml falcon 
for overnight growth culture. The master plate was incubated overnight at 37°C, 
and the overnight growth culture tubes were incubated in the G25 Incubator 
Shaker at 225 rpm, 37°C.  
 
 
Figure 2-2 A schematic representation of the a) bacterial culture on the plate. b) 
master plate for plasmid extraction. 
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The next day, the overnight cultures were centrifuged at 6,800 g for 10 min at 
room temperature using ROTANTA 460R centrifuge. For each colony, the 
plasmid DNA was extracted from the bacteria using QIAprep® Spin MiniPrep Kit 
following manufacturer’s instructions. The eluted DNA was quantified by 
NanoDrop and stored at -20°C for later transfection.   
The DNA was sent for sequencing to the Medical Research Council Protein 
Phosphorylation and Ubiquitination Unit (MRC PPU) for DNA sequencing and 
services at the University of Dundee, Scotland. The sequences were then 
analysed using BioEditTM (BioEdit Sequence Alignment Editor, Copyright© 1997-
2013 Tom Hall, Ibis Biosciences, Carlsbad, CA, USA) and Serial ClonerTM (v2.6, 
Softonic Corporate, New York, USA) programmes. The obtained DNA 
sequences were subsequently aligned using ClustalW2 (The European 
Bioinformatics Institute (EMBL-EBI), Hinxton, Cambridge, UK) to the expected 
sequences, and similarities/differences in sequences were investigated. 
2.1.6 Preparation of large quantities of plasmid DNA  
For each mutation, the colony containing the correct sequence match (excluding 
silent mutations) of mutated DNA was transferred from its master plate (see 
above). Using a sterile loop, a small amount of bacteria was taken and stirred 
into a 50 ml falcon tube containing 5 ml LB-Medium, Ampicillin (100 µg/ml) then 
incubated for 1 hr in G25 Incubator Shaker at 225 rpm, 37°C. Following the 
incubation, the cultured bacteria were distributed equally between two of 1 L 
flasks containing 250 ml LB-Medium and Ampicillin (100 µg/ml), for overnight 
culture in the G25 Incubator Shaker at 225 rpm, 37°C.  
PureYieldᵀᴹ Plasmid MaxiPrep System Kit was used to produce DNA from the 
cultured bacteria, following manufacturer’s instructions. The eluted DNA was 
quantified using the NanoDrop, stored and sequenced as previously described. 
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2.2 Protein Production 
2.2.1 Cell Transfection  
MATERIALS 
 0.1% PBS/EDTA: PBS, 10% v/v Ethylene Diamine Tetra Acetic Acid 
EDTA (Sigma-Aldrich). 
 0.2 μm Filters (ThermoFisher Sientific). 
 1 ml Cryotubes (ThermoFisher Scientific). 
 1.5 ml Micro-Centrifuge Tubes, Eppendorf (ThermoFisher Scientific). 
 10 cm Dishes, Cell Culture Dish 100 mm x 20 mm Style (Corning®, New 
York, USA). 
 10 ml Disposable Plastic Syringe without Needle (Terumo Europe N.V., 
Leuven, Belgium). 
 10% Freezing Medium: 10% v/v DMSO (Sigma-Aldrich), 90% v/v FBS, 
filter sterilised.  
 10% v/v filter sterilised Glycerol (ThermoFisher Sientific). 
 2.5 M CaCl2 (Sigma-Aldrich). 
 2X HEPES Buffer 4-(2-Hydroxyethyl)-1-Piperazineethanesulfonic Acid 
(0.021% w/v Na2HPO4 (Sigma-Aldrich), 1.19% w/v HEPES (Sigma-
Aldrich), 1.64% w/v NaCl (ThermoFisher Sientific), pH 7.05, in ddH2O, 
filter sterilised). 
 5 cm X400 TC Dish Nunclon, 58 mm x 15 mm (ThermoFisher Sientific). 
 5 ml Costar Strippette Disposable Plastic Serogical Pipette (Corning®).  
 Antibiotic Antimycotic Solution (100x), Stabilised with 10,000 units 
penicillin, 10 mg streptomycin and 25 μg amphotericin B per ml, filter- 
sterile, BioReagent (Sigma-Aldrich). 
 CKX41 Microscope (Olympus, Hamburg, Germany). 
 Corning® Costar® TC-Treated 24-Well Plates (Corning®). 
 DULBECCO’S Phosphate Buffered Saline (PBS sterile) pH 7.4 PBS 
(Invitrogen). 
 Fisherbrand™ Electric Pipet Controller (ThermoFisher Sientific). 
 Gilson Pipette (Gilson, Dunstable , UK). 
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 Growth Medium / Antibiotic: Growth Medium, 1% v/v Antibiotic-
Antimycotic.  
 Growth Medium: Dulbecco's Modified Eagle Medium “DMEM” F12 Ham 
(Invitrogen), 5% v/v Foetal Bovine Serum FBS, (ThermoFisher Sientific), 
5% v/v Nu Serum (Scientific Laboratory Supplies Ltd (SLS), Nottingham, 
UK). 
 IncuSafe, IR Sensor, Safe Cell Incubator (Sanyo, Japan). 
 Integra Vacusafe Aspirator (Integra Biosciences Ltd, Thatcham, UK). 
 L-Histidinol (L-His) Selection Medium: Growth Medium, 250 µM filter 
sterile L-His (SLS). 
 Lipofectamine® 2000 (Invitrogen). 
 Pasteur Pipette Rubber Bulb (Sigma-Aldrich). 
 Pasteur Pipettes, short form 150 mm (Kimble Chase Life Science and 
Research Products, LLC., Meiningen, Germany). 
 Pipetman Diamond Tips-Autoclavable TowerPack™ (Gilson). 
 Reduced Serum Medium, Gibco™ Opti-MEM™ (modification of Eagle's 
Minimum Essential Media, ThermoFisher Sientific). 
 ROTANTA 35 centrifuge, (Hettich Zentrifugen). 
 Selection Medium: Growth Medium, 0.4% v/v selection marker G418/ 
Neomycin (Invitrogen). 
 T75 Flask (Corning®). 
 TipOne® Filter Tips (Star Lab, Hamburg, Germany). 
 Trypsin-EDTA: 1X Trypsin-EDTA (Sigma-Aldrich). 
Cell Culture Passaging  
 A 1 ml vial of βγ-CHO cell line was taken from liquid nitrogen (LN2), rapidly 
defrosted by incubation in a 37°C water bath for one minute. The 1 ml cell content 
of the vial was added to 9 ml of selection medium and centrifuged at 800 g for 4 
min. The pellet was then re-suspended in 10 ml of selection medium and 
incubated in a T75 flask at 37°C, 5% CO2 IncuSafe Incubator (this is the 
incubation condition for all the subsequent culture work) until confluency was 
reached. To split the cells, medium was aspirated using glass Pasteur pipettes 
and Vacusafe aspirator; the cells were gently washed by adding 10 ml 
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PBS/EDTA, followed by aspirating the medium. Next, 1 ml of Trypsin-EDTA was 
added for a few minutes to detach the cells and 9 ml of selection medium were 
added to deactivate the trypsin and re-suspend the cells. 1 ml of the re-
suspended cells was added to T75 flask containing 9 ml growth medium (1:10) 
and incubated at 37°C for freezing or further passaging as required. 
cDNA Transfection 
To prepare cells for transfection, re-suspended cells were seeded in 1:10 
concentration into 3 of 10 cm petri dishes each containing 9 ml of selection 
medium by adding 1 ml of re-suspended cells in each dish. The cells were then 
incubated overnight to reach 30% confluency to be ready for Calcium Phosphate 
transfection which was used for R95Q, D97N and F98I mutations. Another type 
of transfection was used later in this project for the other mutations, which was 
the Lipofectamin 2000 method. For this method of transfection, 1 ml of re-
suspended cells was seeded in 1:5 concentrations into 3 of 5 cm Petri dishes 
each, containing 4 ml of selection medium. The cells were then incubated 
overnight to reach confluency. 
Calcium Phosphate Method 
The next morning, the medium was replaced with 10 ml of fresh growth medium 
and incubated for 2 hours. The DNA reaction mixture was prepared an hour 
before transfection as per the following protocol in Table 2-4. 
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Table 2-4 Transfection reaction mix. 
Reagent  
Transfection 
A 
Transfection 
B 
cDNA pMLP-α 10 µg 20 µg 
Selection vector pMSV-His  
(1:10 of DNA concentration) 
1 µg 2 µg 
 CaCl2 filter sterilised 0.25 M 0.25 M 
Filter sterilised ddH2O Up to 500 µl Up to 500 µl 
2X HEPES buffer 500 μL 500 μL 
 
Two different concentrations of plasmid DNA were used (10 µg, 20 µg) for each 
mutation to increase the chances of obtaining single clones with the new plasmid. 
For each transfection, 500 μl of HEPES buffer pH 7.05 were added into a 50 ml 
falcon tube, air bubbles were induced using a 5 ml Strippette and Electric Pipette 
Controller whilst the DNA reaction mixture was added drop-wise using a Gilson 
pipette. The transfection mixture was then left to stand at room temperature for 
30 min. The DNA preparation was then added dropwise across one of the 
incubated petri dishes for each DNA concentration and incubated for 4 hrs at 
37°C incubator. 
The next step was glycerol shock for the mutated plasmid to enter the cells. The 
media were gently removed from the two transfected petri dishes, in addition to 
a one control dish that was not transfected, 2 ml of 10% v/v filter sterilised 
Glycerol were added to each dish and incubated for 3 min. Glycerol was removed 
and the dishes were washed quickly for three times with 5 ml PBS. Finally, 10 ml 
of growth medium were added, and petri dishes were incubated for two days at 
37°C incubator. 
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Lipofectamine® 2000 Method 
For the last group of mutations (R95E, G96V, D97K), a new transfection method 
with higher efficiency was used. In this method, 11 µg of DNA was transfected in 
5 cm confluent dishes of CHO cells with 1:1 v/v ratio of Lipofectamine in a final 
volume of 500 µl. Two reaction Eppendorf tubes were prepared, each one 
containing either mutated DNA plasmid or Lipofectamine in final volume of 250 
µl in Opti-MEM™ medium, and then incubated separately at RT for 5 min. 
Subsequently, the two tubes were combined together and incubated for 15 min 
at RT. During the incubation, media was changed to fresh growth media for the 
plate, which was going to be transfected. After the incubation period, 
DNA/Lipofectamine mixture was added dropwise to the plate and incubated for 
6 hrs in a 37°C incubator. After 6 hrs, the medium was changed to fresh growth 
medium from the transfected plate and a control plate. Unlike the Calcium 
Phosphate method, cells were incubated at 37°C incubator for one day only.  
Clone Selection 
At this stage, both methods of transfection were treated the same. The cells were 
split at different concentrations (1:50, 1:100, 1:150, and 1:200) in duplicates 
using growth medium, and incubated for 2 days. Two controls (un-transfected) 
were split 1:50 and 1:200. The medium was then changed to L-His selection 
medium, and every two days, until sparse clones appeared. All dishes were 
checked under a CKX41 microscope for suitable clones. 24 single clones were 
selected that were large, healthy and as far apart from other clones as possible. 
The selected clones were then transferred into 24-well plate; each well 
containing 500 μl of growth medium/antibiotic for its corresponding clone. The 
cells were transferred using glass cloning cylinders, glass Pasteur pipette and 
rubber bulb after they were detached by Trypsin/EDTA. The 24-well plates were 
incubated until 60-70% confluency was reached. At this stage, the medium was 
harvested for ELISA, to measure the amount of fibrinogen produced by each 
clone, and the cells were trypsinised to be transferred into two of 5 cm dishes 
containing 4.5 ml growth medium/antibiotic per clone, and incubated until 
confluency. When ELISA results were available, only the highest 8-10 fibrinogen 
producing clones were kept. At confluency, each of the two dishes per clone 
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were trypsinised by 0.5 ml of Trypsin/EDTA, one for freezing (see below), whilst 
the other was re-suspended in 4.5 of growth medium/antibiotic and split in 1:10 
into a 10 cm dish and incubated until confluency was reached again. When the 
cells in the petri dishes were confluent again, their media were changed to 
serum-free media with antibiotic Antimycotic for a week. The media were then 
harvested for a second ELISA in order to select the highest producing clone for 
the fibrinogen expression stage. The following five highest producing clones 
were retained in LN2 as a backup whereas the other clones were discarded.  
Cell Freezing 
The other 5 cm dish was re-suspended in 9.5 of growth medium/antibiotic then 
centrifuged at 800 g, room temperature for 4 min using ROTANTA 35 centrifuge, 
the pellet was then re-suspended in 1 ml of 10% freezing medium and transferred 
into 1 ml Cryotubes. The tubes were incubated overnight at -80°C then 
transferred to liquid nitrogen.  
2.2.2 Fibrinogen ELISA 
MATERIALS  
 Blocking Buffer: 1% w/v Bovine Serum Albumin (BSA) (Sigma-Aldrich). 
 Buffer A: Coating Buffer; 0.039% w/v of Sodium Phosphate Monobasic 
Dihydrate NaH2PO4.2H2O (Sigma-Aldrich), 0.1.335% w/v of Sodium 
Phosphate Dibasic Dihydrate Na2HPO4.2H2O (Sigma-Aldrich), 0.8474% 
w/v of NaCl in ddH2O,  pH 7.2. 
 Buffer B: Buffer A, 0.2% v/v Tween20, 2.075% w/v NaCl (ThermoFisher 
Scientific), pH 7.2. 
 Buffer C: Citrate Phosphate Buffer; 0.73% w/v Citric Acid.H2O (Sigma-
Aldrich), 1.187% w/v Na2HPO4.2H2O, in ddH2O, pH 5.0.  
 Buffer E (stop buffer): 1.5 M Sulfuric Acid (Sigma-Aldrich).  
 Coating Fibrinogen Antibody: 3 µl of Polyclonal Rabbit Anti-Human 
Fibrinogen Antibody (DAKO, Agilent Technologies), 12 ml of Coating 
Buffer A (1:4000) dilution. 
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 Detecting Fibrinogen Horseradish Peroxidase HRP-Antibodies: 1 µl Goat 
Polyclonal to Fibrinogen HRP (Abcam, Biotech, Cambridge, UK), 16 ml 
buffer B. 
 Dynex, MRX TC Revelation Microplate reader (LABEQUIP LTD, Ontario, 
Canada). 
 F96 Maxisorp Nunc-Immuno Plate NUNC (Sigma-Aldrich). 
 OPD solution: 4 tablets of 1,2-Phenylenediamine Dihydrochloride OPD (2 
mg, DAKO, Agilent Technologies), 5 µl of 30% Hydrogen Peroxide 
(Sigma-Aldrich) in12 ml buffer C. 
 Plastic Film Thermo Scientific™ Sealing Tapes (ThermoFisher Scientific). 
 Stuart Microplate Shaker/ SSM5 Shaker (Bibby Scientific Limited (Group 
HQ), Staffordshire, UK). 
 
A 96-well Maxisorp plate was coated by adding 100 µl of fibrinogen antibody 
(1:4000) to each well, then covered by a plastic film and incubated overnight in 
the cold room. In all the following steps, unless stated otherwise, the plate was 
covered and incubated at room temperature on a shaker at 400 rpm for 60 min. 
Next day, the antibodies were removed and the plate was blocked by adding 150 
µl of 1% w/v BSA blocking buffer to each well and incubated. During the 
incubation period, a standard curve was prepared by diluting recombinant 
fibrinogen standard 100 µg/ml in buffer B as follows: 1 µg/ml, 500 ng/ml, 250 
ng/ml, 125 ng/ml, 62.5 ng/ml, 31.25 ng/ml, 15.63 ng/ml, 7.81 ng/ml, 3.91 ng/ml, 
1.95 ng/ml and blank. At the end of the incubation, the blocking buffer was 
removed and the plate was washed 3 times with 200 µl per well buffer B (this is 
how all the subsequent washes were performed). Total of 100 µl of each 
standard or neat media samples were added to the wells, in duplicate, incubated 
again for 120 min. Following the incubation, the standards and samples were 
removed and the plate was washed before 100 µl per well of the HRP-labelled 
antibodies were added, and incubated. The HRP-antibodies were removed 
afterwards and the plate was washed. Total of 100 µl per well of OPD solution 
were then added for a few minutes while waiting for the yellow colour to develop. 
The reaction was stopped by adding 100 µl per well of buffer E just before the 
plate was read using Dynex, Microplate reader at wavelength λ=490 nm. The 
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fibrinogen concentration of each sample was plotted against the standard curve 
using Microsoft Excel 2013. 
2.2.3 Fibrinogen Expression 
MATERIALS 
 0.1 M PMSF: 1.74% w/v of Phenyl Methane Sulfonyl Fluoride PMSF 
(Sigma-Aldrich) in 99.7% Isopropanol (Sigma-Aldrich). 
 850 cm2 Roller Bottle Vented Cap (Corning®). 
 Beads: 4% w/v Cytodex Microcarrier Beads - Cytodex1, 131-220 μm, 
(SLS) in 10 mM PBS, autoclaved. 
 CK2 Microscope (Olympus). 
 Growth Medium with Antibiotic: 2% v/v Antibiotic-Antimycotic in Growth 
Medium. 
 ITS Medium: DMEM F12, 2% v/v Antibiotic-Antimycotic, 0.001% w/v filter-
sterile Insulin Transferrin Sodium Selenite Supplement ITS (Roche 
Diagnostics, Burgess Hill, UK), 0.004% w/v filter-sterile Aprotinin (Sigma-
Aldrich). 
 Jencons Wheaton R2P Roller Cultural Apparatus Incubator 
(ThermoFisher Scientific). 
 Serum Free Medium/ Antibiotic: 2% v/v Antibiotic-Antimycotic in DMEM 
F12 Ham.  
 Supplement Free Medium: DMEM F12 Ham. 
 Whatman Filter Paper Grade 2 (ThermoFisher Scientific).  
 
According to the fibrinogen concentration data obtained with the ELISA from the 
serum-free medium incubation, the highest expressing clone was taken from the 
liquid nitrogen, defrosted and seeded in a T75 flask in growth medium with 
antibiotic to confluency (as per section 2.2.1). When confluent, the cells were 
split into threeT75 flasks; two were used for freezing new stock samples of this 
highest producing clone into 6 frozen vials as stated above. The third flask was 
used for further splitting into 4 other flasks to proceed with mutated fibrinogen 
expression. The cells were subsequently split into fourty of 10 cm petri dishes 
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and incubated until confluency was reached. Each two dishes (20 ml cells re-
suspension) were combined into one roller bottle that contained 200 ml growth 
medium with antibiotic. The cells were incubated in the roller bottles incubator at 
37°C, 5% CO2 for two days, these incubation conditions were used throughout 
the expression stage in the roller bottles. The medium was changed every 2 days 
by replacing 100 ml of current medium by the same amount of fresh growth 
medium with antibiotic. During this period, beads were prepared in PBS and 
autoclaved to be ready when needed. When the cells became confluent, PBS 
was aspirated from the precipitated autoclaved beads; and they were washed 
twice by 500 ml of supplement free medium, mixed and left to sediment again. 
After the washes, 500 ml of growth medium with antibiotic was added to the 
beads and mixed to give a suspension of beads in medium. For each roller bottle, 
100 ml of medium was discarded and replaced by 50 ml of the beads suspension 
and 50 ml growth medium with antibiotic, and incubated for three days. Following 
the incubation period, the cells were checked for their adherence to the beads 
and for confluency. Once confluency was reached, cells were washed from the 
serum present in the growth medium by adding 50 ml of serum free medium with 
antibiotic, the bottle was laid down and rolled slowly for a full turn. The medium 
was then discarded again and replaced by 100 ml of serum free medium with 
antibiotic and incubated overnight to ensure the full removal of serum. The serum 
free medium was replaced by 200 ml of ITS medium, incubated for two days. 
The next step was starting the media collection every two days by replacing a 
100 ml of ITS medium in the roller bottle by a fresh 100 ml of the same medium. 
The collected medium was filtered and 1 ml aliquot was reserved for ELISA 
before adding PMSF to 0.15 mM final concentration. The media and the ELISA 
aliquots were stored at -40°C until the media were used for fibrinogen 
precipitation and purification. The ELISA aliquots were used to perform ELISA 
every two weeks to monitor the fibrinogen production. 
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2.2.4 Fibrinogen Precipitation 
MATERIALS  
 1 L Nalgene Centrifuge Bottles (ThermoFisher Scientific). 
 Avanti J26S x PI Centrifuge (Beckman Coulter, High Wycombe, UK). 
 Cling Film (The Lab Warehouse, Grays, UK). 
 JA 25.50 rotor of Avanti J26S x PI Centrifuge (Beckman Coulter). 
 Jenway 1000 Stirrer (Keison Products, Chelmsford, UK). 
 JLA 8.100 Rotor of Avanti J26S x PI Centrifuge (Beckman Coulter). 
 Pellet Cocktail: 0.066% w/v ε-Amino Caproic Acid-Aminohexanoic acid 
(εACA) (SLS), 0.079%  w/v Benzamidine Hydrochloride Hydrate (SLS), 
5 µM Pepstatin A (SLS), 5 µM Leupiptin (SLS), 100 µM PMSF,  996.098 
U/ml Soybean Trypsin Inhibitor, (SLS),  1 mM EDTA (Sigma-Aldrich), 
300 mM NaCl (ThermoFisher Scientific), 200 mM Tris-Base, pH 7.4 
(Sigma-Aldrich), in ddH2O. 
 Protease Inhibitor Cocktail: 2.18%  w/v εACA, 2.62%  w/v  Benzamidine, 
1 µM Pepstatin A, 35 µM Leupiptin, 3.5 mM PMSF, 700 mM MES-
Hydrate 2-(N-Morpholin Ethanesulfonic Acid  Hydrate buffer pH 5.6 
(SLS) . 
 Saturated Ammonium Sulphate: 76% w/v Ammonium Sulphate 
(ThermoFisher Scientific) in ddH2O. 
 
When adequate amount of expression medium was available, precipitation was 
started, 6 L of collected medium was defrosted and poured equally between two 
of 5 L beakers, 100 ml of protease inhibitors cocktail, which were prepared on 
ice were added to each beaker and stirred at 500 rpm in the cold room. While 
the medium and proteases were stirring, 2 L of saturated ammonium sulphate 
were added for each 3 L of medium slowly by filtration; foaming was avoided by 
slowing down the stirring during the addition of ammonium sulphate. Ammonium 
sulphate was added slowly at 4°C to prevent denaturation of fibrinogen by 
creating an uneven pH around the protein. The beaker was then covered by cling 
film and incubated in the cold room overnight with no stirring. Next day, one of 
the 5 L of medium was distributed between 6 of 1 L Nalgene centrifuge bottles, 
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placed in pre-cooled JLA 8.100 rotor of the Beckman Coulter centrifuge and 
centrifuged at 14,500 g, 4°C, maximum acceleration with no break for 
deceleration, for 45 min. After the first run, the medium was discarded and the 
same steps were repeated by transferring the remaining 5 L of medium in the 
same bottles. After the second run, the pellets were dissolved in 2.8 ml of pellet 
protease inhibitor cocktail per bottle and kept on ice for 30 min in a 50 ml Nalgene 
centrifuge tube. They were then placed in a pre-cooled JA 25.50 rotor and spun 
at 43,000 g, 4°C, maximum acceleration and deceleration, for 30 min. The 
supernatant was collected in 5 ml aliquots and stored at -80°C until purification.  
2.2.5 Fibrinogen Purification 
MATERIALS 
 1 M CaCl2 (Sigma-Aldrich). 
 10 ml Disposable Plastic Syringe without Needle (Terumo Europe N.V.). 
 AKTA AVANT Chromatography System (GE Healthcare Life Sciences, 
Buckinghamshire, UK). 
 Anti-Fibrinogen monoclonal antibodies (mAb), Clone IF-1 (10 mg; 
Kamiya BioMedical Co, Tukwila, WA, USA) / CnBr activated Sepharose 
4B (1.5 mg; VWR; Lutterworth, UK). 
 EDTA (Sigma-Aldrich). 
 Elution Buffer B1: 20 mM Tris, 300 mM NaCl, 5 mM EDTA, pH 7.4. 
 Equilibration Buffer A1: 20 mM Tris, 300 mM NaCl, 1 mM CaCl2, pH 7.4. 
 NaCl (ThermoFisher Scientific). 
 Tris-Base (Sigma-Aldrich). 
 Tube roller (Star Lab). 
 Wash Buffer I A2: 20 mM Tris, 1 M NaCl, 1 mM CaCl2, pH 7.4. 
 Wash Buffer II A3: 5 mM Na-Acetate (Sigma-Aldrich), 300 mM NaCl, 1 
mM CaCl2, pH 6.0. 
 XK16/20 column (GE Healthcare Life Sciences). 
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Fibrinogen was purified by affinity chromatography using an AKTA AVANT and 
IF-1 Anti-Fibrinogen calcium-dependant monoclonal antibodies. 5 ml of the 
supernatant, which were collected from each precipitation were defrosted each 
time and 10 mM final concentration of CaCl2 was added, and incubated on a 
roller at room temperature for 10 min just prior to the injection using a syringe 
that is compatible to the injected volume. Following sample loading with 1 column 
volume (each column volume equals 7.438 ml), the column was washed using 
5X column volumes of washing buffer A2 then A3, and the fibrinogen was eluted 
from the column using 7X column volumes of EDTA containing buffer B1. Finally, 
the column was equilibrated with 5X column volumes of buffer A1. The eluates 
of the fibrinogen peak fraction collector in 2 ml aliquots were chosen by using 
1.51 extension co-efficient and collected, pooled and stored at -80°C until 
dialysis. 
2.2.6 Dialysis 
MATERIALS 
 10X Dialysis Buffer: 500 mM Tris pH 7.4, 1 M NaCl, pH 7.4. 
 100,000 MWCO, 5-20 ml Pierce™ Protein Concentrator (ThermoFisher 
Scientific).  
 NanoDrop (ND-1000 Spectrophotometer V3.10, ThermoFisher Scientific). 
 D-tube Dialyzer Maxi, MWCO 12-14 kDa (Merck Chemicals GmbH, 
Darmstadt, Germany). 
 
The eluted fibrinogen was defrosted, pooled and kept cool on ice in the cold 
room. The concentration started by adding the fibrinogen in two of Pierce™ 
Protein concentrators, spun at 3,000 g for 30 min. The fibrinogen was refilled in 
each concentrator after each spin, the amount of fibrinogen added and the time 
of spin varied according to how fast the elution buffer was passed through the 
membrane filtering the fibrinogen. This process was continued until the 
remaining fibrinogen in the concentrators was approximately 1 ml; at that point, 
the fibrinogen was transferred into D-tube Dialyzer in cold room. Fibrinogen was 
stirred at low speed 50 rpm for 1 hr in a 500 ml dialysis buffer, the dialysis buffer 
was then replaced by a fresh 1 L dialysis buffer, and incubated overnight while 
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still stirring at low speed in the cold room. Next morning, the dialysis buffer, was 
replaced again with a fresh 500 ml dialysis buffer, and stirred again for 1 hr. The 
concentration of fibrinogen was read at absorbance 280 nm using the NanoDrop 
(extinction coefficient 15.1). The purified fibrinogens were then aliquoted and 
stored at -80°C ready for functional analysis (Duval et al., 2014). 
2.3 SDS-PAGE 
MATERIALS  
 1X Running Buffer: 5% v/v of 20X NuPage MES SDS Running Buffer, pH 
7.3 (Invitrogen), 0.25% v/v NuPage Antioxidant (Invitrogen), ddH2O up to 
500 ml. 
 G:Box (SYNGENE, Cambridge, UK). 
 Gel Code® Blue Stain Reagent (ThermoFisher Scientific). 
 Ladder: Precision Plus Protein Standards (Bio Rad, Hercules, CA, USA). 
 Lid: X-Cell superlock (ThermoFisher Scientific). 
 NuPage 4-12% Bis-Tris Gel (Invitrogen). 
 NuPage Lithium dodecyl sulfate (LDS) Sample Buffer 4X, pH 8.4 (Novex 
life cell technologies, Carlsbad,  USA). 
 PowerPac™ Basic 300 Power Pac 300 V Power Supply (Bio Rad). 
 Sample Reducing Buffer 10X (Novex). 
 Stuart Microplate Shaker/ SSM5 Shaker (Bibby Scientific Limited). 
 Tank: Mini-Cell (Novex). 
 
The sample reduction reaction buffer was prepared by adding 2.5 µg fibrinogen 
to 1X of (LDS) Sample buffer, 1X of Sample Reducing buffer final concentrations, 
made up to 25 µl by ddH2O. The samples were vortexed, heated at 95°C for 10 
min then transferred on ice before they were loaded (25 µl per well) into the gel. 
To identify the produced bands, 5 µl of the Ladder (5-250 KDa) were loaded as 
a reference well. Running buffer was added to the tank and run at 140 Volt for 
90 min. Next, the gel was washed by ddH2O and incubated in the coomassie 
blue stain on a shaker at 60 rpm, room temperature for 1 hr, followed by washing 
4 times by ddH2O on a shaker at 60 rpm, room temperature for 15 min each. 
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After the last wash, fresh ddH2O was added and the gel was incubated overnight 
in the cold room. The gel was imaged using G:Box. 
2.4 Fibrinogen Clotability Assay 
MATERIALS  
 1 M CaCl2 (Sigma-Aldrich). 
 250 U/ml α-Thrombin (Sigma-Aldrich). 
 Activation Mix: 0.1 U/ml Thrombin, 5 mM CaCl2 in 1 X TBS. 
 Eppendorf™ MiniSpin™ Microcentrifuges (Sigma-Aldrich). 
 NanoDrop (ND-1000 Spectrophotometer V3.10, ThermoFisher Scientific). 
 
This method is relying on volumes rather than concentrations. To test the 
clotability of the produced mutants, 20 µl of each recombinant fibrinogen was 
added to TBS at final volume of 50 µl, and measured using NanoDrop 3 times 
each at Abs=1 mg/ml to exclude the thrombin and Calcium when blanking them, 
λ=280 nm. Next, 20 µl of activation mix was added to the fibrinogen and 
incubated at 37°C water bath for 2 hrs, a blank control reading was also made 
by adding the activation mix to 50 µl TBS. After incubation, the samples were 
centrifuged at 13,000 g for 1 hr in a micro-centrifuge to pellet the coagulated 
fibrin. The supernatants were transferred to fresh tubes and measured using 
NanoDropp again 5 times to measure the non-coagulated protein remaining in 
the supernatant. The results were analysed using Excel 2013 and GraphPad 
Prism 7.0 using one way ANOVA multiple comparison using WT as a control 
column and Dunnett’s test for p-value. 
2.5 Turbidity and Lysis Analysis 
MATERIALS  
 1 M CaCl2 (Sigma-Aldrich). 
 1X Tris-Buffered Saline (TBS): 50 mM Tris-Base, 100 mM NaCl, pH 7.4. 
 11 µM Human Glu-plasminogen (Enzyme Research \laboratories Ltd, 
Swansea, UK). 
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 140,000 pM Tissue Plasminogen Activator (tPA) (Pathway Diagnostics, 
Dorking, UK). 
 250 U/ml α-Thrombin (Sigma-Aldrich). 
 384-Well Plate (Greiner bio-one, Stonehouse, UK). 
 Activation Mix for Lysis: 25 mM CaCl2, 1.25 U/ml α-Thrombin, 500 pM tPA 
(Pathway Diagnostics) in 10 µl final volume TBS. 
 Bio-Tek ELX808 Microtiter Plate Reader (Labtech International; Ringmer, 
UK). 
 Lysis Mix: 1.2 µM Human Glu-plasminogen (Enzyme Research 
\laboratories Ltd) in 1X TBS, pH 7.4 in 10 µl final volume TBS. 
 Master Mix for turbidity: 10 mM CaCl2, 0.2 U/ml Human α-Thrombin 
(Sigma-Aldrich), in 50 ul TBS for 96 well-plate and 25 ul TBS for 348 well-
plate final volume, pH 7.4. 
 NaCl (ThermoFisher Scientific). 
 Tris-Base (Sigma-Aldrich). 
 
2.5.1 Turbidity Using a 348-Well Microtiter Plate 
For R95Q, D97N, F98I, 25 µl of fibrinogen were added in triplicates to 348 well-
plate and combined with 25 µl of Master Mix just before the reading, to achieve 
final concentrations of 0.5 mg/ml fibrinogen, 5 mM CaCl2 and 0.1 U/ml α-
Thrombin in final volume of 50 µl. Absorbency was measured at 340 nm, every 
12 sec for 2 hrs at 37°C, using microtiter plate reader (Duval et al., 2014). The 
results were analysed using Excel 2013 and GraphPad Prism 7.0 using one way 
ANOVA. 
For the new mutants (F95E, G96V, D97K), where the amount of protein was less 
than other mutants, 25 µl of fibrinogen was combined with 25 µl Master Mix to 
achieve final concentrations of 0.2 mg/ml fibrinogen, 5 mM CaCl2 and 0.1 U/ml 
Thrombin in final volume of 50 µl. The plate was read in the same conditions as 
above, and the results were analysed using Excel 2013 and GraphPad Prism 7.0 
using one way ANOVA multiple comparison using WT as a control column and 
Dunnett’s test for p-value. 
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2.5.2 Lysis Using a 348-Well Microtiter Plate 
In each well of the 348-well microtiter plate, 30 µl of fibrinogen were added to the 
final concentration of 0.5 mg/ml, and then 10 µl of Lysis Mix was added to the 
final concentration 0.24 µM plasminogen. Next, 10 µl of the Activation Mix for 
Lysis were added just before reading the plates with 10 sec gaps between each 
column to the final concentration of 5 mM CaCl2, 0.25 U/ml α-Thrombin, 100 pM 
tPA. Absorbency was measured at 340 nm, every 12 sec for 2 hrs at 37°C, using 
a microtiter plate reader (Duval et al., 2014). The results were analysed using 
Excel 2013 and GraphPad Prism 7.0 using one way ANOVA multiple comparison 
using WT as a control column and Dunnett’s test for p-value. 
2.6 Circular Dichroism Spectroscopy 
MATERIALS 
 1 mm Path-Length Cuvette (Applied Photophysics, Surrey, UK). 
 1 X TBS: 50 mM Tris-Base, 100 mM NaCl, pH 7.4. 
 Chirascan Plus Spectropolarimeter (Applied Photophysics). 
 NaCl (ThermoFisher Scientific). 
 Tris-Base (Sigma-Aldrich). 
To study the effects of the mutations on the secondary structure of the proteins, 
Circular Dichroism spectroscopy (CD-spectra) technique was used. To perform 
the experiment, 0.2 mg/ml final concentration in 200 µl final volume TBS was 
transferred into a cuvette and the far-UV spectroscopy was recorded for 190-260 
nm spectra using a Chirascan Plus Spectropolarimeter. The results were 
analysed using CDNN (Circular Dichroism analysis using neutral Network) 
analysis software. CD spectra was performed with the help of Dr Nasir Khan, 
School of Molecular and Cellular Biology, University of Leeds. 
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2.7 Labelling Fibrinogen 
MATERIALS 
 AlexaFluor® Antibody Labelling Kit (Molecular probes® by life 
technologies, Paisley, UK). 
 NanoDrop (ND-1000 Spectrophotometer V3.10, ThermoFisher Scientific). 
 10 mM PBS (One tablet of PBS dissolved in 200 ml of deionized water 
yields 0.01 M Phosphate Buffer, 0.0027 M Potassium Chloride (KCl) and 
0.137 M NaCl, pH 7.4, at 25°C. Sigma-Aldrich). 
 
Mutated fibrinogen was fluorescently labelled with AlexaFluor488 dye according 
to the manufacturer’s instructions. 100 µl of each mutant was dialysed overnight 
in PBS to purify them from any ammonium that may remain from the ammonium 
sulphate precipitation. The concentration of the produced labelled protein was 
measured by a NanoDrop at 280 nm (protein) and 494 nm (dye) using the 
formula provided by the manufacturer. The degree of labelling was calculated 
using the formula provided by the manufacturer. 
2.8 Laser Scanning Confocal Microscopy 
MATERIALS 
 1 M CaCl2 (Sigma-Aldrich). 
 1X TBS. 
 250 U/ml α-Thrombin (Sigma-Aldrich). 
 AlexaFluor488-labelled fibrinogen. 
 Scanning Confocal Electron Microscopy LSM700 inverted Zeiss (Zeiss, 
Jena, Germany). 
 Uncoated 15 µ-slide VI 0.4 (Ibidi GmbH, Martinsried, Munich, Germany). 
 
The clot for confocal microscopy was prepared in 40 µl per each channel of the 
slide final volume in TBS by adding fibrinogen to the final concentration of 0.5 
mg/ml, AlexaFluor488-labelled fibrinogen to the final concentration of 25 µg/ml, 
CaCl2 to the final concentration of 5 mM and just before transferring the clot to 
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its corresponding channel of the slide, thrombin was added to the final 
concentration of 0.1 U/ml, mixed quickly by pipetting. The 40 µl of clot mix were 
then transferred into the corresponding channel of the slide, while care was taken 
to avoid the presence of bubbles. The slide was kept in a humidity chamber at 
room temperature overnight to prevent dehydration of the clot. The clot was then 
imaged using a X40/1.3 Oil objective, at wavelength 494 nm emission and 519 
excitation for AlexaFluor488. Z-stacks were taken at 20.3 µm thick for 30 slices. 
The images were then analysed for fibre density, using imageJ-win64.exe (Fiji) 
and quantified using macro plugins of the programme New Clot Density PC1024 
batch and the results were analysed using Excel 2013 and GraphPad Prism 7.0 
using one way ANOVA multiple comparison using WT as a control column and 
Dunnett’s test for p-value. 
2.9 Blood Preparation  
MATERIALS 
 1% v/v of 0.5 M EDTA (Sigma-Aldrich). 
 10 ml Disposable Plastic Syringe without Needle (Terumo Europe N.V.). 
 2.5 ml Disposable Plastic Syringe without Needle (Terumo Europe N.V.). 
 Real-time PCR (Transnetyx, Cordova, USA). 
 Surflu Winged Infusion Set (Terumo Europe N.V.). 
2.9.1 Human Blood 
Blood was taken by venepuncture (median cubital vein) from healthy volunteers, 
after informed consent under the ethical approval from the School of Medicine 
Research Ethics Committee, reference number HSLTLM12045 (Appendix B). 
Before obtaining the blood, the first 2.5 ml of blood were discarded using 2.5 ml 
syringe and winged needle. Using 10 ml syringe and the same needle, 10 ml of 
fresh blood were collected in 1% v/v EDTA. 
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2.9.2 Murine Blood 
Murine blood was kindly provided by Dr Cédric Duval. All procedures were 
performed according to accepted standards of humane animal care, approved 
by the ethical review committee of the University of Leeds, and conducted under 
license from the United Kingdom Home Office. All animals were maintained in 
individually ventilated cages, at 21°C 50-70% humidity, light/dark cycle 12/12  hrs 
on standard diet ad libitum. FGA-/- mice (Suh et al., 1995), on C57BL/6J 
background, were generated from FGA-/- (male) x FGA+/- (female) crossing, and 
genotypes were determined using real-time PCR. Animals were bled from the 
inferior vena cava, under terminal anaesthesia, with 1% v/v EDTA, and 
terminated by cervical dislocation. Three mice were used in the plate-binding 
assay method; 30 weeks old male, 21 and 28 weeks old females.  
2.9.3 Isolation of Red Blood Cells 
MATERIALS 
 10 mM PBS (One tablet of PBS dissolved in 200 ml of deionized water at 
25°C. Sigma-Aldrich). 
 Jouan CR3i centrifuge (DJB Labcare Limited, Buckinghamshire, UK). 
 
Blood was centrifuged at 1,040 g 4°C for 10 min. To wash the RBCs, a mark was 
drawn on the top of the plasma layer. The plasma was then removed, discarded 
and replaced by the same amount of PBS. The tube was then inverted gently 10 
times to mix the blood and PBS before centrifuging the blood at 1,040 g, 4°C for 
5 min, this washing step was repeated again for 3 more times. After the last 
wash, the supernatant was discarded and the produced RBCs were used in the 
different experiments. When the supernatant was discarded in each wash, a very 
small amount from the surface of the RBCs was discarded as well to ensure the 
elimination of white blood cells and other cells and that only RBCs were 
collected. Murine blood was isolated using the same method in a micro-
centrifuge. EDTA anticoagulation, centrifuge speeds and number of washes 
were taken from Carvalho et al. (2010). 
 
 
78 
 
2.10 Fibrinogen-Red Blood Cell Plate-Binding Assay 
MATERIALS 
 0.5% v/v DiD Vybrant™ Cell-Labelling Solution (Molecular Probes Europe 
BV, Leiden, The Netherlands). Mouse Anti-Human CD51/CD61 (Integrin 
alpha v beta 3 αvβ3) purified antibodies 100 µg (OriGene Technologies, 
Inc., Rockville, USA). 
 10 mM PBS (One tablet of PBS dissolved in 200 ml of deionized water at 
25°C. Sigma-Aldrich). 
 F96 Maxisorp Nunc-Immuno Plate NUNC (Sigma-Aldrich). 
 Fibrinogen, Plasminogen Depleted, Human Plasma (Calbiochem, San 
Diego, USA). 
 Mouse anti-Melanoma Human cells Monoclonal Antibody Integrin alpha V 
αV (NKI-M9) 200 µg (Santa Cruz Biotechnology, Inc., Dallas, USA). 
 Normal Mouse IgG unconjugated, affinity purified isotope control 
immunoglobulin 200 µg (Santa Cruz Biotechnology, Inc.). 
 Plastic Film Thermo Scientific™ Sealing Tapes (ThermoFisher Scientific). 
 Stuart Microplate Shaker/ SSM5 Shaker (Bibby Scientific Limited). 
 
 
Figure 2-3 A schematic representation of the steps of fibrinogen-RBCs plate 
binding assay. Coating with RBCs, adding fibrinogen, haemolysing, then storage for 
ELISA. 
 
Commercial fibrinogen was used in the optimisation steps. Washed RBCs were 
diluted to 5% haematocrit (Ht) in PBS. First, 100 µl/ well of the 5% RBCs were 
coated in a Maxisorp plate and incubated on a shaker at 400 rpm, room 
temperature for 1 hr. By the end of the incubation, the plate was washed gently 
3 times by PBS then drained on tissue between washes, to prevent hard tapping 
of the plate which may get rid of RBCs. To test the interaction of the RBC with 
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fibrinogen, 100 µl per well of 20 µg/ml of fibrinogen were incubated for 1 hr, on a 
shaker at 400 rpm, room temperature, and then washed as above. Next, the cells 
were haemolysed by adding 100 µl per well of ddH2O incubated for a few minutes 
on the shaker. The plate was then stored at -80°C overnight for future 
quantitation of RBC-bound fibrinogen by ELISA, as described in section 2.2.2 
and the results were analysed using Excel 2013 and GraphPad Prism 7.0 using 
one way ANOVA multiple comparison using WT as a control column and 
Dunnett’s test for p-value. A schematic representation of the method is shown in 
Figure 2-3. DiD Vybrant™ Cell-Labelling Solution was used in the optimisation 
steps of the experiment. 
The same experiment was done to determine the effect of some inhibitory 
antibodies on the binding between fibrinogen and RBCs. To each 20 µg/ml of 
WT fibrinogen, 10 µg/ml final concentration of either IgG, αV, αVβ3 antibodies 
were added in 100 µl total volume in PBS. 
2.11 Fibrinogen-Red Blood Cell Binding Assay in Solution  
MATERIALS 
 1% w/v (BSA) (Sigma-Aldrich). 
 10 mM PBS (One tablet of PBS dissolved in 200 ml of deionized water at 
25°C. Sigma-Aldrich). 
 Coating Fibrinogen Antibody: 3 µl of Polyclonal Rabbit Anti-Human 
Fibrinogen Antibody (DAKO, Agilent Technologies), 12 ml of Coating 
Buffer A (1:4000) dilution. 
 Dynex, MRX TC Revelation Microplate reader (LABEQUIP LTD). 
 Eptifibatide (Tocris, Abingdon, UK). 
 F96 Maxisorp Nunc-Immuno Plate NUNC (Sigma-Aldrich). 
 Mouse Anti-Human CD51/CD61 (Integrin alpha v beta 3 αvβ3) purified 
antibodies 100 µg (OriGene Technologies, Inc., Rockville, USA). 
 Mouse anti-Melanoma Human cells Monoclonal Antibody Integrin alpha V 
αV (NKI-M9) 200 µg (Santa Cruz Biotechnology, Inc., Dallas, USA). 
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 Normal Mouse IgG unconjugated, affinity purified isotope control 
immunoglobulin 200 µg (Santa Cruz Biotechnology, Inc.). 
 Plastic Film Thermo Scientific™ Sealing Tapes (ThermoFisher Scientific). 
 Stuart Microplate Shaker/ SSM5 Shaker (Bibby Scientific Limited). 
 Tube roller (Star Lab). 
 
 
Figure 2-4 A schematic representation of the steps of fibrinogen-RBCs binding 
assay in solution.  Mixing fibrinogen and RBCs in solution, transfer to ELISA plate, 
haemolysis then read fibrinogen released at 405 nm. 
 
A Maxisorp plate was coated with 100 µl Fibrinogen Antibodies (1:4,000) on a 
shaker at room temperature, 400 rpm for 1 hr then blocked by 300 µl of 1% BSA 
overnight in the cold room. The next day, fibrinogen and RBCs were mixed 
together in PBS as follows, 20 µg/ml of fibrinogen were incubated with 5% Ht of 
RBCs to 300 µl total volume on a roller at room temperature for 30 min. The plate 
was washed once using the ELISA washing buffer before adding 100 µl of the 
fibrinogen-RBC mix in duplicates and incubating on a shaker at 400 rpm, room 
temperature, for 2 hrs. The plate was then washed 3 times by PBS, drained 
gently, before adding 100 µl ddH2O per well to haemolyse the RBCs. The plate 
was incubated on the shaker at 400 rpm room temperature for a few minutes for 
the haemolysis. The produced haemoglobin was then measured using endpoint 
Dynex, Microplate reader at 405 nm filter. The results were analysed using Excel 
2013 and GraphPad Prism 7.0 using one way ANOVA multiple comparison using 
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WT as a control column and Dunnett’s test for p-value. A schematic 
representation of the method is shown in Figure 2-4.  
The same experiment was done to determine the effect of some inhibitory 
antibodies in addtiton to the αIIbβ3 integrin inhibitor eptifibatide on the binding 
between fibrinogen and RBCs. To each 20 µg/ml of WT fibrinogen, 10 µg/ml final 
concentration of either IgG, αV, αVβ3 antibodies or 5 µg/ml of eptifibatide were 
added together with 5% RBC in 300 µl total volume in PBS.  
2.12 Flow Cytometry  
MATERIALS 
 10 mM PBS (One tablet of PBS dissolved in 200 ml of deionized water at 
25°C. Sigma-Aldrich). 
 BD LSR Fortessa™ Cell Analyser from BD Bioscinces (Becton, Dickinson 
U.K. Limited). 
 CD235a (Glycoprotein A)- phycoerythrin (PE) Antibody (Miltenyi Biotec 
GmbH, Bergisch Gladbach, Germany). 
 Eppendorf™ MiniSpin™ Microcentrifuges (Sigma-Aldrich). 
 FacsDiva™ software from BD Bioscinces (Becton, Dickinson U.K. 
Limited). 
 Fibrinogen From Human Plasma, AlexaFluor488 Conjugate (ThermoFisher 
Scientific). 
 Haemocytometer (Optik Labor, Neubauer Improved, Lancing, UK), Depth 
0.100 mm and 0.0025 mm2. 
 Mouse Anti-Human CD51/CD61 (αvβ3) purified 100 µg (OriGene 
Technologies, Inc.). 
 Mouse anti-Melanoma Human cells Monoclonal Antibody Integrin alpha V 
αV (NKI-M9) 200 µg (Santa Cruz Biotechnology, Inc.). 
 Normal Mouse IgG unconjugated, affinity purified isotope control 
immunoglobulin 200 µg (Santa Cruz Biotechnology, Inc.). 
 Tube roller (Star Lab). 
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Red blood cells were counted using a haemocytometer. To prepare the samples, 
1x104 RBC/ml were added to 5 µg/ml final concentration of AlexaFluor488-
labelled fibrinogen to the final volume of 400 µl in PBS. 20 µl of CD235a 
antibodies (RBC marker) were then added to the cell-protein mixture and 
incubated on the roller for 30 min at RT in foil wrapped tubes. Next, cells were 
washed by adding 400 µl PBS, mixed gently then centrifuged for 5 min at 1,000 
g on a micro-centrifuge. The supernatant was discarded and the cells re-
suspended in 400 µl PBS, mixed gently again, and then taken to the flow 
cytometer and analysed using FacsDiva™ software.  
RBC-bound fibrinogen was quantified on the basis of fluorescence of the  
phycoerythrin (PE)-conjugated CD235a antibodies and AlexaFluor488-labelled 
fibrinogen. Fluorescence was detected using a 488 nm laser and 530/30 nm 
band pass (bp) filter for AlexaFluor488, and 575/26 nm bp filter for PE. Several 
controls were used; PE-labelled RBCs an AlexaFluor488-labelled commercial 
fibrinogen separately, and compensated for bleed-over from one channel into 
the other. Bleed-over compensation was taken out according to the controls. 
Labelled RBCs and fibrinogen were separated according to the forward FSC and 
side SSC scatter. The results were analysed using Excel 2013 and GraphPad 
Prism 7.0 using one way ANOVA multiple comparison using WT as a control 
column and Dunnett’s test for p-value. A schematic representation of the gating 
strategy is shown in Figure 2-5. 
The experiment was performed using the same inhibitory antibodies as in the 
solution assay to study the binding site of fibrinogen on the RBC. 
Flow cytometry experiments were performed with the help of Dr Sally Boxall, Bio-
imaging and Flow Cytometry Facility Manager, Faculty of Biological Sciences, 
University of Leeds. 
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Figure 2-5 A schematic representation of the gating strategy of the flow 
cytometric experiment of the fibrinogen and RBCs interaction. FSC and SSC 
gate, gated on RBCs population then CD235a labelled then to fibrinogen labelled. % of 
positive labelling for PE and FITC was measured. 
 
2.13 Platelet Spreading Assay 
2.13.1 Isolation of Human Platelets  
MATERIAL 
 0.3 Citric Acid: Citric Acid Monohydrate (Sigma-Aldrich). 
 10 ml Disposable Plastic Syringe without Needle (Terumo Europe N.V.). 
 2.5 ml Disposable Plastic Syringe without Needle (Terumo Europe N.V.). 
 50 ng/ml Prostaglandin E1 (PG E1) (Sigma-Aldrich). 
 Acid Citrate-Dextrose ACD: 113.8 mM D-Glucose Anhydrous 
(ThermoFisher Scientific), 29.9 mM Tri-Na Citrate dehydrate (Sigma-
Aldrich), 72.6 mM NaCl, 2.9 mM Citric Acid Monohydrate (Sigma-Aldrich). 
 Modified Tyrodes Buffer MTB: 15 mM NaCl, 5 mM HEPES Sodium Salt 
(Sigma-Aldrich), 0.55 mM NaH2PO4 anh. (Sigma-Aldrich), 7 mM NaHCO3 
anh. (ThermoFisher Scientific), 2.7 mM KCl, 0.5 mM magnesium chloride 
MgCl2 (ThermoFisher Scientific), 5.6 D-Glucose Anh. 
 Wash Buffer: (0.036 M Citric Acid Monohydrate (Sigma-Aldrich), 0.01 M 
EDTA (Sigma-Aldrich), 0.005 M Glucose (ThermoFisher Scientific), 0.005 
M KCl (Sigma-Aldrich), 0.09 M NaCl, 2.9 mM Citric Acid. 
 Z1 Coulter® Particle Counter (Beckman Coulter). 
 
 
84 
 
Platelets were kindly provided by the laboratory of Prof Khalid Naseem using 
method that is adapted and based on (Vargas et al., 1982). All buffers were 
incubated at 37°C before use. Venous blood was collected into 1:5 ACD 
containing tube using the same phlebotomy protocol as section 2.9.1. Blood was 
centrifuged at 200 g, 20°C for 20 min. Next, platelet rich plasma was transferred 
into a clean 12 ml falcon tube, and then PG E1 was added to platelets in a final 
concentration of 50 ng/ml to prevent platelet activation. platelet rich plasma 
containing PG E1 was centrifuged at 800 g, 20°C for 12 min. After centrifugation, 
platelet poor plasma supernatant was removed and the tube was left to drain. 
The pellet was gently re-suspended in 1 ml of MTB and counted using the Z1 
coulter. 
2.13.2 Staining of Actin Fibres in Spread Platelets for Fluorescent 
Microscope 
MATERIALS  
 0.2% Triton-X 100 in water. 
 10 mM PBS (One tablet of PBS dissolved in 200 ml of deionized water at 
25°C. Sigma-Aldrich). 
 200 U/ml AlexaFluor488-Phalloidin (Molecular Probes™ Invitrogen 
detection technologies).  
 5 mg/ml Fatty Acid Free BSA 10 G (Sigma-Aldrich): was boiled for 10 min 
to denature the protein and cooled down before used. 
 Corning® Costar® TC-Treated 24-Well Plates (Corning®). 
 Cover glass 13 mm round thickness of 0.13-0.17 mm (VWR Lutterworth, 
UK). 
 Fisherbrand Microscopic Slides T/F Ground 1.0-1.2 mm (ThermoFisher 
Scientific). 
 Paraformaldehyde, 4% in PBS (ThermoFisher Scientific). 
 Vectashield Mounting Medium for Fluorescence (Vector Laboratories, 
Inc., Burlingame, USA). 
 Zeiss AX10 Fluorescent Microscope (Zeiss). 
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The experiment was started by coating coverslips with 200 µl of 100 µg/ml 
fibrinogen on the centre of each cover slip, which were placed in the wells of a 
24-well plate. The plate was incubated in a humidity chamber at 4°C overnight. 
Next morning, the coverslips were washed 3 times by 300 µl of PBS. Washing 
steps were repeated between every step of the experiment. The coverslips were 
blocked by adding 300 µl per well of denatured BSA and incubated at room 
temperature for 1 hr. Next, 300 µl per well of 5 x 106 Cell/ml washed platelets 
were added and incubated at 37°C for 45 min then fixed by 300 µl per well of 4% 
Paraformaldehyde at room temperature for 10 min. Subsequently, platelets were 
permeabilised with 300 µl per well of 0.2% Triton-X100 at room temperature for 
5 min, before 1 unit (5 µl) of Phalloidin in 300 µl per well of PBS were added to 
each well, and incubated at room temperature, in the dark for 1 hr. The coverslips 
were mounted on slides by adding a tiny drop of mounting medium on the slide 
then the coverslip was transferred on the slide with the platelets facing the slide. 
Care was taken not to introduce bubbles. The slides were left in the dark for 
about 1 hr to dry, then stored in the cold room to be imaged the next day. The 
slides were imaged by 63x oil lens of Zeiss fluorescent microscope, at 
wavelength 495-518 nm, using Zen Software and analysed using ImageJ by 
applying automatic threshold to calculate Platelet count/ field of view 
(1790.52X1341.60 micron) and percent surface coverage. The results were 
analysed using Excel 2013 and GraphPad Prism 7.0 using one way ANOVA 
multiple comparison using WT as a control column and Dunnett’s test for p-value. 
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Chapter 3 Recombinant Fibrinogen Generation 
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3.1 Introduction 
In this project, six different mutants were produced in the coiled-coil region of the 
Aα-chain of fibrinogen. The initial concept of the choice of the new residues to 
be introduced relied on changing the charge of the side-chain of the original 
residue, whilst ensuring that the new residue has a similar size. The main 
residues R95 (positive) and D97 (negative) were changed following this concept 
to neutral amino acids (Q95 and N97) and oppositely charged amino acids 
(negative E95 and positive K97). F98I was chosen because it is a naturally 
occurring mutant that was described previously in a patient and it is located 
immediately after the RGD sequence (Riedelova-Reicheltova et al., 2014). G96V 
was not in the initial plan of the project, but was produced because it was 
described to have an effect on the interaction between fibronectin and fibroblast 
(Pierschbacher and Ruoslahti, 1984). 
The process of generating the mutated fibrinogen was started by Site-Directed 
Mutagenesis which is a fundamental tool that has been used in modern 
recombinant DNA technology and which introduces a specific new nucleotide 
substitution in the gene sequence and its coded protein (Ho et al., 1989). A big 
part of this project was the production of mutated fibrinogen; this was achieved 
by transfecting the mutated expression vector pMLP-Aα in CHO cells. The Aα 
expression vector was constructed by the insertion of a pVuII/SspI Aα cDNA 
fragment from p549.12 into p284 cleaved with SmaI, the vector was sequenced 
to confirm the absence of other accidental mutations (Binnie et al., 1993). The 
cells were simultaneously co-transfected with the selection plasmid pMSV-His. 
CHO cells have the advantage of expressing and secreting a significantly 
constant level of recombinant fibrinogen for a long period in serum free medium 
(Kim et al., 2012). This fibrinogen is found to be stable for a few days at 37°C 
(Binnie et al., 1993). L-histidinol selection is dependent on the fact that removal 
of an essential amino acid (histidine) would stop the growth of the cells and 
subsequently causes their death. Addition of a single gene coding for an enzyme 
(histidinol dehydrogenase) able to metabolise a precursor into the lacking amino 
acid that is able to penetrate the cell membrane is the basis of this selection 
strategy (Hartman and Mulligan, 1988). In a medium that is lacking the essential 
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amino acid histidine, but contains its precursor L-histidinol, cells can grow and 
survive if they are able to metabolise it to histidine by the action of histidinol 
dehydrogenase, an enzyme that catalyses the terminal reaction of histidine 
biosynthesis in bacteria and is a product of the hisD gene (Hartman and Mulligan, 
1988). Only cells successfully transfected with pMSV-His can survive in the 
presence of L-histidinol. 
After successful transfection, protein was expressed in CHO cells then 
precipitated by ammonium sulfate. Protein solubility increases by the addition of 
salt, which is called salting-in, however this solubility decreases to the extent of 
precipitation by increasing the salt concentration above the saturation level, 
which is called salting-out (Wingfield, 2001). The use of salt saturation of 
ammonium sulfate in precipitating proteins is dependent on the concentration 
and nature of the protein, in addition to the pH and temperature of the solution. 
5-10% oversaturating the salt would precipitate about 90% of the protein (King, 
1972). However, salting out does not result in a homogenous protein lysate, the 
produced protein will require some more steps to be purified. Next, proteins were 
purified using antibody affinity chromatography in which the column was packed 
with immobilised calcium-dependent IF1 monoclonal antibody, which is the solid 
phase that allows the separation of the contaminants (Cuatrecasas, 1970, 
Coelho et al., 2012). When proteins passed through the column, fibrinogen which 
has high affinity for the antibodies, in the presence of calcium, binds whereas 
other proteins will flow through. Fibrinogen was later eluted by EDTA which 
chelate calcium (Cuatrecasas, 1970, Coelho et al., 2012). 
This chapter will cover the production of six mutated fibrinogen starting from 
primer design through transfection, expression, purification and finally the 
confirmation of purity and integrity of the produced fibrinogen. 
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3.2 Results  
3.2.1 Generation of Mutants by Site-Directed Mutagenesis 
Mutagenesis for R95Q and D97N was repeated a number of times (12 attempts) 
in order to get bacterial colonies after the transformation step. This was achieved 
by changing the conditions in the reaction one at a time in each repeat (Table 3-1, 
Table 3-3) and changing the PCR run conditions (Table 3-2, Table 3-4). 
Mutagenesis for the new mutants (R95E and D97K) was started from the last 
optimised conditions stage of the R95Q and D97N that successfully generated 
the mutated colonies. However, more optimisations were again required to 
produce these new mutants, because with some conditions, colonies were 
produced but they did not have the mutations as stated in Table 3-6 which shows 
the reaction conditions and Table 3-4, demonstrating PCR runs accompanying 
each condition. In contrast, G96V produced the mutated colonies from the first 
attempt (Table 3-6). Work on F98I was started at the roller bottle of fibrinogen 
expression stage, because the previous stages (mutagenesis and transfection) 
were performed by a visiting collaborator (Miss Ana Filippa Guedes, University 
of Lisbon).  
Mutagenesis was performed using QuickChange II Site-Directed Mutagenesis 
Kit, as described in Table 3-1. 
R95Q 
This was the first mutant produced as shown in Table 3-1. First, the PfuUltra 
High-Fidelity DNA polymerase was used following the Site-Directed Mutagenesis 
protocol, employing different amounts of template DNA (10, 20, 40 ng) and XL1-
Blue Super-Competent Cells, but no colonies were produced.  A few changes to 
the protocol were undertaken to optimise the method. The focus in these 
attempts was by changing the PCR conditions (Table 3-2). Extension time was 
decreased to reduce copy error, whereas PCR cycle number was increased to 
18 cycles since 16 cycles is recommended by the Site-Directed Mutagenesis 
protocol for a single amino acid change, but this failed to produce results. 
Increasing the number of cycles to 18 was suggested to increase the yield by 
 
 
90 
 
enhancing the chance for the mutated cDNA to be replicated, which is still within 
the optimum number of cycles that preserve the enzyme and other reaction 
constituent efficiency. However, these changes did not affect the reaction and no 
colonies were produced. 
Table 3-1 Site-Directed Mutagenesis first set of attempts for R95Q and D97N using 
QuickChange II Site-Directed Mutagenesis Kit. Each total reaction is 50 µl, reaction 
steps and mixtures that were used are summarised in separate table. 
Conditions 
Attempts 
1 2 3 4 
Mutation R95Q, D97N R95Q, D97N R95Q, D97N R95Q, D97N 
Template DNA 10, 20 ng 20, 40 ng 20, 40 ng 20, 40 ng 
Reaction 
Buffer 
1X 
dNTP 200 µM 
Primers (F+R) 
each 
125 ng 
PfuUltra High-
Fidelity DNA 
polymerase 
2.5U 
PCR  
PCR 
reaction A 
for 16 cycles 
PCR 
reaction B 
for 18 cycles 
PCR 
reaction A 
for 16 cycles 
PCR 
reaction A 
for 18 cycles 
DpnI (1 hr at 37°c) 10 U/µl 
Transformation 50µl of XL1-Blue Super-Competent Cells 
DpnI treated DNA 1 µl 4 µl 
Results No colonies 
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Table 3-2 PCR steps that were used in the first set of attempts for R95Q and D97N. 
PCR Steps PCR Reaction A PCR Reaction B 
Initial 
Denaturation 
95°C for 30 sec 95°C for 30 sec 
Cycle 
Denaturation 
95°C for 30 sec 95°C for 30 sec 
Cycle Annealing 55°C for 60 sec 55°C for 60 sec 
Cycle Extension 68°C for 435 sec 68°C for 390 sec 
 
Following successive failures to obtain colonies, the next step was to change the 
enzyme to Phusion High-Fidelity DNA Polymerase, in addition to various 
changes among the different attempts in the PCR mixture (Table 3-3), as well as 
reaction conditions (Table 3-4). These changes included using different amounts 
of template DNA ranging from low (5 ng) to high (40 ng). The bacteria which were 
used for transformation were replaced by XL10 Gold Ultra-Competent Cells, 
which provide the highest efficiency available for the E. coli strains for 
transformation of ligated and large DNA.  
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Table 3-3 Site-Directed Mutagenesis second set of attempts for R95Q and D97N 
using Phusion® High-Fidelity DNA Polymerase Mutagenesis Kit. Each total 
reaction is 50 µl, PCR reactions steps that were used are summarised in separate table. 
Conditions 
Attempts 
5 6 7 8 9 10 11 12 
Mutation R95Q R95Q R95Q 
R95Q 
D97N 
R95Q D97N D97N D97N 
Template 
DNA 
5 
 ng 
20,40 
ng 
10,40 
ng 
10,40 
ng 
20,40 
ng 
10,20,40 
ng 
10,20 
ng 
10,20 
ng 
Phusion 
Buffer (HF) 
1X 
GC buffer - 1X - - - - - - 
dNTP 200 µM 
Primers 
(F+R) each 
0.5 µM 0.5 µM 0.5 µM 
0.5 µM 
New 
0.5 µM 0.5 µM 0.5 µM 
0.5 µM 
Old 
DMSO - - 6% 2,12% 6% 2, 6% 6% 6, 12% 
Phusion 
Polymerase 
1U 1U 1U 1U 2U 2U 2U 2U 
PCR  
C for 
25 
cycles 
D for 
35 
cycles 
E reaction for 18 cycles 
DpnI (10U/µl) 10 U/µl 
Parental DNA 
Digestion 
Time 
1 hr 
1:30 
hrs 
1:30 hrs 
Transformation 
50µl of XL1-Blue 
Super-Competent 
Cells 
XL10 Gold Ultra-Competent Cells 
DpnI treated 
DNA 
1 µl 
Results No colonies 
Presence 
of 
mutated 
colonies 
Colonies, no 
mutation 
Presence 
of 
mutated 
colonies 
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Table 3-4 PCR steps. These PCR conditions were used in the second set of attempts 
for R95Q and D97N in addition to all attempts of R95E, G96V and D97K. 
Step 
PCR Reaction 
C 
PCR Reaction 
D 
PCR Reaction 
E 
Initial 
Denaturation 
98°C for 30sec 98°C for 30sec 98°C for 30sec 
Cycle Denaturation 98°C for 10sec 98°C for 10sec 98°C for 30sec 
Cycle Annealing 72°C for 30sec 72°C for 105sec 60°C for 30sec 
Cycle Extension 72°C for 30sec - 72°C for 210sec 
Final Extension 72°C for 420sec 72°C for 600sec 72°C for 600sec 
 
In order to improve the efficiency of the mutagenesis reaction, some additives 
were used according to the manufacturer’s instructions. One of the additives was 
DMSO and the other was the GC buffer, the later buffer was used only once 
replacing the HF buffer. Both additives were to improve the amplification and 
reaction performance for the difficult templates with high GC or secondary 
structure contents. 
During the optimisation process, one major change was undertaken that was 
using new primers after evaluating the primers physical properties. The primers 
of R95Q (forward and reverse) were analysed using OligoEvaluator™, an online 
software by Sigma-Aldrich used to assess the presence of secondary structures, 
which make amplification difficult. Based on the results of the primer properties 
analysis by the OligoEvaluator™ which are shown in Table 3-5, new shorter 
primers were designed. Both the original forward and reverse primers of R95Q 
mutant had moderate secondary structures and 40% GC contents and no primer 
dimer. The new primers had weak secondary structures and 34.9% GC contents, 
which was less than the original. Melting temperatures (Tm) for the modified 
(77.9°C) primers were a slightly less than the original ones (82.2°C). Taking into 
account all analysis, the data would suggest that the secondary structure could 
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be the factor that had affected the primer efficiency and prevented the successful 
insertion of the mutation in the DNA. 
The final change in the optimisation process was by increasing the Phusion High-
Fidelity DNA Polymerase up to 2U as recommended by the protocol depending 
on the primer length and complexity. Finally, this time, colonies were produced; 
and by sequencing, the correct mutation was found in the extracted DNA 
plasmid.  
D97N 
The generation of this mutant started for the first few attempts with the PfuUltra 
High-Fidelity DNA polymerase Site-Directed Mutagenesis protocol, in line with 
R95Q and showed the same negative results (Table 3-1).  
When the R95Q primers were evaluated, D97N primers were evaluated as well 
for their physical properties using the OligoEvaluator™ and the results are shown 
in Table 3-5. In case of D97N both forward and reverse original primers had 
strong secondary structures, which were improved to moderate secondary 
structures in both new primers. The GC content of the new primers were slightly 
higher (36.4%) than the original ones (35.6%). Original reverse D97N was the 
only primer to have primer dimer. Again, Tm for each modified primer was a 
slightly less than the original ones. 
The generation of D97N was temporarily stopped, whilst R95Q was being 
generated, then resumed after the successful generation of R95Q mutant. The 
same successful conditions of the last attempt of R95Q mutant were used as 
described in Table 3-3 and Table 3-4. The results were presence of colonies; 
nonetheless, the DNA sequencing showed that the cDNA was not mutated yet. 
The experiment was repeated again with only one change, which was increasing 
the DpnI digestion time to 1:30 hrs, in order to allow longer time for the enzyme 
to digest the parent DNA. At the end of the experiment, colonies were present, 
but the DNA sequencing indicated that the mutations were not present yet. 
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Table 3-5 Oligo Evaluator Results by Sigma. Representation of the some of elements that included in the primers’ assessment by Oligo Evaluator 
website for the presence of secondary structure. 
Sequence 
Type 
Oligo 
Type 
Sequence Base Count 
Tm 
(°C) 
GC% 
Primer 
Dimer 
Secondary 
Structure 
Original R95Q-F 
CGTTGACCACTAATATAATGGAAATTTTGCAAGGCGATTTTTCCT
CAGCC 
A =  14,  U = 0,  G = 9,  C = 11,  T = 16,  
I = 0, Total = 50 
82.6 40 No Moderate 
Modified R95Q-F2 CGTTGACCACTAATATAATGGAAATTTTGCAAGGCGATTTTTC 
A =  13,  U = 0,  G = 8,  C = 7,  T = 15,  
I = 0, Total = 43 
77.9 34.9 No Weak 
Original R95Q-R 
GGCTGAGGAAAAATCGCCTTGCAAAATTTCCATTATATTAGTGGT
CAACG 
A =  16,  U = 0,  G = 11,  C = 9,  T = 14,  
I = 0, Total = 50 
82.6 40 No Moderate 
Modified R95Q-R2 GAAAAATCGCCTTGCAAAATTTCCATTATATTAGTGGTCAACG 
A =  15,  U = 0,  G = 7,  C = 8,  T = 13,  
I = 0, Total = 43 
77.9 34.9 No Weak 
Original D97N-F TATAATGGAAATTTTGAGAGGCAATTTTTCCTCAGCCAATAACCG 
A =  15,  U = 0,  G = 8,  C = 8,  T = 14,  
I = 0, Total = 45 
79.1 35.6 No Strong 
Modified D97N-F2 CGTTGACCACTAATATAATGGAAATTTTGAGAGGCGATTTTTCC 
A =  13,  U = 0,  G = 9,  C = 7,  T = 15,  
I = 0, Total = 44 
77.9 36.4 No Moderate 
Original D97N-R CGGTTATTGGCTGAGGAAAAATTGCCTCTCAAAATTTCCATTATA 
A =  14,  U = 0,  G = 8,  C = 8,  T = 15,  
I = 0, Total = 45 
79.1 35.6 Yes Strong 
Modified D97N-R2 GGAAAAATCGCCTCTCAAAATTTCCATTATATTAGTGGTCAACG 
A =  15,  U = 0,  G = 7,  C = 9,  T = 13,  
I = 0, Total = 44 
77.9 36.4 No Moderate 
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The original primers were used again with some changes this time, 2U of the 
Phusion High-Fidelity DNA Polymerase was used instead if 1U of the enzyme as 
in the previous attempts of the original primers. Moreover, DMSO was used to 
overcome the secondary structure and even the primer dimer; these conditions 
combined successfully produced D97N mutated colonies.  
R95E 
The mutagenesis process for this variant started following the successful 
generation of R95Q and D97N. Representation of the attempts can be found in 
Table 3-6 and PCR conditions are shown in Table 3-4. 
A few attempts were performed for R95E mutant using 10 ng and 20 ng of 
template DNA and different concentrations of DMSO, but the results were either 
no colonies or colonies where the mutation was not present, as shown in 
Table 3-6. Finally mutated colonies were present in the fourth attempt, when 10% 
DMSO was used. 
D97K 
This mutant was generated in line with the R95E mutant, but it did not produce 
colonies for the conditions used for R95E mutant, as shown in Table 3-6 (PCR 
conditions are shown in Table 3-4). 
One more attempt for D97K was performed by increasing the amount of Phusion 
High-Fidelity DNA Polymerase up to 3U. This change was successful and 
generated D97K bacterial colonies.   
G96V 
Only one attempt was enough to produce the successful mutated colonies of 
G96V mutation using 20 ng DNA, 6% DMSO and 2U Phusion polymerase as 
shown in Table 3-6 (PCR conditions are shown in Table 3-4).  
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Table 3-6 Site-Directed Mutagenesis attempts for R95E, G96V and D97K using 
Phusion® High-Fidelity DNA Polymerase Mutagenesis Kit. Each total reaction is 50 
µl, PCR reactions steps that were used are summarised in separate table. 
Conditions 
Attempts 
1 2 3 4 5 6 
Mutation 
R95E 
D97K 
R95E 
D97K 
R95E 
D97K 
R95E 
D97K 
D97K G96V 
Template DNA 20 ng 
10,20 
ng 
10,20 
ng 
20 ng 20 ng 20 ng 
Phusion Buffer 
(HF) 
1X 
dNTP 200 µM 
Primers (F+R) 
each 
0.5 µM 0.5 µM 0.5 µM 0.5 µM 0.5 µM 0.5 µM 
DMSO 12% 6% 6% 8, 10% 6, 10% 6% 
Phusion 
Polymerase 
2U 2U 2U 2U 3U 2U 
PCR  E reaction for 18 cycles 
DpnI (10U/µl) 10 U/µl 
Parental DNA 
Digestion Time 
1:30 hrs 
Transformation XL10 Gold Ultra-competent Cells 
DpnI treated DNA 1 µl 3 µl 1 µl 
Results 
Colonies, no 
mutation 
No colonies 
Colonies R95E  
10% DMSO 
Presence of mutated 
colonies 
 
3.2.2 Sequencing  
The next step after mutagenesis of all the constructs was DNA extraction and full 
mutated Aα-chain cDNA sequencing. The converted amino-acid sequences of 
the five mutants are shown in the next few tables. Amino acids numbering is for 
the mature protein, and starts at position 20 (A, red) where the pro-peptide is 
cleaved and the mature fibrinogen starts. Full DNA sequence is presented 
in Appendix A. 
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For R95E, the original amino acid Arginine, which is positive (R, AGA), was 
replaced by a negative Glutamate (E, GAA) (Table 3-7). 
Table 3-7 Representatitive part from the sequencing alignment shows the results 
of R95E using the serial cloner programme. The sequencing shows replacement of 
R (Arginine) by E (Glutamate), highlighted in green. Red A is where the mature 
fibrinogen starts. 
WT       1  MFSMRIVCLVLSVVGTAWTADSGEGDFLAEGGGVRGPRVVERHQSACKDSDWPFCSDEDW 60 
R95E     1  MFSMRIVCLVLSVVGTAWTADSGEGDFLAEGGGVRGPRVVERHQSACKDSDWPFCSDEDW 60 
 
WT       61  NYKCPSGCRMKGLIDEVNQDFTNRINKLKNSLFEYQKNNKDSHSLTTNIMEILRGDFSSA 120 
R95E     61  NYKCPSGCRMKGLIDEVNQDFTNRINKLKNSLFEYQKNNKDSHSLTTNIMEILEGDFSSA 120 
 
WT       121  NNRDNTYNRVSEDLRSRIEVLKRKVIEKVQHIQLLQKNVRAQLVDMKRLEVDIDIKIRSC 180 
R95E     121  NNRDNTYNRVSEDLRSRIEVLKRKVIEKVQHIQLLQKNVRAQLVDMKRLEVDIDIKIRSC 180 
 
For R95Q, the original amino acid Arginine, which is positive (R, AGA), was 
replaced by a neutral Glutamine (R, CAA) (Table 3-8). 
Table 3-8 Representatitive part from the sequencing shows the results of R95Q 
using the serial cloner programme. The sequencing shows replacement of R 
(Arginine) by Q (Glutamine), highlighted in green. Red A is where the mature fibrinogen 
starts. 
WT       1  MFSMRIVCLVLSVVGTAWTADSGEGDFLAEGGGVRGPRVVERHQSACKDSDWPFCSDEDW 60 
R95Q     1  MFSMRIVCLVLSVVGTAWTADSGEGDFLAEGGGVRGPRVVERHQSACKDSDWPFCSDEDW 60 
 
WT       61  NYKCPSGCRMKGLIDEVNQDFTNRINKLKNSLFEYQKNNKDSHSLTTNIMEILRGDFSSA 120 
R95Q     61  NYKCPSGCRMKGLIDEVNQDFTNRINKLKNSLFEYQKNNKDSHSLTTNIMEILQGDFSSA 120 
 
WT       121  NNRDNTYNRVSEDLRSRIEVLKRKVIEKVQHIQLLQKNVRAQLVDMKRLEVDIDIKIRSC 180 
R95Q     121  NNRDNTYNRVSEDLRSRIEVLKRKVIEKVQHIQLLQKNVRAQLVDMKRLEVDIDIKIRSC 180 
 
For G96V, the original amino acid, Glycine (G, GGC) was replaced by a Valine 
(V, GTC) (Table 3-9). Both amino acids are neutral and this mutant was chosen 
based on the literature (Pierschbacher and Ruoslahti, 1984). 
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Table 3-9 Representatitive part from the sequencing shows the results of G96V 
using the serial cloner programme. The sequencing shows replacement of G 
(Glycine) by V (Valine), highlighted in green. Red A is where the mature fibrinogen starts. 
WT       1  MFSMRIVCLVLSVVGTAWTADSGEGDFLAEGGGVRGPRVVERHQSACKDSDWPFCSDEDW 60 
R95Q     1  MFSMRIVCLVLSVVGTAWTADSGEGDFLAEGGGVRGPRVVERHQSACKDSDWPFCSDEDW 60 
 
WT       61  NYKCPSGCRMKGLIDEVNQDFTNRINKLKNSLFEYQKNNKDSHSLTTNIMEILRGDFSSA 120 
R95Q     61  NYKCPSGCRMKGLIDEVNQDFTNRINKLKNSLFEYQKNNKDSHSLTTNIMEILRVDFSSA 120 
 
WT       121  NNRDNTYNRVSEDLRSRIEVLKRKVIEKVQHIQLLQKNVRAQLVDMKRLEVDIDIKIRSC 180 
R95Q     121  NNRDNTYNRVSEDLRSRIEVLKRKVIEKVQHIQLLQKNVRAQLVDMKRLEVDIDIKIRSC 180 
 
For D97K, the original amino acid Aspartate, which is negative (D, GAT), was 
replaced by a positive Lysine (K, AAA) (Table 3-10). 
Table 3-10 Representatitive part from the sequencing shows the results of D97K 
using the serial cloner programme. The sequencing shows replacement of D 
(Aspartate) by K (Lysine), highlighted in green. Red A is where the mature fibrinogen 
starts. 
WT        1 MFSMRIVCLVLSVVGTAWTADSGEGDFLAEGGGVRGPRVVERHQSACKDSDWPFCSDEDW 60 
D97K      1 MFSMRIVCLVLSVVGTAWTADSGEGDFLAEGGGVRGPRVVERHQSACKDSDWPFCSDEDW 60  
                 
WT        61 NYKCPSGCRMKGLIDEVNQDFTNRINKLKNSLFEYQKNNKDSHSLTTNIMEILRGDFSSA 120 
D97K      61 NYKCPSGCRMKGLIDEVNQDFTNRINKLKNSLFEYQKNNKDSHSLTTNIMEILRGKFSSA 120 
 
WT        121 NNRDNTYNRVSEDLRSRIEVLKRKVIEKVQHIQLLQKNVRAQLVDMKRLEVDIDIKIRSC 180 
D97K      121 NNRDNTYNRVSEDLRSRIEVLKRKVIEKVQHIQLLQKNVRAQLVDMKRLEVDIDIKIRSC 180 
  
For D97N, the original amino acid Aspartate (D, GAT), which is negative, was 
replaced by a neutral Asparagine (N, AAT) (Table 3-11). 
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Table 3-11 Representatitive part from the sequencing shows the results of D97N 
using the serial cloner programme. The sequencing shows replacement of D 
(Aspartate) by N (Asparagine), highlighted in green. Red A is where the mature 
fibrinogen starts. 
WT        1 MFSMRIVCLVLSVVGTAWTADSGEGDFLAEGGGVRGPRVVERHQSACKDSDWPFCSDEDW 60 
D97N      1 MFSMRIVCLVLSVVGTAWTADSGEGDFLAEGGGVRGPRVVERHQSACKDSDWPFCSDEDW 60  
                 
WT        61 NYKCPSGCRMKGLIDEVNQDFTNRINKLKNSLFEYQKNNKDSHSLTTNIMEILRGDFSSA 120 
D97N      61 NYKCPSGCRMKGLIDEVNQDFTNRINKLKNSLFEYQKNNKDSHSLTTNIMEILRGNFSSA 120 
 
WT        121 NNRDNTYNRVSEDLRSRIEVLKRKVIEKVQHIQLLQKNVRAQLVDMKRLEVDIDIKIRSC 180 
D97N      121 NNRDNTYNRVSEDLRSRIEVLKRKVIEKVQHIQLLQKNVRAQLVDMKRLEVDIDIKIRSC 180 
 
3.3 Protein Production 
3.3.1 Transfection 
Two different transfection methods were used in this project, because the initial 
protein yield was low. The first method was Calcium-Phosphate transfection (10 
or 20 µg of cDNA), which relies on shocking the cells with 10% glycerol to 
introduce the new plasmid. The second method involves Lipofectamine 2000 (11 
µg of cDNA), which relies on coating the plasmid in a liposome-like structure to 
facilitate its entry into cells. In both cases, transfection of cDNA was performed 
in CHO cells (containing fibrinogen Bβ- and γ-chains), that were grown in G418 
selection medium before transfection. The successfully transfected cells were 
selected by addition of the L-histidinol selection marker. Twenty-four clones that 
originated from single cells were plated in 24-well plates for each condition of 
Calcium-Phosphate method (R95Q, D97N) and up to 48 for Lipofectamine 
method (R95E, G96V, D97K). At 70-100% confluency, the cells were split into 
two 5 cm dishes, the supernatants were collected for ELISA and the highest 
fibrinogen producing clones, relative to their confluency (Figure 3-1, Figure 3-2, 
Figure 3-3, Figure 3-4, Figure 3-5), were frozen in liquid nitrogen, reserving 1 ml 
for further splitting into 10 cm dishes for the serum free expression stage. Once 
confluent, the cells were incubated in serum free medium for a week. By the end 
of the incubation period, cells were discarded but the supernatants were 
collected for a second ELISA to determine the clones which were to be taken 
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forward for the expression stage (in serum-free conditions). The highest six 
producing clones were frozen in LN2, while the others were discarded. 
Representative figures for the first ELISA results and the chosen clone are shown 
below. 
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For R95E (lipofectamine, 11 µg DNA), 41 clones were picked and the highest 
expressing clones were 6, 12, 13, 14, 15, 25, 26, 30, 31, 33, 37, 38 (Figure 3-1). 
 
Figure 3-1 Representation of the ELISA plate of R95E clones selection stage. The 
highest fibrinogen producing (11 µg DNA) clones highlighted in green (6, 12, 13, 14, 15, 
25, 26, 30, 31, 33, 37, 38). The numbers represent the ratio of concentration (ng/ml) to 
confluency at collection (%).    
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For R95Q (Figure 3-2), plate A (calcium-phosphate, 10 µg DNA), the highest 
expressing clones were 1, 2, 3, 4, 5, 6, 8, 10, 11, 12, 13, 14, 21, 22, 24. For plate 
B (calcium-phosphate, 20 µg DNA), the highest expressing clones were 3, 4, 5, 
8, 9, 11, 12, 13, 15, 20, 22. 
 
Figure 3-2 Representation of the ELISA plate of R95Q clones selection stage. The 
highest fibrinogen producing A (10 µg DNA) clones highlighted in green (1, 2, 3, 4, 5, 6, 
8, 10, 11, 12, 13, 14, 21, 22, 24). The highest fibrinogen producing B (20 µg DNA) clones 
highlighted in green (3, 4, 5, 8, 9, 11, 12, 13, 15, 20, 22). The numbers represent the 
ratio of concentration (ng/ml) to confluency at collection (%).  
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For G96V (lipofectamine, 11 µg DNA), 48 clones were picked up and the highest 
expressing clones were 12, 13, 20, 21, 37, 38, 40, 42, 43, 46, 47, 48 (Figure 3-3). 
 
Figure 3-3 Representation of the ELISA plate of G96V clones selection stage. The 
highest fibrinogen producing (11 µg DNA) clones highlighted in green (12, 13, 20, 21, 
37, 38, 40, 42, 43, 46, 47, 48). The numbers represent the ratio of concentration (ng/ml) 
to confluency at collection (%). Clone number 12 was above the highest level of the 
absorbance of the standard.    
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For D97K (lipofectamine, 11 µg DNA), 42 clones were picked up and the highest 
expressing clones were 1, 3, 4, 5, 7, 18, 24, 27, 28, 29, 37, 42 (Figure 3-4). 
 
Figure 3-4 Representation of the ELISA plate of D97K clones selection stage.  The 
highest fibrinogen producing (11 µg DNA) clones highlighted in green (1, 3, 4, 5, 7, 18, 
24, 27, 28, 29, 37, 42). The numbers represent the ratio of concentration (ng/ml) to 
confluency at collection (%).    
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For D97N (Figure 3-5), plate A (calcium-phosphate, 10 µg DNA) the highest 
expressing clones were 2, 3, 4, 6, 8, 10, 11, 12, 14, 18, 21, 23, 24. Plate B 
(calcium-phosphate, 20 µg DNA) the highest expressing clones were 1, 2, 6, 9, 
10, 12, 13, 15, 16, 20, 21, 24. 
 
Figure 3-5 Representation of the ELISA plate of D97N clones selection stage.  The 
highest fibrinogen producing A (10 µg DNA) clones highlighted in green (2, 3, 4, 6, 8, 
10, 11, 12, 14, 18, 21, 23, 24). The highest fibrinogen producing B (20 µg DNA) clones 
highlighted in green (1, 2, 6, 9, 10, 12, 13, 15, 16, 20, 21, 24). The numbers represent 
the ratio of concentration (ng/ml) to confluency at collection (%). 
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In the serum free conditions, the highest fibrinogen producing clones by the 
calcium-phosphate method were A12 for R95Q and A18 for D97N (Table 3-12), 
in addition to that performed by Miss Ana Filipa Guedes, A16 for F98I. The 
highest fibrinogen producing clones by Lipofectamine 2000 method were 14 for 
R95E, 12 for G96V and 37 for D97K (Table 3-13). These clones, which were 
used for fibrinogen expression in roller bottles, are highlighted in red, while the 
yellow highlighted clones were frozen in LN2 as a backup.  
Table 3-12 R95Q and D97N highest producing clones in serum free condition are 
highlighted in yellow. The two clones that proceeded to the expression stage are 
highlighted in red. 
R95Q D97N 
Clone number concentration ng/ml Clone number concentration ng/ml 
A1 123.50 A2 6.52 
A2 153.59 A3 7.49 
A3 160.20 A4 8.34 
A4 97.06 A6 10.80 
A5 89.96 A8 9.55 
A6 87.72 A10 8.84 
A8 44.62 A11 7.25 
A10 55.36 A12 12.63 
A11 30.94 A14 9.47 
A12 266.67 A18 16.56 
A13 32.39 A21 13.94 
A14 3.50 A23 9.00 
A21 27.53 A24 10.59 
A22 47.51 B1 4.74 
A24 52.76 B2 3.48 
B3 129.91 B6 5.98 
B4 82.09 B9 5.24 
B5 108.43 B10 6.45 
B8 63.13 B13 8.84 
B9 56.10 B15 10.34 
B11 47.45 B16 5.17 
B12 90.51 B20 6.56 
B13 84.81 B21 9.89 
B15 40.87   
B20 53.59   
B22 13.31   
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Table 3-13 R95E, G96V and D97K highest producing clones in serum free 
condition are highlighted in yellow. The two clones that proceeded to the expression 
stage are highlighted in red. 
R95E G96V D97K 
Clone 
number 
concentration 
ng/ml 
Clone 
number 
concentration 
ng/ml 
Clone 
number 
concentration 
ng/ml 
6 184.49 12 569.03 1 132.32 
12 303.41 13 179.69 3 57.46 
13 65.21 20 129.77 4 464.89 
14 392.45 21 178.75 5 308.00 
15 89.95 37 284.56 7 105.19 
25 242.24 38 4.64 18 82.56 
26 58.33 40 22.14 24 157.08 
30 52.85 42 13.32 27 189.30 
31 28.20 43 4.21 28 49.56 
33 223.76 46 125.93 29 10.79 
37 29.24 47 3.76 37 663.65 
38 291.92 48 62.75 42 115.60 
 
3.3.2 Fibrinogen Expression 
As with most of the experiments in this project, the expression of the mutants 
was performed in two different stages, R95Q, D97N and F98I followed by the 
second set of mutants R95E, G96V and D97K. The expression process itself 
was composed of two stages, in the first stage the cells and the bottles were 
prepared to be ready for fibrinogen expression on the roller system in the 
incubator. This stage included splitting the cells into flasks followed by 10 cm 
dishes and in the end by seeding them into the bottles. Cells were given 
adequate time to grow in the bottles until they reached confluency before adding 
the beads which were aimed at increasing the surface area for the cells to grow. 
Once the cells had adhered to the beads and confluent again, they were washed 
with serum free medium and incubated overnight in the same medium. Next, the 
second stage of ITS medium started by replacing the serum free medium with 
ITS medium, and the collection consisted of replacing and keeping 100 ml ITS 
medium per bottle, 3 times a week. ELISA was performed to evaluate the cell 
ability to produce fibrinogen and 24 collections of the fibrinogen production over 
eight weeks are shown in Figure 3-6.   
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Figure 3-6 Fibrinogen expression over time. The medium samples were collected 
from the roller bottles three times per week over 8 weeks and ELISA was performed 
every 2 weeks, and at the end of the collection, to evaluate the production of fibrinogen. 
 
For the first set of mutants (R95Q, D97N, F98I), fibrinogen production was fairly 
low, this is why the decision was made to use another method for transfection of 
subsequent mutants. Using Lipofectamine, the expression was enhanced and 
the amount of fibrinogen produced was increased. However, for R95E and 
G96V, most of the bottles were terminated early throughout the collection period, 
ending up with 5 roller bottles of R95E and only 3 bottles of G96V by the end of 
collection 24. This may be due to the high fibrinogen production, which was not 
well tolerated by the cells. In the discarded bottles, there were lots of dead cells 
without any signs of infection. The loss of these bottles had affected the final 
yield of fibrinogen production. 
3.3.3 Fibrinogen Purification 
The medium was collected for 8 weeks and precipitated with saturated 
ammonium Sulphate to precipitate the protein of interest. Ammonium sulphate 
was added slowly at 4°C to prevent denaturation of fibrinogen by creating an 
uneven pH around the protein. Foaming was avoided by slowing down the 
stirring during the addition of ammonium sulphate. The media was centrifuged 
after an overnight incubation and the pellet was re-suspended in a mixture of 
protease inhibitors to protect the protein from degradation. The dissolved pellet 
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was centrifuged again and the supernatant which contained the fibrinogen was 
stored at -80°C until purification. Fibrinogen was purified using an IF1 antibody 
(calcium dependent monoclonal antibody against fibrinogen) affinity 
chromatography using a number of buffers in each step of purification. The first 
step involves equilibration of the protein in neutral pH 7.4 and low salt in the 
presence of calcium ion to facilitate its attachment to the column. Next steps are 
washing of column-bound fibrinogen using high salt and low pH buffers to 
eliminate any contaminants, in the presence of calcium. The last step is the 
elution of fibrinogen from the column using an EDTA-containing buffer to chelate 
the calcium. The protein was stored at -80°C until finishing the purification of all 
precipitated solutions of each mutant. An example of the purification 
chromatograms is shown in Figure 3-7 for R95Q, F98I in addition to the wild type, 
which was kindly provided by Miss Helen McPherson (PhD student). The peaks 
of the two mutations are considerably lower compared to the wild type.  
 
Figure 3-7 An example representation of affinity chromatography purification of 
(a): WT, (b): R95Q, (c): F98I. The purification steps are injection, wash 1, wash 2, 
elution, equilibration using an extension coefficient of 1.51. Fibrinogen peak between 
120-160 ml for WT, 130-140 ml for R95Q and 120-140 ml for F98I. WT has been kindly 
provided by Miss Helen McPherson (PhD student). 
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3.3.4 Concentration and dialysis 
The yield was different among the different mutants. The purified fibrinogens for 
all mutations were concentrated by centrifugation then dialysed for 1 hr, 
overnight, and 1 hr, by replacing the dialysis buffer each time. The fibrinogen 
concentration was then measured against the dialysis buffer, using the 
NanoDrop and further concentrating was performed if required in some mutants 
to the final concentrations and volumes as shown in Table 3-14.  
Table 3-14 Final fibrinogen yield of each mutants and its final volume. 
Mutation Concentration Volume Total protein 
R95E 1.78 mg/ml 0.6 ml 1.07 mg 
R95Q 1.69 mg/ml 1.5 ml 2.53 mg 
G96V 0.21 mg/ml 2.5 ml 0.51 mg 
D97K 2.60 mg/ml 1.5 ml 3.98 mg 
D97N 1.04 mg/ml 1.0 ml 1.04 mg 
F98I 2.64 mg/ml 2.0 ml 4.53 mg 
 
3.4 SDS-PAGE 
The integrity and the purity of the produced fibrinogen chains for all variants were 
tested using SDS-PAGE and the results are shown in Figure 3-8. The gel shows 
that the samples are pure and contain all three fibrinogen chains with no 
significant degradation or contaminating proteins. 
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Figure 3-8 SDS page for all mutated fibrinogen against wild type fibrinogen. 2.5 
µg of protein were loaded and stained by coomassie blue dye. The gel represents all 
fibrinogen chains Bβ, γ and the mutated Aα-chain, with clear bands for each polypeptide 
chain, high purity and integrity and no noticeable protein degradation. The figure is a 
composite of two gels. 
 
3.5 Discussion  
The aim of this project was to test the effects of mutating the RGD sequence, 
located in the coiled-coil segment of the Aα-chain of fibrinogen, on the interaction 
of fibrinogen with RBCs. 
As indicated above, the design of the proposed mutations relied on changing the 
charge of the original amino acid to either a neutral or opposite charge as follows  
1. R95E: Arginine (+ve) to Glutamate (-ve) 
2. R95Q: Arginine (+ve) to Glutamine (neutral) 
3. D97K: Aspartate (-ve) to Lysine (+ve) 
4. D97N: Aspartate (-ve) to Asparagine (neutral) 
These changes of amino acids take the size of each amino acid into 
consideration, so that the replacement new amino acid has approximately the 
 
Aα 
  
Bβ 
γ 
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same size as the original residue. The reason for this strategy was that we could 
focus on the effect of changing the polar, charge-based interactions only, while 
excluding or minimising any other factors that may affect the properties of the 
new mutated fibrinogen. 
The next mutation that was produced was G96V, in which Glycine was replaced 
by Valine which are both hydrophobic. The choice for this mutation was based 
on a previous report from the literature (Pierschbacher and Ruoslahti, 1984). 
Pierschbacher and Ruoslahti produced synthetic fibronectin peptides then 
coupled them to immobilised fibronectin on plastic to study the ability of these 
peptides to attach to fibroblasts, they found that all the fibronectin synthetic 
peptides that stimulated this interaction with fibroblast contained the amino acid 
sequence of Arg-Gly-Asp-Ser or Arg-Gly-Asp-Cys (Pierschbacher and Ruoslahti, 
1984). A reduction was found in the attachment-stimulating activity of these 
peptides with the increase in their size, which they suggested resulted from less 
accessibility of these peptides to the substrate or lower stability of their 
conformation (Pierschbacher and Ruoslahti, 1984). The authors tested the 
attachment ability of these peptides by making different substitutions of the 
amino acids, one of these substitutions was replacing glycine by valine, which 
decreased the interaction of these peptides with fibroblasts (Pierschbacher and 
Ruoslahti, 1984). When these studies were applied to intact fibrinogen and fibrin, 
no interaction was found between immobilised fibrinogen on plastic surface and 
fibroblasts (Pierschbacher and Ruoslahti, 1984). Nonetheless, fibrinogen or fibrin 
polypeptides were transferred to nitrocellulose following their separation on SDS-
PAGE, then their attachment to fibroblast was tested; however, the attachment 
was found to be absent or very weak compared to fibronectin (Pierschbacher 
and Ruoslahti, 1984). It was suggested that this absence of interaction might be 
caused by destruction of the binding site on fibrinogen or because this binding 
site is cryptic. Another suggestion was that the effect of the binding site on 
fibrinogen might be weakened by its surrounding sequences leading to the loss 
of its recognition by the fibroblast (Pierschbacher and Ruoslahti, 1984). 
Comparing the hydrophobic sequences that are surrounding both the RGD 
sequences (amino and carboxylic) in fibronectin, these RGDs are surrounded by 
more hydrophilic sequences in fibrinogen (Pierschbacher and Ruoslahti, 1984).  
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The last fibrinogen mutation produced in this project was F98I, and this is the 
first time that this naturally occurring mutant has been produced as recombinant 
fibrinogen. This novel heterozygous mutation was first identified in a woman who 
had two repeated miscarriages, but she did not present with any history of 
thrombosis or bleeding (Riedelova-Reicheltova et al., 2014). Laboratory 
investigations revealed the presence of impaired polymerisation profile and 
fibrinolysis, in addition to increased platelet aggregation upon activation 
(Riedelova-Reicheltova et al., 2014). Scanning electron microscopy showed 
short curly fibrin fibres, which might be a result of decreased interaction between 
the Aα-98Ile (aliphatic side chain amino acid) with its neighbouring amino acids 
compared to the Aα-98Phe (bulky aromatic side chain amino acid) that can affect 
lateral aggregation of the protofibrils (Riedelova-Reicheltova et al., 2014). This 
mutation is situated just next to the RGD sequence, position 98 in the coiled-coil 
region, so was of interest to this project.  
Producing the mutants was a long process and included some difficulties and 
complications. The site-directed mutagenesis required a lot of optimisation and 
manipulation before the mutated colonies were successfully produced, 
especially for R95Q and D97N. The other mutations were slightly easier to 
produce because they were started from the last successful conditions of Site-
Directed Mutagenesis, although some more manipulations were still required, 
such as increasing the concentration of polymerase. Sequencing faced some 
mismatches when aligning the mutated fibrinogen plasmid with the published 
sequence of the protein. A new updated fibrinogen Aα-chain nucleobases 
sequence was used in which there was no effect on the amino acid sequences 
of the original fibrinogen. Transfection was quite a long process and every step 
depended on the previous one.  
In the clone selection stage, sometimes the cells were re-split to lower 
concentrations because it was not possible to harvest single cell clones if they 
were not sparse enough. Looking at the highest three clones that were chosen 
to proceed to the expression stage for the first set of mutants (R95Q, D97N and 
F98I), all of them were from the transfection with 10 µg of DNA, indicating this 
concentration is optimal for transfection. However, the Calcium-Phosphate 
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transfection was replaced by Lipofectamine 2000 transfection for R96E, G96V 
and D97K to increase transfection efficiency and only one concentration of DNA 
was used (11 µg). Comparing the two methods, in the former, HEPES saline 
solution was mixed with a solution that contained CaCl2 and DNA to produce a 
layer of calcium phosphate and DNA precipitate onto the cells, glycerol shock is 
used in this method to increase the efficiency of the transfection (Kingston et al., 
2003). In the latter method, a positive cationic lysosome surrounded the negative 
anionic DNA to facilitate its entry inside the cells through the negative charged 
cell membrane (Dalby et al., 2004). After transfection was completed and single 
clones were selected, medium was harvested from each clone for ELISA to 
evaluate fibrinogen production and keep the highest producing clone. Another 
ELISA was performed for the production in serum-free media of those high 
producing clones to choose the highest producing clone to be used in serum-
free conditions. The results of these two ELISAs showed an increase in the 
efficiency of the production of fibrinogen when Lipofectamine was used. 
However, for R95E and G96V, cell death was high during the expression stage 
for no obvious reason. One explanation may be related to the high fibrinogen 
production that was not tolerated by the cells. Another possibility is bacterial 
infection, which can be difficult to diagnose in atypical cases. Random insertion 
of the vector in the genome could be a third reason. This high production of 
fibrinogen did not help in the net yield of fibrinogen especially in the case of 
G96V, followed by R95E, because the cells died and many bottles were 
prematurely discarded, so the high production could not overcome the low 
amount of collected media. The loss of some of the protein during the 
precipitation, purification and concentration steps was also a limiting factor in 
obtaining high amounts of protein. After purification, the integrity of the produced 
mutated fibrinogens was tested by SDS-PAGE and showed that the produced 
fibrinogens contain intact fibrinogen chains Bβ and γ in addition to the mutated 
Aα-chain. All chains showed high purity and integrity. The produced fibrinogen 
was later used in the functional analysis of the clot structure, as well as the 
interaction between fibrinogen and RBCs in relation to the effect of these 
mutations, detailed in the next Chapters. 
 
 
 
116 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4 Effect of the Mutations on Clot Structure  
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4.1 Introduction  
The first step after successful production of the fibrinogen mutants (R95E, R95Q, 
G96V, D97K, D97N) in the Aα-RGD (95-97) sequence, in addition to the novel 
recombinant production of F98I (Riedelova-Reicheltova et al., 2014), was to 
study the effect of these mutations on the clot structure and stability. Fibrin fibre 
thickness and network density are major determinants of clot structure. Clots with 
thick fibres and loose fibrin conformation lyse faster than compact clots that are 
made up of thinner fibres (Collet et al., 2000). This most likely due to the fact that 
lysis is more dependent on the clot three-dimensional configuration rather than 
the fibre diameter (Standeven et al., 2005, Collet et al., 2000). The difference in 
lysis rate between coarse clots that are made up of thick fibres and fine clots with 
thin fibres may be because the binding fronts of tPA are wider in the coarse clot 
and moved faster when compared with fine clots (Weisel, 2007). Different factors 
can affect the polymerisation process and subsequently the clot conformation, 
including pH and ionic strength, calcium and chloride concentrations as well as 
other proteins in the plasma (Di Stasio et al., 1998, Carr et al., 1986). 
Factors that affect clot structure have an impact on its mechanical properties, 
which are essential for its haemostasis and wound healing functions (Standeven 
et al., 2005, Weisel, 2005, Di Stasio et al., 1998). Turbidity is a method that is 
used widely to monitor clot formation as a function of time (Weisel and 
Nagaswami, 1992). Alteration of fibrinogen and thrombin concentrations both 
have effects on the rate of polymerisation and hence final clot properties 
(Hantgan and Hermans, 1979). Increasing thrombin concentrations reduce the 
time to removal of fibrinopeptides, thereby decreasing the time of protofibril 
formation, as well as number of protofibrils packed in by lateral aggregation, 
which is known as the lag phase, hence affecting the clot structure producing 
clots with less stiffness (Hantgan and Hermans, 1979, Weisel and Nagaswami, 
1992, Domingues et al., 2016). In clots made of purified fibrinogen, high thrombin 
concentrations also decrease the final turbidity, which reflects the formation of 
thinner fibres because turbidity is directly related to the average size of fibre 
bundles or even a single fibre, which is known as maximum absorbance (OD)  
(Carr and Hermans, 1978, Weisel and Nagaswami, 1992, Undas et al., 2012). 
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There is no turbidity increase during the initial lag phase of half-staggered, 
double stranded protofibril formation, but turbidity increases rapidly as protofibril 
lateral aggregation takes place (Wolberg, 2007, Carr and Hermans, 1978).  
Alterations in fibrinogen concentrations also affect the polymerisation profile as 
well as clot structure. Higher fibrinogen levels shorten the lag phase, while 
increasing the fibre size and overall turbidity (Standeven et al., 2005). Calcium 
was found to affect clot structure by altering fibre thickness since it enhances 
lateral aggregation of protofibrils (Carr et al., 1986). It was suggested that binding 
of calcium ion to fragment D protects this fragment from being attacked by 
plasmin and induces certain plasmin resistant conformations of fibrinogen. 
These conformations are favourable for fibrinogen function in gelation and 
polymerisation, which may be stabilised by the effect of calcium ions (Haverkate 
and Timan, 1977, Okada and Blomback, 1983). The degree of crosslinking by 
FXIII may affect the structural changes of the clot at increasing calcium 
concentration and also increases in the rigidity of the gel, while in the absence 
of calcium no crosslinking can take place (Okada and Blomback, 1983). Although 
the release of both fibrinopeptides is only slightly affected by calcium 
concentrations, the presence of calcium decreases the activation required for 
gelation taking in consideration the shortening in the clotting time. Short 
polymers and compact clots are present with short clotting time while long 
polymers and porous structures are present with long clotting time (Okada and 
Blomback, 1983). 
This chapter will assess the secondary structures of the new proteins to confirm 
if the mutations affect the fibrinogen structure and function. The effect of the 
mutations on clot structure and function were studied using some of the well-
known techniques in this field. The ability of these new mutated fibrinogens to 
clot was tested by a clotability method followed by turbidity and lysis studies in 
which the effects of the mutations on clotting time, fibre thickness, and rate of 
lysis were evaluated. Clot fibre density was assessed by confocal microscopy.  
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4.2 Results  
4.2.1 Effect of the Mutations on Secondary Structure of the protein 
by Circular Dichroism Spectra 
Circular dichroism (CD) spectra were performed on the mutants in two different 
batches due to the availability of proteins at that time. CD spectra were used to 
study the effect of the mutations on the secondary structure of the protein. The 
results of each set of mutants were presented against the relevant WT and blank. 
CD spectra curves in Figure 4-1 show a slight decrease in α-helical content for 
the neutrally charged Q95 and N97 mutants, indicating that the charged residues 
might be important for the correct folding of the protein. However, this slight 
change in the secondary structure is considered minimal and largely does not 
affect protein functions.   
2 0 0 2 2 0 2 4 0 2 6 0
-3 0
-2 0
-1 0
0
1 0
2 0
W a v e le n g th  (n m )
C
D
  
S
p
e
c
tr
a
 (
m
d
e
g
r
e
e
) W T
R 9 5 Q
D 9 7 N
F 9 8 I
2 0 0 2 2 0 2 4 0 2 6 0
-3 0
-2 0
-1 0
0
1 0
2 0
W a v e le n g th  (n m )
C
D
  
S
p
e
c
tr
a
 (
m
d
e
g
r
e
e
) W T
R 9 5 E
G 9 6 V
D 9 7 K
 
Figure 4-1 Effect of the mutations on the integrity of the proteins using CD 
spectra. Total of 0.2 mg/ml of fibrinogen in final volume of 200 µl TBS. Experiments 
were performed (n=1). a) First set of mutatnt (R95Q, D97N, F98I) compared to WT. b) 
Second set of mutants (R95E, G96V, F98I) compared to WT.   
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A closer view of the α-helical content itself is shown in Table 4-1 which showed 
the slight decrease of R95Q and D97N as well as a slight increase of D97K. The 
overall structural analysis show that the secondary structure components of the 
mutants were almost the same as the WT, apart from the slight changes 
mentioned above.  
Table 4-1 Effect of the mutations on the composition of the secondary structure 
of the proteins using CD spectra. Total of 0.2 mg/ml of fibrinogen in final volume of 
200 µl TBS. n=1 
195-260 nm 
WT 
% 
R95E 
% 
R95Q 
% 
G96V 
% 
D97K 
% 
D97N 
% 
F98I 
% 
Helix 31.3 29.7 27.9 31.8 33.9 26.8 29.6 
Antiparallel 10.6 11.6 13.9 10.6 9.4 15 12.4 
Parallel 8.8 9.3 9.4 8.7 8.1 9.7 9 
β-turn 17.2 17.6 18.1 17.2 16.8 18.4 17.7 
Random 
Coil 
31.8 33.1 31.8 30.9 29.6 32.3 31.0 
 
4.2.2 Effect of Mutations on Clotability 
Fibrinogen clotability assay was performed in order to test the ability of the 
recombinant proteins to form a clot. The way in which the experiment was 
performed relied on the volume of the reaction constituents without consideration 
of the differences in concentrations between mutants because this way was 
more suitable for the low amount of available proteins. However, when the 
experiment was repeated for the purpose of protocol optimisation by a member 
of the group taking into account the concentration of the protein rather than 
relying on its volume, there was no significant difference from the data that was 
obtained by adjusting the concentrations. The concentration of the proteins was 
measured before adding the activation mix then in the supernatant after clot 
formation. The clotability is expressed as percentage of the amount of protein 
incorporated into the clot over the original protein concentration (Figure 4-2). 
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Figure 4-2 Effect of the mutations on the fibrinogen clotability. Total of 20 µl 
fibrinogen, 30 µl TBS, 20 µl activation mix (5 mM CaCl
2
, 0.1 U/mL thrombin), incubated 
at 37°C water bath for 2 hrs. Concentration of fibrinogen was measured before and after 
the addition of the activation mix then the percent clotability was calculated. Significance 
compared to WT **P<0.01. Error bars represent Standard Error of mean (SEM) (n=3). 
One-way ANOVA multiple comparisons in GraphPad prism, Dunnett’s post hoc test 
were used.   
 
As shown in Figure 4-2, R95E, D97K and F98I had similar clotability to WT, 
followed by R95Q and D97N having a slight decrease but this did not reach a 
statistical significance. G96V had significantly lower clotability of around 68% 
compared to the WT. The higher similarity in clotability between WT fibrinogen 
and the oppositely charged mutants (negative E95 and positive K97) may 
suggest that the charge of the side chain in these RGD residues provides 
fibrinogen with more stability. Hence, when the RGD was mutated by charged 
residues, clotability was more similar to the WT rather than when the sequence 
was mutated by neutral residues. A charged residue at this point in the 
polypeptide chain may be important for correct folding of the protein domain.  
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4.2.3 Effect of the Mutations on Clot Formation and Fibre 
Thickness by Turbidity assay 
Fibrinogen R95Q, D97N, F98I 
Before the production of all mutants was completed, turbidity was first performed 
for the first set of mutants (R95Q, D97N, F98I) in a 384-well plate. The 
experiment was performed using 0.5 mg/ml of fibrinogen and 0.1 U/ml of 
thrombin. Looking at the polymerisation profile in Figure 4-3a, both R95Q and 
D97N had clearly lower maximum absorbency than WT whereas F98I was only 
slightly lower. The maximum OD profile in Figure 4-3b, which refers to fibre 
diameter or thickness (Metassan et al., 2009) showed significantly thinner fibres 
for R95Q and D97N compared with WT and to a lesser extent, F98I showed 
thinner fibres than WT. R95Q had a clearly and significantly longer lag phase 
compared to the WT in agreement with its slow clotting tendency that appeared 
on the polymerisation profile. On the other hand, there was no statistically 
significant differences between the lag phase of D97N and F98I compared to the 
WT as shown in Figure 4-3c.  
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Figure 4-3 Turbidity analysis for WT, R95Q, D97N, F98I in 384-well plate.  Total of 
0.5mg/ml fibrinogen, 5mM CaCl
2
, 0.1 U/mL thrombin. a) Absorbency measurements 
were made every 12 sec for 2 hrs at 340 nm. b) Maximum OD in the turbidity analysis 
for fibre thickness assessment. c) Lag Phase representation of clotting time. 
Significance compared to WT **P<0.01, ***P<0.001, ****P<0.0001. Error bars represent 
Standard Error of mean of the intra assay variations (SEM) (n=3). One-way ANOVA 
multiple comparisons in GraphPad prism, Dunnett’s post hoc test were used.  
a 
b 
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Using Lower Concentrations of Fibrinogen 
Because of the lower availability of the second set of mutants (R95E, G96V and 
D97K), a decision was made to use lower concentrations of fibrinogen in the 
turbidity experiment. Before proceeding with the turbidity experiments using the 
lower fibrinogen concentrations in the 384-well plate, a couple of test 
experiments were performed to confirm the concentrations of thrombin and 
fibrinogen that could be used to produce turbidity curves with sufficient changes 
in maximum absorbency, appropriate lag phase in the order of a few hundred 
seconds and acceptable polymerisation rates. Normal WT fibrinogen (0.5 mg/ml 
fibrinogen + 0.1 U/ml thrombin) was compared with two different combinations 
of WT fibrinogen and thrombin which were 0.2 mg/ml fibrinogen + 0.1 U/ml 
thrombin and 0.2 mg/ml fibrinogen + 0.04 U/ml thrombin.  
Average results of the two test experiments are shown in Figure 4-4. As might 
be expected, the turbidity curves (Figure 4-4a) are overall lower due to the lower 
fibrinogen concentration for both the tested concentrations of thrombin; however, 
using the original amount of thrombin (0.1 U/ml) showed better profile with a 
similar appearance to the WT. The thickness of fibres represented by the 
maximum OD (Figure 4-4b)  was almost the same for both tested concentrations 
showing significantly thinner fibres compared to the normal WT condition, but the 
lag phase (Figure 4-4c)  was significantly longer with 0.04 U/ml thrombin 
concentration compared to WT condition. Considering these effects of 
decreasing the fibrinogen concentration, a decision was made to use the 
combination of (0.2 mg/ml fibrinogen + 0.1 U/ml thrombin) in the turbidity of the 
second set of mutants. 
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Figure 4-4 Turbidity analysis test for lower fibrinogen concentration in 384-well 
plate. Original WT (0.5 mg/ml fibrinogen, 5 mM CaCl
2
, 0.1 U/mL thrombin) compared to 
two different combinations (0.2 mg/ml WT, 5 mM CaCl
2
, 0.1 U/mL thrombin) and (0.2 
mg/ml WT, 5 mM CaCl
2
, 0.04 U/mL thrombin). a) Absorbency measurements were 
made every 12 sec for 2 hrs at 340 nm. b) Maximum OD in the turbidity analysis for fibre 
thickness assessment. c) Lag Phase representation of clotting time. Significance 
compared to WT ***P<0.001. Error bars represent Standard Error of mean of the intra 
assay variations (SEM) (n=2). One-way ANOVA multiple comparisons in GraphPad 
prism, Dunnett’s post hoc test were used.   
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R95E, G96V, D97K  
Polymerisation profiles (Figure 4-5) illustrated lower maximum absorbency for all 
the mutants compared to WT, which was more pronounced for R95E and G96V, 
as shown in Figure 4-5a. The maximum OD profile in Figure 4-5b showed 
significantly thinner fibres for both R95E and G96V compared to WT. D97K also 
had thinner fibres but less significantly than the other two mutants. The lag phase 
profile in Figure 4-5c showed a significantly longer time to lateral aggregation for 
R95E compared to the WT. G96V came next with a slight increase of the lag 
phase, whilst D97K had a slightly shorter lag phase than WT, but these effects 
of the latter two mutants did not reach statistical significance.   
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Figure 4-5 Turbidity analysis for WT, R95E, G96V, D97K in 384-well plate. Total of 
0.2 mg/ml fibrinogen, 5 mM CaCl
2
, 0.1 U/mL thrombin. a) Absorbency measurements 
were made every 12 sec for 2 hrs at 340 nm. b) Maximum OD in the turbidity analysis 
for fibre thickness assessment. c) Lag Phase representation of clotting time. 
Significance compared to WT *P<0.05, ***P<0.001, ****P<0.0001, Error bars represent 
Standard Error of mean (SEM) (n=3). One-way ANOVA multiple comparisons in 
GraphPad prism, Dunnett’s post hoc test were used.   
a 
b 
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The results of both sets of mutants were normalised to their relevant WT in order 
to be comparable in one graph. Maximum OD representing fibre thickness in 
Figure 4-6a was similar for R95E, R95Q, G96V, D97K and D97N showing 
significant thinner fibres that that of WT. However, this effect failed to reach 
statistical significance for F98I. In case of lag phase Figure 4-6b, normalised 
values for all mutants showed consistent results with their original ones being a 
significantly slower for R95Q and R95E. However, there were no statistically 
significant differences for the lag phase of G96V, D97K, D97N and F98I 
compared to the WT.  
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Figure 4-6 Normalised values of the turbidity analysis to compare the effect of all 
mutants to the WT. Total of 0.5 mg/ml fibrinogen to the left of dotted line or 0.2 mg/ml 
fibrinogen to the right of dotted line, 5 mM CaCl
2
, 0.1 U/mL thrombin. a) % of the lag 
phase representing clotting time. b) % of the Max OD in the turbidity analysis for fibre 
thickness assessment. Significance compared to WT *P<0.05, **P<0.01, ****P<0.0001. 
Error bars represent Standard Error of mean (SEM) (n=3). One-way ANOVA multiple 
comparisons in GraphPad prism, Dunnett’s post hoc test were used.   
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4.2.4 Effect of the Mutations on Clot Lysis  
In this experiment, G96V was not used because there was not enough protein 
left, and D97N was analysed only once due to the limited amount of protein 
available. Lysis profiles Figure 4-7 a and b were divided into two graphs 
according to ease of presentation and to avoid overlap between the mutants. 
The lysis was assessed by calculating the time required for half of the clot to lyse 
for each mutant, as shown in Figure 4-7c. When comparing all the mutants to 
the WT, it appears that the oppositely charged mutants (negative E95 and 
positive K97) had a slightly elongated time to half-lysis that failed to reach 
statistical significance, whereas the other mutants had a slightly shorter half-lysis 
time that did not reach statistical significance. R95E required the longest time to 
clot and the longest time to lyse, but D97K required a slightly shorter time to clot 
and longer time to lyse, compared to WT. R95Q and D97N required longer time 
to clot and shorter time to lyse than WT. F98I clots lysed slightly faster than WT. 
However, there were no statistically significant differences between the lysis time 
of the mutants and the WT. 
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Figure 4-7 Turbidity and lysis analysis for WT and all mutants in 384-well plate. 
Total of 0.5 mg/ml fibrinogen, 5 mM CaCl
2
, 0.1 U/mL thrombin, 100 pM tPA, 0.24 µM 
plasminogen. Absorbency measurements were made every 12 sec for 2 hrs, 37°C at 
340 nm. a) Lysis curve of R95E and R95Q compared to WT. b) Lysis curve of D97K, 
D97N and F98I compared to WT. c) Time to 50 % lysis of all mutants compared to WT. 
Error bars represent (SEM). n=3, D97N (n=1). The lysis profiles are presented in two 
separate curves to avoid overlapping between mutants and for clarity of presentation. 
One-way ANOVA multiple comparisons in GraphPad prism, Dunnett’s post hoc test 
were used. 
 
a 
b 
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4.2.5 Effect of the Mutations on Clot Structure using Laser 
Scanning Confocal Microscopy 
The effects of the mutations on fully hydrated clot three-dimensional structure 
were analysed by confocal microscopy. Clots were formed by incubating 
fluorescently-labelled fibrinogen of each variant with thrombin and CaCl2 
overnight, and then imaged using the laser scanning confocal microscope. 
Representative images of clots from each mutant and the WT are shown in 
Figure 4-8. The images showed that all mutants had shorter fibres, which were 
more branched than the WT. Fibre counts are shown in Figure 4-9. R95Q 
showed significantly higher whilst D97N almost identical fibre count compared to 
WT, although the fibres looked shorter. R95Q fibres were highly branched and 
formed quite large branching points, giving the clot a heterogeneous appearance 
with larger pores. D97N fibres were less defined, clumped in a lot of branching 
points, with smaller pores showing a heterogeneous appearance. R95E formed 
significantly less dense clots compared to the WT, with slightly shorter and less 
branched fibres, forming a more porous clot. D97K and F98I had a significantly 
higher fibre count than WT, with shorter and more branched fibres. D97K formed 
larger pores, whilst F98I showed smaller pores, compared to WT. The general 
appearance of all mutants is in agreement with the turbidity data which indicated 
thinner fibres for all mutants. G96V was not used in this experiment due its 
concentration and amount being too low. Comparing with the turbidity curve, the 
higher the fibre number of D97K and F98I, the faster the clotting and the opposite 
is true for the other mutants. 
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Figure 4-8 Representative images of the mutated fibrinogen clots taken by laser 
scanning confocal microscopy. Each clot is made by 0.5 mg/mL unlabelled 
fibrinogen, with 25 µg/mL Alexa488-fibrinogen, 5 mM CaCl
2
, 0.1 U/mL thrombin, final 
volume 40 µl. n=3. Scale bar= 20 µm. 
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Figure 4-9 Average fibres count of mutated fibrinogen clots taken by laser 
scanning confocal microscopy. Each clot is made by 0.5 mg/mL unlabelled 
fibrinogen, with 25 µg/mL Alexa488-fibrinogen, 5 mM CaCl
2
, 0.1 U/mL thrombin, final 
volume 40 µl. Error bars represent Standard Error of Mean (SEM). n=3. Significance 
compared to WT, *P<0.05, ****P<0.0001. One-way ANOVA multiple comparisons in 
GraphPad prism, Dunnett’s post hoc test were used. 
 
4.3 Discussion   
The structure of clots can indicate their tendency to increase the risk of 
cardiovascular diseases, e.g. clots formed with compact structures of thin fibres 
and small pores that are resistant to fibrinolysis (Hooper et al., 2012). 
Assessment of fibrin involvement in thrombotic risk can be achieved by the direct 
analysis of clot structure and fibrinolysis (Hooper et al., 2012), and targeting fibrin 
clot properties was suggested for finding novel therapies for thrombotic and 
cardiac diseases (Sumaya et al., 2018). 
The results of this chapter indicate the structural and functional effects of the 
mutations in fibrinogen including its ability to clot, its polymerisation profile, as 
well as the clot ability to lyse, and its structure. Although no clear changes in 
secondary structure of the proteins, which may affect fibrinogen function, were 
observed, all mutants showed changes in their turbidity and lysis profiles which 
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varied in their extent. Clear changes in the clot structure were also observed by 
confocal microscopy. A summary of the results is shown in Table 4-2. 
Table 4-2 Summary of the results of the effect of the mutations on clot structure 
and properties, compared to the WT. Arrows represent the increase or decrease in 
each particular parameter. One arrow represents a statistically non-significant effects, 
two arrows represent statistically significant effects. *P<0.05, **P<0.01, ***P<0.001, 
****P<0.0001.  
 R95E R95Q G96V D97K D97N F98I 
Clotability 93.7% 88.4% 
68.8% 
** 
96.4% 84.9% 94.2% 
Max OD 
↓↓ 
*** 
↓↓ 
**** 
↓↓ 
**** 
↓↓ 
* 
↓↓ 
**** 
↓↓ 
*** 
Lag 
phase 
↑↑ 
**** 
↑↑ 
** 
↑ ↓ ↑ ↓ 
Time to 
½ lysis 
↑ ↓ - ↑ ↓ ↓ 
Clot 
structure 
Shorter and 
slightly less 
branched 
 
Shorter and 
highly 
branched 
- 
Shorter and 
highly 
branched 
 
Much 
shorter and 
highly 
branched 
Shorter and 
highly 
branched 
 
Fibre 
density 
↓↓ 
* 
↑↑ 
* 
- 
↑↑ 
**** 
≈ 
↑↑ 
**** 
α-helix 
count 
≈ ↓ ≈ ↑ ↓ ≈ 
 
The analysis of CD spectra showed slight changes in the amount of α-helical 
content of the secondary structures of R95Q and D97N, compared to WT. This 
indicates that the loss of charge in the RGD site may affect the structure of the 
protein although these changes were minimal. For all other mutants R95E, 
G96V, D97K and F98I, there were no changes in the fibrinogen secondary 
structures caused by the mutations. 
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Compared to the WT which had 97.6% clotability, all mutants showed similar 
clotting tendency except for G96V. This may in part be due to its very low 
concentration compared to the other mutants. While the method is dependent on 
the volume of the solutions and not on protein concentration, very low 
concentrations may increase the variability and noise of the assay. Mutating the 
centre of the RGD may have more effect on altering the clotting tendency of the 
fibrinogen molecule maybe because the mutation disturbs the core of the region, 
and consequently the coiled coil of the molecule, which provides an essential 
backbone to the longitudinal shape of the fibrinogen and fibrin protein. 
Otherwise, alteration in the tertiary structure may occur since no changes in the 
secondary structure were observed by the CD spectra for this mutant. 
Turbidity profiles showed clearly lower maximum absorbency for R95E, R95Q, 
G96V, D97N and F98I and to a lesser extent for D97K compared to the WT. 
Looking at the maximum OD curves, fibrin fibres made by all mutants were 
significantly thinner than the WT. Looking at the lag phase profiles, the rate of 
formation of fibrin fibres varied between the mutants; being significantly delayed 
for R95E and R95Q compared to the WT, followed by G96V and D97N. For D97K 
and F98I, there were no statistically significant differences in rates of formation 
of the fibres compared to the WT. These results were consistent with the 
normalised results. These changes reflect the importance of the RGD sequence 
in producing normal clots and restoring the normal function of fibrinogen. 
Turbidity curves indicating effects of mutating the Aα-chain RGD sequence 
clearly showed alterations in structure of clots that were formed by the new 
mutated fibrinogens. It was observed that mutating this site of fibrinogen affected 
the fibre thickness producing thinner fibres. The effect of the mutations may 
occur by inhibiting the protofibril lateral aggregation process, which results in 
thinner fibres. This may be explained by the delay in the lag phase, reflecting a 
delay in the formation of the fibrin fibres and their growth to the extent in which 
lateral aggregation starts to occur (Weisel and Nagaswami, 1992, Weisel, 2007).  
Turbidity and lysis profiles showed that the effects of mutations on fibrinolysis did 
not reach statistical significance. Neutral charged mutants; Q95 and N97 showed 
a very small decrease in lysis time, followed by F98I, whereas the charged 
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mutants; negative R95E and positive D97K showed a slightly slower half-lysis 
time compared to the WT, but these changes did not reach statistical 
significance. Comparing the opposite results of clotability and lysis that were 
obtained by the neutral charge changes in the residues Q95 and N97 to the 
charged residues of negative E95 and positive K97 may reflect the importance 
of the presence of charge in fibrinogen molecule in order to provide the molecule 
with more stability. The more normally clotable charged mutants required slightly 
more time to lyse in comparison to the slight decrease in clotability that was 
observed for the neutral mutants.  
Another way to assess clot structure is the use of laser scanning confocal 
microscopy to study the three-dimensional structure of fully hydrated fibrin 
network (Blomback et al., 1989). Analysing the confocal images, mutations in the 
Aα-RGD sequence influenced fibre thickness, in agreement with the turbidity 
results with all recombinant fibrinogens (R05E, R95Q, G96V, D97k, D97N, and 
F98I) showing thinner fibres compared to the WT.  Clots were described as 
coarse and fine, depending on the degree of lateral aggregation of the protofibrils 
assuming that the coarse clots have more branching point forming a network of 
bundle fibres (Muller et al., 1984). However, branching junctions were found in 
the fine clots which may be formed as a result of twisting of two or more 
protofibrils around each other, this action could be the determinant of the clot 
strength (Muller et al., 1984). According to this assumption all clots formed by 
the produced Aα-RGD mutants were fine clots because they all had thinner fibres 
and as mentioned above this may be due to inhibition of the lateral aggregation 
(Weisel and Nagaswami, 1992, Weisel, 2007). Contrary to Muller’s et al 
suggestions, R95E and D97K had slightly less branching points than the WT and 
the other mutants but they had high clotability and required slightly more time to 
lyse. The slight increase in clot stability of R95E and D97K may be due to the 
opposite change in charge of the  residues at positions 95 and 97. The highly 
altered clot structures for R95Q and D97N may explain their low maximum 
absorbency in turbidity and is consistent with the thinner fibres which were 
measured by turbidity. These two mutants may have much impaired protofibril 
lateral aggregation compared with the other mutants. F98I had significantly more 
fibres which were shorter, more branched and less porous than the WT which 
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agreed with the slightly lower maximum absorbency, hence thinner fibres, 
measured by turbidity. These changes which were observed by confocal images 
in this project, agreed with the structural appearance by SEM of the natural form 
of this mutant in which the fibres were short and curly (Riedelova-Reicheltova et 
al., 2014). In the study by Riedelova-Reicheltova et al, regarding the naturally 
occurring form of F98I, it was found that this mutation had lower interaction with 
its neighbouring amino acids compared to the WT using molecular modelling. 
The authors suggested that this alteration may affect the protofibril lateral 
aggregation to form the short and curly fibres (Riedelova-Reicheltova et al., 
2014). According to Riedelova-Reicheltova et al, interaction of the new aliphatic 
side chain of isoleucine instead of the bulky aromatic side chain of phenyl alanine 
with its aromatic surrounding amino acids may be another cause of the presence 
of thinner fibres (Riedelova-Reicheltova et al., 2014). Due to its limited optical 
resolution, inability to measure the thickness by confocal microscopy tends to 
limit the comparison between the turbidity and the confocal images to visual 
assessment rather than calculated analysis (Blomback et al., 1989). 
The advantages of studying clot structure by spectrophotometry methods  were 
addressed by Wolberg et al., in that fibrin fibre structure and clot lysis can be 
evaluated using plate-reading spectrophotometers that only require small 
sample volumes, and are easy to use for multiple sample analysis (Wolberg et 
al., 2002). Compared to the end-point, single sample spectrophotometers, these 
plate-reading spectrophotometers are found to be susceptible to a degree of 
errors owing to uncaptured scattered light. These errors can be negligible in case 
of turbidity because they do not affect the ability to detect changes in clot 
structure (Wolberg et al., 2002). 
Assessment of clot structure may aid the diagnosis of some diseases which are 
caused by altered clot structure and function such as cryptogenic stroke (Undas 
et al., 2009a). Another example was the case of the woman who had the multiple 
miscarriages which were caused by the naturally occurring F98I fibrinogen 
variant, and who had no obvious thrombotic symptoms. The laboratory 
assessment however showed alterations in clot structure which may explain the 
 
 
138 
 
patient’s symptoms, and are consistent with our results (Riedelova-Reicheltova 
et al., 2014). 
In summary, the mutations demonstrated effects on fibrin clot structure 
represented by the changes in polymerisation profiles, lysis rate, fibres 
thickness, fibre branching, and clot heterogeneity. However, the mutations did 
not significantly affect the clotability (apart from G96V) of the proteins or their 
secondary structures.  
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Chapter 5  Plate-Based Fibrinogen-RBC Binding Studies  
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5.1 Introduction 
RGD is a sequence which is known to be the recognition site on fibrinogen and 
some other proteins for the αIIbβ3 integrin on platelets (Xiao et al., 2004, Oyama 
et al., 2017). These peptides are present in two different sites on the Aα-chain of 
fibrinogen, residues 95-97 and 572-574 (Hook et al., 2017). 
This project’s hypothesis was that altering the RGD sequence would reduce the 
interaction of fibrinogen with the RBCs. This reduction is depending on the 
assumption that the site of interaction of the RBC with fibrinogen is β-integrin 
dependent and might share some structural similarities with the platelets integrin 
(Carvalho et al., 2010). The study by Carvalho et al. has indicated that 
Eptifibatide, (an αIIbβ3 inhibitor) leads to decrease, but not full elimination of 
binding between fibrinogen and RBCs, when tested by AFM (Carvalho et al., 
2010). This was in a comparison study between RBCs and platelets in the 
presence of calcium ion. In the case of platelets, Eptifibatide blocked the binding 
with fibrinogen completely. These findings indicated that the binding site of 
fibrinogen on RBCs is not αIIbβ3 but a related integrin (Carvalho et al., 2010). 
Red blood cells are the most abundant blood cells in the body, and subsequently 
they are major regulators of blood rheology and flow (De Oliveira et al., 2012). 
RBCs can be used in studying the mechanism of cell adhesion, cellular 
interaction and involvement in thrombosis and cardiovascular disease (Lavalle 
et al., 1996, Chien and Jan, 1973). On the other hand, because RBCs are 
anucleated cells, they are prone to in vitro loss of function and viability, by 
accumulation of waste, nutrient depletion, in addition to morphological and other 
biochemical changes. In the early 1970s, their role in cell to cell interactions, 
which may be involved in RBC aggregation, was investigated. A study by Chien 
and Jan suggested that RBC aggregation was not the result from a balance 
between attractive and repulsive electrostatic interactions on the RBC surface, 
but due to interactions between the RBC surface and macro molecules that are 
present in the suspension (Chien and Jan, 1973). Another early study suggested 
a possible relationship between RBC and fibrin(ogen). The authors suggested 
the existence of a possible proteolytic activity in the RBC wall that could alter 
fibrin structure (Murray and Rearick, 1974). 
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Later studies suggested some sort of interaction between fibrinogen and RBCs, 
based on the fact that fibrinogen induces RBC hyper-aggregation (De Oliveira et 
al., 2012). In another study, it was found that Monafram (a platelet αIIBβ3 inhibitor) 
was capable of slowing down RBC aggregation, but not the strength of this 
aggregation, which was regardless of the presence or absence of platelets 
(Gafarova et al., 2012). The authors hypothesised the existence of a specific 
receptor on the RBC that interacts with fibrinogen and is able to speed up the 
aggregation in normal conditions, and that this receptor is different from the 
platelet receptor for fibrinogen. In some of their experiments they found that 
binding of fibrinogen to the erythrocyte unknown receptor resulted in abnormal 
increase in the strength of the aggregation of the cells (Gafarova et al., 2012). In 
the presence of fibrinogen, the authors found that Monafram can decrease the 
strength of this aggregation. Although the effect of Monafram on RBC 
aggregation was independent of the platelet count, they found that the presence 
of platelets had some effect on the strength of RBC aggregation, however the 
mechanism of this effect remained undetermined (Gafarova et al., 2012). These 
data are in agreement with the possibility of a fibrinogen receptor on the RBC 
membrane that is related to (and also different from) the platelet αIIBβ3 integrin 
receptor for fibrinogen (Carvalho et al., 2010). 
Due to the fact that blocking the receptor on the RBC membrane decreased the 
interaction with fibrinogen, and assuming that the fibrinogen AαR95G96D97 
sequence is responsible for the interaction with RBC, new fibrinogen variants 
with mutated AαR95G96D97F98 sequence should show altered ability to bind to 
RBCs. This chapter examines this interaction through the development of 
binding assays in static conditions that are plate-based. 
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5.2 Results  
5.2.1 Effect of the Mutations on Interaction between Red Blood 
Cells and Fibrinogen by Static Plate-Binding Assay 
In order to study the presence of any kind of binding between fibrinogen and 
RBCs, and the effect of the mutations on this binding, several interaction 
experiments have been developed. Effect of mutations (R95E, R95Q, G96V, 
D97K, D97N and F98I) on the binding of fibrinogen with RBCs was tested in 
static condition using a maxisorp plate to develop a plate-binding assay. Before 
using the mutants, several steps of optimisation processes were performed. The 
optimisation can be divided into three stages; choosing a way to measure the 
binding, coating with fibrinogen to measure the released haemoglobin from the 
RBCs, and finally coating with RBCs to measure bound fibrinogen to the RBCs 
by fibrinogen ELISA. 
Mode of Measuring the Binding 
Three modes of measuring the binding between fibrinogen and RBCs were 
tested, using 5% v/v DiD dye, auto-fluorescence (Casella et al., 2004) and 
haemoglobin release. Initially, the plate was coated with 80 µg/ml of fibrinogen, 
blocked with 1% w/v BSA, before different RBCs were added in different 
Haematocrit (Ht) levels of 5, 10, 25, 50, and 100%. All plates were washed and 
wells were filled with PBS for fluorescence reading, and water to haemolyse the 
cells for haemoglobin reading. The haemoglobin readings were taken on a range 
of wavelengths (650-700 nm) to select a wavelength that works best with the 
newly developed technique. The results of the three types of experiments 
suggested that the use of released haemoglobin, as indicator for the binding 
between fibrinogen and RBCs, was the best option. For DiD-labelled RBCs, the 
results are presented in Figure 5-1. The signals were too high to be detected and 
the readings showed “overflow” at 650 nm (data not shown). For the other 
wavelengths except 660 nm, there was no detection of fluorescence on the DiD-
labelled RBCs (Figure 5-1). At 660 nm, there was a slight change in DiD-labelled 
RBCs signal, reflecting a decrease in binding with increasing haematocrit, which 
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looked unconvincing. The auto-fluorescence readings were similar among all 
concentrations of the RBCs and among the different wavelength tested (650-700 
nm, data not shown), suggesting that this method was not the correct way to 
assess the binding between fibrinogen and RBCs. Relying on these data, both 
auto-fluorescence and DiD dye were excluded as indicators of the binding 
between fibrinogen and RBCs. 
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Figure 5-1 Plate-Binding assay of fibrinogen interaction with RBCs. Plates were 
coated with 80 µg/ml fibrinogen and DiD-labelled RBCs test concentrations were 5, 10, 
25, 50, 100 % Ht. Signals at 660 nm showed a decrease in the interaction between 
fibrinogen and RBCs as the haematocrit of RBCs increase. Other wavelengths showed 
no interaction between fibrinogen and RBCs, subsequently, they are overlaid by 670 
nm.   
 
The third method for measuring the binding of fibrinogen to RBCs was the 
release of haemoglobin by haemolysed RBCs. The 96-well plate was scanned 
for different wavelengths (400-557 nm) to confirm the optimum wavelength for 
haemoglobin measurements. Figure 5-2 shows 400-414 nm provided the highest 
level of detection.  
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Figure 5-2 Plate-binding assay of fibrinogen interaction with RBCs to test the 
optimum absorbance wavelength of released haemoglobin. Wavelength of 400-414 
nm showed the highest level of detection for haemoglobin released from fibrinogen-
bound RBCs. Plate was coated with 80 µg/ml fibrinogen and RBCs test concentrations 
were 5, 10, 25, 50, 100% Ht. 
 
Fibrinogen Coating 
In this stage, the experiment was performed as described in the methods 
section 2.10 but with minor adjustments. The plate was coated with different 
concentrations of fibrinogen (20-80 µg/ml) then different concentrations of RBCs 
(5-50 % Ht) were added to the plate. Lower concentrations of RBCs (1, 2.5 % 
Ht) were also tested, as well as lower concentrations of fibrinogen (1, 2.5, 5, 10 
µg/ml), but no binding was detectable (data not shown). The data of those 
experiments suggested the optimum value of 50% Ht for RBCs and 20 µg/ml of 
fibrinogen, as shown in Figure 5-3. Following coating with fibrinogen, the plate 
was initially blocked with BSA, but this was subsequently excluded as a 
precautious measure to ensure that the binding signal did not result from the 
attachment of RBCs to BSA.  
It was noticed that the blood would wash off during the washing steps and gather 
around the edges of the wells. This loss of RBCs was the cause of repeating the 
experiment several times to try to find out a way to overcome this issue. When 
RBCs were washed off the plate this was affecting the values between the 
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duplicates and causing high intra-assay variation. Several precautions were 
undertaken over the different optimisation experiments to try to overcome the 
washing off RBCs. These adjustments to the method ranged from decreasing 
the number of washes after each addition of samples, changing the mode of 
washing using pipetting instead of discarding the contents by inversion, to 
draining the plate contents on paper tissues; this did not work especially well. 
The difference between the absorbance of the duplicates, which was 
represented on Figure 5-3 by large error bars was still an issue that resulted from 
the washing off of RBCs. Accumulation of RBCs around the edges may cause 
an increase in the haemoglobin absorbance signal reflecting an artefactual 
increase in RBCs content rather than the binding between fibrinogen and RBCs.
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Figure 5-3 Representative graph of the optimisation steps of plate-binding assay 
between fibrinogen and RBCs. Plates were coated with 20, 40, 80 µg/ml fibrinogen, 
RBCs test concentrations were 5, 10, 25, 50 % Ht. 20 µg/ml fibrinogen and 50% Ht was 
the best combination.   
 
Red Blood Cells Coating 
The next stage for optimising the plate-binding assay method was changing the 
coating of the plate to RBCs instead of fibrinogen. Surprisingly the RBCs 
attached well to the plate and did not wash off after the addition of fibrinogen. A 
new design of the protocol was introduced to accommodate the change in the 
experimental conditions as described in methods section 2.10. In this case, the 
plate was coated with RBCs then fibrinogen was added to the coated RBCs. The 
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binding of fibrinogen to RBCs consisted of haemolysing the RBCs with water and 
measuring the amount of fibrinogen in the lysate by fibrinogen ELISA.  
In this method, the same combinations of RBCs 5, 10, 15, 20, 25 % Ht were 
tested with 5, 10, 20, 40, 80 µg/ml fibrinogen (Figure 5-4). The results of this set-
up showed that 5% Ht was the optimum concentration of RBCs for coating, whilst 
20 µg/ml of fibrinogen showed strong binding between fibrinogen and RBCs, 
comparable with higher concentrations of fibrinogen (40 and 80 µg/ml). On this 
basis 20 µg/ml of fibrinogen was chosen to proceed with the mutants considering 
the low amount of protein which was available. 
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Figure 5-4 ELISA-based plate-binding assay between fibrinogen and RBCS.  Plates 
were coated with RBCs (5, 10, 15, 20, 25 % Ht), fibrinogen test concentrations were 5, 
10, 20, 40, 80 µg/ml. ELISA on the lysate was used to detect the fibrinogen that bound 
to RBCs. 5% Ht and 20 µg/ml fibrinogen showed the best combination. 
 
Confirming the Source of Fibrinogen 
In order to exclude that the data produced in the previous section were due to 
fibrinogen binding to the plate, two different conditions were used. One row of 
the 96-well plate was coated normally with 5% Ht RBCs then washed. When 
fibrinogen was added to the plate, it was added to the coated RBCs row, in 
addition to an extra row where no RBCs were present. A series of fibrinogen 
concentrations were used including very low concentrations; (0.625, 1.25, 2.5, 5, 
10, 20 µg/ml), as shown in Figure 5-5. Fibrinogen was incubated, washed and 
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then 100 µl/well of water were added to the plate to haemolyse the RBCs and to 
transfer the contents to the new plate, which was coated with fibrinogen 
antibodies for ELISA. The results in the figure showed binding between 
fibrinogen and RBCs but no binding of fibrinogen to the wells of the second plate. 
This reflected that only RBC-bound fibrinogen was transferred to the new plate 
for ELISA and there was no increase in the binding signal of the fibrinogen when 
RBCs were not present. This confirms that the results of the fibrinogen-RBCs 
plate binding assay reflected the RBC-bound fibrinogen and not the added 
fibrinogen. 
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Figure 5-5 Comparison between RBC-free fibrinogen (green) and RBC-bound 
fibrinogen (red) by fibrinogen ELISA of plate-binding assay. Fibrinogen 0.625, 1.25, 
2.5, 5, 10, 20 µg/ml were added to the plate with and without 5% Ht RBCs. RBC-bound 
fibrinogen has shown increase of detected signal of fibrinogen whereas there was no 
change in the RBC-free fibrinogen signal. 
 
Amount of Fibrinogen in Blanks 
In order to exclude that the data produced in the previous section were not due 
to pre-existing fibrinogen on the surface of RBCs, fibrinogen ELISA was 
performed on lysates from serial RBC haematocrits, without addition of 
fibrinogen (Figure 5-6). There was an little detectable amount of fibrinogen 
detected on RBCs (~0.004 µg/ml), indicating that the washed RBCs do not have 
an amount of fibrinogen on their surface that affects the reading of fibrinogen 
concentrations following addition of our recombinant fibrinogens. 
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Figure 5-6 Detection of fibrinogen amounts on serial concentrations of RBC 
without added fibrinogen. Plates were coated with RBCs (5, 10, 15, 20 % Ht). 
Fibrinogen in the lysate was detected by ELISA, and showed no change in the amount 
of RBC-bound fibrinogen, confirming that washed RBCs have minute amount of 
fibrinogen on their surfaces. 
 
Effect of Mutations on Fibrinogen-RBC Binding 
The next step was to start using the fibrinogen variants (R95E, R95Q, G96V, 
D97K, D97N, F98I, and WT) to test if they have any effect on the binding of 
exogenous fibrinogen to RBCs. The experiment was undertaken in two different 
sets because fibrinogen variants were produced in different batches as 
described in methods section 2.10. Plates were coated with RBCs (5% Ht) before 
20 µg/ml of fibrinogen were added to test the effect of the mutations on the 
fibrinogen binding to the RBCs. The RBCs were then haemolysed, and the lysate 
was transferred to a plate pre-coated with fibrinogen antibodies in order to 
quantify the amount of fibrinogen present in the lysate by ELISA. The results of 
these experiments are shown in Figure 5-7. 
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Figure 5-7 RBC-Fibrinogen-plate binding assay for the mutants. Plates were coated 
with RBCs (5 % Ht), and 20 µg/ml recombinant fibrinogen were added. There were no 
significant differences in the amount of binding between the mutants and the RBCs 
compared to WT. Error bars represent Standard Error of Mean (SEM). (n=4). . One-way 
ANOVA multiple comparisons in GraphPad prism, Dunnett’s post hoc test were used. 
 
There were no statistically significant differences in the amount of fibrinogen 
bound to RBCs compared to the WT showing a slight increase for R95E, R95Q, 
D97N and F98I and a slight decrease for G96V, with a more pronounced, but still 
not significant decrease for D97K, compared to the WT. Altogether, these data 
suggested that the mutations did not significantly alter the interaction between 
fibrinogen and RBCs and there was no significant difference in the binding 
compared to the WT. 
Binding of Fibrinogen Mutants to RBCs from Fibrinogen-Knockout Mice 
To confirm any effects of the mutations on the binding of fibrinogen to RBCs were 
not due to a pre-existing fibrinogen on the surface of the RBCs, blood from 
fibrinogen-KO mice was used in this experiment so only the influence of 
recombinant fibrinogen was present. The blood was washed and the RBCs were 
isolated using the same method as human blood (methods section 2.10). As for 
the previous section, there was no significant effect of the mutations on the 
binding of fibrinogen to the RBCs from fibrinogen-KO mice, compared to WT 
(Figure 5-8). All mutants showed similar binding to that of WT, except a slight, 
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but not significant, increase for F98I, that agreed with the results obtained using 
human blood. D97K binding was still lower, but to a much lesser extent, which 
could be considered similar to WT. 
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Figure 5-8 Plate-binding assay for mutant fibrinogens and RBCs from fibrinogen 
Knockout mice. Plates were coated with RBCs (5 % Ht), and 20 µg/ml recombinant 
fibrinogen were added. The results showed statistically non-significant changes 
between the binding of mutants and that of WT. Error bars represent Standard Error of 
Mean (SEM). (n=3). One-way ANOVA multiple comparisons in GraphPad prism, 
Dunnett’s post hoc test were used.   
 
5.2.2 Effect of the Mutations on Interactions between Fibrinogen 
and RBCs in Solution. 
Another method to test the interaction between fibrinogen and RBCs in solution 
was established. This method was adapted from the plate-binding assay, where 
now the interaction between fibrinogen and RBCs was performed in solution, 
before the binding was measured using a plate-based assay. Another difference 
between the two methods was that the evaluation of the binding of fibrinogen to 
RBCs occurred through analysis of the released haemoglobin. 
The first step consisted of combining fibrinogen and RBCs in solution as 
described in methods section 2.11. The mixture was then transferred onto a plate 
pre-coated with fibrinogen binding antibodies. Following binding of fibrinogen 
(and the bound RBCs) to the plate, and washing steps, the amount of 
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haemoglobin released due to osmotic shock after addition of water was 
measured as an indication of binding.  
The results of this method are shown in Figure 5-9. The differences in the binding 
of fibrinogen to RBCs between R95E, R95Q and D97N mutants and the WT did 
not reach statistical significance being slightly increased, in agreement with the 
plate-binding assay results. D97K showed a slightly higher but statistically non-
significant binding of fibrinogen and RBCs compared to that of WT, in 
contradiction with the plate-binding assay experiments. However, G96V and 
F98I showed similar binding to that of WT, unlike the data obtained in the plate-
binding assay. However, these changes were minimal, as for the previous 
method and can therefore be considered as similar to WT. 
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Figure 5-9 Effect of mutations on fibrinogen-RBC binding by plate-based solution-
interaction assay. Total of, 20 µg/ml fibrinogen were mixed with RBCs (5% Ht). No 
statistically significant differences in the binding of mutants to the RBCs compared to 
WT were observed. B PBS: blank of only PBS. Error bars represent Standard Error of 
Mean (SEM). n=3. One-way ANOVA multiple comparisons in GraphPad prism, 
Dunnett’s post hoc test were used. 
  
5.3 Discussion 
This chapter describes several experiments to test the effect(s) of the produced 
mutants (R95E, R95Q, G96V, D97K, D97N and F98I) on the binding of fibrinogen 
to the RBC, in comparison to WT. This binding was hypothesised to be through 
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the RGD site, which is in the coiled-coil residues 95-97 of the Aα-chain of 
fibrinogen (Carvalho et al., 2018), and which was mutated in the recombinant 
fibrinogens studied. The amount of fibrinogen bound to the RBCs showed small 
and non-significant changes for all mutants. A slight but statistically non-
significant increase of the binding between fibrinogen and RBCs was observed 
for D97N and F98I and to a lesser extent for R95E and R95Q, whilst there was 
a non-significant decrease of the binding for G96V and D97K compared to WT. 
Plate-binding assay was the first choice because the aim was first to assess the 
effect of the mutations on interaction between the RBCs and fibrinogen, and this 
technique has been used previously to study the interaction of fibrinogen with 
different components such as FXIII and platelets (Achyuthan et al., 1994, Leung 
and Nachman, 1982). Achyuthan et al. found some advantages in using 
microtiter plate binding assay over other methods. When studying the interaction 
of FXIII and FXIIIa with different forms of fibrinogen, this method only requires 
very low amounts of sample and can be applied for a large number of samples 
(Achyuthan et al., 1994). They also found that this method showed high 
specificity and sensitivity in addition to its quick application. They were able to 
identify fibrin binding site with FXIII purified from human plasma and recombinant 
FXIII produced in bacteria (Achyuthan et al., 1994). This study developed binding 
assays based on a previous study by Leung and Nachman, who labelled proteins 
including fibrinogen with radioactive iodine to study their interaction with platelet 
glycoprotein Thrombospondin, which was adsorbed on the plate. The radio-
active complex was then analysed by SDS-PAGE (Leung and Nachman, 1982).  
Similarly, in this chapter, fibrinogen was added to the wells coated with RBCs 
then quantified by ELISA. This is a colorimetric method relying on the direct 
proportional increase of the colour in relation to the amount of fibrinogen. Another 
example for using the plate-binding assay is the colorimetric method that was 
used by Bellavite et al., who suggested that the use of multi-well microplate is of 
benefit particularly to assess different reaction conditions. In this case the 
authors used the assay to evaluate platelet adhesion by determining the activity 
of platelet Acid Phosphatase enzyme, which was proven to be a good indicator 
for platelet mass and number (Bellavite et al., 1994). In our case, changes in 
colour were an indication of the amount of fibrinogen present in the reaction. 
 
 
153 
 
A large number of optimisation steps were undertaken before the method was 
established to measure the interaction of fibrinogen with RBCs. The final design 
was to coat the plate with RBCs, and then in a separate step the fibrinogen that 
bound to the coated RBCs was measured by fibrinogen ELISA. At the start of 
the experimental development when the plate was coated with fibrinogen, RBCs 
wash off was highly variable and limited the usability of the method. This wash 
off of the RBCs from the plate may be caused by their relative weak attachment 
to the plate.  
The results of the plate-binding assay reflect that the mutations may enhance 
the RGD sequence to express more affinity and interactions rather than blocking 
it. It is possible that the mutations induced conformational changes that exposed 
the RGD sequence for more interaction. These data, although minimal, were 
opposite to what was hypothesised at the start of this project. The hypothesis for 
these mutants in the RGD site (95-97) was that they would block the binding 
between fibrinogen and RBCs, assuming that this sequence is the binding site 
on fibrinogen. Because the effect of the differently charged mutant (negative E95 
to the neutral Q95) on the binding between fibrinogen and RBCs were almost 
similar to the WT, this may exclude any effect of charge on the binding between 
fibrinogen and RBCs in static conditions using plate-binding assays. Binding of 
positive K97 was lower than that of neutral N97, but the D97K was variable in its 
effect among the different techniques so this difference between these two 
differently charged mutants in the same site may actually be negligible. These 
two mutations on D97 were opposite in the fibrinogen-RBCs plate-binding assay 
when human blood was used, but not when fibrinogen-KO mice blood was used, 
or in the solution Binding assay.  
All mutants were tested for their effect on the binding between fibrinogen and 
RBCs by plate binding assay again using murine fibrinogen-knockout blood. This 
was to confirm that fibrinogen amount which was detected by ELISA was due to 
the added mutated fibrinogen and not related to any pre-existing fibrinogen 
already bound to and present on the RBCs from the blood and released by 
haemolysis. This was confirmed by measuring the fibrinogen concentrations 
from lysates of different RBCs haematocrit. In this case, only very low amount of 
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fibrinogen was detected, with no difference among the different haematocrits. If 
the fibrinogen, which was detected by ELISA resulted from RBCs, it would 
increase as the haematocrit increases. Adding mutated fibrinogen to the 
fibrinogen KO mice showed no significant difference in the binding of fibrinogen 
to the RBCs compared to the WT, confirming that the plate-binding assay method 
excluded the RGD (95-97) site from being the prime binding site of fibrinogen 
and RBCs. A small, but statistically non-significant, increase in the F98I was 
observed in the experiments using blood from fibrinogen-knockout mice, which 
agreed with the prothrombotic tendency associated with the naturally occurring 
F98I mutation found in a patient with dysfibrinogenaemia and multiple 
miscarriages in pregnancy (Riedelova-Reicheltova et al., 2014). This mutant was 
found to play a role in increasing thrombosis by altering clot structure, as 
described in the previous chapter section 4.3.  
Another method of binding was established in this project, which was aimed at 
examining the binding interaction in solution rather than in static conditions. The 
idea for this method was to establish another method that may be considered 
more physiologically relevant. In this method, released haemoglobin after RBCs 
haemolysis was measured to evaluate the binding between fibrinogen and 
RBCs. The results of this method were consistent with the previous method in 
showing no significant effect of the mutants on the binding of fibrinogen to RBCs, 
compared to the WT. D97K and G96V had different effects to that produced by 
plate binding assay, reflecting the fluctuation of the effect of these two mutants 
between the different methods. The structural conformation of these mutants 
may be weaker than the other mutants making them more affected by the state 
of the binding either in liquid or static state.  
The results based on this assay suggested that RBCs do not bind fibrinogen 
through this RGD site but the binding will require further testing using different 
assay.  
In conclusion, the two methods for quantification of the binding between 
fibrinogen and the RBCs showed that the mutations in the Aα-95-97 RGD did not 
significantly affect the binding. This may mean that this RGD sequence is not the 
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primary site on fibrinogen to bind RBCs. To fully confirm these findings, the more 
sensitive flow cytometry technique was used next.   
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Chapter 6 Solution-Based Fibrinogen-RBC Binding Studies  
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6.1 Introduction 
Flow cytometry may be used to analyse millions of blood cells in the samples 
even with no requirement for pre-experimental sample preparation (Seliger et al., 
2012). Flow cytometry is able to identify a single cell type and isolate it in a group 
of cells such as platelets or RBCs in the whole blood or in mixed sample of cells 
(Lazarus et al., 1995). Platelets are difficult to be handled in the laboratory 
because they are easily activated during blood sampling and in vitro, but flow 
cytometry has the ability to overcome this problem by isolating the specific 
groups when gating on size, allowing for the identification of the required cells 
specifically (Lazarus et al., 1995). This can be achieved by using two-parameter 
analysis such as in case of platelets; the size which is represented by forward 
light scatter (FSC) combined with fluorochrome-labelled platelet antibodies 
(Lazarus et al., 1995).  
In this chapter, the identification of RBCs was performed using specific labelled-
antibodies against RBCs rather than relying solely on size gating to exclude 
smaller cells such as platelets. The use of these antibodies was a way to detect 
the binding of the labelled fibrinogen to the labelled RBCs, to ensure that the 
signal was specific to RBCs and not to other cells. 
A new method for evaluating the binding interactions between fibrinogen and an 
unknown site on RBCs, and the effect of the produced mutations in the Aα-95-
98 RGDF sequence on this binding, was established and optimised. The effect 
of the mutations on the fibrinogen binding to the RBCs in solution was performed 
first by using the haematocrit as the indicator for the amount of RBCs for the 
reaction. This was changed later because the signal from the RBCs was low 
indicating that more antibodies were required. A titration of the optimum amount 
of antibodies required for labelling the RBCs was performed to improve the 
signal. The principle of this experiment was to detect the binding of fluorescently 
labelled fibrinogen with fluorescently labelled RBCs. 
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6.2 Results  
My initial plans were to optimise a number of conditions before analysing the 
binding of the mutated fibrinogens to RBCs (data not shown). Recombinant 
fibrinogens were used first in the actual experiment in combination with a specific 
RBC haematocrit (Ht). To label RBCs, CD235aPE antibodies were added to the 
compact RBCs in a ratio of 1:11 v/v then diluted to the required amount for the 
experiment which was 0.01- 5% Ht. The low signals obtained using this method 
suggested that the amount of antibodies used was not enough to produce a clear 
signal of the binding between fibrinogen and RBCs. Subsequently, a titration 
experiment was performed to evaluate the required amount of antibodies in 
relation to a specific cell count of RBCs. Next, the combination of RBC-CD235aPE 
was tested in relation to AlexaFluor488-labelled fibrinogens. 
1.2.1 Initial optimisation work 
A few experiments were performed using a wide range of conditions with a 
combination of different concentrations of RBCs and fibrinogen. Regarding 
fibrinogen, the choice of the required concentration of AlexaFluor488-labelled 
fibrinogen was limited due to the low availability of recombinant fibrinogens. Two 
different concentrations were tested; the concentration which was used for laser 
scanning confocal microscopy (5 µg/ml), in addition to a lower concentration (1 
µg/ml). The choice of 5 µg/ml concentration was made because the signal was 
too low with the lower concentration. Commercial fibrinogen was used in the 
optimisation steps and the controls. 
For the RBCs, a large range of concentrations was used and more attempts were 
required to decide the best RBC haematocrit to be used in the experiment. 
Preparations of the reaction mixtures started from 50% Ht down to 0.01% Ht. 
50% Ht was prepared in the first experiment together with 5 % Ht, but was not 
used on the flow cytometer, because the 5% Ht gave signals that were too high. 
On the other hand, 0.01% Ht showed too low signals by the flow cytometer. In 
the middle of the range, 1% Ht was used and gave strong signals.  
The flow cytometer optimisation experiments were performed in a way similar as 
described in the methods section 2.12, but with slight changes as shown in 
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Figure 6-1. The CD235aPE antibodies were added to the RBCs in a ratio of 1:11 
v/v and then incubated at 4˚C in the cold room for 20 min according to the 
manufacturer’s instructions. The RBCs were then combined with AlexaFluor488-
labelled fibrinogen in final concentrations ranging between 0.01-5% Ht and 5 
µg/ml fibrinogen in a final volume of 400 µl. The following steps were similar to 
the methods section; 30 min incubation on a roller at room temperature, wash, 
centrifugation, re-suspension followed by flow cytometer analysis. 
 
 
Figure 6-1 Schematic representation of the binding between fibrinogen and RBCs 
in solution using flow cytometer. Antibodies CD235aPE were added to RBCs in 1:11 
ratio v\v and incubated for 20 min. 5 µg/ml of AlexaFluor488-labelled fibrinogen were 
combined with 0.01-5% Ht RBCs final concentrations in final volume of 400 µl then 
incubated for 30 min, washed, centrifuged, re-suspended then taken to the flow 
cytometer. 
 
Two different buffers were tested in the optimisation process: PBS and HEPES 
(150 mM NaCl, 0.1 % D-glucose. 2.7 mM KCl, 10 mM HEPES, 2 mM MgCl2, pH 
7.45) (de Witt et al., 2014). No difference on the RBC binding to fibrinogen was 
observed with the HEPES buffer, so PBS was used for all subsequent 
experiments. Another factor was tested for its effect on the CD235aPE antibodies 
was the temperature. Incubation in the cold room or at room temperature did not 
have any effect on the binding of CD235aPE antibodies to RBCs, so room 
temperature incubation was chosen for all subsequent experiments. 
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The binding between fibrinogen and RBCs was assessed using two gating 
strategies. The first involved gating to exclude the debris only, relying on 
including all cells because the RBCs were labelled. However, this was further 
divided into two types of inclusion criteria; one including only single positive cells; 
the other including all cells even if they were in clumps. The second gating 
strategy involved gating based on size, where small cells such as platelets were 
excluded to ensure the presence of RBCs only. This type of gating was not taken 
into consideration in later experiments because the CD235aPE antibodies are 
specific for the RBC and ensure that only labelled RBCs are evaluated.   
6.2.1 Evaluation of RBC Concentration 
After confirming 5 µg/ml as the best concentration of AlexaFluor488-labelled 
fibrinogen to be used in the experiment, more work was done to confirm the 
optimal concentration of the RBCs that would show the best binding with the 
chosen amount of labelled fibrinogen and be appropriate to be processed in the 
flow cytometer at the same time. Two lower concentrations (0.1% and 0.01% Ht) 
of RBCs were used, either labelled or unlabelled, with controls described in 
Figure 6-2. In this experiment, the temperature was tested as stated above to 
confirm that the temperature for the RBC-labelling step did not affect the binding 
between fibrinogen and RBCs. An additional tube of CD235aPE-labelled RBCs 
was prepared and incubated at room temperature on the roller instead of the cold 
room. The results are shown in Figure 6-3 (all cells gating strategy) and 
Figure 6-4 (size gating strategy). 
For both gating strategies, the results showed no difference between the cold 
room and the room temperature incubation of the RBCs with the labelling 
antibodies, subsequently, the choice was made to incubate at room temperature 
on a roller to ensure a better mixing of the cells and antibodies. The signals with 
0.01% Ht were lower than that of 0.1% Ht, so the decision was to confirm the 
choice of 0.1% Ht.  
The results confirmed that interactions occur between the AlexaFuor488-labelled 
fibrinogen and the CD235aPE-labelled RBCs, by flow cytometry, showing no 
signal for the controls as expected. The aim of using flow cytometry in this thesis 
chapter was to study the binding between RBCs and fibrinogen in solution, this 
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binding was proposed to occur via an integrin receptor on the RBC membrane. 
Excluding clumps may exclude parts of the RBC membrane that carry the 
integrin on its surface and bind fibrinogen, subsequently affecting the total 
binding level. To ensure that all possible expected binding between the RBCs 
and the integrin was included, an all-cells inclusion criterion was chosen in the 
final method when the mutants were used in the experiment. Gating with size 
was excluded as well since the CD235aPE antibodies are specific for the RBCs 
which mean that no contamination with other cells should be present.  
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Figure 6-2 Schematic representation to the reaction conditions of the final optimisation experiment for flow cytometry analysis of 
fibrinogen-RBCs binding. Red boxes represent the control RBCs without adding fibrinogen. The yellow boxes represent the controls of commercial 
unlabelled fibrinogen. The small blue boxes represent the reaction conditions of commercial AlexaFluor488-labelled fibrinogen. In all cases either 
unlabelled or CD235aPE  labelled RBCs were used. FBG: fibrinogen. 
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Figure 6-3 Optimisation reaction of binding interaction between fibrinogen and 
RBC, no gating was used. Beige and pink bars represent cold room (4°C) and room 
temperature (RT) incubation respectively. a) % of single CD235aPE-labelled RBCs (0.1% 
Ht) showing binding with AlexaFluor488-labelled fibrinogen. b) % of all CD235aPE-labelled 
RBCs (0.1% Ht), including clumps, showing binding with AlexaFluor488-labelled 
fibrinogen. c) % of single CD235aPE-labelled RBCs (0.01% Ht) showing binding with 
AlexaFluor488-labelled fibrinogen. d) % of all CD235aPE-labelled RBC (0.01% Ht), 
including clumps, showing binding with AlexaFluor488-labelled fibrinogen. RBC: 
unlabelled RBCs. RBC FBG: unlabelled RBCs + unlabelled fibrinogen. RBC AF: 
unlabelled RBCs + AlexaFluor488-labelled fibrinogen. CD: CD235aPE-labelled RBCs. CD 
FBG: CD235aPE-labelled RBCs + unlabelled fibrinogen. CD AF: CD235aPE-labelled 
RBCs + AlexaFluor488-labelled fibrinogen. Unlabelled and AlexFluor488-labelled 
fibrinogens were used at 5 µg/ml. The figure shows that there was no binding in the 
controls compared to the reaction conditions. 
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Figure 6-4 Optimisation reaction of binding interaction between fibrinogen and 
RBC, using gating on size of the cells. Beige and pink bars represent cold room (4°C) 
and room temperature (RT) incubation respectively. a) % of single CD235aPE-labelled 
RBCs (0.1% Ht) showing binding with AlexaFluor488-labelled fibrinogen.  b) % of all 
CD235aPE-labelled RBCs (0.1% Ht), including clumps, showing binding with 
AlexaFluor488-labelled fibrinogen. c) % of single CD235aPE-labelled RBCs (0.01% Ht) 
showing binding with AlexaFluor488-labelled fibrinogen. d) % of all CD235aPE-labelled 
RBC (0.01% Ht), including clumps, showing binding with AlexaFluor488-labelled 
fibrinogen. RBC: unlabelled RBCs. RBC FBG: unlabelled RBCs + unlabelled fibrinogen. 
RBC AF: unlabelled RBCs + AlexaFluor488-labelled fibrinogen. CD: CD235aPE-labelled 
RBCs. CD FBG: CD235aPE-labelled RBCs + unlabelled fibrinogen. CD AF: CD235aPE-
labelled RBCs + AlexaFluor488-labelled fibrinogen. Unlabelled and AlexFluor488-labelled 
fibrinogens were used at 5 µg/ml. The figure shows that there was no binding in the 
controls compared to the reaction conditions. 
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6.2.2 Effect of the mutations on fibrinogen binding to RBCs in 
solution 
All mutants (R95E, R95Q, G96V, D97K, D97N and F98I) in addition to the WT 
were tested for their effect on the binding between fibrinogen and RBCs. The 
experiment was repeated three times using the conditions that were selected 
above and shown in Figure 6-5. The controls were 0.1% Ht unlabelled RBCs,  
0.1% Ht unlabelled RBCs + 5 µg/ml commercial AlexaFluor488-labelled 
fibrinogen, 0.1% Ht CD235aPE-labelled RBCs, 0.1% Ht CD235aPE-labelled RBCs 
+ 5 µg/ml commercial AlexaFluor488-labelled fibrinogen. The tests were 0.1% Ht 
CD235aPE-labelled RBCs + 5 µg/ml AlexaFluor488-labelled recombinant 
fibrinogen. The experiment was performed as described in the methods 
section 2.12 and shown in Figure 6-1, except that the amount of RBCs used was 
dependent on the haematocrit (0.1 % Ht CD235aPE-labelled RBCs) instead of on 
RBC count as described in the methods. 
A representation of the scatter-plot generated from the flow cytometry data is 
shown in Figure 6-6a, for the WT. The plot is composed of four quarters which 
were chosen based on the location of each negative control tested separately: 
1. Quarter 1 (Q1): AlexaFluor488-labelled fibrinogen positive cell 
2. Quarter 2 (Q2): Double positives (AlexaFluor488-labelled fibrinogen and CD-
235aPE RBCs) 
3. Quarter 3 (Q3): Double negatives. 
4. Quarter 4 (Q4): CD-235aPE positive RBCs. 
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Figure 6-5 Schematic representation of the reaction conditions for flow cytometry analysis of fibrinogen-RBCs binding. Red boxes represent 
the controls RBCs without adding fibrinogen. The green boxes represent the controls of commercial AlexaFluor488-labelled fibrinogen. The small blue 
boxes represent the different AlexaFluor488-labelled variants of fibrinogen (5 µg/ml) FBG: fibrinogen. 
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Figure 6-6 Effect of different mutations on the binding between fibrinogen and 
RBCs. a) Representative scatter-plot graph for fibrinogen WT. Q1: AlexaFluor488-
fibrinogen positive cells, Q2: Double positive cells, Q3: Double negatives cells, Q4: 
CD235aPE positive cells (n=1). b) 5 µg/ml of AlexaFluor488-labelled variants in solution 
with 0.1% Ht (MFI: Mean Fluoresence Intensity). R95E, R95Q and D97K showed 
significant increase binding to RBCs, compared to the WT. The other mutants showed 
no change in binding. Error bars represent Standard Error of Mean (SEM). n=3: *P<0.05, 
****P<0.0001. One-way ANOVA multiple comparisons in GraphPad prism, Dunnett’s 
post hoc test were used. 
 
The cells on the scatter-plot in Figure 6-6a were accumulating towards the centre 
of the plot showing no distinct single cell for each population so it was not 
possible to distinguish individual cells from aggregates. This may be because 
the amount of CD-235aPE antibodies was too low compared to the cell count 
a 
b 
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which means that not every positively bound RBC was shown. Although the 
results shown in Figure 6-6b represent significant increases of binding to RBCs 
for fibrinogens R95E, R95Q and D97K, the experiment was thought to require 
more optimisation, and the physiological relevance of such increase remains 
unclear. G96V, D97N and F98I binding were similar to WT. Based on these data, 
a validation experiment, including a titration of the amount of the CD-235aPE 
antibodies was required before proceeding with the experiments on the mutated 
fibrinogens again. 
6.2.3 Validation of the Flow Cytometry Results by Titration of the 
Antibodies   
In order to validate the method further, a titration of two steps was performed. 
The first step was to choose the right amount of CD235aPE labelling antibodies 
relative to the number of cells, whereas the second step was to choose the 
optimum amount of CD235aPE-labelled RBCs relative to the concentration of 
fibrinogen that had been used (5µg/ml). Due to the limitation of the available 
fibrinogen, its concentration had to be kept constant. 
 Optimal RBC Number / Antibody Ratio Determination 
The first step was to find out the optimum ratio of RBCs count to the amount of 
CD235aPE labelling antibodies. Three different cell counts were used (106, 105, 
and 104 RBC/ml) in combination with 1:11 v/v (manufacturer’s instructions) of 
CD235aPE antibodies. Because the final volume of the fibrinogen and RBCs was 
400 µl, 40 µl of the antibodies were added to each tube of the different RBC 
count giving a final reaction volume of 440 µl. The cells were incubated on a 
roller at room temperature for 20 min, washed and re-suspended as above then 
taken to the flow cytometer. The cell number with the highest signal was selected 
to proceed to the second step. The results are shown in Figure 6-7, together with 
a control of 1% Ht unlabelled RBCs. RBCs at 106 and 105 cell/ml were too 
concentrated and had to be diluted by adding PBS; subsequently these two 
concentrations were excluded. One difficulty arose when processing the cells for 
the experiment, which involved a centrifugation step after the final wash; the 
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RBCs agglutinated and the pellet required more mixing to re-suspend. This 
agglutination may be because of the high attachment tendency of the RBCs to 
different surfaces, which was observed in its ability to stick to the plates in the 
binding assay experiment. The presence of fibrinogen on the surface of the 
bound RBCs may also induce RBC hyper-aggregation (de Almeida et al., 2009).   
1
%
 u
n
la
b
e
ll
e
d
-R
B
C
s
 
 1
0
4  R
B
C
/m
l
 1
0
5
 R
B
C
/m
l
 1
0
6
 R
B
C
/m
l
0
2 0
4 0
6 0
8 0
E x p e r im e n t c o n d itio n s
%
 C
D
2
3
5
a
P
E
-l
a
b
e
ll
e
d
  
R
B
C
s
 
Figure 6-7 Titration of the number of RBCs to the amount of CD-235aPE antibodies. 
Three different cell counts to the same amount of antibodies (1:11 v:v) were tested. 1% 
unlabelled RBCs were used as a negative control.  
Effect of Adding Fibrinogen to the Ratio 
The second step was to find the best RBC count that gives the highest binding 
signal when incubated with 5 µg/ml fibrinogen. This step relied on the previous 
step that 104 RBC/ml:40 µl antibodies was the best ratio to be used in the 
fibrinogen-RBC binding method. 103 RBC/ml and 102 RBC/ml were also used in 
addition to the 104 RBC/ml. To keep the ratio between the RBCs and antibodies 
constant, the amount of antibodies that was added to each tube was as follow: 
1. 102 RBC/ml + 0.4 µl CD235aPE antibodies 
2. 103 RBC/ml + 4 µl CD235aPE antibodies 
3. 104 RBC/ml + 40 µl CD235aPE antibodies 
At this stage fibrinogen was added after washing the cells, and incubated at room 
temperature on roller for 20 min. Cells were then washed, re-suspended and 
sent to the flow cytometer for analysis.  
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Figure 6-8 shows the result of the best RBC count to provide optimal binding 
signal with fibrinogen. Again, 104 RBC/ml showed the highest binding signal to 
fibrinogen. However, the figure shows a degree of interaction for both 103 and 
102 RBC/ml, but both conditions were excluded because after the washing and 
centrifugation steps, the pellet was very small to the degree that it was not clearly 
visible. The difficulty of re-suspending the pellet after the final wash for the 104 
RBC/ml condition was observed again and raised the concern of possibly 
affecting the results. Consequently, before proceeding with the experiment using 
the mutants and to confirm if these observations were reproducible, this titration 
experiment was repeated again. A new condition was introduced in the repeated 
titration to try to overcome the agglutination issue of the RBCs which involved 
adding a lower amount of the antibodies.  
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Figure 6-8 Titration of RBCs concentration to a set amount of fibrinogen binding.  
Control: 1% unlabelled RBCs. RBC-ve: 1% unlabelled RBC + AlexaFluor488-fibrinogen. 
102 RBC+ve, 0.4AB:  102 RBC/ml + 0.4 µl CD235aPE + AlexaFluor488-fibrinogen. 103 
RBC+ve, 4AB: 103 RBC + 4 µl CD235aPE + AlexaFluor488-fibrinogen. 104 RBC+ve, 
40AB: 104 RBC/ml + 40 µl CD235aPE + AlexaFluor488-fibrinogen. AlexFluor488-labelled 
fibrinogen was used at 5 µg/ml. 
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Final validation experiment to confirm RBC/ antibodies ratio  
In this last optimisation experiment and for the same concentration of RBCs (104 
RBC/ml), three different volumes of the CD235aPE antibodies were used (40, 30, 
20 µl). Again 104 RBC/ml + 40 µl CD235aPE antibodies had the highest binding 
signal with fibrinogen (Figure 6-9), but agglutination of the cells was still a 
problem. Although it showed less binding signal compared to the amount of 
antibodies, 20 µl antibodies was chosen to minimise the effect of agglutination 
on the fibrinogen-RBC binding. 
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Figure 6-9 Titration of the amount of antibodies to a set concentration of RBCs.  
AF: AlexaFluor488-fibrinogen only. AF, RBC-ve: Alexa AlexaFluor488-fibrinogen + 1% 
unlabelled RBCs. RBC, 40AB: RBCs + 40 µl CD235aPE. RBC, 20AB: RBCs + 20 µl 
CD235aPE. AF, RBC, 40AB: RBC + 40 µl CD235aPE + AlexaFluor488-fibrinogen. AF, 
RBC, 30AB: RBCs + 30 µl CD235aPE + AlexaFluor488-fibrinogen. AF, RBC, 20AB: 
RBCs + 20 µl CD235aPE + AlexaFluor488-fibrinogen. Amount of 104 RBC/ml and 5 µg/ml 
AlexFluor488-labelled fibrinogen were used, unless specified. 
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6.2.4 RBC-Fibrinogen Binding Using the New Method  
Next, the mutants were used for the final assessment of the effects of the 
mutations on the binding between fibrinogen and RBCs, in solution using the flow 
cytometry following the protocol stated in material and methods section 2.12. 
Briefly, 104 RBC/ml + 20 µl CD235aPE were combined with 5 µg/ml AlexaFluor488-
labelled recombinant fibrinogen in a final volume of 420 µl, incubated for 30 min 
at room temperature, washed and re-suspended in PBS then analysed by flow 
cytometry. The results are shown in Figure 6-10 as MFI. 
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Figure 6-10 Effect of different mutants on the binding between fibrinogen and 
RBCs. Total of 5 µg/ml of Alexa Fluor488-labelled variants in solution with 104 RBC/ml + 
20 µl of CD235aPE. All mutants showed statistically non-significant changes in the 
binding to the RBCs, compared to the WT. Error bars represent Standard Error of Mean 
(SEM). n=3 (except R95E n=1, G96V n=2, D97N n=0). One-way ANOVA multiple 
comparisons in GraphPad prism, Dunnett’s post hoc test were used. 
 
As shown in Figure 6-10, R95E was analysed only once whereas G96V was 
analysed twice, due to the limited amounts of labelled proteins available for these 
two mutants. The pattern of the effects of the mutants is consistent with the 
results that obtained by plate-binding assay and solution assay, where the 
differences in the binding between fibrinogen and RBCs were statistically non-
significant showing slight increase for R95Q, D97K (except plate-binding assay), 
D97N and F98I, whilst G96V showed a slight decrease compared to the WT. 
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Although R95E showed a statistically non-significant differences in binding signal 
being a slightly higher than the WT in other methods, here it showed a slightly 
lower MFI than the WT, but this would need repeating as there was only one 
measurement done for this mutant. When compared to the WT, the slight 
changes in binding between fibrinogen mutants and RBCs failed to reach 
statistical significance. Figure 6-11 (histogram) and Figure 6-12  (scatter-plot) 
show representative data from one experiment for each mutant. The results of 
these two figures do not strictly reflect the actual results since they are from one 
experiment only. 
Figure 6-11 shows histograms of WT compared to each mutant separately, these 
figures are representative and they do not reflect the actual results because they 
were chosen from the experiment that include the single R95E sample analysis. 
The histogram shows a clear separation between the negative RBCs population 
(top left) that represent no binding of fibrinogen, and the positively fibrinogen-
bound RBCs (bottom right). In this case, the negative population was higher than 
the positive one. In Figure 6-12, Q1 and Q4 are the AlexaFluor488-fibrinogen and 
CD235aPE positive quadrants respectively. Q3 is the double negative quadrant 
whereas Q2 is the double positive quadrant from which the MFI was calculated 
reflecting the degree of binding between fibrinogen and RBCs. Although the 
double positive population in Q2 looks very low, it shows double positive cells 
that are distributed as a single cell population. Although it is shown in the figures 
that the positive signal of binding between the RBCs and each of the mutants 
was very low compared to the negative population, the presence of this signal 
was good evidence indicating the presence of binding between the RBC and 
fibrinogen, which was successfully detected by the flow cytometry method. 
However, the mutations had no significant effect on the binding of fibrinogen to 
RBCs, compared to WT, when tested in solution.   
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Figure 6-11 Representative histogram indicating the increase of binding of 
fibrinogen. Blue lines represent the recombinant WT. Coloured lines represent the 
mutants. The left area represents the negative population of RBCs whereas the right 
area represents the RBCs that have bond to fibrinogen. Histogram gated on RBC 
showing fibrinogen binding and calculated by the FlowJo7 software (n=1) 
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Figure 6-12 Representative scatter-plots produced by the flow cytometer. Side scatter represents AlexaFluor488-fibrinogen intensity (in the 
FITC channel) and forward scatter represents CD235aPE intensity. Q1: AlexaFluor488-fibrinogen positive cells, Q2: Double positive cells, Q3: 
Double negatives cells, Q4: CD235aPE positive cells (n=1). 
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6.3 Discussion  
Analysis of fibrinogen binding to the RBCs in solution using flow cytometry has 
shown that compared to the WT, there were no statistically significant differences 
between the mutants and the WT showing a slight increase in the binding of 
R95Q, followed by D97K and to a lesser extent for F98I, whilst G96V showed a 
slight decrease in binding together with R95E (n=1). All these effects failed to 
reach statistical significance. The data correlated largely with the results of the 
fibrinogen-RBC plate-binding assay and solution binding assay. The effects of 
the mutations were fluctuating between each other, but in general they were just 
marginally changed compared to the WT.  
In this study, flow cytometry was explored to find a robust and well-established 
solution-based method to study the binding between fibrinogen and RBCs. 
Lominadze and Dean (2002) previously measured the interaction between RBCs 
and fibrinogen using labelled fibrinogen as has been done in this thesis, but they 
evaluated the binding using fluorescence measurements by spectrophotometer 
and quantified the binding sites using phase-contrast microscopy (Lominadze 
and Dean, 2002). Specific binding between RBCs and fibrinogen was found by 
their study, which they suggested to be integrin dependent and they were able 
to inhibit this binding using an RGDS peptide that is an integrin antagonist 
(Lominadze and Dean, 2002).  
Agglutination of the RBCs as a result of the presence of the CD235aPE antibodies 
was a slight issue, which was the reason for using less CD235aPE antibodies to 
ensure that all cells were taking into account. The agglutination may be caused 
by the binding of RBCs to fibrinogen, which may induce erythrocyte hyper-
aggregation in addition to the high tendency of the RBCs to attach to surrounding 
surfaces, which was also observed in other methods of this thesis or by 
centrifugation as in the case of flow cytometry (de Almeida et al., 2009). Some 
studies which used flow cytometry for studying the interaction between fibrinogen 
and platelets, such as Kasahara et. al. (1987), ensured that no aggregation of 
platelets took place in order to measure the interaction of individual platelets, so 
they avoided centrifugation of platelets and used low density platelets (2 x 108 
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cells/ml) suspension (Kasahara et al., 1987). These authors demonstrated that 
by not centrifuging the platelets, non-bound fibrinogen would be present in the 
sample; however, they confirmed that its effect was negligible. So they were able 
to measure the fluorescence intensity of individual platelets with sufficiently weak 
signal from non-bound fibrinogen (Kasahara et al., 1987). 
Two more studies investigated platelets and fibrinogen interactions using flow 
cytometry for its ability to detect the binding of a single cell to fibrinogen. 
(Warkentin et al., 1990, Abrams et al., 1990). Warkentin et al. avoided using 
centrifugation in their protocol, because it can cause damage to the platelets’ 
membrane. They found that this damage is minor and should not affect fibrinogen 
binding response to the agonist activated platelets in vitro, however, this could 
cause damage to the platelets, which were activated in vivo (Warkentin et al., 
1990). These authors diluted whole blood and measured the binding between 
fibrinogen and platelets using FITC-conjugated polyclonal anti-fibrinogen 
antibodies. They found that this was a sensitive method for measuring fibrinogen, 
but that the binding could be non-specific, because the antibody cannot 
discriminate between free and platelet-bound fibrinogen (Warkentin et al., 1990). 
On the other hand, Abrams et al., chose to use monoclonal antibodies that were 
fluorescein-labelled against platelet-specific glycoprotein GPIb antibodies, so 
there was no need for washing or centrifugation, because labelled-platelets are 
easily distinguished from other cells when used in flow cytometry (Abrams et al., 
1990). Although the CD235aPE antibodies are specific for RBCs, all experiments 
were performed on washed RBCs rather than whole blood to be consistent with 
the other experiments presented in this thesis. In this project, as mentioned 
above, a final wash was performed after the incubation of fibrinogen with labelled 
RBCs to eliminate non-bound fibrinogen. This final wash was established in the 
initial method relying on haematocrit. In this method, there was no effect of the 
antibodies on agglutination, because the amount of antibodies was low. On the 
other hand, to overcome the agglutination limitation in the later method, the 
amount of CD235aPE antibodies was decreased to a minimum that still can show 
effect on the binding. 
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The use of a monoclonal antibody to provide required specificity was the reason 
for using CD235aPE in this thesis. Monoclonal antibodies were used previously 
in flow cytometry analysis to determine the number of RBC membrane-derived 
vesicles in thalassaemia patients in comparison to normal individuals 
(Pattanapanyasat et al., 2004). In whole blood, vesicles of RBC membrane were 
identified depending on their size using the FSC and side light scattered (SSC). 
They used two colour immunostaining of specific FITC/PE conjugated 
monoclonal antibodies to glycophorin A and CD41a to further distinguish the 
RBC vesicles from platelets and their vesicles (Pattanapanyasat et al., 2004). 
The authors found that this method has advantages of using small volumes; it is 
quick, reproducible and easy to perform (Pattanapanyasat et al., 2004).  
The effect of the mutations in the RGD sequence of the amino-terminal half of 
fibrinogen Aα-chain was suggested to non-significantly enhance the binding 
between fibrinogen and RBCs instead of inhibiting them, especially for R95Q, 
D97N, F98I followed by D97K compared to the WT. The statistically non-
significant effect of G96V showed decrease in binding to RBCs whilst R95E 
binding was studied only once and was non-significantly lower than the WT. The 
enhancing effects of the mutations in the RGD can be a result of conformational 
changes in the tertiary structure that might expose the sequence for the 
interaction with fibrinogen, or because the initial binding between fibrinogen and 
RBCs might induce conformational changes in the secondary structure that 
again expose the RGD for more binding (Riedelova-Reicheltova et al., 2014). In 
the first flow cytometer experiments there were some significant increases in the 
mutants with oppositely charged amino acids (negative E95 and positive K97) 
and to a lower extent of significance for the neutral Q95. However, the other 
mutants showed no changes. When the method was altered to increase the 
amount of available CD235aPE-labelled RBCs for interaction with fibrinogen, the 
significance of the results was lost, but they were more reproducible. The cells 
were presented in distinct populations rather than the clumps that were found in 
the first method. The optimisation experiment was performed using commercial 
AlexaFluor488-labelled fibrinogen and not the recombinant WT, and an 
observation which needs more investigation was that the effect by commercial 
fibrinogen differs somehow from the WT. When the experiment was optimised 
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with commercial fibrinogen, the binding signal was slightly stronger than when 
recombinant fibrinogen was used. The effect was still consistent, but not as clear 
as when commercial fibrinogen was used. This difference between the two types 
of fibrinogen may be due to the nature of each of them: commercial fibrinogen is 
purified from human plasma, and provided in a lyophilised form which is then 
reconstituted in water, whilst recombinant fibrinogen is expressed in cultured 
cells then purified. However, WT was prepared by the same process as the 
mutant fibrinogens, making it a better control. The difference between 
commercial and recombinant fibrinogen was observed in later stages of the 
project. Therefore, optimisation experiments after this observation were done 
using the WT in the following experiments. 
The non-significant response and the inability to inhibit the binding between 
RBCs and fibrinogen by the different mutants may reflect that the binding of 
RBCs to fibrinogen is largely independent from the fibrinogen RGD sequence, in 
agreement with the other plate-based experiments of RBC-fibrinogen 
interactions.  
In conclusion, there was no effect of the RGD mutations on the binding of 
fibrinogen to RBCs in solution. There was no clear inhibition for this binding, but 
a statistically non-significant enhancement was observed for some mutants. 
 
 
 
180 
 
 
 
 
 
 
 
 
 
 
 
Chapter 7 Study of the Integrin Responsible for Fibrinogen 
Interaction with Platelets and RBCs 
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7.1 Introduction 
Platelets are an important cell type in the body. Physiologically they play a key 
role in haemostasis by balancing bleeding and thrombosis, but at the same time, 
they play a key role in thrombotic diseases, such as myocardial infarction, stroke 
and cerebral infarction (Remijn et al., 2002, Savage et al., 1998). Platelet 
activation starts with agonist-receptor binding and ends with platelet 
aggregations, secretion and shape change (Shattil et al., 1985). This activation 
is required for their binding to fibrinogen, and there are >100,000 copies of αIIbβ3 
on the surface of activated platelet (Shattil et al., 1985). Platelets are activated 
in response to physiological agonist such as ADP, thrombin, and collagen 
binding to their respective receptors on the platelet membrane. This interaction 
between platelets and agonists induces shape changes and activates the αIIbβ3 
integrin which is a glycoprotein heterodimer complex acting as a receptor for 
fibrinogen (Shattil et al., 1987, Shattil et al., 1989, Frojmovic et al., 1994). Binding 
of fibrinogen to this receptor can be used to assess platelet activation, or as in 
this project, adhesion since fibrinogen is an important cofactor for aggregation 
as well as adhesion of the platelet (Shattil et al., 1989). The αIIbβ3 integrin binds 
fibrinogen through a recognition sequence on fibrinogen composed of three 
amino acids; Arg-Gly-Asp (RGD) (Farrell et al., 1992). The interaction between 
this RGD sequence on fibrinogen γ-chain and the integrin is well-defined (Farrell 
et al., 1992). However, the role of the RGD sequence on the Aα-95-97 of 
fibrinogen, which is the focus of this PhD thesis, remains unclear.  
In platelets, actin cytoskeleton is shown to be part of the regulation of the integrin 
αIIbβ3 function, since impairment of actin polymerisation inhibits agonist-induced 
binding of the integrin to fibrinogen (Bennett et al., 1999). It is suggested that the 
affinity of the integrin αIIbβ3 to soluble ligands such as fibrinogen is increased by 
releasing the cytoskeletal constraints on the integrin. This release occurs by 
increasing actin filaments turnover which is induced by inside-out signalling in 
platelets (Bennett et al., 1999). Inside-out signalling is the process of binding 
platelet agonists to the αIIbβ3 integrin caused by its activation; the integrin is 
converted from its low affinity form on platelet surface to high affinity form 
capable of binding to its ligands (Coller and Shattil, 2008, Oberprieler et al., 
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2007). Releasing the cytoskeletal constraints was found to increase cell 
adhesion avidity by increasing the chances of random meetings between the 
integrin and its ligand (Bennett et al., 1999). 
Platelet plasma membrane and lipid bilayer are coated by a membrane skeleton 
that is a lattice-like structure. This skeleton membrane acts as a signal 
transduction regulator due to the nature of its structure; it is interconnected with 
intracellular cytoskeletal elements as well as extracellular glycoproteins (Fox et 
al., 1993). Platelets normally circulate as flat oval discs, however, when platelets 
are activated by agonists such as thrombin or ADP, they transform to compact 
spheres with emerging spikes called filopodia, lamellipodia and veils (Hartwig, 
1992). The reorganisation of actin-myosin cytoskeleton leads to changes in the 
platelet shape, and to the formation of the actin filaments in filopodia (thin finger-
like structures) and lamellipodia (thin sheet-like protrusions), both of which are 
required for platelet spreading (Mattila and Lappalainen, 2008, Roberts et al., 
2009). At the site of vascular injury, adhesion of platelets is vital to stop bleeding 
(Roberts et al., 2009). Spreading of platelets on immobilised fibrinogen was 
evaluated using fluorescently-labelled phalloidin staining. Phallotoxins are a 
group of cyclic peptides that bind specifically to actin. Fluorescent phallotoxins 
have several advantages including that they are small in size, they have long-
term stability, and they have stabilising effects against depolarisation of actin, 
which improves the structural preservation in the preparation (Faulstich et al., 
1988).  
This chapter describes the interaction between fibrinogen and αIIbβ3 platelet 
integrin using platelet spreading assay and the different fibrinogen Aα-chain 
R95GDF98 mutations (R95E, R95Q, G96V, D97K, D97N and F98I). This was to 
validate the assay evaluating whether this RGDF sequence in the Aα-chain binds 
platelet αIIbβ3 integrin (Carvalho et al., 2010), in analogy to studying the role of 
the fibrinogen mutants in RBC binding.     
In order to study the interaction of the RBC integrins with the fibrinogen Aα-chain 
R95GDF98 sequence, antibodies, previously used to identify the potential site of 
interaction (anti-αVβ3), were also used. Another antibody against the αV integrin 
was used as well to confirm the specificity of the binding site (Guedes et al., 
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2016), in addition to the normal isotype IgG. Study of the binding site will be 
performed using antibodies against some integrins thought to be involved in the 
binding of fibrinogen to RBCs. In addition, eptifibatide (an inhibitor of αIIbβ3 
integrin on platelets) will also be used to assess whether the αIIbβ3 integrin is 
involved in RBC-fibrinogen binding, like it is for platelet-fibrinogen interactions.  
7.2 Results  
7.2.1 Studies of the Integrin-Bound Fibrinogen on the Platelets 
Surface     
The effect of the mutations in the RGD sequence on the interaction between 
fibrinogen and platelet αIIbβ3 integrin was tested by visualising the spreading of 
platelets on immobilised fibrinogen. Platelet spreading assay was performed as 
per the protocol from the Prof Khalid Naseem Laboratory (Roberts et al., 2009) 
(section 2.13.2) using 100 µg/ml of recombinant fibrinogen and 5 x 106  cells/ml. 
The interaction was assessed using AlexaFluor488-conjugated phalloidin. Before 
staining, the cells were fixed to ensure that their structures were preserved. The 
cells were then permeabilised to allow the phalloidin to enter the cells, and 
washed with PBS to remove any debris before fixation (Wang et al., 1982, 
Roberts et al., 2009).   
A negative control consisted of 5 mg/ml denatured fatty acid free Bovine Serum 
Albumin (BSA) was coated onto the cover slip. The images in Figure 7-1 show 
that platelets did not adhere in the control experiment (BSA coating) because 
their morphology was different from the shape of the spreading platelets on 
fibrinogen. The control platelets looked irregular in shapes and they did not show 
the spreading projections of lamellipodia. The spreading of platelets was clear 
and the cells looked larger than in the control (BSA) experiment. For R95E, the 
platelet count looked similar to the WT, with a slightly bigger size. For D97K, 
there were statistically non-significant less platelets, with similar size to the WT. 
The similarity of the results of both oppositely charged mutants (negative E95 
and Positive K97) with the WT reflected again that altering the type of the charge 
did not affect the ability of fibrinogen to bind the platelets. In coverslips which 
were coated with R95Q and D97N fibrinogens, platelet count was decreased, 
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but this did not reach statistical significance, but their size appeared larger than 
the WT, but again they failed to reach statistical significance. Platelets on 
coverslips coated with F98I fibrinogen looked slightly larger in size, but almost 
similar in number to the WT fibrinogen. For all mutants, the platelets showed 
lamellipodia as well as small, highly stained, retracted cells, but to different 
extents. Coverslips with WT and oppositely charged mutants (R95E and D97K) 
seemed to have more of the small, highly stained nodular cells than R95Q, D97N 
and F98I coverslips, where lamellipodia were observed. G96V fibrinogen was no 
longer available, so could not be included in this experiment. D97N was studied 
only once for the same reason of limited amount available. 
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Figure 7-1 Comparison of platelets spreading on coverslips coated with mutant fibrinogens. Total of 100 µg/ml fibrinogen, 5 x 106 platelet/ml, 
1 unit/coverslip of AlexaFluor488-phalloidin, and BSA control were used. Images were taken by 63x lens and processed using FIJI software, applying 
automatic threshold. Scale bar = 100 µm. n=3 (except D97N, n=1). Platelets are coloured in green. Yellow arrows point to spread platelets with 
lamellipodia, whilst pink arrows point to retracted platelets. Yellow box is a magnifying part to show the lamellipodia. 
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The images were analysed using FIJI by applying automatic threshold and the 
analysis of spreading results are showed in Figure 7-2 
B
S
A
W
T
R
9
5
E
R
9
5
Q
D
9
7
K
D
9
7
N
F
9
8
I
0
2 0
4 0
6 0
8 0
1 0 0
M u ta n ts
P
la
te
le
ts
 c
o
u
n
t/
 f
ie
ld
 o
f 
v
ie
w
n = 1
B
S
A
W
T
R
9
5
E
R
9
5
Q
D
9
7
K
D
9
7
N
F
9
8
I
0
5
1 0
1 5
2 0
M u ta n ts
P
la
te
le
t 
s
u
rf
a
c
e
 c
o
v
e
ra
g
e
 (
%
)
n = 1
 
Figure 7-2 Quantitative comparison of the effect of different mutants on platelets 
spreading on fibrinogen-coated coverslips. Total of 100 µg/ml fibrinogen, 5 x 106  
platelet/ml, 1 unit/coverslip AlexaFluor488-phalloidin.  a) Platelet count. b) % coverslip 
covered with platelet. Images were taken by 63x lens, field of view (1790.52X1341.60 
micron), and processed using FIJI, applying automatic threshold. Error bars represent 
Standard Error of Mean (SEM).  n=3 (except D97N, n=1). One-way ANOVA multiple 
comparisons in GraphPad prism, Dunnett’s post hoc test were used. 
 
Platelet counts in Figure 7-2a showed that platelet adhesion for all mutants was 
almost similar to WT, except a slight decrease in the R95Q followed by D97K 
compared to the WT. Nonetheless, D97N appeared the most obvious decreased 
mutant compared to the WT, but this was tested only once because there was 
not enough protein of this mutant. The effect of the mutations on the percentage 
of area covered by platelets was in agreement with the platelet counts 
a 
b 
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Figure 7-2b, and showed that R95E slightly increased the spreading, whilst 
R95Q induced a slight decrease followed by D97K. Platelet spreading on F98I 
was similar to WT. However, all these effects were statistically non-significant. 
D97N again had lower percent area of spreading than the WT, but this was from 
a single experiment and did not reach statistical significance.  
7.2.2 Studies of the Integrin-bound Fibrinogen on the RBC Surface     
Fibrinogen-Red Blood Cells Plate-Binding Assay 
Inhibitor of αIIbβ3; anti-αVβ3 and the anti-αV antibodies were used to identify which 
of these integrins are responsible for the binding of fibrinogen to RBCs using 
plate-binding assay, solution binding assay and flow cytometry. The antibodies 
were first used in the plate binding assay as described in the method 
section 2.10. Briefly 100 µl per well of RBCs (5% final concentration) were 
incubated for 1 hr. The plate was then washed and each antibody (10 µg/ml final 
concentrations) was added to 100 µl of 20 µg/ml of recombinant WT final 
concentration, incubated for 1 hr before washing. RBCs were haemolysed with 
100 µl of water and the supernatant was stored at -80°C for quantification of 
bound fibrinogen by ELISA.  
The results of this experiment are shown in Figure 7-3. Strangely, the addition of 
the antibodies marginally enhanced fibrinogen-RBC binding instead of 
decreasing it but, this effect was minimal and failed to reach statistical 
significance. According to the previous study by Guedes et al. (2016), the integrin 
αVβ3 is the binding site of fibrinogen on the RBC membrane. Increased binding 
should not be the case if this integrin is the site of interaction of fibrinogen on the 
RBCs.  
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Figure 7-3 Effect of antibodies on fibrinogen-RBCs binding using WT fibrinogen.  
The results showed unexpected but statistically non-significant increase in binding. Total 
of 10 µg/ml of antibodies, 5% RBC, 20 µg/ml fibrinogen. Error bars represent Standard 
Error of Mean (SEM). n=3. One-way ANOVA multiple comparisons in GraphPad prism, 
Dunnett’s post hoc test were used. WT: wild type, WT+IgG: wild type + anti-IgG 
antibodies, WT+αV: wild type + anti-αV antibodies, WT+αVβ3: wild type + anti-αVβ3 
antibodies. 
 
Fibrinogen-Red Blood Cells Binding Assay in Solution  
The same antibodies (10 µg/ml final concentrations each), as well as Eptifibatide 
(an αIIbβ3 inhibitor, 5 µg/ml), were used in the solution assay presented in chapter 
5. This was to verify whether the small effects of the antibodies on the fibrinogen-
RBCs binding in the plate assay were caused by the static condition of the 
experiment. Briefly, 20 µg/ml of WT fibrinogen, 10 µg/ml of each antibodies 
(except Eptifibatide, 5 µg/ml), and 5% RBCs final concentrations were mixed 
together in a final volume 300 µl. Fibrinogen-RBCs were then transferred to a 
fibrinogen antibodies pre-coated plate in a volume of 100 µl per well for 2 hrs 
incubation as described in the methods section 2.11. The plate was then washed 
and the cells were haemolysed in water and released haemoglobin was 
measured at 405 nm as a reflection of RBCs that bound to fibrinogen. The results 
of this experiment are shown in Figure 7-4. Again there was no significant 
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difference after the addition of the antibodies and they did not block the 
interaction as suggested by Guedes et al (2016).  
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Figure 7-4 Effect of antibodies on WT fibrinogen binding to RBCs by solution-
interaction assay.No clear effect on the fibrinogen-RBCs binding was observed from 
all the inhibitory antibodies tested. Error bars represent Standard Error of Mean (SEM). 
(n=3). One-way ANOVA multiple comparisons in GraphPad prism, Dunnett’s post hoc 
test were used. B PBS: blank PBS. Ept 5: eptifibatide 5 µg/ml.  WT: wild type, WT+IgG: 
wild type + anti-IgG antibodies, WT+αV: wild type + anti-αV antibodies, WT+αVβ3: wild 
type + anti-αVβ3 antibodies 
 
Flow Cytometric Assay 
Using flow cytometry was the last attempt to use the antibodies to study the 
binding between fibrinogen and RBCs, using the method that was relying on 
counting the cells as described in methods section 2.12. Briefly, 5 µg/ml of 
AlexaFluor488-labelled WT fibrinogen was combined with 104 RBC/ml and 20 µl 
of CD235aPE + 10 µg/ml of each type of antibodies, final volume 420 µl. The 
mixture was incubated for 30 min then washed, centrifuged, re-suspended, and 
taken to the flow cytometer. The results in Figure 7-5 are presented as median 
fluorescent intensity (MFI) of the bound fibrinogen and show a statistically non-
significant difference of the binding between WT and RBCs interactions being 
slightly higher when the antibodies were present. This was similar to what have 
been shown by the previous two techniques (plate-binding assay and solution 
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plate-binding assay) confirming that the binding is not through this integrin αvβ3 
so the experiment was not repeated and statistical analysis was not applied. 
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Figure 7-5 Effect of different antibodies added to the WT on the binding between 
fibrinogen and RBCs measured as MFI. Total of 5 µg/ml AlexaFluor488-labelled WT + 
104 RBC/ml + 20 µl CD235aPE + 10 µg/ml antibodies. All antibodies showed increased 
the binding of fibrinogen WT to RBC, n=1. WT: wild type, WT+IgG: wild type + anti-IgG 
antibodies, WT+αV: wild type + anti-αV antibodies, WT+αVβ3: wild type + anti-αVβ3 
antibodies. 
 
7.3 Discussion 
7.3.1 Effect of Fibrinogen RGD Mutations on Platelet Adhesion and 
Spreading     
The data generated in this chapter showed no significant difference in the 
spreading of platelets on coverslips coated with mutated fibrinogens. All the 
mutants showed different degrees of presence of lamellipodia and some densely 
stained cells, which may be retracted cells. In general for all mutants, the 
platelets showed almost similar sizes in the images, which may reflect that the 
degree of spreading was similar to the WT; this may be due to strong interaction 
with fibrinogen. The similarity in size of platelets to the WT may suggest that 
mutations in the Aα- R95GDF98 sequence did not affect the spreading. The 
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amount of available D97N was enough to be used only once whereas G96V was 
not used in this experiment because this mutant was no longer available.     
In the current project, the effect of mutating fibrinogen Aα-95-97 RGD sequence 
on its interaction with platelets was studied to evaluate whether this RGD 
sequence is involved in the binding site of the αIIbβ3 integrin on platelets since no 
effect of these mutations was observed in the interaction of fibrinogen with RBCs. 
This would support the probability to target this sequence as a therapeutic 
strategy for thrombotic disease.  
Looking at the results in this chapter, the spreading of platelets on fibrinogen in 
response to the mutations in the fibrinogen Aα-95-97 RGD sequence reflected 
that the binding of fibrinogen to the integrin αIIbβ3 was not affected by the 
mutations and they did not block or decrease the interaction between fibrinogen 
and platelets. These results are similar to what has been found in the binding 
between fibrinogen and RBCs in that those mutations did not have a significant 
effect on the binding between fibrinogen and platelets. In this project, the 
hypothesis was that mutations in the RGD sequence would inhibit the binding by 
blocking the binding site of fibrinogen to the RBC integrin or αIIbβ3 if it is the 
binding site of fibrinogen on RBCs in addition to platelets. The role of Aα-95-97 
RGD in the binding was tested, but mutating the RGD site did not significantly 
affect the spreading of platelets on fibrinogen or inhibit the binding between 
fibrinogen and αIIbβ3 integrin.  
When spreading, platelets change their dendritic appearance to a fully spread 
form with a smooth membrane (Sandmann and Koster, 2016, White and Escolar, 
1993). Fully spread platelets should have a regular shape. Sandmann and 
Köster, 2016 have found that platelets retracted when spreading on a structured, 
but not on a smooth surface (Sandmann and Koster, 2016). Accordingly, some 
cells appeared in the figurers as densely stained retracted cells. Other platelets 
in our assays showed projections that could be lamellipodia, which allow 
platelets to adhere to underlying surfaces and help to cover the wound, rather 
than the filopodia which act to recruit other platelets and help in the spreading 
(Sandmann and Koster, 2016).  
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Looking at platelet spreading on the mutated fibrinogens by microscopy, it seems 
that the mutations in the RGD sequence had influenced the spreading (fully 
spread appearance with lamellipodia). However, this effect of mutations on the 
spreading was statistically non-significant compared to the WT, indicating that 
the mutations did not affect the binding between the αIIbβ3 integrin of the platelets 
and the RGD sequence on fibrinogen.  
In conclusion, no significant differences were observed, these data showed that 
the Aα-95-97 RGD sequence does not play a significant role in the binding 
between fibrinogen and αIIbβ3 of platelets excluding this site from the binding 
between fibrinogen and RBCs and that the binding site could be γ-400-411 
sequence or the Aα-572-574 RGD sequence (Cheresh et al., 1989b). These 
results were mostly in agreement with the effects of the mutations on the RBC 
binding to fibrinogen by the plate binding assay and the flow cytometry reflecting 
that the Aα-95-97 RGD seems not to have a role in the interaction of fibrinogen 
with either RBCs or platelets. However, some of the results are only preliminary 
as some experiments could not be repeated due to the limited amounts of 
recombinant protein available. 
7.3.2  Effect of Using Integrin Antibodies and Inhibitor on the 
Binding between Fibrinogen and RBC Surface     
In addition to studying the effect of the mutations in fibrinogen Aα-95-97 RGD 
sequence on the binding between fibrinogen and RBCs, the expected binding 
site of fibrinogen on the RBC membrane was investigated using some 
antibodies. The choice of antibodies was based on a study by Guedes et al. 
(2016) suggesting that integrin αVβ3 is involved in the binding of fibrinogen on the 
RBC membrane. Eptifibatide, an inhibitor of the platelets integrin αIIbβ3, was used 
as well in the solution binding assay to find out if this integrin is the binding site 
of fibrinogen on the RBC membrane. Integrin studies were performed in this 
project using all the functional methods of fibrinogen-RBC binding studies; plate 
binding assay, solution binding assay and flow cytometry. 
The results of all experiments were consistent showing that neither αVβ3 nor 
αIIBβ3 are the integrin receptors for fibrinogen on the RBC membrane. This is 
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because there was a non-significant enhancement in the binding between 
fibrinogen and RBCs with the addition of the antibodies or the inhibitor. 
Antibodies blocking the αVβ3 integrin either exposed an unknown integrin on the 
RBC surface and increased RBC binding or induce conformational changes in 
the WT fibrinogen exposing the hidden RGD sequence for more binding when it 
is exposed. The non-specific binding of the RBCs with the plate may block the 
αVβ3 integrin site preventing its binding to the antibodies and subsequently inhibit 
their effect.   
Lominadze and Dean 2002, have suggested that the binding between fibrinogen 
and erythrocytes, which may induce erythrocytes aggregation, is via an integrin 
binding site and is inhibited by RGDS peptide; the integrin receptor antagonist 
(Lominadze and Dean, 2002). They confirmed the presence of specific fibrinogen 
binding sites on the surface of the RBC, which they suggested to be through an 
unidentified integrin type receptor (Lominadze and Dean, 2002). They suggested 
that RBC receptor has low affinity to RGDS, however, they did not exclude the 
presence of a non-integrin type binding  through the RGD as well (Lominadze 
and Dean, 2002). High concentrations of RGDS was required to show significant 
inhibition of the binding reflecting low affinity of the fibrinogen receptor on the 
erythrocytes surface whilst lower concentrations failed to reach significant effects 
(Lominadze and Dean, 2002). Unlike Lominadze and Dean, in this project RGDF 
was investigated rather than the RGDS, and studying the interaction site was via 
antibodies against the integrin rather than using antagonist peptide to the RGD. 
The statistically non-significant effects of RGDF mutations on the binding 
between fibrinogen and RBCs may be because higher concentrations of 
fibrinogen were required to provide statistical significant.  
Addition of eptifibatide in my assays was found to not affect the binding between 
fibrinogen and RBCs. This finding could not confirm the previous results by 
Carvalho et al where RBC-fibrinogen interaction was studied in comparison to 
platelets interaction with fibrinogen using atomic force microscopy (AFM) 
(Carvalho et al., 2010). In this study they indicated that the interaction between 
fibrinogen and RBCs is through β3-related integrin (Carvalho et al., 2010). The 
authors have found that this interaction is inhibited by the αIIbβ3 integrin inhibitor; 
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eptifibatide, but to a lower degree than platelets, which excluded the platelet 
integrin from being the receptor for fibrinogen on the RBC membrane. The 
authors found that the RBC receptor is calcium-dependant and has lower binding 
force than the platelet integrin (Carvalho et al., 2010).  
By using AFM with anti-αV and anti-αVβ3 antibodies, Guedes et al, showed that  
the integrin αVβ3 is the specific receptor of the fibrinogen on the RBC membrane 
(Guedes et al., 2016). The use of these antibodies in the current project did not 
inhibit the binding between fibrinogen and RBCs. Nonetheless, they non-
significantly enhanced this binding, excluding these two integrins from being the 
binding site of fibrinogen on the RBCs. The inconsistency observed between 
these studies may be due to difference in the techniques or the type of fibrinogen 
used. On the other hand, both studies lack any biochemical evidence of the 
presence of the integrin on the RBCs such as a western blotting results or 
knockout mouse studies. However, it should not be ignored that the results of 
the integrin studies in the current project were consistent among all the 
techniques used, suggesting more studies to confirm either one of the findings.  
In conclusion, the consistency of the results obtained using two inhibitory 
antibodies and three different binding methods, in causing a slight enhancement 
of the binding between fibrinogen and RBCs rather than inhibiting it, might 
exclude the integrin αVβ3 from being the binding site for fibrinogen on the RBCs. 
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Chapter 8 Discussion  
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In this project the focus was on fibrinogen binding and interaction with RBCs, 
aiming to establish the site of this interaction on both fibrinogen and RBCs. The 
experimental approach to achieve this aim was by producing recombinant 
fibrinogens with mutations in the integrin binding site, and to study their effect(s) 
on the binding of fibrinogen with RBCs and platelets, and on clot structure and 
function.     
8.1 Overview on the results 
In order to achieve the aims of this project, six mutants of fibrinogen in the A-
chain R95G96D97F98 integrin binding site were produced using recombinant 
technology in βγ-CHO cells (R95E, R95Q, G96V, D97K, D97N, F98I), and 
studied for their effect(s) on clot structure as well as on the binding between 
fibrinogen and RBCs. The recombinant fibrinogens showed some changes in 
clot structure, polymerisation profile and fibrinolysis. The selection of these 
mutations was based on the side-chain sizes of the new residues being similar 
to the original residues, to avoid disruptions to the molecular structure of the 
fibrinogen with a factor other than charge. The data from all experiments 
including clot structure and fibrinogen-RBC binding suggested that the original 
charged residues provide stability to the fibrinogen molecule. Data with neutral 
mutants showed more variability compared to the WT, especially regarding clot 
structure. 
The new recombinant fibrinogens were tested for presence of any changes in 
their secondary structures which may be caused by conformational changes in 
the protein folding that can affect the biological function of the protein (Kelly et 
al., 2005). The CD-spectra curves showed a slight decrease in the α-helix for 
both R95Q and D97N compared to the WT. This decrease was found to be 
minimal and had no effect on the biological functions of fibrinogen; however, it 
cannot be excluded that the mutations may have induced conformational 
changes in the tertiary structure of the protein. All fibrinogen mutants resulted in 
significant effects on clot structure showing thinner fibres and longer clotting 
times that were significant for R95E, R95Q and D97N.   
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The overall results of the effect of the mutations on clot structure and the binding 
between fibrinogen and RBCs are summarised in Table 8-1. Recombinant 
mutated fibrinogens were tested for their effect on the binding between fibrinogen 
and RBCs. This effect was first tested in static conditions using a plate-binding 
assay. The results from this experiment showed no significant changes of 
mutants compared to the WT with regards to the binding between the fibrinogen 
and RBCs. Next, the effect on binding was tested in solution, and evaluated by 
haemoglobin release from RBCs bound to fibrinogen that was captured with 
fibrinogen antibodies. The results were again minimal and statistically non-
significant. Finally the effect was tested in full solution state by using flow 
cytometer and the results again showed no significant differences between the 
mutants. For the sake of conformation of the role of A-chain R95G96D97 on the 
binding between fibrinogen and RBCs, this was tested by different methods and 
all of them suggested that this site does not participate in this binding.    
The use of antibodies in this project has revealed that αvβ3 was not the binding 
site of fibrinogen on the RBC surface, because antibodies against this integrin 
induced the binding of fibrinogen to the RBCs instead of inhibiting this binding. 
The platelet spreading experiment has confirmed that Aα-95-97 RGD is not the 
main binding site for αIIbβ3 on platelets surface.  
8.2 Variable Effects on Clot Structure and Function among 
Mutants  
The R95E, D97K, and F98I mutants showed similar clotability to the WT followed 
by R95Q and D97N, whilst G96V had a significantly lower clotability compared 
to the WT. All mutants showed significantly thinner fibres when converted to fibrin 
and to a lesser extent of significance for D97K than the WT. Although thinner 
fibres were formed, R95E and R95Q had significantly longer lag phase whereas 
the G96V and D97N had only slightly longer clotting time that did not reach 
statistical significance. According to Collet et al., clots that are made up of a large 
number of thin fibres lyse slower than clots made up of a smaller number of 
thicker fibres (Collet et al., 2003). Even when mutants lysed slower than the WT, 
they either had a smaller number of thin fibres (R95E) or a larger number of thin 
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fibres (D97K). Some mutants produced clots that were made up of a large 
number of thin fibres, but still lysed faster than the WT (R95Q and F98I), or a 
similar number of fibres as the WT and lysed faster (D97N). There were no lysis 
results for G96V due to low availability. 
8.2.1 Summary 
In summary, all mutants were found to produce clots with thinner, shorter fibres 
that were highly branched compared to the WT. When it came to the binding 
between the recombinant fibrinogens and RBCs, there were non-significant 
differences between the different methods used (plate-binding assay, plate-
based solution assay and flow cytometry in solution). However, overall, the 
effects of the mutations on RBC binding were not significantly different for any of 
the mutants when compared with the WT taking all three methods into 
consideration.  
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Table 8-1 Summary of the results of the effect of the mutations on clot structure 
and properties, compared to the WT. Arrows represent the increase or decrease in 
each particular parameter. One arrow represents statistically non-significant effect, two 
arrows represent statistical significant effects. *P<0.05, **P<0.01, ***P<0.001, 
****P<0.0001.  
 R95E R95Q G96V D97K D97N F98I 
Clotability 93.7% 88.4% 
68.8% 
** 
96.4% 84.9% 94.2% 
Max OD 
↓↓ 
*** 
↓↓ 
**** 
↓↓ 
**** 
↓↓ 
* 
↓↓ 
**** 
↓↓ 
*** 
Lag phase 
↑↑ 
*** 
↑↑ 
** 
↑ ↓ ↑ ↓ 
Time to ½ 
lysis 
↑ ↓ - ↑ ↓ ↓ 
Clot 
structure 
Shorter 
fibres and 
slightly less 
branched 
 
Shorter 
fibres and 
highly 
branched 
- 
Shorter 
fibres and 
highly 
branched 
 
Much shorter 
fibres and 
highly 
branched 
Shorter 
fibres and 
highly 
branched 
 
Fibre 
density 
↓↓ 
* 
↑↑ 
* 
- 
↑↑ 
**** 
≈ 
↑↑ 
**** 
α-helix 
count 
≈ ↓ ≈ ↑ ↓ ≈ 
Plate-binding 
assay of RBC 
interaction 
↑ ↑ ↓ ↓ ↑ ↑ 
Mice plate-
binding assay 
≈ ≈ ≈ ≈ ≈ ↑ 
Solution-
binding assay 
↑ ↑ ≈ ↑ ↑ ≈ 
Flow 
cytometry 
↓ ↑ ↓ ≈ - ≈ 
Platelets 
spreading 
≈ ↓ - ↓ ↓ ↓ 
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8.3 General discussion 
8.3.1 RGD Aα-95-97 Involvement in Fibrinogen-RBC Binding 
The choice of making mutations in the RGD Aα-95-97 was supported by a 
naturally occurring mutation just after this site (F98I) which was a heterozygous 
point mutation found in a woman with multiple miscarriages, but no bleeding or 
thrombotic symptoms (Riedelova-Reicheltova et al., 2014). The turbidity and 
confocal microscopy experiments in the present study showed that recombinant 
F98I has lower maximum absorbency, with thinner, shorter and more branched 
fibres, lower fibrinolysis and a denser clot structure. This was in agreement with 
the laboratory investigations of the natural F98I, which revealed some changes 
in clot structure showing thin, short, and curly fibres with a lower final turbidity, 
impaired fibrinolysis, and greater platelet aggregation (Riedelova-Reicheltova et 
al., 2014). This mutation was suggested to cause conformational changes that 
causes disturbances to the folding of the coiled-coil region on the Aα-chain of 
fibrinogen (Riedelova-Reicheltova et al., 2014). The mutation was produced as 
a recombinant mutation for the first time in the laboratory in the present project 
to study its effect on clot structure and the binding with RBCs.   
Similar to F98I, the G96V mutation was selected based on previous studies. The 
results which were obtained for the binding between fibrinogen and RBCs 
showed that this mutant did not affect this binding, despite a previous report 
showing an effect on the binding between fibronectin and fibroblasts  
(Pierschbacher and Ruoslahti, 1984). The presence and involvement of the RGD 
sequence in cell attachment was first discovered in fibronectin by Pierschbacher 
and Ruoslahti, 1984.  Substitution of Glycine with Valine (G96V) was found to 
diminish the binding of fibroblasts to fibronectin (Pierschbacher and Ruoslahti, 
1984). However, it was found that in an Arg-Gly-Asp-Ser (RGDS) sequence, 
when Ser was replaced with Cys (RGDC), no loss of the binding was observed. 
This indicated that the Serine residue was not required for the binding activity of 
the molecule, which therefore totally relied on the Arg-Gly-Asp (RGD) sequence 
(Pierschbacher and Ruoslahti, 1984).   
 
 
201 
 
Other mutations which were selected in the present study to test the binding 
between fibrinogen and RBCs were also based on synthetic peptides tested in 
the Pierschbacher and Ruoslahti study of interactions between fibronectin and 
fibroblasts. The authors found that deletion of Arginine (R) or Aspartic acid (D) 
lost binding activity of the molecule, and substitution of Aspartic acid with 
Asparagine (D97N) diminished the binding between fibronectin and fibroblasts 
(Pierschbacher and Ruoslahti, 1984). The results of similar mutations in 
fibrinogen in this project showed that D97N did not have significant effect on the 
binding between fibrinogen and RBCs compared to the WT, although it did show 
somewhat slightly lower binding in all experiments compared to other mutants 
that failed to reach statistical significance.     
Not many studies have been performed on the RGD sequence which was the 
focus of this project or on its interaction with RBCs. Mutations in fibrinogen to 
inhibit its binding with different cells were previously used to confirm which of the 
three sites was involved in the binding of fibrinogen to platelets. Farrell et al. 
1992, produced three different mutations in the Aα and γ chains of fibrinogen. In 
the Aα-chain, the D97E, which was one of the sites that were mutated in this 
project but with different residues. The other mutant in the Aα-chain was D574E 
whereas in the γ-chain, the α2β2γ’2 recombinant fibrinogen was produced 
replacing the two γ-chains by two γ’-chains (Farrell et al., 1992). In similar results 
to what we have achieved with Aα-95-98 RGD, the authors found that mutations 
in either RGD binding sites of fibrinogen did not show a great effect on the 
aggregation. On the other hand, the γ-carboxylic binding site was able to inhibit 
the aggregation when it was mutated showing its role in the adjacent platelet 
bridging during the aggregation; so it was possible to confirm the site of 
fibrinogen-platelet binding as the γ-chain C-terminus of the common γ-chain 
splice variant (Farrell et al., 1992). These results agreed with Kloczewiak et al 
1984 that γ-chain is the main interaction site of platelets with fibrinogen 
(Kloczewiak et al., 1984) but contradicted Hawiger et al, 1989 who suggested a 
role for both alpha RGD sites and gamma chain in the binding between platelet 
integrin and fibrinogen (Hawiger et al., 1989). This controversy keeps the door 
open for more research in the area of allocating the site of interaction on 
fibrinogen with different cell types.  
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The involvement of the Aα-95-97 RGD in the binding of fibrinogen to αIIbβ3 
platelet integrin was investigated recently, in addition to the other two sites (Aα-
572-574 RGD and γC-12 AGDV-containing dodecapeptide), in a study by 
Kononova et al. (2017). The authors found that a single molecule of both the Aα 
and γ chains contributed almost the same in the binding with the platelet integrin. 
However, with high concentrations of fibrinogen, it was found that both the Aα-
RGDs bind significantly more than the γ-chain dodecapeptide most probably 
because there are two different RGD sites compared to one γC-12 (Kononova et 
al., 2017). According to their results more fibrinogen may be required to show 
significant results. Although the amount of fibrinogen which was used in the 
platelet spreading assay (100 µg/ml) was relatively high in the method developed 
by the Naseem Laboratory, the results failed to show a statistically significant 
effect. This may mean that any change in the binding between fibrinogen and 
RBCs reflects the effects of the mutations with no influence of the amount of 
fibrinogen used. In another study, it was found that both RGD and γ-chain 
synthetic peptides are able to inhibit the binding of αIIbβ3 on platelets to different 
adhesive proteins such as fibronectin and vWF (Tranqui et al., 1989). However, 
mutations in the Aα-95-97 RGD in present study did not show any inhibition of 
the binding between fibrinogen and platelets, excluding this RGD from being 
the site of interaction between fibrinogen and platelets.    
8.3.2 RGD Site on Fibrinogen 
While the use of synthetic peptides by some studies was aimed at inhibiting 
interactions between fibrinogen and platelets, and thereby subsequent platelet 
activation, in the present study the focus was on abolishing the interaction 
between fibrinogen and RBCs by mutating the proposed site(s) of interaction. 
Introducing mutations was used in early and more recent studies to evaluate the 
effect of these mutations on fibrinogen binding. To confirm the involvement of 
the both RGD sequences in the binding of fibrinogen and other adhesive proteins 
to different cells, Pytela et al (1986) found that the amino acid substitution of 
aspartic acid by glutamic acid was inactive in synthetic peptide and had no effect 
on the binding to platelets, which was confirmed later by other studies as stated 
above (Pytela et al., 1986).  
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In a more recent study on the involvement of the Aα-95-97 RGD in the binding 
between RBCs and fibrinogen, Carvalho et al, 2018 investigated its involvement 
in a way similar to our route of mutating the RGD site to abolish this interaction. 
The authors compared the relative roles of the two RGD sites on the Aα-chain in 
the binding between fibrinogen and RBCs (Carvalho et al., 2018). Three 
mutations were studied, namely D97E, D574E and a D97E/D574E double 
mutant and compared to WT fibrinogen. Using AFM, they found that the D97E 
had a lower binding force to the RBCs and a lower rupture force compared to the 
WT followed by the double mutant, however, the D574E showed a stronger 
binding force and a higher rupture force than the WT, suggesting that Aα-95-97 
RGD provides the main binding site for RBCs on fibrinogen (Carvalho et al., 
2018).  
The results in which D97E inhibited the binding contradict the results presented 
in this thesis, which showed no significant effect of mutations at this site. In 
addition, Pytela et al, 1986 also showed that there was no effect of this specific 
mutation on the binding of platelets with fibrinogen. The difference between the 
results of Carvalho et al and the present study may relate to differences in the 
techniques that were used in the studies. Another reason may be the 
electromagnetic charge of the mutation, since in the Carvalho et al the authors 
replaced the negative aspartic acid with a negative glutamic acid (Carvalho et 
al., 2018). So in their case, they replaced an amino acid with a similar size and 
charge, which means that the degree of any disruption to the molecule was not 
as much as when we changed the charge to its opposite (positive lysine: K) or to 
neutral (asparagine: D). The disturbances in the structure of the molecule in the 
present study may have led to increased exposure of the cryptic Aα-95-97 RGD 
for enhanced binding with RBCs (Riedelova-Reicheltova et al., 2014) 
The involvement of F98I in thrombosis (Riedelova-Reicheltova et al., 2014) drew 
our attention to investigate this residue which is located right next to the RGD. In 
the present study, the RGDF mutant was found to slightly enhance the binding 
between fibrinogen and RBCs, supporting thrombotic rather than inhibitory 
effects. It was found previously that the tripeptide RGD is not enough to inhibit 
the binding between fibrinogen and platelets or endothelial cells. There was a 
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requirement for the presence of a fourth amino acid in position X (RGDX) for the 
synthetic peptide to be able to inhibit the binding of both cells to fibrinogen 
(Tranqui et al., 1989). This is not in agreement with the suggestion from synthetic 
peptide studies about the non-involvement of serine residue in the binding 
between fibronectin and fibroblast above (Pierschbacher and Ruoslahti, 1984) 
This disagreement may be due to the difference in the proteins in which the 
synthetic peptide was located in either fibrinogen or fibronectin. In a more recent 
study, RGD containing disintegrins of snake venom, which are able to inhibit 
ADP- and collagen-mediated platelet activation and aggregation were 
investigated (Oyama et al., 2017). The authors confirmed that the composition 
of the amino acid residues in the RGD loop was very important for the binding, 
and that the selectivity of these disintegrins was influenced by the amino acids 
nearby the RGD sequence (Oyama et al., 2017). 
The results of this project suggested the presence of a discrepancy in the effect 
of the mutations on the binding of fibrinogen to RBCs, which may be related to 
the charge and biophysical nature of the newly introduced residue. The 
replacement of an Arginine by neutral or oppositely charged residue would 
encourage the new fibrinogen to favour the binding with RBCs rather than to 
inhibit it. Previously in the case of platelets, this inhibitory effect was found to be 
increased with the increase of hydrophobicity of amino acid X for example RGDS 
had less inhibitory potential than RGDF (Tranqui et al., 1989). However, when 
the Arginine residue was changed by a more acidic residue such as Histidine 
(HGDF) or neutral such as glutamine (QGDF), a discrepancy effect was detected 
with opposite effects on the binding of fibrinogen to both cells (Tranqui et al., 
1989). 
8.3.3 Integrin Studies 
In addition to investigating the involvement of the Aα-95-98 RGDF in the binding 
between fibrinogen and RBCs, the binding site on the RBC is equally important 
in participating in this binding. The way that the RGD is recognised by its ligand 
was found to depend on the conformation of the sequence, which subsequently 
depends on any substitution of the residues and the chemistry of the residue that 
follows the tripeptide (Pierschbacher and Ruoslahti, 1987). This suggests that 
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the specificity of the receptor relies on the conformation of the RGD, which is 
affected by its neighbouring residues (Park et al., 2002). In the present study, 
this conformation may be affected by the mutations as well. In the platelet 
spreading method presented in this thesis, the Aα-95-98 RGD may be excluded 
from being the site of interaction between fibrinogen and αIIbβ3 using adsorbed 
fibrinogen on the coverslips. A previous study excluded any role of the platelet 
glycoprotein αIIbβ3 in the binding between RBCs and fibrinogen which may occur 
through the adherence of the platelets or platelet micro-particles (MP) in the 
RBCs (De Oliveira et al., 2012). No staining for the RBCs was detected as a 
result of the platelet marker CD41 as per Carvalho et al, 2010. In spite of using 
different methods, there was agreement between the results of the adsorbing 
fibrinogen on the AFM functionalised tip in the Carvalho et al. (2010) and the 
soluble fibrinogen in De Oliveira et al. study because immobilising fibrinogen 
could cause conformational changes in fibrinogen structure (De Oliveira et al., 
2012, Carvalho et al., 2010). Adsorbed fibrinogen in this project was used in 
solution assay and plate-binding assay as well. By using RGD and RGDS 
peptides, De Oliveira et al. contradicted the results that suggested the 
involvement of the RGD sequence in fibrinogen-RBC interaction and the 
presence of integrin-like receptor involvement of the interaction between soluble 
fibrinogen and RBCs (De Oliveira et al., 2012). However, it was shown that this 
interaction is age dependant and higher in young RBCs than older ones (De 
Oliveira et al., 2012). Finally the authors assign the CD47 surface receptor on 
the RBC membrane as a mediator for their interaction with fibrinogen, because 
the antibodies against this receptor decreased binding of soluble fibrinogen to 
the RBCs (De Oliveira et al., 2012). Our results may agree with the findings of 
De Oliveira et al. of excluding the RGD sequence from the binding of fibrinogen 
with RBCs, because by mutating this sequence there was no significant effect 
on fibrinogen-RBC binding. 
Using antibodies against αV and αVβ3; the endothelial receptor that bound 
fibrinogen via RGD, Guedes et al, 2016 showed that this receptor may be the 
integrin on the RBC membrane that is responsible for its binding with fibrinogen 
at the single-molecule level using AFM (Guedes et al., 2016). Our results do not 
confirm these findings, because by all techniques in the present study, using 
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either of these two antibodies slightly enhanced the binding compared to the WT. 
This may exclude this integrin as the site of binding of fibrinogen on the surface 
of the RBCs. The discrepancy in the results between Guedes et al. and the 
present study may be caused by the nature of the techniques that were used in 
the two studies. According to De Oliveira et al. fibrinogen adsorbed on the AFM 
tip may cause conformational changes that affect the binding of fibrinogen with 
the RBCs. This could be the case in fibrinogen-RBCs solution and plate-binding 
assays, because fibrinogen was adsorbed on the plate. Nonetheless, the results 
of these two techniques were consistent with the results of the flow cytometer, 
which involved the presence of fibrinogen in solution and not adsorbed to any 
surface.  
In this project antibodies against αVβ3 and αV integrins were used to establish if 
the αVβ3 is the binding site of the fibrinogen on the RBCs. Using antibodies 
against the glycoproteins αIIbβ3 and GPIb in addition to RGDS peptides, Wick et 
al. suggested the presence of similar proteins to these integrins on the surface 
of the young RBCs facilitate their interaction with the vWF (Wick et al., 1993). 
These results were contradicted by the results of another group who used well-
characterised monoclonal antibodies against several integrins. The authors 
found GPIV and α4β1 non-RGD recognised integrins on the surface of 
reticulocytes of anaemic patients. These integrins were decreased as the 
reticulocyte maturated to erythrocytes (Joneckis et al., 1993). Their results 
demonstrated the absence of the adhesion receptors GPIb, αIIbβ3, αVβ3 and αVβ5 
for vWF and receptors αIIbβ3, αVβ3 and αMβ2 for fibronectin on the reticulocyte 
(Joneckis et al., 1993). 
In addition to the interaction between fibrinogen and RBCs, the effect of the 
mutations in the Aα-95-98 RGD on the binding between fibrinogen and platelets 
was also studied in this project to elucidate if this sequence is involved in this 
binding interaction. However, results from the present study did not show 
inhibition in the binding between fibrinogen and platelets in response to mutating 
the Aα-95-98 RGD, which may exclude this site from being the site of interaction 
with the αIIbβ3 integrin on platelets.  
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8.4 Project limitations 
Difficulties with this project started from the first step of mutagenesis, a series of 
experimental repeats were performed in a long process of method optimisation 
before the successful mutants were produced. Next, production of the protein 
was a very long and costly process that concluded with a low yield of fibrinogen 
for most of the mutants. The low amount of available fibrinogen was the main 
limiting factor in this project.  
Some experiments such as scanning electron microscopy and clot retraction, 
which were initially planned to study the effect of RBCs on the clot structure were 
cancelled. This was because these particular experiments required higher 
amounts of fibrinogen than the other methods, which were not sufficiently 
available due to the low yield and concentrations of the recombinant fibrinogens. 
When planning the SEM and clot retraction experiments, the calculations 
revealed that the amount of recombinant fibrinogen which was required for the 
experiment for some of the mutants was about 50% of the total volume of the 
reaction mixture. Adding recombinant fibrinogen up to 50% of the clot volume 
would highly dilute the clot preparation mixture, which contains blood to the 
extent that may prevent clotting. On the other hand, to study the effect of mutants 
on clot structure by SEM, the required fibrinogen concentration was too high 
compared to the available recombinant fibrinogens.  
For fibrinogen-RBCs binding under static conditions of the plate-binding assay, the 
experiment was run under non-physiological conditions, since binding was affected 
by the static conditions which might affect the conformation of fibrinogen. This 
condition is different from the physiological binding conditions which might be seen 
if the experiment was perform under shear stress (i.e. under flow conditions). 
Addition of thrombin would convert fibrinogen to fibrin, which would resemble the 
physiological condition in case of injury, and might lead to activation of RBCs that is 
similar to platelet activation and subsequently enhance the binding of RBCs and 
fibrinogen. At the time of experiment a suitable positive control such as platelets was 
not available to test the sensitivity of the assay.  
For fibrinogen-RBC binding in solution by flow cytometry, AlexaFluor488-labelled 
recombinant fibrinogen was required. Labelling the fibrinogen by itself caused a 
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respectful amount of fibrinogen to be lost and the concentration of the labelled 
recombinant fibrinogen was lower than unlabelled ones. This limited the amount 
of available fibrinogen even more than what was available for the other methods. 
The flow cytometry experiment was performed by two different ways; firstly by 
using haematocrit as the measurement tool for the amount of RBCs required for 
the experiment. Secondly by counting RBCs in a step to improve the binding 
signal between fibrinogen and RBCs. Repeating the experiment was not possible 
for all the mutants because some of them were not available for the updated 
method of flow cytometry.   
One of the most important limiting factors in this project was the availability of 
volunteers for blood donation. The initial plan of the project was to study the 
effect of the mutations on binding between fibrinogen and RBCs on different 
blood Rh-groups, but this was omitted because of the difficulty of getting 
volunteers.  
Some other techniques were proposed to be used in this project, but the nature 
of the RBC prevented us from proceeding with these techniques. RBCs were 
found to be difficult to be processed in the lab; for example Carr and Hardin, 
mentioned that clots made with RBCs were difficult to be studied for their 
structure. For light scattering the gels of whole blood were too turbid and electron 
microscope showed two dimensional images instead of three dimensional 
networks, which made the measurements difficult to perform (Carr and Hardin, 
1987). Gersh et al had confirmed this difficulty of processing the RBCs in clots 
by describing their incorporation in the clot as uncontrollable and variable. They 
added that presence of RBCs in the clot would interfer with laboratory techniques 
such as turbidity (Gersh et al., 2009).   
8.5 Clinical relevance and Future direction 
Red blood cells interactions with fibrinogen are potentially a very important area 
of research due to the effect this binding may have on erythrocyte hyper-
aggregation with major implications for cardiovascular disease and thrombus 
formation (Brust et al., 2014). Working on the binding to find the exact site of 
fibrinogen interaction on the RBCs can be a therapeutic target to find an inhibitor 
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for the integrin site on RBCs that resembles the effect of the eptifibatide inhibition 
on platelet integrin αIIbβ3. The new RBC integrin inhibitor would be able to block 
the binding between RBCs and fibrinogen and subsequently decrease the 
tendency of thrombosis. 
Proceeding with the study of the binding to specify the site of interaction both in 
fibrinogen and RBC would be of great benefit. To find the binding site on 
fibrinogen and based on the results presented in this thesis, the Aα-95-98 RGD 
should be excluded in relation to RBC binding and the attention should be 
focused on the other two sites of Aα-272-274 RGD and γC-12 dodecapeptide. 
However, it was clearly established that mutating the Aα-95-98 RGDF site 
changed the clot structure, which may still be a cause of thrombosis or bleeding 
that may be taken into account for any naturally occurring mutations in this 
sequence.  
In conclusion, Aα-95-98 RGDF has no obvious effect on the binding between red 
blood cells and fibrinogen, or platelets and fibrinogen. Nonetheless, mutations at 
this site changed clot structure and polymerisation profile, as well as the 
susceptibility to lysis. These alterations may be of importance in the occurrence 
and risk of thrombosis and consequently cardiovascular disease, so should be 
taken into account in the diagnosis of suspected thrombosis with no clear cause, 
which might be achieved by in vivo studies in mice. 
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Appendix A Sequencing  
>pMLP+FbgAa WT with AA to be mutated 
CATCATCAATAATATACCTTATTTTGGATTGAAGCCAATATGATAATGAGGGGGTGGAGTTTGTGAC
GTGGCGCGGGGCGTGGGAACGGGGCGGGTGACGTAGTAGTGTGGCGGAAGTGTGATGTTGCAAGTGT
GGCGGAACACATGTAAGCGACGGATGTGGCAAAAGTGACGTTTTTGGTGTGCGCCGGTGTACACAGG
AAGTGACAATTTTCGCGCGGTTTTAGGCGGATGTTGTAGTAAATTTGGGCGTAACCGAGTAAGATTT
GGCCATTTTCGCGGGAAAACTGAATAAGAGGAAGTGAAATCTGAATAATTTTGTGTTACTCATAGCG
CGTAATATTTGTCTAGGGCCCAAGCTTGTTTGCAAAAGCCTAGGCCTCCAAAAAAGCCTCCTCACTA
CTTCTGGAATAGCTCAGAGGCCGAGGCGGCCTCGGCCTCTGCATAAATAAAAAAAATTAGTCAGCCA
TGGGGCGGAGAATGGGCGGAACTGGGCGGAGTTAGGGGCGGGATGGGCGGAGTTAGGGGCGGGACTA
TGGTTGCTGACTAATTGAGATGCATGCTTTGCATACTTCTGCCTGCTGGGGAGCCTGGGGACTTTCC
ACACCTGGTTGCTGACTAATTGAGATGCATGCTTTGCATACTTCTGCCTGCTGGGGAGCCTGGGGAC
TTTCCACACCCTAACTGACACACATTCCACAGCTGGTTCTTTCCGCCTCAGAAGGGTACCCGGTCCT
CCTCGTATAGAAACTCGGACCACTCTGAGACGAAGGCTCGCGTCCAGGCCAGCACGAAGGAGGCTAA
GTGGGAGGGGTAGCGGTCGTTGTCCACTAGGGGGTCCACTCGCTCCAGGGTGTGAAGACACATGTCG
CCCTCTTCGGCATCAAGGAAGGTGATTGGTTTATAGGTGTAGGCCACGTGACCGGGTGTTCCTGAAG
GGGGGCTATAAAAGGGGGTGGGGGCGCGTTCGTCCTCACTCTCTTCCGCATCGCTGTCTGCGAGGGC
CAGCTGTTGGGCTCGCGGTTGAGGACAAACTCTTCGCGGTCTTTCCAGTACTCTTGGATCGGAAACC
CGTCGGCCTCCGAACGTACTCCGCCACCGAGGGACCTGAGCGAGTCCGCATCGACCGGATCGGAAAA
CCTCTCGAGAAAGGCGTCTAACCAGTCACAGTCGCAAGGTAGGCTGAGCACCGTGGCGGGCGGCAGC
GGGTGGCGGTCGGGGTTGTTTCTGGCGGAGGTGCTGCTGATGATGTAATTAAAGTAGGCCGTCTTGA
GACGGCGGATGGTCGAGCTTGAGGTGTGGCAGGCTTCAGATCTGGCCATACACTTGAGTGACAATGA
CATCCACTTTGCCTTTCTCTCCACAGGTGTCCACTCCCAGGTCCAACCTGATCAGAATTGCGCCGCT
CTCGAGTGAATTGTCGACCGCGGCCCCCTGGAGTGTCCTCAGGAGCCAGCCCCACCCTTAGAAAAGA
TGTTTTCCATGAGGATCGTCTGCCTGGTCCTAAGTGTGGTGGGCACAGCATGGACTGCAGATAGTGG
TGAAGGTGACTTTCTAGCTGAAGGAGGAGGCGTGCGTGGCCCAAGGGTTGTGGAAAGACATCAATCT
GCCTGCAAAGATTCAGACTGGCCCTTCTGCTCTGATGAAGACTGGAACTACAAATGCCCTTCTGGCT
GCAGGATGAAAGGGTTGATTGATGAAGTCAATCAAGATTTTACAAACAGAATAAATAAGCTCAAAAA
TTCACTATTTGAATATCAGAAGAACAATAAGGATTCTCATTCGTTGACCACTAATATAATGGAAATT
TTGAGAGGCGATTTTTCCTCAGCCAATAACCGTGATAATACCTACAACCGAGTGTCAGAGGATCTGA
GAAGCAGAATTGAAGTCCTGAAGCGCAAAGTCATAGAAAAAGTACAGCATATCCAGCTTCTGCAAAA
AAATGTTAGGGCCCAGTTGGTTGATATGAAACGACTGGAGGTGGACATTGATATTAAGATCCGATCT
TGTCGAGGGTCATGCAGTAGGGCTTTAGCTCGTGAAGTAGATCTGAAGGACTATGAAGATCAGCAGA
AGCAACTTGAACAGGTCATTGCCAAAGACTTACTTCCCTCTAGAGATAGGCAACACTTACCACTGAT
AAAAATGAAACCAGTTCCAGACTTGGTTCCCGGAAATTTTAAGAGCCAGCTTCAGAAGGTACCCCCA
GAGTGGAAGGCATTAACAGACATGCCGCAGATGAGAATGGAGTTAGAGAGACCTGGTGGAAATGAGA
TTACTCGAGGAGGCTCCACCTCTTATGGAACCGGATCAGAGACGGAAAGCCCCAGGAACCCTAGCAG
TGCTGGAAGCTGGAACTCTGGGAGCTCTGGACCTGGAAGTACTGGAAACCGAAACCCTGGGAGCTCT
GGGACTGGAGGGACTGCAACCTGGAAACCTGGGAGCTCTGGACCTGGAAGTGCTGGAAGCTGGAACT
CTGGGAGCTCTGGAACTGGAAGTACTGGAAACCAAAACCCTGGGAGCCCTAGACCTGGTAGTACCGG
AACCTGGAATCCTGGCAGCTCTGAACGCGGAAGTGCTGGGCACTGGACCTCTGAGAGCTCTGTATCT
GGTAGTACTGGACAATGGCACTCTGAATCTGGAAGTTTTAGGCCAGATAGCCCAGGCTCTGGGAACG
CGAGGCCTAACAACCCAGACTGGGGCACATTTGAAGAGGTGTCAGGAAATGTAAGTCCAGGGACAAG
GAGAGAGTACCACACAGAAAAACTGGTCACTTCTAAAGGAGATAAAGAGCTCAGGACTGGTAAAGAG
AAGGTCACCTCTGGTAGCACAACCACCACGCGTCGTTCATGCTCTAAAACCGTTACTAAGACTGTTA
TTGGTCCTGATGGTCACAAAGAAGTTACCAAAGAAGTGGTGACCTCCGAAGATGGTTCTGACTGTCC
CGAGGCAATGGATTTAGGCACATTGTCTGGCATAGGCACCCTGGATGGGTTCCGCCATAGGCACCCT
GATGAAGCTGCCTTCTTCGACACTGCCTCAACTGGAAAAACATTCCCAGGTTTCTTCTCACCTATGT
TAGGAGAGTTTGTCAGTGAGACTGAGTCTAGGGGCTCAGAATCTGGCATCTTCACAAATACAAAGGA
ATCCAGTTCTCATCACCCTGGGATAGCTGAATTCCCTTCCCGTGGTAAATCTTCAAGTTACAGCAAA
CAATTTACTAGTAGCACGAGTTACAACAGAGGAGACTCCACATTTGAAAGCAAGAGCTATAAAATGG
CAGATGAGGCCGGAAGTGAAGCCGATCATGAAGGAACACATAGCACCAAGAGAGGCCATGCTAAATC
TCGCCCTGTCAGAGGTATCCACACTTCTCCTTTGGGGAAGCCTTCCCTGTCCCCCTAGACTAAGTTA
AATGGGCGGCCGCAATTCTGATCATAATCAGCCATACCACATTTGTAGAGGTTTTACTTGCTTTAAA
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AAACCTCCCACACCTCCCCCTGAACCTGAAACATAAAATGAATGCAATTGTTGTTGTTAACTTGTTT
ATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCATCACAAATTTCACAAATAAAGCATTTTTTT
CACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCA 
 
Key of the colouring primers 
MiniPrep sequencing primer 
GATTCAGACTGGCCCTTCTG 
MaxiPrep sequencing primer 
Forward: 
AaF1: TTCTCATTCGTTGACCACTAATATA  
AaF3: GATGAAGCTGCCTTCTTCGA 
pMLP-F1: AAGTGTGGCGGAACACATG 
pMLP-F3: CCTTTCTCTCCACAGGTGTC 
F4:  TGCTGGACACTGGACTTCTG 
F5: AGTGGTGACCTCCGAAGATG 
Reverse: 
pMLP-R1: TTGTTGTTAACTTGTTTATTGCAGC 
R5: CATCTTCGGAGGTCACCACT  
R6: AGCTCTTGCTTTCAAATGTGG 
  
AGA: Arginine (R) 
GGC: Glycine (G) 
GAT: Aspartate (D) 
TTT: Phenylalanine (F) 
ATG: Start codon 
TAG: Stop codon 
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>pMLP+FbgAa R95E 
CATCATCAATAATATACCTTATTTTGGATTGAAGCCAATATGATAATGAGGGGGTGGAGTTTGTGACGTG
GCGCGGGGCGTGGGAACGGGGCGGGTGACGTAGTAGTGTGGCGGAAGTGTGATGTTGCAAGTGTGGCGGA
ACACATGTAAGCGACGGATGTGGCAAAAGTGACGTTTTTGGTGTGCGCCGGTGTACACAGGAAGTGACAA
TTTTCGCGCGGTTTTAGGCGGATGTTGTAGTAAATTTGGGCGTAACCGAGTAAGATTTGGCCATTTTCGC
GGGAAAACTGAATAAGAGGAAGTGAAATCTGAATAATTTTGTGTTACTCATAGCGCGTAATATTTGTCTA
GGGCCCAAGCTTGTTTGCAAAAGCCTAGGCCTCCAAAAAAGCCTCCTCACTACTTCTGGAATAGCTCAGA
GGCCGAGGCGGCCTCGGCCTCTGCATAAATAAAAAAAATTAGTCAGCCATGGGGCGGAGAATGGGCGGAA
CTGGGCGGAGTTAGGGGCGGGATGGGCGGAGTTAGGGGCGGGACTATGGTTGCTGACTAATTGAGATGCA
TGCTTTGCATACTTCTGCCTGCTGGGGAGCCTGGGGACTTTCCACACCTGGTTGCTGACTAATTGAGATG
CATGCTTTGCATACTTCTGCCTGCTGGGGAGCCTGGGGACTTTCCACACCCTAACTGACACACATTCCAC
AGCTGGTTCTTTCCGCCTCAGAAGGGTACCCGGTCCTCCTCGTATAGAAACTCGGACCACTCTGAGACGA
AGGCTCGCGTCCAGGCCAGCACGAAGGAGGCTAAGTGGGAGGGGTAGCGGTCGTTGTCCACTAGGGGGTC
CACTCGCTCCAGGGTGTGAAGACACATGTCGCCCTCTTCGGCATCAAGGAAGGTGATTGGTTTATAGGTG
TAGGCCACGTGACCGGGTGTTCCTGAAGGGGGGCTATAAAAGGGGGTGGGGGCGCGTTCGTCCTCACTCT
CTTCCGCATCGCTGTCTGCGAGGGCCAGCTGTTGGGCTCGCGGTTGAGGACAAACTCTTCGCGGTCTTTC
CAGTACTCTTGGATCGGAAACCCGTCGGCCTCCGAACGTACTCCGCCACCGAGGGACCTGAGCGAGTCCG
CATCGACCGGATCGGAAAACCTCTCGAGAAAGGCGTCTAACCAGTCACAGTCGCAAGGTAGGCTGAGCAC
CGTGGCGGGCGGCAGCGGGTGGCGGTCGGGGTTGTTTCTGGCGGAGGTGCTGCTGATGATGTAATTAAAG
TAGGCCGTCTTGAGACGGCGGATGGTCGAGCTTGAGGTGTGGCAGGCTTCAGATCTGGCCATACACTTGA
GTGACAATGACATCCACTTTGCCTTTCTCTCCACAGGTGTCCACTCCCAGGTCCAACCTGATCAGAATTG
CGCCGCTCTCGAGTGAATTGTCGACCGCGGCCCCCTGGAGTGTCCTCAGGAGCCAGCCCCACCCTTAGAA
AAGATGTTTTCCATGAGGATCGTCTGCCTGGTCCTAAGTGTGGTGGGCACAGCATGGACTGCAGATAGTG
GTGAAGGTGACTTTCTAGCTGAAGGAGGAGGCGTGCGTGGCCCAAGGGTTGTGGAAAGACATCAATCTGC
CTGCAAAGATTCAGACTGGCCCTTCTGCTCTGATGAAGACTGGAACTACAAATGCCCTTCTGGCTGCAGG
ATGAAAGGGTTGATTGATGAAGTCAATCAAGATTTTACAAACAGAATAAATAAGCTCAAAAATTCACTAT
TTGAATATCAGAAGAACAATAAGGATTCTCATTCGTTGACCACTAATATAATGGAAATTTTGGAAGGC
GATTTTTCCTCAGCCAATAACCGTGATAATACCTACAACCGAGTGTCAGAGGATCTGAGAAGCAGAATTG
AAGTCCTGAAGCGCAAAGTCATAGAAAAAGTACAGCATATCCAGCTTCTGCAAAAAAATGTTAGGGCCCA
GTTGGTTGATATGAAACGACTGGAGGTGGACATTGATATTAAGATCCGATCTTGTCGAGGGTCATGCAGT
AGGGCTTTAGCTCGTGAAGTAGATCTGAAGGACTATGAAGATCAGCAGAAGCAACTTGAACAGGTCATTG
CCAAAGACTTACTTCCCTCTAGAGATAGGCAACACTTACCACTGATAAAAATGAAACCAGTTCCAGACTT
GGTTCCCGGAAATTTTAAGAGCCAGCTTCAGAAGGTACCCCCAGAGTGGAAGGCATTAACAGACATGCCG
CAGATGAGAATGGAGTTAGAGAGACCTGGTGGAAATGAGATTACTCGAGGAGGCTCCACCTCTTATGGAA
CCGGATCAGAGACGGAAAGCCCCAGGAACCCTAGCAGTGCTGGAAGCTGGAACTCTGGGAGCTCTGGACC
TGGAAGTACTGGAAACCGAAACCCTGGGAGCTCTGGGACTGGAGGGACTGCAACCTGGAAACCTGGGAGC
TCTGGACCTGGAAGTGCTGGAAGCTGGAACTCTGGGAGCTCTGGAACTGGAAGTACTGGAAACCAAAACC
CTGGGAGCCCTAGACCTGGTAGTACCGGAACCTGGAATCCTGGCAGCTCTGAACGCGGAAGTGCTGGGCA
CTGGACCTCTGAGAGCTCTGTATCTGGTAGTACTGGACAATGGCACTCTGAATCTGGAAGTTTTAGGCCA
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GATAGCCCAGGCTCTGGGAACGCGAGGCCTAACAACCCAGACTGGGGCACATTTGAAGAGGTGTCAGGAA
ATGTAAGTCCAGGGACAAGGAGAGAGTACCACACAGAAAAACTGGTCACTTCTAAAGGAGATAAAGAGCT
CAGGACTGGTAAAGAGAAGGTCACCTCTGGTAGCACAACCACCACGCGTCGTTCATGCTCTAAAACCGTT
ACTAAGACTGTTATTGGTCCTGATGGTCACAAAGAAGTTACCAAAGAAGTGGTGACCTCCGAAGATGGTT
CTGACTGTCCCGAGGCAATGGATTTAGGCACATTGTCTGGCATAGGCACCCTGGATGGGTTCCGCCATAG
GCACCCTGATGAAGCTGCCTTCTTCGACACTGCCTCAACTGGAAAAACATTCCCAGGTTTCTTCTCACCT
ATGTTAGGAGAGTTTGTCAGTGAGACTGAGTCTAGGGGCTCAGAATCTGGCATCTTCACAAATACAAAGG
AATCCAGTTCTCATCACCCTGGGATAGCTGAATTCCCTTCCCGTGGTAAATCTTCAAGTTACAGCAAACA
ATTTACTAGTAGCACGAGTTACAACAGAGGAGACTCCACATTTGAAAGCAAGAGCTATAAAATGGCAGAT
GAGGCCGGAAGTGAAGCCGATCATGAAGGAACACATAGCACCAAGAGAGGCCATGCTAAATCTCGCCCTG
TCAGAGGTATCCACACTTCTCCTTTGGGGAAGCCTTCCCTGTCCCCCTAGACTAAGTTAAATGGGCGGCC
GCAATTCTGATCATAATCAGCCATACCACATTTGTAGAGGTTTTACTTGCTTTAAAAAACCTCCCACACC
TCCCCCTGAACCTGAAACATAAAATGAATGCAATTGTTGTTGTTAACTTGTTTATTGCAGCTTATAATGG
TTACAAATAAAGCAATAGCATCACAAATTTCACAAATAAAGCATTTTTTTCACTGCATTCTAGTTGTGGT
TTGTCCAAACTCATCA 
GAA is the mutated Glutamate (E). 
>pMLP+FbgAa R95Q 
CATCATCAATAATATACCTTATTTTGGATTGAAGCCAATATGATAATGAGGGGGTGGAGTTTGTGACGTG
GCGCGGGGCGTGGGAACGGGGCGGGTGACGTAGTAGTGTGGCGGAAGTGTGATGTTGCAAGTGTGGCGGA
ACACATGTAAGCGACGGATGTGGCAAAAGTGACGTTTTTGGTGTGCGCCGGTGTACACAGGAAGTGACAA
TTTTCGCGCGGTTTTAGGCGGATGTTGTAGTAAATTTGGGCGTAACCGAGTAAGATTTGGCCATTTTCGC
GGGAAAACTGAATAAGAGGAAGTGAAATCTGAATAATTTTGTGTTACTCATAGCGCGTAATATTTGTCTA
GGGCCCAAGCTTGTTTGCAAAAGCCTAGGCCTCCAAAAAAGCCTCCTCACTACTTCTGGAATAGCTCAGA
GGCCGAGGCGGCCTCGGCCTCTGCATAAATAAAAAAAATTAGTCAGCCATGGGGCGGAGAATGGGCGGAA
CTGGGCGGAGTTAGGGGCGGGATGGGCGGAGTTAGGGGCGGGACTATGGTTGCTGACTAATTGAGATGCA
TGCTTTGCATACTTCTGCCTGCTGGGGAGCCTGGGGACTTTCCACACCTGGTTGCTGACTAATTGAGATG
CATGCTTTGCATACTTCTGCCTGCTGGGGAGCCTGGGGACTTTCCACACCCTAACTGACACACATTCCAC
AGCTGGTTCTTTCCGCCTCAGAAGGGTACCCGGTCCTCCTCGTATAGAAACTCGGACCACTCTGAGACGA
AGGCTCGCGTCCAGGCCAGCACGAAGGAGGCTAAGTGGGAGGGGTAGCGGTCGTTGTCCACTAGGGGGTC
CACTCGCTCCAGGGTGTGAAGACACATGTCGCCCTCTTCGGCATCAAGGAAGGTGATTGGTTTATAGGTG
TAGGCCACGTGACCGGGTGTTCCTGAAGGGGGGCTATAAAAGGGGGTGGGGGCGCGTTCGTCCTCACTCT
CTTCCGCATCGCTGTCTGCGAGGGCCAGCTGTTGGGCTCGCGGTTGAGGACAAACTCTTCGCGGTCTTTC
CAGTACTCTTGGATCGGAAACCCGTCGGCCTCCGAACGTACTCCGCCACCGAGGGACCTGAGCGAGTCCG
CATCGACCGGATCGGAAAACCTCTCGAGAAAGGCGTCTAACCAGTCACAGTCGCAAGGTAGGCTGAGCAC
CGTGGCGGGCGGCAGCGGGTGGCGGTCGGGGTTGTTTCTGGCGGAGGTGCTGCTGATGATGTAATTAAAG
TAGGCCGTCTTGAGACGGCGGATGGTCGAGCTTGAGGTGTGGCAGGCTTCAGATCTGGCCATACACTTGA
GTGACAATGACATCCACTTTGCCTTTCTCTCCACAGGTGTCCACTCCCAGGTCCAACCTGATCAGAATTG
CGCCGCTCTCGAGTGAATTGTCGACCGCGGCCCCCTGGAGTGTCCTCAGGAGCCAGCCCCACCCTTAGAA
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AAGATGTTTTCCATGAGGATCGTCTGCCTGGTCCTAAGTGTGGTGGGCACAGCATGGACTGCAGATAGTG
GTGAAGGTGACTTTCTAGCTGAAGGAGGAGGCGTGCGTGGCCCAAGGGTTGTGGAAAGACATCAATCTGC
CTGCAAAGATTCAGACTGGCCCTTCTGCTCTGATGAAGACTGGAACTACAAATGCCCTTCTGGCTGCAGG
ATGAAAGGGTTGATTGATGAAGTCAATCAAGATTTTACAAACAGAATAAATAAGCTCAAAAATTCACTAT
TTGAATATCAGAAGAACAATAAGGATTCTCATTCGTTGACCACTAATATAATGGAAATTTTGCAAGGC
GATTTTTCCTCAGCCAATAACCGTGATAATACCTACAACCGAGTGTCAGAGGATCTGAGAAGCAGAATTG
AAGTCCTGAAGCGCAAAGTCATAGAAAAAGTACAGCATATCCAGCTTCTGCAAAAAAATGTTAGGGCCCA
GTTGGTTGATATGAAACGACTGGAGGTGGACATTGATATTAAGATCCGATCTTGTCGAGGGTCATGCAGT
AGGGCTTTAGCTCGTGAAGTAGATCTGAAGGACTATGAAGATCAGCAGAAGCAACTTGAACAGGTCATTG
CCAAAGACTTACTTCCCTCTAGAGATAGGCAACACTTACCACTGATAAAAATGAAACCAGTTCCAGACTT
GGTTCCCGGAAATTTTAAGAGCCAGCTTCAGAAGGTACCCCCAGAGTGGAAGGCATTAACAGACATGCCG
CAGATGAGAATGGAGTTAGAGAGACCTGGTGGAAATGAGATTACTCGAGGAGGCTCCACCTCTTATGGAA
CCGGATCAGAGACGGAAAGCCCCAGGAACCCTAGCAGTGCTGGAAGCTGGAACTCTGGGAGCTCTGGACC
TGGAAGTACTGGAAACCGAAACCCTGGGAGCTCTGGGACTGGAGGGACTGCAACCTGGAAACCTGGGAGC
TCTGGACCTGGAAGTGCTGGAAGCTGGAACTCTGGGAGCTCTGGAACTGGAAGTACTGGAAACCAAAACC
CTGGGAGCCCTAGACCTGGTAGTACCGGAACCTGGAATCCTGGCAGCTCTGAACGCGGAAGTGCTGGGCA
CTGGACCTCTGAGAGCTCTGTATCTGGTAGTACTGGACAATGGCACTCTGAATCTGGAAGTTTTAGGCCA
GATAGCCCAGGCTCTGGGAACGCGAGGCCTAACAACCCAGACTGGGGCACATTTGAAGAGGTGTCAGGAA
ATGTAAGTCCAGGGACAAGGAGAGAGTACCACACAGAAAAACTGGTCACTTCTAAAGGAGATAAAGAGCT
CAGGACTGGTAAAGAGAAGGTCACCTCTGGTAGCACAACCACCACGCGTCGTTCATGCTCTAAAACCGTT
ACTAAGACTGTTATTGGTCCTGATGGTCACAAAGAAGTTACCAAAGAAGTGGTGACCTCCGAAGATGGTT
CTGACTGTCCCGAGGCAATGGATTTAGGCACATTGTCTGGCATAGGTACTCTGGATGGGTTCCGCCATAG
GCACCCTGATGAAGCTGCCTTCTTCGACACTGCCTCAACTGGAAAAACATTCCCAGGTTTCTTCTCACCT
ATGTTAGGAGAGTTTGTCAGTGAGACTGAGTCTAGGGGCTCAGAATCTGGCATCTTCACAAATACAAAGG
AATCCAGTTCTCATCACCCTGGGATAGCTGAATTCCCTTCCCGTGGTAAATCTTCAAGTTACAGCAAACA
ATTTACTAGTAGCACGAGTTACAACAGAGGAGACTCCACATTTGAAAGCAAGAGCTATAAAATGGCAGAT
GAGGCCGGAAGTGAAGCCGATCATGAAGGAACACATAGCACCAAGAGAGGCCATGCTAAATCTCGCCCTG
TCAGAGGTATCCACACTTCTCCTTTGGGGAAGCCTTCCCTGTCCCCCTAGACTAAGTTAAATGGGCGGCC
GCAATTCTGATCATAATCAGCCATACCACATTTGTAGAGGTTTTACTTGCTTTAAAAAACCTCCCACACC
TCCCCCTGAACCTGAAACATAAAATGAATGCAATTGTTGTTGTTAACTTGTTTATTGCAGCTTATAATGG
TTACAAATAAAGCAATAGCATCACAAATTTCACAAATAAAGCATTTTTTTCACTGCATTCTAGTTGTGGT
TTGTCCAAACTCATCA 
CAA is the mutated Glutamine (Q). 
>pMLP+FbgAa G96V 
CATCATCAATAATATACCTTATTTTGGATTGAAGCCAATATGATAATGAGGGGGTGGAGTTTGTGACGTG
GCGCGGGGCGTGGGAACGGGGCGGGTGACGTAGTAGTGTGGCGGAAGTGTGATGTTGCAAGTGTGGCGGA
ACACATGTAAGCGACGGATGTGGCAAAAGTGACGTTTTTGGTGTGCGCCGGTGTACACAGGAAGTGACAA
TTTTCGCGCGGTTTTAGGCGGATGTTGTAGTAAATTTGGGCGTAACCGAGTAAGATTTGGCCATTTTCGC
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GGGAAAACTGAATAAGAGGAAGTGAAATCTGAATAATTTTGTGTTACTCATAGCGCGTAATATTTGTCTA
GGGCCCAAGCTTGTTTGCAAAAGCCTAGGCCTCCAAAAAAGCCTCCTCACTACTTCTGGAATAGCTCAGA
GGCCGAGGCGGCCTCGGCCTCTGCATAAATAAAAAAAATTAGTCAGCCATGGGGCGGAGAATGGGCGGAA
CTGGGCGGAGTTAGGGGCGGGATGGGCGGAGTTAGGGGCGGGACTATGGTTGCTGACTAATTGAGATGCA
TGCTTTGCATACTTCTGCCTGCTGGGGAGCCTGGGGACTTTCCACACCTGGTTGCTGACTAATTGAGATG
CATGCTTTGCATACTTCTGCCTGCTGGGGAGCCTGGGGACTTTCCACACCCTAACTGACACACATTCCAC
AGCTGGTTCTTTCCGCCTCAGAAGGGTACCCGGTCCTCCTCGTATAGAAACTCGGACCACTCTGAGACGA
AGGCTCGCGTCCAGGCCAGCACGAAGGAGGCTAAGTGGGAGGGGTAGCGGTCGTTGTCCACTAGGGGGTC
CACTCGCTCCAGGGTGTGAAGACACATGTCGCCCTCTTCGGCATCAAGGAAGGTGATTGGTTTATAGGTG
TAGGCCACGTGACCGGGTGTTCCTGAAGGGGGGCTATAAAAGGGGGTGGGGGCGCGTTCGTCCTCACTCT
CTTCCGCATCGCTGTCTGCGAGGGCCAGCTGTTGGGCTCGCGGTTGAGGACAAACTCTTCGCGGTCTTTC
CAGTACTCTTGGATCGGAAACCCGTCGGCCTCCGAACGTACTCCGCCACCGAGGGACCTGAGCGAGTCCG
CATCGACCGGATCGGAAAACCTCTCGAGAAAGGCGTCTAACCAGTCACAGTCGCAAGGTAGGCTGAGCAC
CGTGGCGGGCGGCAGCGGGTGGCGGTCGGGGTTGTTTCTGGCGGAGGTGCTGCTGATGATGTAATTAAAG
TAGGCCGTCTTGAGACGGCGGATGGTCGAGCTTGAGGTGTGGCAGGCTTCAGATCTGGCCATACACTTGA
GTGACAATGACATCCACTTTGCCTTTCTCTCCACAGGTGTCCACTCCCAGGTCCAACCTGATCAGAATTG
CGCCGCTCTCGAGTGAATTGTCGACCGCGGCCCCCTGGAGTGTCCTCAGGAGCCAGCCCCACCCTTAGAA
AAGATGTTTTCCATGAGGATCGTCTGCCTGGTCCTAAGTGTGGTGGGCACAGCATGGACTGCAGATAGTG
GTGAAGGTGACTTTCTAGCTGAAGGAGGAGGCGTGCGTGGCCCAAGGGTTGTGGAAAGACATCAATCTGC
CTGCAAAGATTCAGACTGGCCCTTCTGCTCTGATGAAGACTGGAACTACAAATGCCCTTCTGGCTGCAGG
ATGAAAGGGTTGATTGATGAAGTCAATCAAGATTTTACAAACAGAATAAATAAGCTCAAAAATTCACTAT
TTGAATATCAGAAGAACAATAAGGATTCTCATTCGTTGACCACTAATATAATGGAAATTTTGAGAGTC
GATTTTTCCTCAGCCAATAACCGTGATAATACCTACAACCGAGTGTCAGAGGATCTGAGAAGCAGAATTG
AAGTCCTGAAGCGCAAAGTCATAGAAAAAGTACAGCATATCCAGCTTCTGCAAAAAAATGTTAGGGCCCA
GTTGGTTGATATGAAACGACTGGAGGTGGACATTGATATTAAGATCCGATCTTGTCGAGGGTCATGCAGT
AGGGCTTTAGCTCGTGAAGTAGATCTGAAGGACTATGAAGATCAGCAGAAGCAACTTGAACAGGTCATTG
CCAAAGACTTACTTCCCTCTAGAGATAGGCAACACTTACCACTGATAAAAATGAAACCAGTTCCAGACTT
GGTTCCCGGAAATTTTAAGAGCCAGCTTCAGAAGGTACCCCCAGAGTGGAAGGCATTAACAGACATGCCG
CAGATGAGAATGGAGTTAGAGAGACCTGGTGGAAATGAGATTACTCGAGGAGGCTCCACCTCTTATGGAA
CCGGATCAGAGACGGAAAGCCCCAGGAACCCTAGCAGTGCTGGAAGCTGGAACTCTGGGAGCTCTGGACC
TGGAAGTACTGGAAACCGAAACCCTGGGAGCTCTGGGACTGGAGGGACTGCAACCTGGAAACCTGGGAGC
TCTGGACCTGGAAGTGCTGGAAGCTGGAACTCTGGGAGCTCTGGAACTGGAAGTACTGGAAACCAAAACC
CTGGGAGCCCTAGACCTGGTAGTACCGGAACCTGGAATCCTGGCAGCTCTGAACGCGGAAGTGCTGGGCA
CTGGACCTCTGAGAGCTCTGTATCTGGTAGTACTGGACAATGGCACTCTGAATCTGGAAGTTTTAGGCCA
GATAGCCCAGGCTCTGGGAACGCGAGGCCTAACAACCCAGACTGGGGCACATTTGAAGAGGTGTCAGGAA
ATGTAAGTCCAGGGACAAGGAGAGAGTACCACACAGAAAAACTGGTCACTTCTAAAGGAGATAAAGAGCT
CAGGACTGGTAAAGAGAAGGTCACCTCTGGTAGCACAACCACCACGCGTCGTTCATGCTCTAAAACCGTT
ACTAAGACTGTTATTGGTCCTGATGGTCACAAAGAAGTTACCAAAGAAGTGGTGACCTCCGAAGATGGTT
CTGACTGTCCCGAGGCAATGGATTTAGGCACATTGTCTGGCATAGGCACCCTGGATGGGTTCCGCCATAG
GCACCCTGATGAAGCTGCCTTCTTCGACACTGCCTCAACTGGAAAAACATTCCCAGGTTTCTTCTCACCT
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ATGTTAGGAGAGTTTGTCAGTGAGACTGAGTCTAGGGGCTCAGAATCTGGCATCTTCACAAATACAAAGG
AATCCAGTTCTCATCACCCTGGGATAGCTGAATTCCCTTCCCGTGGTAAATCTTCAAGTTACAGCAAACA
ATTTACTAGTAGCACGAGTTACAACAGAGGAGACTCCACATTTGAAAGCAAGAGCTATAAAATGGCAGAT
GAGGCCGGAAGTGAAGCCGATCATGAAGGAACACATAGCACCAAGAGAGGCCATGCTAAATCTCGCCCTG
TCAGAGGTATCCACACTTCTCCTTTGGGGAAGCCTTCCCTGTCCCCCTAGACTAAGTTAAATGGGCGGCC
GCAATTCTGATCATAATCAGCCATACCACATTTGTAGAGGTTTTACTTGCTTTAAAAAACCTCCCACACC
TCCCCCTGAACCTGAAACATAAAATGAATGCAATTGTTGTTGTTAACTTGTTTATTGCAGCTTATAATGG
TTACAAATAAAGCAATAGCATCACAAATTTCACAAATAAAGCATTTTTTTCACTGCATTCTAGTTGTGGT
TTGTCCAAACTCATCA 
GTC is the mutated Valine (V). 
>pMLP+FbgAa D97K 
CATCATCAATAATATACCTTATTTTGGATTGAAGCCAATATGATAATGAGGGGGTGGAGTTTGTGACGTG
GCGCGGGGCGTGGGAACGGGGCGGGTGACGTAGTAGTGTGGCGGAAGTGTGATGTTGCAAGTGTGGCGGA
ACACATGTAAGCGACGGATGTGGCAAAAGTGACGTTTTTGGTGTGCGCCGGTGTACACAGGAAGTGACAA
TTTTCGCGCGGTTTTAGGCGGATGTTGTAGTAAATTTGGGCGTAACCGAGTAAGATTTGGCCATTTTCGC
GGGAAAACTGAATAAGAGGAAGTGAAATCTGAATAATTTTGTGTTACTCATAGCGCGTAATATTTGTCTA
GGGCCCAAGCTTGTTTGCAAAAGCCTAGGCCTCCAAAAAAGCCTCCTCACTACTTCTGGAATAGCTCAGA
GGCCGAGGCGGCCTCGGCCTCTGCATAAATAAAAAAAATTAGTCAGCCATGGGGCGGAGAATGGGCGGAA
CTGGGCGGAGTTAGGGGCGGGATGGGCGGAGTTAGGGGCGGGACTATGGTTGCTGACTAATTGAGATGCA
TGCTTTGCATACTTCTGCCTGCTGGGGAGCCTGGGGACTTTCCACACCTGGTTGCTGACTAATTGAGATG
CATGCTTTGCATACTTCTGCCTGCTGGGGAGCCTGGGGACTTTCCACACCCTAACTGACACACATTCCAC
AGCTGGTTCTTTCCGCCTCAGAAGGGTACCCGGTCCTCCTCGTATAGAAACTCGGACCACTCTGAGACGA
AGGCTCGCGTCCAGGCCAGCACGAAGGAGGCTAAGTGGGAGGGGTAGCGGTCGTTGTCCACTAGGGGGTC
CACTCGCTCCAGGGTGTGAAGACACATGTCGCCCTCTTCGGCATCAAGGAAGGTGATTGGTTTATAGGTG
TAGGCCACGTGACCGGGTGTTCCTGAAGGGGGGCTATAAAAGGGGGTGGGGGCGCGTTCGTCCTCACTCT
CTTCCGCATCGCTGTCTGCGAGGGCCAGCTGTTGGGCTCGCGGTTGAGGACAAACTCTTCGCGGTCTTTC
CAGTACTCTTGGATCGGAAACCCGTCGGCCTCCGAACGTACTCCGCCACCGAGGGACCTGAGCGAGTCCG
CATCGACCGGATCGGAAAACCTCTCGAGAAAGGCGTCTAACCAGTCACAGTCGCAAGGTAGGCTGAGCAC
CGTGGCGGGCGGCAGCGGGTGGCGGTCGGGGTTGTTTCTGGCGGAGGTGCTGCTGATGATGTAATTAAAG
TAGGCCGTCTTGAGACGGCGGATGGTCGAGCTTGAGGTGTGGCAGGCTTCAGATCTGGCCATACACTTGA
GTGACAATGACATCCACTTTGCCTTTCTCTCCACAGGTGTCCACTCCCAGGTCCAACCTGATCAGAATTG
CGCCGCTCTCGAGTGAATTGTCGACCGCGGCCCCCTGGAGTGTCCTCAGGAGCCAGCCCCACCCTTAGAA
AAGATGTTTTCCATGAGGATCGTCTGCCTGGTCCTAAGTGTGGTGGGCACAGCATGGACTGCAGATAGTG
GTGAAGGTGACTTTCTAGCTGAAGGAGGAGGCGTGCGTGGCCCAAGGGTTGTGGAAAGACATCAATCTGC
CTGCAAAGATTCAGACTGGCCCTTCTGCTCTGATGAAGACTGGAACTACAAATGCCCTTCTGGCTGCAGG
ATGAAAGGGTTGATTGATGAAGTCAATCAAGATTTTACAAACAGAATAAATAAGCTCAAAAATTCACTAT
TTGAATATCAGAAGAACAATAAGGATTCTCATTCGTTGACCACTAATATAATGGAAATTTTGAGAGGCA
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AATTTTCCTCAGCCAATAACCGTGATAATACCTACAACCGAGTGTCAGAGGATCTGAGAAGCAGAATTG
AAGTCCTGAAGCGCAAAGTCATAGAAAAAGTACAGCATATCCAGCTTCTGCAAAAAAATGTTAGGGCCCA
GTTGGTTGATATGAAACGACTGGAGGTGGACATTGATATTAAGATCCGATCTTGTCGAGGGTCATGCAGT
AGGGCTTTAGCTCGTGAAGTAGATCTGAAGGACTATGAAGATCAGCAGAAGCAACTTGAACAGGTCATTG
CCAAAGACTTACTTCCCTCTAGAGATAGGCAACACTTACCACTGATAAAAATGAAACCAGTTCCAGACTT
GGTTCCCGGAAATTTTAAGAGCCAGCTTCAGAAGGTACCCCCAGAGTGGAAGGCATTAACAGACATGCCG
CAGATGAGAATGGAGTTAGAGAGACCTGGTGGAAATGAGATTACTCGAGGAGGCTCCACCTCTTATGGAA
CCGGATCAGAGACGGAAAGCCCCAGGAACCCTAGCAGTGCTGGAAGCTGGAACTCTGGGAGCTCTGGACC
TGGAAGTACTGGAAACCGAAACCCTGGGAGCTCTGGGACTGGAGGGACTGCAACCTGGAAACCTGGGAGC
TCTGGACCTGGAAGTGCTGGAAGCTGGAACTCTGGGAGCTCTGGAACTGGAAGTACTGGAAACCAAAACC
CTGGGAGCCCTAGACCTGGTAGTACCGGAACCTGGAATCCTGGCAGCTCTGAACGCGGAAGTGCTGGGCA
CTGGACCTCTGAGAGCTCTGTATCTGGTAGTACTGGACAATGGCACTCTGAATCTGGAAGTTTTAGGCCA
GATAGCCCAGGCTCTGGGAACGCGAGGCCTAACAACCCAGACTGGGGCACATTTGAAGAGGTGTCAGGAA
ATGTAAGTCCAGGGACAAGGAGAGAGTACCACACAGAAAAACTGGTCACTTCTAAAGGAGATAAAGAGCT
CAGGACTGGTAAAGAGAAGGTCACCTCTGGTAGCACAACCACCACGCGTCGTTCATGCTCTAAAACCGTT
ACTAAGACTGTTATTGGTCCTGATGGTCACAAAGAAGTTACCAAAGAAGTGGTGACCTCCGAAGATGGTT
CTGACTGTCCCGAGGCAATGGATTTAGGCACATTGTCTGGCATAGGCACCCTGGATGGGTTCCGCCATAG
GCACCCTGATGAAGCTGCCTTCTTCGACACTGCCTCAACTGGAAAAACATTCCCAGGTTTCTTCTCACCT
ATGTTAGGAGAGTTTGTCAGTGAGACTGAGTCTAGGGGCTCAGAATCTGGCATCTTCACAAATACAAAGG
AATCCAGTTCTCATCACCCTGGGATAGCTGAATTCCCTTCCCGTGGTAAATCTTCAAGTTACAGCAAACA
ATTTACTAGTAGCACGAGTTACAACAGAGGAGACTCCACATTTGAAAGCAAGAGCTATAAAATGGCAGAT
GAGGCCGGAAGTGAAGCCGATCATGAAGGAACACATAGCACCAAGAGAGGCCATGCTAAATCTCGCCCTG
TCAGAGGTATCCACACTTCTCCTTTGGGGAAGCCTTCCCTGTCCCCCTAGACTAAGTTAAATGGGCGGCC
GCAATTCTGATCATAATCAGCCATACCACATTTGTAGAGGTTTTACTTGCTTTAAAAAACCTCCCACACC
TCCCCCTGAACCTGAAACATAAAATGAATGCAATTGTTGTTGTTAACTTGTTTATTGCAGCTTATAATGG
TTACAAATAAAGCAATAGCATCACAAATTTCACAAATAAAGCATTTTTTTCACTGCATTCTAGTTGTGGT
TTGTCCAAACTCATCA 
AAA is the mutated Lysine (K). 
>pMLP+FbgAa D97N 
CATCATCAATAATATACCTTATTTTGGATTGAAGCCAATATGATAATGAGGGGGTGGAGTTTGTGACGTG
GCGCGGGGCGTGGGAACGGGGCGGGTGACGTAGTAGTGTGGCGGAAGTGTGATGTTGCAAGTGTGGCGGA
ACACATGTAAGCGACGGATGTGGCAAAAGTGACGTTTTTGGTGTGCGCCGGTGTACACAGGAAGTGACAA
TTTTCGCGCGGTTTTAGGCGGATGTTGTAGTAAATTTGGGCGTAACCGAGTAAGATTTGGCCATTTTCGC
GGGAAAACTGAATAAGAGGAAGTGAAATCTGAATAATTTTGTGTTACTCATAGCGCGTAATATTTGTCTA
GGGCCCAAGCTTGTTTGCAAAAGCCTAGGCCTCCAAAAAAGCCTCCTCACTACTTCTGGAATAGCTCAGA
GGCCGAGGCGGCCTCGGCCTCTGCATAAATAAAAAAAATTAGTCAGCCATGGGGCGGAGAATGGGCGGAA
CTGGGCGGAGTTAGGGGCGGGATGGGCGGAGTTAGGGGCGGGACTATGGTTGCTGACTAATTGAGATGCA
TGCTTTGCATACTTCTGCCTGCTGGGGAGCCTGGGGACTTTCCACACCTGGTTGCTGACTAATTGAGATG
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CATGCTTTGCATACTTCTGCCTGCTGGGGAGCCTGGGGACTTTCCACACCCTAACTGACACACATTCCAC
AGCTGGTTCTTTCCGCCTCAGAAGGGTACCCGGTCCTCCTCGTATAGAAACTCGGACCACTCTGAGACGA
AGGCTCGCGTCCAGGCCAGCACGAAGGAGGCTAAGTGGGAGGGGTAGCGGTCGTTGTCCACTAGGGGGTC
CACTCGCTCCAGGGTGTGAAGACACATGTCGCCCTCTTCGGCATCAAGGAAGGTGATTGGTTTATAGGTG
TAGGCCACGTGACCGGGTGTTCCTGAAGGGGGGCTATAAAAGGGGGTGGGGGCGCGTTCGTCCTCACTCT
CTTCCGCATCGCTGTCTGCGAGGGCCAGCTGTTGGGCTCGCGGTTGAGGACAAACTCTTCGCGGTCTTTC
CAGTACTCTTGGATCGGAAACCCGTCGGCCTCCGAACGTACTCCGCCACCGAGGGACCTGAGCGAGTCCG
CATCGACCGGATCGGAAAACCTCTCGAGAAAGGCGTCTAACCAGTCACAGTCGCAAGGTAGGCTGAGCAC
CGTGGCGGGCGGCAGCGGGTGGCGGTCGGGGTTGTTTCTGGCGGAGGTGCTGCTGATGATGTAATTAAAG
TAGGCCGTCTTGAGACGGCGGATGGTCGAGCTTGAGGTGTGGCAGGCTTCAGATCTGGCCATACACTTGA
GTGACAATGACATCCACTTTGCCTTTCTCTCCACAGGTGTCCACTCCCAGGTCCAACCTGATCAGAATTG
CGCCGCTCTCGAGTGAATTGTCGACCGCGGCCCCCTGGAGTGTCCTCAGGAGCCAGCCCCACCCTTAGAA
AAGATGTTTTCCATGAGGATCGTCTGCCTGGTCCTAAGTGTGGTGGGCACAGCATGGACTGCAGATAGTG
GTGAAGGTGACTTTCTAGCTGAAGGAGGAGGCGTGCGTGGCCCAAGGGTTGTGGAAAGACATCAATCTGC
CTGCAAAGATTCAGACTGGCCCTTCTGCTCTGATGAAGACTGGAACTACAAATGCCCTTCTGGCTGCAGG
ATGAAAGGGTTGATTGATGAAGTCAATCAAGATTTTACAAACAGAATAAATAAGCTCAAAAATTCACTAT
TTGAATATCAGAAGAACAATAAGGATTCTCATTCGTTGACCACTAATATAATGGAAATTTTGAGAGGCA
ATTTTTCCTCAGCCAATAACCGTGATAATACCTACAACCGAGTGTCAGAGGATCTGAGAAGCAGAATTG
AAGTCCTGAAGCGCAAAGTCATAGAAAAAGTACAGCATATCCAGCTTCTGCAAAAAAATGTTAGGGCCCA
GTTGGTTGATATGAAACGACTGGAGGTGGACATTGATATTAAGATCCGATCTTGTCGAGGGTCATGCAGT
AGGGCTTTAGCTCGTGAAGTAGATCTGAAGGACTATGAAGATCAGCAGAAGCAACTTGAACAGGTCATTG
CCAAAGACTTACTTCCCTCTAGAGATAGGCAACACTTACCACTGATAAAAATGAAACCAGTTCCAGACTT
GGTTCCCGGAAATTTTAAGAGCCAGCTTCAGAAGGTACCCCCAGAGTGGAAGGCATTAACAGACATGCCG
CAGATGAGAATGGAGTTAGAGAGACCTGGTGGAAATGAGATTACTCGAGGAGGCTCCACCTCTTATGGAA
CCGGATCAGAGACGGAAAGCCCCAGGAACCCTAGCAGTGCTGGAAGCTGGAACTCTGGGAGCTCTGGACC
TGGAAGTACTGGAAACCGAAACCCTGGGAGCTCTGGGACTGGAGGGACTGCAACCTGGAAACCTGGGAGC
TCTGGACCTGGAAGTGCTGGAAGCTGGAACTCTGGGAGCTCTGGAACTGGAAGTACTGGAAACCAAAACC
CTGGGAGCCCTAGACCTGGTAGTACCGGAACCTGGAATCCTGGCAGCTCTGAACGCGGAAGTGCTGGGCA
CTGGACCTCTGAGAGCTCTGTATCTGGTAGTACTGGACAATGGCACTCTGAATCTGGAAGTTTTAGGCCA
GATAGCCCAGGCTCTGGGAACGCGAGGCCTAACAACCCAGACTGGGGCACATTTGAAGAGGTGTCAGGAA
ATGTAAGTCCAGGGACAAGGAGAGAGTACCACACAGAAAAACTGGTCACTTCTAAAGGAGATAAAGAGCT
CAGGACTGGTAAAGAGAAGGTCACCTCTGGTAGCACAACCACCACGCGTCGTTCATGCTCTAAAACCGTT
ACTAAGACTGTTATTGGTCCTGATGGTCACAAAGAAGTTACCAAAGAAGTGGTGACCTCCGAAGATGGTT
CTGACTGTCCCGAGGCAATGGATTTAGGCACATTGTCTGGCATAGGTACTCTGGATGGGTTCCGCCATAG
GCACCCTGATGAAGCTGCCTTCTTCGACACTGCCTCAACTGGAAAAACATTCCCAGGTTTCTTCTCACCT
ATGTTAGGAGAGTTTGTCAGTGAGACTGAGTCTAGGGGCTCAGAATCTGGCATCTTCACAAATACAAAGG
AATCCAGTTCTCATCACCCTGGGATAGCTGAATTCCCTTCCCGTGGTAAATCTTCAAGTTACAGCAAACA
ATTTACTAGTAGCACGAGTTACAACAGAGGAGACTCCACATTTGAAAGCAAGAGCTATAAAATGGCAGAT
GAGGCCGGAAGTGAAGCCGATCATGAAGGAACACATAGCACCAAGAGAGGCCATGCTAAATCTCGCCCTG
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TCAGAGGTATCCACACTTCTCCTTTGGGGAAGCCTTCCCTGTCCCCCTAGACTAAGTTAAATGGGCGGCC
GCAATTCTGATCATAATCAGCCATACCACATTTGTAGAGGTTTTACTTGCTTTAAAAAACCTCCCACACC
TCCCCCTGAACCTGAAACATAAAATGAATGCAATTGTTGTTGTTAACTTGTTTATTGCAGCTTATAATGG
TTACAAATAAAGCAATAGCATCACAAATTTCACAAATAAAGCATTTTTTTCACTGCATTCTAGTTGTGGT
TTGTCCAAACTCATCA 
ATT is the mutated Asparagine (N) 
>pMLP+FbgAa F98I 
CATCATCAATAATATACCTTATTTTGGATTGAAGCCAATATGATAATGAGGGGGTGGAGTTTGTGACGTG
GCGCGGGGCGTGGGAACGGGGCGGGTGACGTAGTAGTGTGGCGGAAGTGTGATGTTGCAAGTGTGGCGGA
ACACATGTAAGCGACGGATGTGGCAAAAGTGACGTTTTTGGTGTGCGCCGGTGTACACAGGAAGTGACAA
TTTTCGCGCGGTTTTAGGCGGATGTTGTAGTAAATTTGGGCGTAACCGAGTAAGATTTGGCCATTTTCGC
GGGAAAACTGAATAAGAGGAAGTGAAATCTGAATAATTTTGTGTTACTCATAGCGCGTAATATTTGTCTA
GGGCCCAAGCTTGTTTGCAAAAGCCTAGGCCTCCAAAAAAGCCTCCTCACTACTTCTGGAATAGCTCAGA
GGCCGAGGCGGCCTCGGCCTCTGCATAAATAAAAAAAATTAGTCAGCCATGGGGCGGAGAATGGGCGGAA
CTGGGCGGAGTTAGGGGCGGGATGGGCGGAGTTAGGGGCGGGACTATGGTTGCTGACTAATTGAGATGCA
TGCTTTGCATACTTCTGCCTGCTGGGGAGCCTGGGGACTTTCCACACCTGGTTGCTGACTAATTGAGATG
CATGCTTTGCATACTTCTGCCTGCTGGGGAGCCTGGGGACTTTCCACACCCTAACTGACACACATTCCAC
AGCTGGTTCTTTCCGCCTCAGAAGGGTACCCGGTCCTCCTCGTATAGAAACTCGGACCACTCTGAGACGA
AGGCTCGCGTCCAGGCCAGCACGAAGGAGGCTAAGTGGGAGGGGTAGCGGTCGTTGTCCACTAGGGGGTC
CACTCGCTCCAGGGTGTGAAGACACATGTCGCCCTCTTCGGCATCAAGGAAGGTGATTGGTTTATAGGTG
TAGGCCACGTGACCGGGTGTTCCTGAAGGGGGGCTATAAAAGGGGGTGGGGGCGCGTTCGTCCTCACTCT
CTTCCGCATCGCTGTCTGCGAGGGCCAGCTGTTGGGCTCGCGGTTGAGGACAAACTCTTCGCGGTCTTTC
CAGTACTCTTGGATCGGAAACCCGTCGGCCTCCGAACGTACTCCGCCACCGAGGGACCTGAGCGAGTCCG
CATCGACCGGATCGGAAAACCTCTCGAGAAAGGCGTCTAACCAGTCACAGTCGCAAGGTAGGCTGAGCAC
CGTGGCGGGCGGCAGCGGGTGGCGGTCGGGGTTGTTTCTGGCGGAGGTGCTGCTGATGATGTAATTAAAG
TAGGCCGTCTTGAGACGGCGGATGGTCGAGCTTGAGGTGTGGCAGGCTTCAGATCTGGCCATACACTTGA
GTGACAATGACATCCACTTTGCCTTTCTCTCCACAGGTGTCCACTCCCAGGTCCAACCTGATCAGAATTG
CGCCGCTCTCGAGTGAATTGTCGACCGCGGCCCCCTGGAGTGTCCTCAGGAGCCAGCCCCACCCTTAGAA
AAGATGTTTTCCATGAGGATCGTCTGCCTGGTCCTAAGTGTGGTGGGCACAGCATGGACTGCAGATAGTG
GTGAAGGTGACTTTCTAGCTGAAGGAGGAGGCGTGCGTGGCCCAAGGGTTGTGGAAAGACATCAATCTGC
CTGCAAAGATTCAGACTGGCCCTTCTGCTCTGATGAAGACTGGAACTACAAATGCCCTTCTGGCTGCAGG
ATGAAAGGGTTGATTGATGAAGTCAATCAAGATTTTACAAACAGAATAAATAAGCTCAAAAATTCACTAT
TTGAATATCAGAAGAACAATAAGGATTCTCATTCGTTGACCACTAATATAATGGAAATTTTGAGAGGCGA
TATTTCCTCAGCCAATAACCGTGATAATACCTACAACCGAGTGTCAGAGGATCTGAGAAGCAGAATTG
AAGTCCTGAAGCGCAAAGTCATAGAAAAAGTACAGCATATCCAGCTTCTGCAAAAAAATGTTAGGGCCCA
GTTGGTTGATATGAAACGACTGGAGGTGGACATTGATATTAAGATCCGATCTTGTCGAGGGTCATGCAGT
AGGGCTTTAGCTCGTGAAGTAGATCTGAAGGACTATGAAGATCAGCAGAAGCAACTTGAACAGGTCATTG
CCAAAGACTTACTTCCCTCTAGAGATAGGCAACACTTACCACTGATAAAAATGAAACCAGTTCCAGACTT
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GGTTCCCGGAAATTTTAAGAGCCAGCTTCAGAAGGTACCCCCAGAGTGGAAGGCATTAACAGACATGCCG
CAGATGAGAATGGAGTTAGAGAGACCTGGTGGAAATGAGATTACTCGAGGAGGCTCCACCTCTTATGGAA
CCGGATCAGAGACGGAAAGCCCCAGGAACCCTAGCAGTGCTGGAAGCTGGAACTCTGGGAGCTCTGGACC
TGGAAGTACTGGAAACCGAAACCCTGGGAGCTCTGGGACTGGAGGGACTGCAACCTGGAAACCTGGGAGC
TCTGGACCTGGAAGTGCTGGAAGCTGGAACTCTGGGAGCTCTGGAACTGGAAGTACTGGAAACCAAAACC
CTGGGAGCCCTAGACCTGGTAGTACCGGAACCTGGAATCCTGGCAGCTCTGAACGCGGAAGTGCTGGGCA
CTGGACCTCTGAGAGCTCTGTATCTGGTAGTACTGGACAATGGCACTCTGAATCTGGAAGTTTTAGGCCA
GATAGCCCAGGCTCTGGGAACGCGAGGCCTAACAACCCAGACTGGGGCACATTTGAAGAGGTGTCAGGAA
ATGTAAGTCCAGGGACAAGGAGAGAGTACCACACAGAAAAACTGGTCACTTCTAAAGGAGATAAAGAGCT
CAGGACTGGTAAAGAGAAGGTCACCTCTGGTAGCACAACCACCACGCGTCGTTCATGCTCTAAAACCGTT
ACTAAGACTGTTATTGGTCCTGATGGTCACAAAGAAGTTACCAAAGAAGTGGTGACCTCCGAAGATGGTT
CTGACTGTCCCGAGGCAATGGATTTAGGCACATTGTCTGGCATAGGCACCCTGGATGGGTTCCGCCATAG
GCACCCTGATGAAGCTGCCTTCTTCGACACTGCCTCAACTGGAAAAACATTCCCAGGTTTCTTCTCACCT
ATGTTAGGAGAGTTTGTCAGTGAGACTGAGTCTAGGGGCTCAGAATCTGGCATCTTCACAAATACAAAGG
AATCCAGTTCTCATCACCCTGGGATAGCTGAATTCCCTTCCCGTGGTAAATCTTCAAGTTACAGCAAACA
ATTTACTAGTAGCACGAGTTACAACAGAGGAGACTCCACATTTGAAAGCAAGAGCTATAAAATGGCAGAT
GAGGCCGGAAGTGAAGCCGATCATGAAGGAACACATAGCACCAAGAGAGGCCATGCTAAATCTCGCCCTG
TCAGAGGTATCCACACTTCTCCTTTGGGGAAGCCTTCCCTGTCCCCCTAGACTAAGTTAAATGGGCGGCC
GCAATTCTGATCATAATCAGCCATACCACATTTGTAGAGGTTTTACTTGCTTTAAAAAACCTCCCACACC
TCCCCCTGAACCTGAAACATAAAATGAATGCAATTGTTGTTGTTAACTTGTTTATTGCAGCTTATAATGG
TTACAAATAAAGCAATAGCATCACAAATTTCACAAATAAAGCATTTTTTTCACTGCATTCTAGTTGTGGT
TTGTCCAAACTCATCA 
ATT is the mutated Isoleucine (I) 
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Appendix B Ethics 
UNIVERSITY OF LEEDS RESEARCH ETHICS COMMITTEE APPLICATION FORM 1 
 
 
 
Please read each question carefully, taking note of instructions and completing 
all parts. If a question is not applicable please indicate so. The superscripted 
numbers refer to sections of the guidance notes, available at 
www.leeds.ac.uk/ethics. Where a question asks for information which you have 
previously provided in answer to another question, please just refer to your 
earlier answer rather than repeating information.  
 
Research ethics training courses: http://www.sddu.leeds.ac.uk/sddu-research-
ethics-courses.html  
 
To help us process your application enter the following reference numbers, if 
known and if applicable: 
Ethics reference number: HSLTLM12045 
Grant reference and/ or 
student number: 
 
 
PART A: Summary 
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A.1 Which Faculty Research Ethics Committee would you like to 
consider this application?2  
 
 
 
 
 
 
 
 
 
 
A.2 Title of the research3  
 
Role of different components on fibrin clot structure and function 
 
A.3  Principal investigator’s contact details4 
Name (Title, first name, 
surname) 
Prof Helen Philippou 
Position Professor 
Department/ School/ 
Institute 
Division of Cardiovascular and Diabetes 
Research LIGHT LICAMM 
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Faculty Medicine 
Work address (including 
postcode) 
LIGHT Laboratories, Clarendon Way, University 
of Leeds, Leeds, LS2 9NL 
Telephone number 01133437768 
University of Leeds email 
address 
h.philippou@leeds.ac.uk 
 
Name (Title, first name, 
surname) 
Prof Robert Ariëns 
Position Professor 
Department/ School/ 
Institute 
Division of Cardiovascular and Diabetes 
Research, LIGHT LICAMM 
Faculty Medicine 
Work address (including 
postcode) 
LIGHT Laboratories, Clarendon Way, University 
of Leeds, Leeds, LS2 9NL 
Telephone number 01133437734 
University of Leeds email 
address 
r.a.s.ariens@leeds.ac.uk 
 
A.4 Purpose of the research:5 (Tick as appropriate) 
 Research 
 Educational qualification:  Please specify: 
_______________________ 
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 Educational Research & Evaluation6 
 Medical Audit or Health Service Evaluation7 
 Other 
 
 
A.5 Select from the list below to describe your research: (You may select 
more than one) 
 Research on or with human participants 
 Research with has potential significant environmental impact.8  If 
yes, please give details: 
  
 Research working with data of human participants 
 New data collected by questionnaires/interviews 
 New data collected by qualitative methods 
 New data collected from observing individuals or populations 
 Research working with aggregated or population data 
 Research using already published data or data in the public 
domain 
 Research working with human tissue samples9 
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A.6 Will the research involve any of the following:10 (You may select more 
than one) 
 
If your research involves any of the following an application must be 
made to the National Research Ethics Service (NRES) via IRAS 
www.myresearchproject.org.uk as NHS ethical approval will be required. 
There is no need to complete any more of this form. Contact governance-
ethics@leeds.ac.uk for advice.  
 Patients and users of the NHS (including NHS patients treated in the 
private sector)11 
 Individuals identified as potential participants because of their status 
as relatives or carers of  patients and users of the NHS 
 Research involving adults in Scotland, Wales or England who lack 
the capacity to consent for themselves12 
 A prison or a young offender institution in England and Wales (and is 
health related)14 
 Clinical trial of a medicinal product or medical device15 
 Access to data, organs or other bodily material of past and present 
NHS patients9 
 Use of human tissue (including non-NHS sources) where the 
collection is not covered by a Human Tissue Authority licence9 
 Foetal material and IVF involving NHS patients 
 The recently deceased under NHS care 
 None of the above 
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You must inform the Research Ethics Administrator of your NRES 
number and approval date once approval has been obtained.  
 
If the University of Leeds is not the Lead Institution, or approval has been 
granted elsewhere (e.g. NHS) then you should contact the local Research 
Ethics Committee for guidance.  The UoL Ethics Committee need to be 
assured that any relevant local ethical issues have been addressed.  
 
A.7 Will the research involve NHS staff recruited as potential research 
participants (by virtue of their professional role) or NHS premises/ 
facilities? 
Yes       No         
If yes, ethical approval must be sought from the University of Leeds. Please 
note that NHS R&D approval is needed in addition, and can be applied for 
concurrently: www.myresearchproject.org.uk.  
Contact governance-ethics@leeds.ac.uk for advice.  
 
 
 
248 
 
 
A.8 Will the participants be from any of the following groups? (Tick as 
appropriate) 
 Children under 1616 
 Adults with learning disabilities12 
 Adults with other forms of mental incapacity or mental illness 
 Adults in emergency situations 
 Prisoners or young offenders14 
 Those who could be considered to have a particularly dependent 
relationship with the investigator, eg members of staff, students17 
 Other vulnerable groups 
 No participants from any of the above groups 
Please justify the inclusion of the above groups, explaining why the 
research cannot be conducted on non vulnerable groups. 
 
 
A Criminal Record Bureau (CRB) check will be needed for researchers working 
with children or vulnerable adults (see www.crb.gov.uk and 
http://store.leeds.ac.uk/browse/extra_info.asp?modid=1&prodid=2162&deptid
=34&compid=1&prodvarid=0&catid=243)  
 
 
 
249 
 
A.9 Give a short summary of the research18  
This section must be completed in language comprehensible to the lay 
person.  Do not simply reproduce or refer to the protocol, although the protocol 
can also be submitted to provide any technical information that you think the 
ethics committee may require. This section should cover the main parts of the 
proposal. 
 
People at risk of cardiovascular problems, e.g. heart attack, can have 
differences in their components (proteins) of the blood clotting system. These 
differences can be beneficial, detrimental, or not have any effect. We hope to 
understand the contribution of these differences to cardiovascular problems, 
and thus aid future drug development against these diseases. The purpose of 
this study is to investigate the effect of different components (proteins) on 
blood coagulation, for instance factor XIII which is known to strengthen the 
blood clot. This will involve adding the proteins to the donated sample, and 
using standard clotting assays (e.g. aPTT, PT, turbidity, thrombin generation, 
ROTEM, platelet aggregometry, permeation, confocal and electron 
microscopy imaging, binding assay; protocols attached) to determine how 
much longer the sample takes to clot compared to whole 
blood/plasma/cells/proteins without any extra components. 
 
Each volunteer will be asked to donate up to 54 mls of blood in a single visit to 
a private patient room in the LIGHT laboratories, with a maximum of 2 visits 
per week. The blood will then either  
 be used as is and tested on the same day, except where preparation 
of the sample for testing requires multiple days. In this case, samples 
will be prepared as expediently as possible and discarded once testing 
is complete. This will be within a maximum of 3 days. A log will be 
taken of each sample together with the timeline of the test(s) being 
performed and the date the cellular specimen is discarded. 
 separated to isolate biological cells (e.g. platelets, red blood cells) for 
testing. These will be tested and then discarded on the same day, 
except where preparation of the sample for testing requires multiple 
days. In this case, samples will be prepared as expediently as 
possible and discarded once testing is complete. This will be within a 
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maximum of 3 days. A log will be taken of each sample together with 
the timeline of the test(s) being performed and the date the cellular 
specimen is discarded. 
 Separating the donated blood into platelet poor plasma 
(decellularised) and either testing it on the same day or storing it for 
future use. To produce decellularised plasma, samples will be 
centrifuged at room temperature for 20 mins at 3,000xg. The cells are 
pelleted by this centrifugation and we carefully pipette the plasma from 
the top half of the tube). Regular blood smears will be performed to 
confirm that the plasma does not contain any cells.  
 used to isolate a particular protein from the donated blood (e.g. 
coagulation or complement proteins which are of interest to our 
research group) and either testing it on the same day or storing it for 
future use 
 separated into plasma and combined with other volunteers donated 
plasma to produce a normal pool and stored for future use 
 
For the individual samples, we anticipate getting up to 100 volunteers per year. 
For the normal pool, we will aim to get up to 25 volunteers to reduce person-
to-person variability and anticipate doing this annually. 
 
In addition, volunteers may be asked to complete a questionnaire detailing 
basic information (age, height, weight, gender, medical history of 
cardiovascular disease or diabetes, smoking history, exercise and dietary 
habits, plus any agents taken from a list of known agents that may alter blood 
coagulation).  
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A.10 What are the main ethical issues with the research and how will 
these be addressed?19 
Indicate any issues on which you would welcome advice from the ethics 
committee. 
 
People who have a dependent relationship with the investigators will not be 
recruited. 
Volunteers may be asked to complete a questionnaire of basic information 
(age, height, weight, gender, medical history of cardiovascular disease or 
diabetes, smoking history, exercise and dietary habits, plus any agents taken 
from a list of known agents that may alter blood coagulation). They can choose 
not to complete any or all of this questionnaire. Volunteer name and contact 
details will be kept solely on the consent form and an encrypted file on a private 
folder on the secure university network. A volunteer ID code will be used as 
the only link between the volunteer name and contact details, and any stored 
samples and questionnaires. Volunteer consent forms and questionnaires will 
be stored in a locked cupboard on university premises. This will allow the 
researchers to go back to the same volunteer on subsequent occasions if 
required. Information from the questionnaire may be input into an encrypted 
database which will be stored in a private folder on secure university network.  
 
 
 
 
PART B: About the research team 
 
B.1  To be completed by students only20 
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Name (Title, first name, 
surname) 
 
Qualification working 
towards (eg Masters, 
PhD) 
 
Supervisor’s name (Title, 
first name, surname) 
 
Department/ School/ 
Institute 
 
Faculty  
Work address (including 
postcode) 
 
Supervisor’s telephone 
number 
 
Supervisor’s email 
address 
 
Module name and number 
(if applicable) 
 
 
B.2  Other members of the research team (eg co-investigators, co-
supervisors) 21 
Name (Title, first name, 
surname) 
Dr Emma Hethershaw 
Position Post-doctoral research fellow 
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Department/ School/ 
Institute 
Division of Cardiovascular and Diabetes 
Research, LIGHT LICAMM 
Faculty Medicine 
Work address (including 
postcode) 
LIGHT Laboratories, Clarendon Way, University 
of Leeds, Leeds, LS2 9NL 
Telephone number 01133437743 
Email address e.hethershaw@leeds.ac.uk 
 
 
Name (Title, first name, 
surname) 
Dr Cedric Duval 
Position Post-doctoral research fellow 
Department/ School/ 
Institute 
Division of Cardiovascular and Diabetes 
Research, LIGHT LICAMM 
Faculty Medicine 
Work address (including 
postcode) 
LIGHT Laboratories, Clarendon Way, University 
of Leeds, Leeds, LS2 9NL 
Telephone number 01133433235 
Email address c.duval@leeds.ac.uk 
 
 
 
Part C: The research 
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C.1 What are the aims of the study?22 (Must be in language comprehensible 
to a lay person.) 
 
The aim of this study is to identify the effect, if any, of different components 
(proteins) on blood clot structure and function.  
 
C.2 Describe the design of the research. Qualitative methods as well as 
quantitative methods should be included. (Must be in language 
comprehensible to a lay person.) 
It is important that the study can provide information about the aims that it 
intends to address. If a study cannot answer the questions/ add to the 
knowledge base that it intends to, due to the way that it is designed, then 
wasting participants’ time could be an ethical issue. 
A number of different components (proteins) will be tested to see what effect 
they have on blood clot structure and function. This will be achieved by mixing 
different components with the donated whole blood, plasma, purified blood 
cells, or purified blood proteins and using standard clotting assays (e.g. aPTT, 
PT, turbidity, thrombin generation, ROTEM, platelet aggregometry, 
permeation, confocal and electron microscopy imaging, binding assay; 
protocols attached) to determine any differences in clotting time, rate of 
clotting, structure of the clot formed, and the breakdown of the clot. 
Each volunteer will be asked to donate up to 54 mls of blood in a single visit to 
a private patient room in the LIGHT laboratories, with a maximum of 2 visits 
per week. Volunteers blood samples will either  
 be used as is and tested on the same day, except where preparation 
of the sample for testing requires multiple days. In this case, samples 
will be prepared as expediently as possible and discarded once testing 
is complete. This will be within a maximum of 3 days. A log will be 
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taken of each sample together with the timeline of the test(s) being 
performed and the date the cellular specimen is discarded. 
 separated to isolate biological cells (e.g. platelets, red blood cells) for 
testing. These will be tested and then discarded on the same day, 
except where preparation of the sample for testing requires multiple 
days. In this case, samples will be prepared as expediently as 
possible and discarded once testing is complete. This will be within a 
maximum of 3 days. A log will be taken of each sample together with 
the timeline of the test(s) being performed and the date the cellular 
specimen is discarded. 
 Separating the donated blood into platelet poor plasma 
(decellularised) and either testing it on the same day or storing it for 
future use. To produce decellularised plasma, samples will be 
centrifuged at room temperature for 20 mins at 3,000xg. The cells are 
pelleted by this centrifugation and we carefully pipette the plasma from 
the top half of the tube). Regular blood smears will be performed to 
confirm that the plasma does not contain any cells. 
 used to isolate a particular protein from the donated blood (e.g. 
coagulation or complement proteins which are of interest to our 
research group) and either testing it on the same day or storing it for 
future use 
 separated into plasma and combined with other volunteers donated 
plasma to produce a normal pool and stored for future use 
Additionally, volunteers may be asked to complete a questionnaire of basic 
information (age, height, weight, gender, any known cardiovascular disease, 
smoking history, exercise and dietary habits) which may be used to check for 
correlations with laboratory data obtained. 
 
 
C.3 What will participants be asked to do in the study?23 (e.g. number of 
visits, time, travel required, interviews) 
 
Provide a maximum of 54 mls of blood in a single visit to a private patient room 
in the LIGHT laboratories, with a maximum of 2 visits per week. Additionally, 
the volunteer may be asked to provide basic information including age, height, 
weight, gender, medical history of cardiovascular disease or diabetes, smoking 
history, exercise and dietary habits, plus any agents taken from a list of known 
agents that may alter blood coagulation (questionnaire attached). This 
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questionnaire will not have the volunteers name or contact details on it, only 
the volunteer ID code. The only places linking the volunteer name and contact 
details with the volunteer ID code will be the paper consent forms, which will 
be kept in a locked cupboard in a locked office on university premises, and an 
encrypted file on a private folder on the secure university network. These will 
be discarded once no longer required, or if the respondent requested that they 
no longer wanted to take part.  
 
 
C.4 Does the research involve an international collaborator or research 
conducted overseas:24 
(Tick as appropriate)  
Yes       No 
If yes, describe any ethical review procedures that you will need to 
comply with in that country: 
 
 
 
Describe the measures you have taken to comply with these: 
 
 
 
Include copies of any ethical approval letters/ certificates with your application. 
 
C.5 Proposed study dates and duration  
Research start date (DD/MM/YY): 14/02/13   Research end date (DD/MM/YY): 
13/02/18 
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Fieldwork start date (DD/MM/YY): _________________   Fieldwork end date 
(DD/MM/YY): _________________ 
 
 
C.6. Where will the research be undertaken? (i.e. in the street, on UoL 
premises, in schools)25 
 
The LIGHT laboratories, University of Leeds 
 
 
RECRUITMENT & CONSENT PROCESSES 
 
How participants are recruited is important to ensure that they are not induced 
or coerced into participation. The way participants are identified may have a 
bearing on whether the results can be generalised. Explain each point and give 
details for subgroups separately if appropriate. 
 
C.7 How will potential participants in the study be:  
(i) identified? 
 
N/A 
 
 
 
(ii) approached?  
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N/A 
 
 
 
(iii) recruited?26 
 
Volunteers will be found by putting a notice up in the building and asking 
people to contact the relevant member of the research team (e.g. Cedric Duval 
or Emma Hethershaw). An item will also be included the weekly institute 
newsletter 
 
 
C.8 Will you be excluding any groups of people, and if so what is the 
rationale for that?27 
Excluding certain groups of people, intentionally or unintentionally may be 
unethical in some circumstances.  It may be wholly appropriate to exclude 
groups of people in other cases 
 
N/A 
 
C.9 How many participants will be recruited and how was the number 
decided upon?28 
It is important to ensure that enough participants are recruited to be able to 
answer the aims of the research. 
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For the individual samples, we anticipate getting up to 100 volunteers per year, 
based on predicted experimental requirements. 
For the normal pool, we will aim to get up to 25 volunteers to reduce person-
to-person variability and anticipate doing this annually, based on usage of 
previous normal pools. 
 
 
If you have a formal power calculation please replicate it here. 
 
N/A 
 
Remember to include all advertising material (posters, emails etc) as part of 
your application 
 
C10 Will the research involve any element of deception?29  
If yes, please describe why this is necessary and whether participants will be 
informed at the end of the study. 
 
No 
 
C.11 Will informed consent be obtained from the research participants?30  
Yes       No 
If yes, give details of how it will be done. Give details of any particular 
steps to provide information (in addition to a written information sheet) 
e.g. videos, interactive material. If you are not going to be obtaining 
informed consent you will need to justify this.  
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A verbal description of what is required (i.e. up to 54 mls of blood and basic 
information on the volunteer questionnaire) will be discussed with the 
volunteers with a description of what their blood will be used for. A written 
information sheet will also be provided containing the same information. 
 
 
If participants are to be recruited from any of potentially vulnerable 
groups, give details of extra steps taken to assure their protection. 
Describe any arrangements to be made for obtaining consent from a 
legal representative. 
 
Not applicable 
 
Copies of any written consent form, written information and all other 
explanatory material should accompany this application. The information 
sheet should make explicit that participants can withdrawn from the research 
at any time, if the research design permits.  
Sample information sheets and consent forms are available from the University 
ethical review webpage at 
http://researchsupport.leeds.ac.uk/index.php/academic_staff/good_practice/e
thical_review_process/university_ethical_review-1.  
 
C.12 Describe whether participants will be able to withdraw from the 
study, and up to what point (eg if data is to be anonymised). If withdrawal 
is not possible, explain why not. 
 
 
Volunteers are able to withdraw from the study at any point if they are donating 
individual samples. Those volunteers who donate blood to be spun down to 
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plasma and pooled with other people’s plasma and frozen will not be able to 
withdraw from the study once they have donated the blood. This will be 
explained to them at the time. 
 
C.13 How long will the participant have to decide whether to take part in 
the research?31 
It may be appropriate to recruit participants on the spot for low risk research; 
however consideration is usually necessary for riskier projects. 
 
Participants will be given 2 weeks to decide if they wish to participate. 
 
 
C.14 What arrangements have been made for participants who might not 
adequately understand verbal explanations or written information, or 
who have special communication needs?32 (e.g. translation, use of 
interpreters etc. It is important that groups of people are not excluded due to 
language barriers or disabilities, where assistance can be given.) 
 
Not applicable 
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C.15 Will individual or group interviews/ questionnaires discuss any 
topics or issues that might be sensitive, embarrassing or upsetting, or is 
it possible that criminal or other disclosures requiring action could take 
place during the study (e.g. during interviews or group discussions)?33 
The information sheet should explain under what circumstances action may be 
taken. 
Yes       No                 If yes, give details of procedures in place to deal 
with these issues.  
 
 
 
C.16 Will individual research participants receive any payments, fees, 
reimbursement of expenses or any other incentives or benefits for taking 
part in this research?34 
Yes       No 
If Yes, please describe the amount, number and size of incentives and 
on what basis this was decided. 
 
 
 
 
RISKS OF THE STUDY 
C.17 What are the potential benefits and/ or risks for research 
participants?35  
 
There are no other benefits from being involved in this study than the 
knowledge that the provided sample will further scientific research in 
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haemostasis and thrombosis, and ultimately may help to develop better 
screening assays and new therapeutics. There is a slight risk of bruising from 
the puncture site of blood being drawn. 
 
 
C.18 Does the research involve any risks to the researchers themselves, 
or people not directly involved in the research? Eg lone working36  
Yes       No 
 
If yes, please describe: 
__________________________________________________ 
 
 
Is a risk assessment necessary for this research?  
NB: Risk assessments are a University requirement for all fieldwork 
taking place off campus. For guidance contact your Faculty Health and 
Safety Manager or visit 
http://www.leeds.ac.uk/safety/fieldwork/index.htm.  
Yes       No         If yes, please include a copy of your risk assessment 
form with your application.  
 
 
DATA ISSUES 
C.19 Will the research involve any of the following activities at any stage 
(including identification of potential research participants)? (Tick as 
appropriate) 
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 Examination of personal records by those who would not normally 
have access 
 Access to research data on individuals by people from outside the 
research team 
 Electronic transfer of data 
 Sharing data with other organisations 
 Exporting data outside the European Union 
 Use of personal addresses, postcodes, faxes, e-mails or telephone 
numbers 
 Publication of direct quotations from respondents 
 Publication of data that might allow identification of individuals to be 
identified 
 Use of audio/visual recording devices 
 FLASH memory or other portable storage devices 
 Storage of personal data on or including any of the following: 
 Manual files  
Home or other personal computers 
 Private company computers 
 Laptop computers 
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C.20. How will the research team ensure confidentiality and security of 
personal data? E.g. anonymisation procedures, secure storage and coding of 
data.37 You may wish to refer to the data protection and research webpage.  
 
The questionnaire is confidential and anonymous and the generic nature of the information 
gathered does not allow for individual respondents to be identified. The only issue here relates 
to the option for respondents to provide their contact details on the consent form if they 
volunteer for subsequent blood donations. Volunteer name and contact details will be kept 
solely on the consent form and an encrypted file on a private folder on the secure university 
network. Contact details are purely to access the volunteers for subsequent blood donations 
and will not be used in conjunction with analysing any questionnaire or laboratory data. Paper 
questionnaires and consent forms will be kept in a locked cupboard in a locked office on 
secured university premises. A volunteer ID code will be used as the only link between the 
volunteer name and contact details, and any stored samples and questionnaires. 
The nature of donating the blood means that the responses are not anonymous to the 
researcher, but procedures have been put in place to ensure the confidentiality of the 
individual.  
 
 
 
C.21 For how long will data from the study be stored? Please explain why 
this length of time has been chosen.38  
RCUK guidance states that data should normally be preserved and accessible 
for ten years, but for some projects it may be 20 years or longer.  
Students: It would be reasonable to retain data for at least 2 years after 
publication or three years after the end of data collection, whichever is longer. 
 
Records will be kept for a minimum of 10 years, in accordance with RCUK 
guidance. 
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_10 years, _0 months 
 
CONFLICTS OF INTEREST 
 
C.22 Will any of the researchers or their institutions receive any other 
benefits or incentives for taking part in this research over and above 
normal salary or the costs of undertaking the research?39  
Yes       No 
If yes, indicate how much and on what basis this has been decided 
_____________________________________________________________
______________ 
 
 
C.23 Is there scope for any other conflict of interest?40 For example will 
the research funder have control of publication of research findings? 
Yes       No        If yes, please explain 
_________________________________________________ 
 
 
C.24 Does the research involve external funding? (Tick as appropriate) 
Yes       No        If yes, what is the source of this funding? Funding 
is primarily obtained from the Medical Research Council, British Heart 
Foundation and the Wellcome Trust 
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PART D: Declarations 
 
 
Declaration by Chief Investigators 
 
1. The information in this form is accurate to the best of my knowledge and 
belief and I take full responsibility for it.  
2. I undertake to abide by the University's ethical and health & safety 
guidelines, and the ethical principles underlying good practice 
guidelines appropriate to my discipline. 
3. If the research is approved I undertake to adhere to the study protocol, 
the terms of this application and any conditions set out by the Research 
Ethics Committee. 
4. I undertake to seek an ethical opinion from the REC before 
implementing substantial amendments to the protocol. 
5. I undertake to submit progress reports if required. 
6. I am aware of my responsibility to be up to date and comply with the 
requirements of the law and relevant guidelines relating to security and 
confidentiality of patient or other personal data, including the need to 
register when necessary with the appropriate Data Protection Officer. 
7. I understand that research records/ data may be subject to inspection 
for audit purposes if required in future. 
8. I understand that personal data about me as a researcher in this 
application will be held by the relevant RECs and that this will be 
managed according to the principles established in the Data Protection 
Act. 
9. I understand that the Ethics Committee may choose to audit this project 
at any point after approval. 
 
Sharing information for training purposes: Optional – please tick as 
appropriate: 
 
I would be content for members of other Research Ethics Committees 
to have access to the information in the application in confidence for 
training purposes. All personal identifiers and references to 
researchers, funders and research units would be removed. 
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Principal Investigator 
 
Signature of Principal Investigator: ....... ..........(This needs to be an 
actual signature rather than just typed. Electronic signatures are acceptable)
  
 
Print name: ..Helen Philippou Date: (dd/mm/yyyy): ..........17/11/2016 
 
 
Supervisor of student research: I have read, edited and agree with the 
form above. 
 
Supervisor’s signature: ................................................................ (This needs 
to be an actual signature rather than just typed. Electronic signatures are 
acceptable)  
 
Print name: ........................................................    Date: (dd/mm/yyyy): 
....................................................... 
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Please submit your form by email to J.M.Blaikie@leeds.ac.uk or if you are in the 
Faculty of Medicine and Health FMHUniEthics@leeds.ac.uk. Remember to 
include any supporting material such as your participant information sheet, 
consent form, interview questions and recruitment material with your application.   
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Checklist: 
 
 I have used layman’s terms to describe my research (applications are 
reviewed by lay members of the committee as well). 
 I have answered all the questions on the form, including those with several 
parts (refer to the guidance if you’re not sure how to answer a question or 
how much detail is required) 
 I have included any relevant supplementary materials such as  
 Recruitment material (posters, emails etc) 
 Sample participant information sheet 
 Sample consent form. Include different versions for different 
groups of participants eg for children and adults. 
 If I am not going to be using participant information sheets or consent 
forms I have explained why not and how informed consent will be 
otherwise obtained. 
 If you are a student have you discussed your application with your 
supervisor and are they satisfied that you have completed the form 
correctly? (This will speed up your application).  
 I have submitted a signed copy of my application. (If you are a student 
your supervisor also needs to sign the form).  
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Role of different components on fibrin clot structure and 
function 
 
Volunteer Information Sheet 
 
 
You are being invited to take part in a research study. Before you decide it is important 
for you to understand why the research is being done and what it will involve. Please 
take the time to read the following information carefully and discuss it if you wish. Please 
ask us if there is anything that is not clear or if you would like more information. Take 
time to decide whether or not you wish to take part. 
 
Purpose of the study 
People at risk of cardiovascular problems, e.g. heart attack, can have differences in their 
components (proteins) of the blood clotting system. These differences can be beneficial, 
detrimental, or not have any effect. We hope to understand the contribution of these 
differences to cardiovascular problems, and thus aid future drug development against 
these diseases. 
 
Why have I been chosen? 
You have been chosen because you are between 18 and 70 years old and are generally 
healthy. 
 
Do I have to take part? 
It is up to you whether or not to take part. If you do decide to participate, you will be 
given this information sheet to keep, asked to sign a consent form, may be asked to give 
telephone or email address (so we can contact you again asking if you would be willing 
to provide subsequent blood donations), and may be asked to complete a questionnaire 
detailing basic information. Completing any part of this questionnaire is voluntary. You 
do not have to provide any information if you do not want to. Your answers will be 
treated in confidence and will not be identifiable. We will hold your information securely 
in accordance with the Data Protection Act (1998). Your name and contact details (if you 
choose to provide these) will be kept solely on the consent form. Your volunteer ID code 
will be the only link between your name and contact details, and any stored samples and 
questionnaires. If you do decide to take part, you are still free to withdraw at any time 
and without giving a reason. If you do decide to participate, your blood sample will 
either:  
 be tested within 6 hours of being taken and any remaining discarded after 6 hours 
 separated into different components (e.g. plasma, cells, proteins) and either tested 
on the same day or stored for future use 
If you do decide to participate, it is accepted that your sample is a gift and may be retained 
for use in future ethically approved research.   
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What will happen to me if I take part? 
The study will take approximately 15 minutes of your time on one or more occasions 
when you will be asked to come to the LIGHT laboratories in the University of Leeds 
where you will see one of our research nurses or Dr Hethershaw. Up to 54 mls of blood 
(which is the equivalent of about 4 tablespoons) will be taken from a vein on the inside 
of your arm. Additionally, you may be asked to complete a questionnaire detailing basic 
information.  
 
What will happen to any samples I give? 
The blood sample provided will be labelled with your volunteer ID code only so that you 
can not be identified. The whole blood will then either: 
 be used as is and tested on the same day 
 separated into different components (e.g. plasma, cells, proteins) and either tested 
on the same day or stored for future use 
Standard blood clotting assays will be used to test the effects of the different components 
of blood clotting system with your sample. Any stored samples will also be labelled with 
your volunteer ID code as the only identifier and so you can not be identified. 
 
What are the possible disadvantages and risks of taking part? 
Giving a blood sample may be uncomfortable and there is a slight risk of bruising from 
the needle piercing the vein to take the blood.  
 
What is there is a problem? 
If you have a concern about any aspect of this study, you should contact one of the 
researchers who will do their best to answer your questions. Our contact numbers are at 
the end of this information sheet.  If you are harmed by taking part in this study, there 
are no special compensation arrangements. If you are harmed due to someone’s 
negligence, then you may have grounds for a legal action but you may have to pay for 
this.  
 
Will my taking part in this study be kept confidential? 
All information which is collected about you during the course of this research will be 
kept strictly confidential.  
 
Contact Details 
If you require any further information please contact us on the telephone numbers below. 
Thank-you for reading this information sheet and for considering participating in the 
research. 
 
 
Dr Emma Hethershaw   Julie Bailey – Research Nurse 
0113 343 7743    0113 343 7702 
e.hethershaw@leeds.ac.uk 
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Role of different components on fibrin clot structure and 
function 
 
Questionnaire 
 
 
Volunteer ID code  
Gender  
Age  
Height (cm)  
Weight (kg)  
Medical history of 
cardiovascular disease or 
diabetes 
 
Smoking history  
Exercise habits per week 
(where your heart rate is 
elevated) 
None    <1 hour   1-5 hours  >5 hours 
Eating habits Poor     Mild       Moderate        Healthy      Very Healthy 
Intense physical exercise in 
last 24 hours 
No                                 Yes 
Any agents from table 1?  
 
 
 
Completing any part of this questionnaire is voluntary. You do not have to provide 
any information if you do not want to. Your answers will be treated in confidence 
and will not be identifiable. We will hold your information securely in accordance 
with the Data Protection Act (1998). 
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TABLE 1 
 
Cyclo-oxygenase (COX)-1 inhibitors (irreversible)  
Aspirin and all proprietary or over-the-counter preparations containing acetylsalicylic acid.  
 
COX-1 and COX-2 inhibitors (reversible) (Nonsteroidal anti-inflammatory drugs 
(NSAIDs)  
Ibuprofen  
Indomethacin, naproxen  
Mefenamic acid  
 
Inhibitors of Platelet Receptors  
Abciximab, tirofiban, eptifibatide (IIb3)  
Ticlopidine, clopidogrel, prasugrel (irreversible), cangrelor (reversible), ticagrelor (reversible) 
(P2Y12)  
 
Phosphodiesterase Inhibitors  
Dipyridamole  
Cilostazole  
 
Anticoagulants  
Heparinoids, vitamin K antagonists and direct thrombin inhibitors may indirectly influence 
platelet function due to inhibition of thrombin.  
 
Cardiovascular Agents  
β-adrenergic blockers (propranolol)  
Vasodilators (nitroprusside, nitroglycerin)  
Diuretics (furosemide)  
Calcium channel blockers  
 
Antimicrobials  Miscellaneous 
Β-lactams (penicillins, cephalosporins)  Clofibrate  
Amphotericin (antifungal)  Dextrans  
Hydroxychloroquine (antimalarial)  Guaifenesin (expectorant)  
Nitrofurantoin  Radiographic contrast media  
 Food/Herbs (at high concentrations)  
Chemotherapeutic agents  Alcohol  
Asparaginase  Caffeine (methylxanthine)  
Plicamycin  Cumin  
Vincristine  Dong quai  
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 Fenugreek  
Psychotropics and Anaesthetics  Garlic, onion, ginger  
Tricyclic antidepressants (imipramine)  Ginseng  
Phenothiazines (chloropromazine)  Fish Oil  
Local and general anaesthesia (halothane)  Tamarind  
Thrombolytic Agents  Turmeric  
Streptokinase  Willow  
Urokinase  Vitamins C and E  
Tissue Plasminogen Activator (TPA)  
Benzodiazepines (diazepam, temazepam) 
Black Tree Fungus (“Chinese mushroom”) 
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Consent Form 
 
Role of different components on fibrin clot structure and 
function Blood Donation 
 
 
Volunteer ID code:  
Date sample taken:     Date test(s) performed:   
Date sample discarded:  
                  
Please 
initial box 
 
1. I confirm that I have read and understood the volunteer 
information sheet for the above study and have had the 
opportunity to ask questions. 
2. I understand that my participation is voluntary and that I am free 
to withdraw at any time, without giving any reason, without any 
legal rights being affected. 
3. I agree that my sample is a gift and may be retained for use in 
future ethically approved research.  
4. I understand that any samples and questionnaires will be labelled 
with my volunteer code only so that I can not be identified from 
them. 
 
Name of volunteer    Date  
 Signature 
 
 
 
 
Contact details (optional) 
 
 
 
 
 
Name of person taking consent  Date  
 Signature 
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Healthy Volunteers Wanted 
 
 
Role of different components on fibrin clot structure and 
function 
 
Volunteers are wanted for a study to the red blood cells binding to 
fibrinogen. We are looking for adults of all ages who are generally 
healthy. The commitment will take between 10-15 minutes and 
involves donating approximately 10 mls of blood in the LIGHT 
laboratories. You may also be asked to complete a questionnaire 
of basic information. This is voluntary. 
 
If you feel you would be available for this study, or have any 
questions regarding the experiment, please contact Aliaa Sabban 
(umas@leeds.ac.uk) (0113 43) 31142. 
 
This study has received ethical approval from the School of 
Medicine Research Ethics Committee, reference number 
HSLTLM12045. 
 
